<?xml version="1.0" encoding="UTF-8"?>
<projectSnippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4261061/results/gene/human/results.xml">
   <result pre="breast cancer, we performed a kinase open reading frame (ORF) screen to identify genes that rescue " exact="HER2" post="-amplified breast cancer cells from HER2 inhibition or suppression. In addition to multiple members" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="g ( 8– 10). Resistance also has been shown to occur in the setting of " exact="PTEN" post=" loss, activating PIK3CA mutations, CCNE amplification, or c-SRC activation ( &lt;a href" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" name="human"/>
   <result pre="&quot;#R10&quot;&gt;10). Resistance also has been shown to occur in the setting of PTEN loss, activating " exact="PIK3CA" post=" mutations, CCNE amplification, or c-SRC activation ( 11– 17)." xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" name="human"/>
   <result pre="so has been shown to occur in the setting of PTEN loss, activating PIK3CA mutations, " exact="CCNE" post=" amplification, or c-SRC activation ( 11– 17). Resistance to lapatini" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lular tyrosine kinase activity, can be induced in HER2-amplified breast cancer cells by activating " exact="PIK3CA" post=" mutations, loss of PTEN ( 18), or by activation of mTORC1 ( 1" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" name="human"/>
   <result pre="an be induced in HER2-amplified breast cancer cells by activating PIK3CA mutations, loss of " exact="PTEN" post=" ( 18), or by activation of mTORC1 ( 19). Since clinically resistant " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" name="human"/>
   <result pre="that confer resistance to the lapatinib-like dual EGFR/HER2 inhibitor AEE788 and to suppression of " exact="HER2" post=" with a short hairpin RNA (shRNA). We reasoned that the &quot;off-target&quot; effects of a small molecule in" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="d, including promotion of survival signaling. In addition, Vegran and colleagues demonstrated that " exact="PRKACA" post=" was one of 16 upregulated genes within a transcriptional signature that distinguishes breast cance" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" name="human"/>
   <result pre="re PRKACA and PIM1. Consistent with these findings, downregulation of a regulatory subunit of PKA, " exact="PRKAR2A" post=", has been reported to confer resistance to trastuzumab in HER2-amplified cells in vitro ( &lt;a href=" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4309158/results/gene/human/results.xml">
   <result pre="le due to the compromised ATP affinity resulting from EGFR/HER1 mutations, and as such, the " exact="T790M" post=" mutation culminates in restoration of wild-type level ATP affinity and a decreased affinity of TKI" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tion of wild-type level ATP affinity and a decreased affinity of TKIs targeting HER receptors. The " exact="T790M" post=" mutation is believed to account for 50% of the resistance to the aforementioned drugs ( &lt;a href=&quot;#" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="=&quot;#B43&quot;&gt;43). Other secondary mutations specific to EGFR/HER1 resistance development include " exact="D761Y" post=", L747S, and T854A ( 44). However, these have only been reported with " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ther secondary mutations specific to EGFR/HER1 resistance development include D761Y, " exact="L747S" post=", and T854A ( 44). However, these have only been reported with low frequency " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ations specific to EGFR/HER1 resistance development include D761Y, L747S, and " exact="T854A" post=" ( 44). However, these have only been reported with low frequency and are not the fo" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ave become resistant to gefitinib or erlotinib. AZD9291 and CO1686 inhibited both the activating ( " exact="L858R" post=") and resistant ( T790M) EGFR mutations in cell culture and in animal models. Convers" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nib or erlotinib. AZD9291 and CO1686 inhibited both the activating ( L858R) and resistant ( " exact="T790M" post=") EGFR mutations in cell culture and in animal models. Conversely, these drugs did not inhib" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ib. AZD9291 and CO1686 inhibited both the activating ( L858R) and resistant ( T790M) " exact="EGFR" post=" mutations in cell culture and in animal models. Conversely, these drugs did not inhibit the wild-t" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="ations in cell culture and in animal models. Conversely, these drugs did not inhibit the wild-type " exact="EGFR" post=" that is present in normal skin and gut cells, thereby reducing the side effects encountered with e" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="In addition to " exact="EGFR" post=" mutations, MET amplification/over-expression was also reported as another common EGFR TKI r" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="In addition to EGFR mutations, " exact="MET" post=" amplification/over-expression was also reported as another common EGFR TKI resistance mechanism in" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="/over-expression was also reported as another common EGFR TKI resistance mechanism in lung cancer. " exact="MET" post=" amplification was observed in 21% of patients with acquired resistance to EGFR TKI (in only 3% of " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="Ciardello et al. ( 59) have shown that " exact="HER2" post=" gene amplification is another mechanism of resistance to EGFR/HER1 targeted therapy. Their study r" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Dacomitinib is a highly effective inhibitor of " exact="EGFR" post=" activating and EGFR T790M acquired resistant mutations as well as the wild-type HER2" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="EGFR activating and EGFR T790M acquired resistant mutations as well as the wild-type " exact="HER2" post=", gefitinib-resistant oncogenic HER2 mutation, and HER2 amplification both in vitr" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; acquired resistant mutations as well as the wild-type HER2, gefitinib-resistant oncogenic " exact="HER2" post=" mutation, and HER2 amplification both in vitro and in vivo in a broad range o" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ions as well as the wild-type HER2, gefitinib-resistant oncogenic HER2 mutation, and " exact="HER2" post=" amplification both in vitro and in vivo in a broad range of human cancer cell lines " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tified as a mechanism of de novo resistance to irreversible panHER inhibitors in NSCLC with " exact="T790M" post=" resistant mutation ( 94). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ntrations, which are clinically achievable may not allow maximum inhibition of cells harboring the " exact="T790M" post=" resistant mutation. Treatment-related adverse effects (diarrhea, acne, and rash) associated with E" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="In cell-free in vitro kinase assays, afatinib potently inhibited wild-type " exact="EGFR" post=" (EC 50 = 0.5 nM), HER2 (14 nM), and HER4 (1 nM), as well as oncogenic L858R acti" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="-type EGFR (EC 50 = 0.5 nM), HER2 (14 nM), and HER4 (1 nM), as well as oncogenic " exact="L858R" post=" activating mutant EGFR (0.4 nM) and L858R-T790M resistant mutant EGFR (10 nM)" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="sub&gt; = 0.5 nM), HER2 (14 nM), and HER4 (1 nM), as well as oncogenic L858R activating mutant " exact="EGFR" post=" (0.4 nM) and L858R-T790M resistant mutant EGFR (10 nM) ( 98, &lt;a href=" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="ogenic L858R activating mutant EGFR (0.4 nM) and L858R-T790M resistant mutant " exact="EGFR" post=" (10 nM) ( 98, 99). Afatinib inhibited auto-phosphorylation of HER me" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre=" of HER members and proliferation in cancer cell lines representing different mutational status of " exact="EGFR" post=" and HER2, including wild-type EGFR (A431), activating mutant EGFR (PC-9 and H" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="and proliferation in cancer cell lines representing different mutational status of EGFR and " exact="HER2" post=", including wild-type EGFR (A431), activating mutant EGFR (PC-9 and H3255, EC 50" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lines representing different mutational status of EGFR and HER2, including wild-type " exact="EGFR" post=" (A431), activating mutant EGFR (PC-9 and H3255, EC 50 = 0.4 and 0.5 nM, respecti" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="l status of EGFR and HER2, including wild-type EGFR (A431), activating mutant " exact="EGFR" post=" (PC-9 and H3255, EC 50 = 0.4 and 0.5 nM, respectively), L858R-T790M mutant EG" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="R (PC-9 and H3255, EC 50 = 0.4 and 0.5 nM, respectively), L858R-T790M mutant " exact="EGFR" post=" (NCI-H1975), L858R-T854A mutant EGFR (transfected 293T), and HER2 amplification (BT474) wit" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="L858R-T790M mutant EGFR (NCI-H1975), L858R-T854A mutant EGFR (transfected 293T), and " exact="HER2" post=" amplification (BT474) with EC 50 below 100 nM, whereas NCI-H1975, T854A transfected 293" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="gression in a broad spectrum of xenograft models carrying epidermoid carcinoma A431 with wild-type " exact="EGFR" post=", gastric cancer NCI-N87 with HER2 over-expression, lung cancer NCI-H1975 with L858R-T790M m" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="ric cancer NCI-N87 with HER2 over-expression, lung cancer NCI-H1975 with L858R-T790M mutant " exact="EGFR" post=", and adenosquamous lung tumor with HER2 YVMA mutation, with superior activity o" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="Lung 2, a single-arm phase II study in 129 patients with lung adenocarcinoma containing activating " exact="EGFR" post=" mutations within exons 18-21, showed antitumor activity after treatment as first or second line wi" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="href=&quot;#B82&quot;&gt;82). Afatinib was more effective (objective response: 66%) in patients with the common " exact="EGFR" post=" mutations ( deletion 19 and L858R) compared to patients with less common mutations (" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="bjective response: 66%) in patients with the common EGFR mutations ( deletion 19 and " exact="L858R" post=") compared to patients with less common mutations (39%) ( 82). In addition, afatinib" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ree patients with lung adenocarcinoma and a non-smoking history, whose tumors exhibited activating " exact="HER2" post=" mutation in exon 20 ( 83). However, afatinib had limited activity in HER2-negative " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="xed and cisplatin as first-line treatment for patients with advanced lung adenocarcinoma harboring " exact="EGFR" post="-activating mutations. Encouragingly, afatinib led to a prolonged PFS, more significantly with comm" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="s. Encouragingly, afatinib led to a prolonged PFS, more significantly with common Del19 and " exact="L858R" post=" mutations ( 86, 87). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ly 2013, afatinib was approved for the first-line treatment of patients with metastatic NSCLC with " exact="EGFR" post=" exon 19 deletions or exon 21 ( L858R) substitution mutations by the US Food and Drug Admini" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="t-line treatment of patients with metastatic NSCLC with EGFR exon 19 deletions or exon 21 ( " exact="L858R" post=") substitution mutations by the US Food and Drug Administration ( 104). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="s in both pre-clinical studies and clinical trials. Combination therapy in NSCLC cells harboring a " exact="T790M" post=" mutation both in vitro and in vivo showed ( 107) that gefitinib (EGF" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="on the intracellular ATP binding domain and irreversibly inhibit both the activating and resistant " exact="EGFR" post=" mutations ( 45, 48, 112). Based on our current knowl" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[5]" name="human"/>
   <result pre="e exploited in certain clinical situations. For example, patients with activating and/or resistant " exact="EGFR" post=" mutations should be considered for the use of third-generation EGFR TKIs, whereas patients with ov" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4316710/results/gene/human/results.xml">
   <result pre="Several polymorphic variations in the promoter region of " exact="EGFR" post=" have been reported to impact on gene expression and function (Figure 1, Supplemental" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre=" a highly polymorphic locus (14–21 CA dinucleotide repeats) situated in the first intron of " exact="EGFR" post=". A lower CA-CSSR1 repeat number was found to modulate EGFR transcription in vivo and" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre=" situated in the first intron of EGFR. A lower CA-CSSR1 repeat number was found to modulate " exact="EGFR" post=" transcription in vivo and in vitro and correlated with increased transcription and p" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="eviously assigned as R497K, rs2227983) is a single nucleotide change (G–A) in the codon 497 of the " exact="EGFR" post=" (Figure 1) leading to an arginine-lysine substitution in the extracellular domain of" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="finity of the receptor, thus dampening downstream impact of activation of downstream target such a " exact="CMYC" post=" and VEGF (Wang et al., 2007; Hsieh et al., 2012). R521K polym" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ceptor, thus dampening downstream impact of activation of downstream target such a CMYC and " exact="VEGF" post=" (Wang et al., 2007; Hsieh et al., 2012). R521K polymorphism has been" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=") in a important binding site for the transcription factor SP1 that is necessary for activation of " exact="EGFR" post=" promoter activity (Liu et al., 2005). This variant is frequent in individuals of Eu" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="boring SNP-216 and CA-SSR1 germline polymorphisms were more likely to present somatic mutations of " exact="EGFR" post=", in particular microdeletions of exon 19. These deletions are common in lung cancer and were repor" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="The most investigated " exact="ERBB2" post=" polymorphism related to cancer risk is I655V (rs1136201) located at the codon 655 (ATC/isoleucine " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="n with ErbB partners, primarily through heterodimerization. Therefore, functional polymorphisms in " exact="ERBB3" post=" were long neglected for this pseudo-kinase (Shi et al., 2010). Recent studies revea" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="Shi et al., 2010). Recent studies revealed at least 1091 polymorphic forms in human " exact="ERBB3" post=" gene (dbSNP database; http://www.ncbi.nlm.nih.gov/snp) (" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="y reported clinical relevance of the polymorphism 276C/T (rs2271188) in the promoter region of the " exact="ERBB3" post=". This variant affected gene expression contributing to genetic susceptibility and was associated w" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="Multiple SNPs in the " exact="ERBB4" post=" promoter region were associated with adverse clinical features (Figure 1, Supplement" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ef=&quot;#F1&quot;&gt;1, Supplemental Table 4). The frequency and prognostic significance of two " exact="ERBB4" post=" promoter region variants, -782G/T (rs62626348) and -815A/T (rs62626347), were investigated in a la" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ef=&quot;#B34&quot;&gt;2014). A genome-wide association study (GWAS) identified a breast cancer risk variant in " exact="ERBB4" post=" at 2q34 (rs13393577) to occur in European and Chinese populations. However, the impact of ErbB4 po" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4323263/results/gene/human/results.xml">
   <result pre="e cohorts, recurrent mutations in genes not previously associated with breast cancer (for example, " exact="TBX3" post=", MLL3, RUNX1 and CBFB) and novel translocations were identified [ &lt;a href=&quot;#C" xpath="/html[1]/body[1]/article[1]/div[3]/div[8]/p[1]" name="human"/>
   <result pre="current mutations in genes not previously associated with breast cancer (for example, TBX3, " exact="MLL3" post=", RUNX1 and CBFB) and novel translocations were identified [ 16, &lt;a h" xpath="/html[1]/body[1]/article[1]/div[3]/div[8]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ions in genes not previously associated with breast cancer (for example, TBX3, MLL3, " exact="RUNX1" post=" and CBFB) and novel translocations were identified [ 16, 17" xpath="/html[1]/body[1]/article[1]/div[3]/div[8]/p[1]" name="human"/>
   <result pre=" previously associated with breast cancer (for example, TBX3, MLL3, RUNX1 and " exact="CBFB" post=") and novel translocations were identified [ 16, 17]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[8]/p[1]" name="human"/>
   <result pre="stance in ER-positive breast cancer and discovered point mutations or rearrangements affecting the " exact="ESR1" post=" ligand-binding domain, which were unique to the different tumors and were not previously identifie" xpath="/html[1]/body[1]/article[1]/div[3]/div[8]/p[1]" name="human"/>
   <result pre="usly identified by cell line studies [ 49]. These findings suggest that functional " exact="ESR1" post=" variants may be selected in a subset of endocrine-resistant luminal tumors and have immense potent" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4331616/results/gene/human/results.xml">
   <result pre=" " exact="PPE" post=" palmar-plantar erythrodysesthesia " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="artial response, SD stable disease, PD progressive disease, NE not evaluable, " exact="ORR" post=" overall response rate, CBR clinical benefit rate (CR; PR; SD ≥ 24 weeks) " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="disease, PD progressive disease, NE not evaluable, ORR overall response rate, " exact="CBR" post=" clinical benefit rate (CR; PR; SD ≥ 24 weeks) " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="HER2" post=" human epidermal growth factor receptor 2, IHC immunohistochemistry, FISH fluorescenc" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HER2 human epidermal growth factor receptor 2, " exact="IHC" post=" immunohistochemistry, FISH fluorescence in situ hybridization, EGFR epidermal growth" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, " exact="FISH" post=" fluorescence in situ hybridization, EGFR epidermal growth factor receptor " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="actor receptor 2, IHC immunohistochemistry, FISH fluorescence in situ hybridization, " exact="EGFR" post=" epidermal growth factor receptor " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" name="human"/>
   <result pre=" " exact="EGFR" post=" epidermal growth factor receptor, FISH fluorescence in situ hybridization, HER2 huma" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" name="human"/>
   <result pre=" EGFR epidermal growth factor receptor, " exact="FISH" post=" fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, IHC&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" EGFR epidermal growth factor receptor, FISH fluorescence in situ hybridization, " exact="HER2" post=" human epidermal growth factor receptor 2, IHC immunohistochemistry, ORR overall resp" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="FISH fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, " exact="IHC" post=" immunohistochemistry, ORR overall response rate (CR; PR) " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ridization, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, " exact="ORR" post=" overall response rate (CR; PR) " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4342830/results/gene/human/results.xml">
   <result pre="cer cells. Therefore, we used BT474 cells engineered to express control shRNA or shRNA targeted to " exact="HUNK" post=" (Fig. 2a) and examined the cells for survival response. Consistent with what we pr" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[1]" name="human"/>
   <result pre=" paradox is exemplified in HER2+ breast cancer in which monoallelic deletion of the autophagy gene " exact="BECN" post="- 1 is frequently found yet these tumors are more sensitive to HER2-targeted therapy [ &lt;a hr" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346363/results/gene/human/results.xml">
   <result pre="lyze miRNA changes should be considered to address these questions. High-risk individuals, such as " exact="BRCA" post=" gene mutation carriers, those with other genetic predispositions to breast cancer, or breast cance" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="es experimentally confirmed as miRNA targets with breast cancer-associated SNPs in their 3′-UTRs ( " exact="APC" post=", BMPR1B, BRCA1, CCND1, CXCL12, CYP1B1, ESR1, IGF1" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="tally confirmed as miRNA targets with breast cancer-associated SNPs in their 3′-UTRs ( APC, " exact="BMPR1B" post=", BRCA1, CCND1, CXCL12, CYP1B1, ESR1, IGF1, IGF1R," xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre=" as miRNA targets with breast cancer-associated SNPs in their 3′-UTRs ( APC, BMPR1B, " exact="BRCA1" post=", CCND1, CXCL12, CYP1B1, ESR1, IGF1, IGF1R, IRS2, " xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="ets with breast cancer-associated SNPs in their 3′-UTRs ( APC, BMPR1B, BRCA1, " exact="CCND1" post=", CXCL12, CYP1B1, ESR1, IGF1, IGF1R, IRS2, PTGS2, " xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="t cancer-associated SNPs in their 3′-UTRs ( APC, BMPR1B, BRCA1, CCND1, " exact="CXCL12" post=", CYP1B1, ESR1, IGF1, IGF1R, IRS2, PTGS2, SLC4A7, " xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="ated SNPs in their 3′-UTRs ( APC, BMPR1B, BRCA1, CCND1, CXCL12, " exact="CYP1B1" post=", ESR1, IGF1, IGF1R, IRS2, PTGS2, SLC4A7, TGFBR1, " xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="eir 3′-UTRs ( APC, BMPR1B, BRCA1, CCND1, CXCL12, CYP1B1, " exact="ESR1" post=", IGF1, IGF1R, IRS2, PTGS2, SLC4A7, TGFBR1, and VEGFA&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre=" APC, BMPR1B, BRCA1, CCND1, CXCL12, CYP1B1, ESR1, " exact="IGF1" post=", IGF1R, IRS2, PTGS2, SLC4A7, TGFBR1, and VEGFA). &lt;a href" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="BMPR1B, BRCA1, CCND1, CXCL12, CYP1B1, ESR1, IGF1, " exact="IGF1R" post=", IRS2, PTGS2, SLC4A7, TGFBR1, and VEGFA). &lt;a href=&quot;#b30-bctt-7-" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre=" BRCA1, CCND1, CXCL12, CYP1B1, ESR1, IGF1, IGF1R, " exact="IRS2" post=", PTGS2, SLC4A7, TGFBR1, and VEGFA). 30 &lt;a hr" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre=", CCND1, CXCL12, CYP1B1, ESR1, IGF1, IGF1R, IRS2, " exact="PTGS2" post=", SLC4A7, TGFBR1, and VEGFA). 30 &lt;a href=&quot;#t2-bctt-7" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre=", CXCL12, CYP1B1, ESR1, IGF1, IGF1R, IRS2, PTGS2, " exact="SLC4A7" post=", TGFBR1, and VEGFA). 30 Table 2 p" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre=", CYP1B1, ESR1, IGF1, IGF1R, IRS2, PTGS2, SLC4A7, " exact="TGFBR1" post=", and VEGFA). 30 Table 2 provides a compr" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="&gt;ESR1, IGF1, IGF1R, IRS2, PTGS2, SLC4A7, TGFBR1, and " exact="VEGFA" post="). 30 Table 2 provides a comprehensive summary o" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="The [G] allele of rs61764370 in the 3′-UTR of " exact="KRAS" post=", which disrupts a binding site for let-7 family members, is associated with an increased risk of d" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="ion promotes myofibrogenesis and regulates antimetastatic and proapoptotic target genes, including " exact="RECK" post=" (reversion-inducing cysteine-rich protein with kazal motifs), SPRY1/2 (Sprouty homolog 1/2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/p[4]" name="human"/>
   <result pre="2 (Sprouty homolog 1/2 of Drosophila gene), PDCD-4 (programed cell death 4), and " exact="PTEN" post=". We have recently shown that high levels of miR-21 expression in the stromal compartment in a coho" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4346691/results/gene/human/results.xml">
   <result pre="limited clinical utility in the management of advanced disease. Germline mutations in E-cadherin ( " exact="CDH1" post=") or mismatch repair genes (Lynch syndrome) were identified many years ago but given their rarity, " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" name="human"/>
   <result pre="rial gene expression signature possibly as a response to H. pylori infection, for example, " exact=" NDUF" post=" (NADH dehydrogenase), whereas intestinal metaplastic tissue expressed a more transformed phenotype" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ding many intestinal differentiation genes which were not expressed in tumor tissues, for example, " exact=" CDX1" post=", MYO1A, and villin A. Later studies examined whether the molecular signature could" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="stinal differentiation genes which were not expressed in tumor tissues, for example, CDX1, " exact=" MYO1A" post=", and villin A. Later studies examined whether the molecular signature could predict sensit" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nd/or platinum agents. It was possible to detect these subtypes by immunohistochemical analysis of " exact=" LGALS4" post=" and CDH17 expression. These studies may ultimately identify predictive biomarkers allowing" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ts. It was possible to detect these subtypes by immunohistochemical analysis of LGALS4 and " exact=" CDH17" post=" expression. These studies may ultimately identify predictive biomarkers allowing physicians to per" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" DNA hypermethylation than any other tumor reported by the TCGA. All EBV-positive tumors displayed " exact=" CDKN2A" post=" promoter hypermethylation and 80% had PIK3CA mutations. In addition, PD-L1/2 expression wa" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="y the TCGA. All EBV-positive tumors displayed CDKN2A promoter hypermethylation and 80% had " exact=" PIK3CA" post=" mutations. In addition, PD-L1/2 expression was elevated in EBV-positive tumors suggesting a role o" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rosatellite unstable (MSI) tumors generally lacked targetable amplifications although mutations in " exact=" PIK3CA" post=", HER2, HER3, and EGFR were noted. BRAF (V600E) mutations were not " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="able (MSI) tumors generally lacked targetable amplifications although mutations in PIK3CA, " exact=" HER2" post=", HER3, and EGFR were noted. BRAF (V600E) mutations were not seen in gastri" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ors generally lacked targetable amplifications although mutations in PIK3CA, HER2, " exact=" HER3" post=", and EGFR were noted. BRAF (V600E) mutations were not seen in gastric MSI tumors u" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ed targetable amplifications although mutations in PIK3CA, HER2, HER3, and " exact=" EGFR" post=" were noted. BRAF (V600E) mutations were not seen in gastric MSI tumors unlike its counterp" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ons although mutations in PIK3CA, HER2, HER3, and EGFR were noted. " exact=" BRAF" post=" (V600E) mutations were not seen in gastric MSI tumors unlike its counterpart in colorectal cancer." xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ric tumors are enriched for the diffuse histological variant and have newly described mutations in " exact=" RHOA" post=" which acts through several effectors to control actin-myosin-dependent cell contractility and moti" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" cell contractility and motility. In addition, a recurrent interchromosomal translocation (between " exact=" CLDN18" post=" and ARHGAP26) implicated in cell motility was found in genomically stable gastric tumors. " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" and motility. In addition, a recurrent interchromosomal translocation (between CLDN18 and " exact=" ARHGAP26" post=") implicated in cell motility was found in genomically stable gastric tumors. Almost half of gastri" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="by marked aneuploidy and focal amplification of receptor tyrosine kinases such as amplification of " exact=" VEGFA" post=" and frequent amplifications of cell cycle mediators ( CCNE1, CCND1, and CDK6&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nases such as amplification of VEGFA and frequent amplifications of cell cycle mediators ( " exact="CCNE1" post=", CCND1, and CDK6). This study has considerably added to our knowledge of the molec" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" name="human"/>
   <result pre="amplification of VEGFA and frequent amplifications of cell cycle mediators ( CCNE1, " exact=" CCND1" post=", and CDK6). This study has considerably added to our knowledge of the molecular subtyping " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; VEGFA and frequent amplifications of cell cycle mediators ( CCNE1, CCND1, and " exact=" CDK6" post="). This study has considerably added to our knowledge of the molecular subtyping of gastric cancer " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ported in esophageal cancer including amplifications on 8q and 17q mapped to the C-MYC and " exact=" ERBB2" post=" oncogenes [ 19, 20]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="The role of " exact=" MYC" post=" in the pathogenesis of esophageal cancer is not well defined and additional research is required. " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n, two genes reported to have homozygous deletions in esophageal cancer are p16/CDKN2A and " exact=" FHIT" post=" [ 24]. Abeloff et al. performed an integrative analysis of array-comparative genomi" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Genes with high copy number and expression correlations included two deletions ( p16/CDKN2, " exact=" MBNL1" post=") and four gains ( EGFR, WT1, NEIL2, and MTMR9). These genes individ" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="expression correlations included two deletions ( p16/CDKN2, MBNL1) and four gains ( " exact="EGFR" post=", WT1, NEIL2, and MTMR9). These genes individually ( P &amp;amp;lt; 0.06" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" name="human"/>
   <result pre="rrelations included two deletions ( p16/CDKN2, MBNL1) and four gains ( EGFR, " exact=" WT1" post=", NEIL2, and MTMR9). These genes individually ( P &amp;amp;lt; 0.06) and collect" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="cluded two deletions ( p16/CDKN2, MBNL1) and four gains ( EGFR, WT1, " exact=" NEIL2" post=", and MTMR9). These genes individually ( P &amp;amp;lt; 0.06) and collectively had progn" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="s ( p16/CDKN2, MBNL1) and four gains ( EGFR, WT1, NEIL2, and " exact=" MTMR9" post="). These genes individually ( P &amp;amp;lt; 0.06) and collectively had prognostic significance " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" both adenocarcinomas and squamous cell carcinomas [ 26]. Inactivating mutations of " exact=" NOTCH1" post=" were identified in 21% of esophageal squamous cell carcinomas but not in adenocarcinomas. " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rs [ 27]. Amplified genes were noted in 37% of gastric/esophageal tumors, including " exact=" ERBB2" post=", FGFR1, FGFR2, EGFR, and MET, suggesting that some of these may be" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="B27&quot;&gt;27]. Amplified genes were noted in 37% of gastric/esophageal tumors, including ERBB2, " exact=" FGFR1" post=", FGFR2, EGFR, and MET, suggesting that some of these may be viable targets" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="fied genes were noted in 37% of gastric/esophageal tumors, including ERBB2, FGFR1, " exact=" FGFR2" post=", EGFR, and MET, suggesting that some of these may be viable targets in esophageal " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" noted in 37% of gastric/esophageal tumors, including ERBB2, FGFR1, FGFR2, " exact=" EGFR" post=", and MET, suggesting that some of these may be viable targets in esophageal cancer althoug" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="astric/esophageal tumors, including ERBB2, FGFR1, FGFR2, EGFR, and " exact=" MET" post=", suggesting that some of these may be viable targets in esophageal cancer although amplification o" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="HER2 is a protooncogene which is encoded by " exact=" ERBB2" post=" found on chromosome 17. It belongs to the HER family of membrane-bound receptor tyrosine kinases w" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ations in gastroesophageal cancers have identified amplified genes in 37% of tumors, most notably, " exact=" ERBB2" post=", FGFR1, FGFR2, EGFR, and MET [ 27]. Until recently " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="oesophageal cancers have identified amplified genes in 37% of tumors, most notably, ERBB2, " exact=" FGFR1" post=", FGFR2, EGFR, and MET [ 27]. Until recently however the &quot;on" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="cers have identified amplified genes in 37% of tumors, most notably, ERBB2, FGFR1, " exact=" FGFR2" post=", EGFR, and MET [ 27]. Until recently however the &quot;one-size fits all" xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ified amplified genes in 37% of tumors, most notably, ERBB2, FGFR1, FGFR2, " exact=" EGFR" post=", and MET [ 27]. Until recently however the &quot;one-size fits all approach&quot; to " xpath="/html[1]/body[1]/article[1]/div[3]/div[14]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nes in 37% of tumors, most notably, ERBB2, FGFR1, FGFR2, EGFR, and " exact=" MET" post=" [ 27]. Until recently however the &quot;one-size fits all approach&quot; to enrolling patient" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4353882/results/gene/human/results.xml">
   <result pre="The overexpression or amplification of the human epidermal growth factor receptor 2 gene ( " exact="HER2" post="/ neu) is associated with high risk of brain metastasis (BM). The identification of patients" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nths) symptomatic BM in the discovery cohort. This was refined by qRT-PCR to a 3-gene classifier ( " exact="RAD51" post=", HDGF, TPR) highly predictive of early BM (HR 5.3, 95 % CI 1.6–16.7; p = 0.00" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="tic BM in the discovery cohort. This was refined by qRT-PCR to a 3-gene classifier ( RAD51, " exact="HDGF" post=", TPR) highly predictive of early BM (HR 5.3, 95 % CI 1.6–16.7; p = 0.005; multivaria" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre=" discovery cohort. This was refined by qRT-PCR to a 3-gene classifier ( RAD51, HDGF, " exact="TPR" post=") highly predictive of early BM (HR 5.3, 95 % CI 1.6–16.7; p = 0.005; multivariate analysis)" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="The overexpression or amplification of the human epidermal growth factor receptor 2 gene ( " exact="HER2" post="/ neu) is associated with high risk of brain metastasis (BM). Approximately 30–50 % of advan" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" ER estrogen receptor, PR progesterone receptor, " exact="HER2" post=" human epidermal growth factor receptor 2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=". The samples showing intermediate expression (scored 2+) were subjected to additional analysis of " exact="HER2" post=" gene copy number using fluorescence in situ hybridization (FISH). Gene amplification by FISH was d" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lify RNA samples, SYBR Green-based qRT-PCR (Applied Biosystems, Foster City, CA) was performed for " exact="RPL13" post="A ribosomal protein gene according to Illumina’s instructions (San Diego, CA). " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="s instructions. The primer sequences are listed in Table 2. Transferrin receptor ( " exact="TFRC" post="), beta cytoskeletal actin ( ACTB) and glyceraldehyde-3-phosphate dehydrogenase ( GAPDH&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre=" listed in Table 2. Transferrin receptor ( TFRC), beta cytoskeletal actin ( " exact="ACTB" post=") and glyceraldehyde-3-phosphate dehydrogenase ( GAPDH) were used as endogenous reference co" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="i&gt;TFRC), beta cytoskeletal actin ( ACTB) and glyceraldehyde-3-phosphate dehydrogenase ( " exact="GAPDH" post=") were used as endogenous reference controls for normalization. Delta threshold cycle (ΔC t&lt;/s" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="Selected controls: " exact="ACTB" post=", GAPDH, TFRC " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="Selected controls: ACTB, " exact="GAPDH" post=", TFRC " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="Selected controls: ACTB, GAPDH, " exact="TFRC" post=" " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="edictive analysis of microarray analysis identified a 13-gene profile [cyclin dependent kinase 4 ( " exact="CDK4" post="), cyclin C ( CCNC), focal adhesion kinase (protein tyrosine kinase 2, PTK2), v-myc a" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="oarray analysis identified a 13-gene profile [cyclin dependent kinase 4 ( CDK4), cyclin C ( " exact="CCNC" post="), focal adhesion kinase (protein tyrosine kinase 2, PTK2), v-myc avian myelocytomatosis vir" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="inase 4 ( CDK4), cyclin C ( CCNC), focal adhesion kinase (protein tyrosine kinase 2, " exact="PTK2" post="), v-myc avian myelocytomatosis viral oncogene homolog ( MYC), BRCA1 associated RING domain " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="se (protein tyrosine kinase 2, PTK2), v-myc avian myelocytomatosis viral oncogene homolog ( " exact="MYC" post="), BRCA1 associated RING domain 1 ( BARD1), RAD51 homolog ( RAD51), Fanconi an" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="-myc avian myelocytomatosis viral oncogene homolog ( MYC), BRCA1 associated RING domain 1 ( " exact="BARD1" post="), RAD51 homolog ( RAD51), Fanconi anemia group G ( FANCG), proliferating cell" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="ocytomatosis viral oncogene homolog ( MYC), BRCA1 associated RING domain 1 ( BARD1), " exact="RAD51" post=" homolog ( RAD51), Fanconi anemia group G ( FANCG), proliferating cell nuclear antige" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="gene homolog ( MYC), BRCA1 associated RING domain 1 ( BARD1), RAD51 homolog ( " exact="RAD51" post="), Fanconi anemia group G ( FANCG), proliferating cell nuclear antigen ( PCNA), papil" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="ated RING domain 1 ( BARD1), RAD51 homolog ( RAD51), Fanconi anemia group G ( " exact="FANCG" post="), proliferating cell nuclear antigen ( PCNA), papillary renal cell carcinoma-translocation " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="olog ( RAD51), Fanconi anemia group G ( FANCG), proliferating cell nuclear antigen ( " exact="PCNA" post="), papillary renal cell carcinoma-translocation associated ( PRCC), translocated promoter re" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="ing cell nuclear antigen ( PCNA), papillary renal cell carcinoma-translocation associated ( " exact="PRCC" post="), translocated promoter region ( TPR), cortactin (CTTN), desmoplakin ( DSP), hepatom" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="llary renal cell carcinoma-translocation associated ( PRCC), translocated promoter region ( " exact="TPR" post="), cortactin (CTTN), desmoplakin ( DSP), hepatoma-derived growth factor ( HDGF)] at e" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="ciated ( PRCC), translocated promoter region ( TPR), cortactin (CTTN), desmoplakin ( " exact="DSP" post="), hepatoma-derived growth factor ( HDGF)] at effectively distinguished patients with early " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="egion ( TPR), cortactin (CTTN), desmoplakin ( DSP), hepatoma-derived growth factor ( " exact="HDGF" post=")] at effectively distinguished patients with early versus late BM [hazard ratio (HR) 5.6, 95 % CI " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="longer follow-up (5 years) data. A predictive model that included only 3 of the original 13 genes: " exact="HDGF" post=", RAD51 and TPR, with corresponding LDA coefficients of 1.06, 0.35 and −1.08, respect" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="-up (5 years) data. A predictive model that included only 3 of the original 13 genes: HDGF, " exact="RAD51" post=" and TPR, with corresponding LDA coefficients of 1.06, 0.35 and −1.08, respectively, was dev" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="a. A predictive model that included only 3 of the original 13 genes: HDGF, RAD51 and " exact="TPR" post=", with corresponding LDA coefficients of 1.06, 0.35 and −1.08, respectively, was developed. The 3-g" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="ized using quantile normalization), b qRT-PCR normalized using the endogenous reference controls ( " exact="ACTB" post=", GAPDH, TFRC). The graph shows apparent inter-panel discordance of BARD1, " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="antile normalization), b qRT-PCR normalized using the endogenous reference controls ( ACTB, " exact="GAPDH" post=", TFRC). The graph shows apparent inter-panel discordance of BARD1, CCNC and &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="zation), b qRT-PCR normalized using the endogenous reference controls ( ACTB, GAPDH, " exact="TFRC" post="). The graph shows apparent inter-panel discordance of BARD1, CCNC and HDGF ex" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="ols ( ACTB, GAPDH, TFRC). The graph shows apparent inter-panel discordance of " exact="BARD1" post=", CCNC and HDGF expression, and minor inter-panel discordance of FANCG and " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="/i&gt;, GAPDH, TFRC). The graph shows apparent inter-panel discordance of BARD1, " exact="CCNC" post=" and HDGF expression, and minor inter-panel discordance of FANCG and PCNA expr" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="&gt;, TFRC). The graph shows apparent inter-panel discordance of BARD1, CCNC and " exact="HDGF" post=" expression, and minor inter-panel discordance of FANCG and PCNA expression " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="ance of BARD1, CCNC and HDGF expression, and minor inter-panel discordance of " exact="FANCG" post=" and PCNA expression " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="/i&gt;, CCNC and HDGF expression, and minor inter-panel discordance of FANCG and " exact="PCNA" post=" expression " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre=" ER estrogen receptor, PR progesterone receptor, " exact="HER2" post=" human epidermal growth factor receptor 2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ndance of identified genes, we employed qRT-PCR technology, which identified a 3-gene classifier ( " exact="RAD51" post=", HDGF, TPR), also seemingly predictive for early BM. However, the significance of th" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="tified genes, we employed qRT-PCR technology, which identified a 3-gene classifier ( RAD51, " exact="HDGF" post=", TPR), also seemingly predictive for early BM. However, the significance of this classifier" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre=" we employed qRT-PCR technology, which identified a 3-gene classifier ( RAD51, HDGF, " exact="TPR" post="), also seemingly predictive for early BM. However, the significance of this classifier was not con" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="a number of genes that could be important in the development of BM. The most important of which is " exact="RAD51" post=", a gene involved in homologous recombination in DNA double strand breaks repair [ " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="ene involved in homologous recombination in DNA double strand breaks repair [ 20]. " exact="RAD51" post=" expression has been linked to response to neoadjuvant therapy [ 23– &lt;a href=&quot;#CR25" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="that RAD51 targeting might be important in HER2-positive breast cancer. High nuclear expression of " exact="HDGF" post=", another gene constituting our 3-gene signature, was earlier found to associate with high tumor gr" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="s by down-regulation of E-cadherin and up-regulation of vimentin. The third gene of our signature— " exact="TPR" post=", a translocated promoter region nuclear basket protein, is poorly characterized but has a normal f" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4359239/results/gene/human/results.xml">
   <result pre="HER2, HER3, and HER4, have been widely implicated in human cancer [ 1]. For example, " exact="EGFR" post=" activating mutations are seen in 10-30% of non-small cell lung cancers (NSCLC), HER2 gene a" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" name="human"/>
   <result pre="ample, EGFR activating mutations are seen in 10-30% of non-small cell lung cancers (NSCLC), " exact="HER2" post=" gene amplification is seen in subsets of breast and gastric cancers, and HER3 and HER4&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="cers (NSCLC), HER2 gene amplification is seen in subsets of breast and gastric cancers, and " exact="HER3" post=" and HER4 activating mutations have also been detected in various solid tumors [ &lt;a href=&quot;#R" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt;HER2 gene amplification is seen in subsets of breast and gastric cancers, and HER3 and " exact="HER4" post=" activating mutations have also been detected in various solid tumors [ 2- &lt;a href=&quot;#" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" kinase inhibitors are approved for use specifically in the setting of NSCLCs harboring activating " exact="EGFR" post=" mutations, anti- EGFR antibodies are used to treat colorectal cancers that harbor wild-type KRA" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" name="human"/>
   <result pre="FR mutations, anti- EGFR antibodies are used to treat colorectal cancers that harbor wild-type " exact="KRAS" post=" alleles, and HER2-targeted agents are used in the setting of HER2-positive breast cancers. In addi" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" name="human"/>
   <result pre="e of sensitivity in a short-term viability assay that was associated with expression levels of the " exact="HER2" post=" and HER3 genes. Thus, the TAK- 285-sensitive cell lines tended to demonstrate relatively hi" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" in a short-term viability assay that was associated with expression levels of the HER2 and " exact="HER3" post=" genes. Thus, the TAK- 285-sensitive cell lines tended to demonstrate relatively higher levels of &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; genes. Thus, the TAK- 285-sensitive cell lines tended to demonstrate relatively higher levels of " exact="HER2" post=" and HER3 RNA, as well as protein. Moreover, increased phosphorylation of HER3, which appear" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="he TAK- 285-sensitive cell lines tended to demonstrate relatively higher levels of HER2 and " exact="HER3" post=" RNA, as well as protein. Moreover, increased phosphorylation of HER3, which appeared to be mediate" xpath="/html[1]/body[1]/article[1]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ls themselves? While it seems that there may be cases of TAK-285-sensitive cells that lack obvious " exact="HER2" post=" gene amplification, detection of HER2 in breast tumors has been optimized over two decades of stud" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4359299/results/gene/human/results.xml">
   <result pre="ve genomic analysis of SCC samples and identified several significantly mutated genes, among which " exact="ADAM29" post=" and FAM135B. These two genes have not been previously described in SCC. Of note, FAM135B" xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/div[9]/p[1]" name="human"/>
   <result pre="s of SCC samples and identified several significantly mutated genes, among which ADAM29 and " exact="FAM135B" post=". These two genes have not been previously described in SCC. Of note, FAM135B has been chara" xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/div[9]/p[1]" name="human"/>
   <result pre="ADAM29 and FAM135B. These two genes have not been previously described in SCC. Of note, " exact="FAM135B" post=" has been characterized as a novel cancer gene that promotes malignancy of SCC cells [ &lt;a href=&quot;#R1" xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/div[9]/p[1]" name="human"/>
   <result pre="&gt;13]. A recent similar study on AC samples revealed many new significantly mutated genes including " exact="DOCK2" post=" and ELMO1 [ 14]. Functional analysis indicated that mutations in ELMO1&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/div[9]/p[1]" name="human"/>
   <result pre="milar study on AC samples revealed many new significantly mutated genes including DOCK2 and " exact="ELMO1" post=" [ 14]. Functional analysis indicated that mutations in ELMO1, found in EAC, " xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/div[9]/p[1]" name="human"/>
   <result pre="i&gt;DOCK2 and ELMO1 [ 14]. Functional analysis indicated that mutations in " exact="ELMO1" post=", found in EAC, significantly enhanced cellular invasion; this suggests the potential contribution " xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/div[9]/p[1]" name="human"/>
   <result pre="irst clinical success in patients with advanced colorectal cancer, especially those with wild-type " exact="KRAS" post=" [ 19, 20]. EGFR mutations (5–10%) [ 21], amplificatio" xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/div[9]/p[1]" name="human"/>
   <result pre=" href=&quot;#R45&quot;&gt;45]. Several molecular mechanisms such as ligand/receptor overexpression or c- " exact="MET" post=" gene amplification can mediate such dysregulation. Notably, gene amplification of c-MET has" xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/div[9]/p[1]" name="human"/>
   <result pre="e, and others, have previously reported the amplification of the region band 13, which harbors the " exact="AURKA" post=" gene, on the long arm of chromosome 20 (20q13) in upper gastrointestinal cancers [ " xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/div[9]/p[1]" name="human"/>
   <result pre="20q13) in upper gastrointestinal cancers [ 75, 76]. In addition, the " exact="AURKA" post=" gene is frequently amplified and/or overexpressed in several types of cancer including those of th" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4368842/results/gene/human/results.xml">
   <result pre="nstrate a substantial HER2 protein overexpression by immunohistochemistry, predominantly driven by " exact="HER2" post=" amplification at the DNA level. The majority of studies of HER2-targeting therapies have been focu" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="variable percentage of cases [ 13, 14]. Additionally, mutations in " exact="HER2" post=" have been described in a small subset of cancers of the breast, lung, ovary, and colon [ &lt;a href=&quot;" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ng, ovary, and colon [ 13]. Anecdotal reports of patients with diverse cancers and " exact="HER2" post=" amplification or mutation responding to anti-HER2 agents have been published [ 15–" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="s analyzed by IHC, 21,642 samples were also examined with ISH. FISH was used for evaluation of the " exact="HER2" post=" amplification status. HER2/CEP17 ratio higher than 2.2 was considered amplified [ &lt;a href=&quot;" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="2 (equivocal) in FISH or HER2/CEP17 ratio &amp;amp;lt;1.8 in FISH was considered non-amplified (ISH-). " exact="HER2" post=" amplification was also evaluated by CISH (INFORM HER2 dual ISH DNA probe cocktail, Ventana). Consi" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="FISH was performed with a probe specific for " exact="HER2" post=" (17q11.2-q12 region) and a probe for the pericentromeric region of chromosome 17 (Abbott Molecular" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4385942/results/gene/human/results.xml">
   <result pre="stance remain unclear. In primary human breast cancers, we observed a positive correlation between " exact="KLF4" post="/ 5 transcript abundance, particularly in the human epidermal growth factor receptor 2 (HER2" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="f=&quot;#bib12&quot;&gt;12, 13 Consistent with these results, promoter demethylation of " exact="KLF4" post=" or KLF5 in breast tumors is associated with an unfavorable clinical course. &lt;a href=&quot;" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="13 Consistent with these results, promoter demethylation of KLF4 or " exact="KLF5" post=" in breast tumors is associated with an unfavorable clinical course. 14 &lt;/su" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="We observed a positive correlation of " exact="KLF4" post="/ 5 expression in the human epidermal growth factor receptor 2 (HER2)-enriched breast cancer" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="HER2)-enriched breast cancer subtype. In addition, in these patients the median expression of both " exact="KLF4" post="/ 5 significantly stratified the distant metastasis-free survival (DMFS). Clinically approve" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Across all tumors, " exact="KLF4" post=" levels showed no significant relationship with DMFS ( Figure 2a). In contrast, ele" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="s showed no significant relationship with DMFS ( Figure 2a). In contrast, elevated " exact="KLF5" post=" was associated with shortened DMFS, consistent with prior observations (hazard ratio (HR), 1.3; 95" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Interestingly, analysis of DMFS in each intrinsic subtype revealed a trend for increased " exact="KLF5" post=" expression and poor outcome in the HER2-enriched tumors (HR, 1.6; CI, 1.0–2.5, nominal P=0." xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ched tumors (HR, 1.6; CI, 1.0–2.5, nominal P=0.05; Figure 2b). Furthermore, " exact="KLF4" post=" expression showed a similar trend in this context (HR, 1.4; CI, 0.9–2.2, P=0.13). No such r" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="al A or luminal B groups ( Supplementary Figure 1). Furthermore, the expression of " exact="KLF4" post="/ 5 together (i.e., &amp;amp;lt; median levels of each gene versus ≥ median levels of eac" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=", 2.4; CI, 1.2–4.5, P=0.011; Figure 2c). HER2-enriched tumors with elevated " exact="KLF4" post="/ 5 levels had DMFS similar to 43% at 15 years post-diagnosis. This effect was unique to the" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="LFs, we analyzed the four survival curves defined by 2 × 2 contingency using the median scores for " exact="KLF4" post="/ 5 ( Supplementary Figure 1). The log-rank test for trend identified a sign" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="We next examined the transcript abundance of " exact="KLF4" post="/ 5 as determined by RNAseq analysis of patient breast tumors via The Cancer Genome Atlas (T" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="nriched tumors ( Figure 3a and Supplementary Figure 2). Given that " exact="KLF4" post="/ 5 appeared to represent positively correlated prognostic factors in the HER2-enriched brea" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ppear to account for upregulation of KLF4. Rather, the translational efficiency of the full-length " exact="KLF4" post=" transcript, as determined using a previously described translation reporter, pMIR-Report-Luc-KLF4-" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" elevated KLF4 was associated with increased levels of miR-206, which can then directly target the " exact="KLF4" post=" 3' UTR ( Figure 3e, right panel). 18, 20 &lt;" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="i&gt; studies, we assessed the copresence of KLF4/5 expression with MCL1, BCL-XL and/or " exact="BCL2" post=" in human tumors ( Table 1). 48, 49 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="e mutual exclusivity/inclusivity in 958 human breast tumors that were analyzed by microarray. Both " exact="KLF4" post="/ 5 cooccurred with MCL1. In addition, KLF4 and BCL-XL expression level" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="8 human breast tumors that were analyzed by microarray. Both KLF4/ 5 cooccurred with " exact="MCL1" post=". In addition, KLF4 and BCL-XL expression levels were mutually inclusive, as were " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" were analyzed by microarray. Both KLF4/ 5 cooccurred with MCL1. In addition, " exact="KLF4" post=" and BCL-XL expression levels were mutually inclusive, as were KLF5 and BCL2. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="/i&gt;. In addition, KLF4 and BCL-XL expression levels were mutually inclusive, as were " exact="KLF5" post=" and BCL2. In agreement with our previous observations ( Figure 3a), KLF4" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=", KLF4 and BCL-XL expression levels were mutually inclusive, as were KLF5 and " exact="BCL2" post=". In agreement with our previous observations ( Figure 3a), KLF4/ 5 e" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="LF5 and BCL2. In agreement with our previous observations ( Figure 3a), " exact="KLF4" post="/ 5 expression cooccurred in these tumors. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ized the RNAseq database generated by TCGA. Across 890 breast tumors, the transcript abundance for " exact="KLF4" post=", KLF5 and MCL1 was positively correlated ( Figure 5e). Using this da" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="eq database generated by TCGA. Across 890 breast tumors, the transcript abundance for KLF4, " exact="KLF5" post=" and MCL1 was positively correlated ( Figure 5e). Using this data set, we ob" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="rated by TCGA. Across 890 breast tumors, the transcript abundance for KLF4, KLF5 and " exact="MCL1" post=" was positively correlated ( Figure 5e). Using this data set, we observed no signif" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="gnificant positive correlations between KLFs and the other anti-apoptotic genes, BCL-XL and " exact="BCL2" post=" (data not shown). Despite these results, extensive ChIP studies in BT474 cells that analyzed 5-kbp" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="f the gene and 3-kbp downstream, failed to identify any KLF4/5 association with the mouse or human " exact="MCL1" post=" loci (see Discussion section). " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ts, and the clear dependence of MCL1 on KLF4/5 expression ( Figures 5b and c), the " exact="MCL1" post=" locus was not enriched in KLF4/5 ChIP assays, in which MIR206 served as a positive control " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="=&quot;#fig5&quot;&gt;Figures 5b and c), the MCL1 locus was not enriched in KLF4/5 ChIP assays, in which " exact="MIR206" post=" served as a positive control (data not shown). 20 These results sugg" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="We found that " exact="KLF4" post="/ 5 mRNA levels were correlated most strongly in the HER2-enriched tumors, and these factors" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="tudies have linked adverse clinical outcome to increased nuclear localization of KLF4, to elevated " exact="KLF5" post=" mRNA and to promoter demethylation of KLF4 or KLF5. 10, &lt;a hr" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="reased nuclear localization of KLF4, to elevated KLF5 mRNA and to promoter demethylation of " exact="KLF4" post=" or KLF5. 10, 11, 12, &lt;a href=&quot;#bib" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="localization of KLF4, to elevated KLF5 mRNA and to promoter demethylation of KLF4 or " exact="KLF5" post=". 10, 11, 12, 13, &lt;a href" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" observed shortened DMFS for patients with HER2-enriched tumors containing elevated levels of both " exact="KLF4" post=" and KLF5, implicating these two KLFs as novel prognostic factors ( Figure 2" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ned DMFS for patients with HER2-enriched tumors containing elevated levels of both KLF4 and " exact="KLF5" post=", implicating these two KLFs as novel prognostic factors ( Figure 2d). " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="In any single breast tumor subtype or in all tumors combined, " exact="KLF4" post=" on its own had little effect ( Figure 2b). In contrast to these results, a previou" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="t ( Figure 2b). In contrast to these results, a previous study associated elevated " exact="KLF4" post=" transcript levels with prolonged DFS. 56 As overall survival, DFS an" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Prognostic significance of " exact="KLF4" post=" and KLF5 in human breast cancer. Kaplan–Meier analysis utilized a previously described brea" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Prognostic significance of KLF4 and " exact="KLF5" post=" in human breast cancer. Kaplan–Meier analysis utilized a previously described breast cancer microa" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="inal A, 175 luminal B, 239 HER2-enriched and 287 basal-like/claudin-low tumors were analyzed. ( a) " exact="KLF4" post="/ 5 were analyzed as single variables for all tumors combined. ( b) KLF4/ 5 we" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="alyzed. ( a) KLF4/ 5 were analyzed as single variables for all tumors combined. ( b) " exact="KLF4" post="/ 5 were analyzed as single variables within the basal-like/claudin-low and the HER2-enriche" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Endogenous KLF4/5 mediate lapatinib resistance in breast cancer models. ( a) Levels of " exact="KLF4" post="/ 5 in primary human breast tumors were determined by RNAseq (Illumina HiSeq RNAseqV2). Uppe" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" qRT-PCR following lapatinib exposure. Expression data were normalized using the housekeeping gene " exact="B2M" post=". ( e) The pMIR-Report-Luc-KLF4-FL translation reporter contains as an insert within the FLuc&lt;/i" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="c-KLF4-FL translation reporter contains as an insert within the FLuc 3' UTR the full-length " exact="KLF4" post=" transcript, including the KLF4 protein coding region and the flanking UTRs, as previously d" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="s as an insert within the FLuc 3' UTR the full-length KLF4 transcript, including the " exact="KLF4" post=" protein coding region and the flanking UTRs, as previously described. 18 &lt;/" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="l HMLE cells and in cells expressing ectopic KLF4 and/or KLF5. ( e) Spearman's correlation between " exact="KLF4" post=", KLF5 and MCL1 levels as determined by RNAseq analysis of 890 human breast tumors. (" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="and in cells expressing ectopic KLF4 and/or KLF5. ( e) Spearman's correlation between KLF4, " exact="KLF5" post=" and MCL1 levels as determined by RNAseq analysis of 890 human breast tumors. ( f) The impac" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ressing ectopic KLF4 and/or KLF5. ( e) Spearman's correlation between KLF4, KLF5 and " exact="MCL1" post=" levels as determined by RNAseq analysis of 890 human breast tumors. ( f) The impact of KLF4/5 knoc" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4389676/results/gene/human/results.xml">
   <result pre="on RNA extracted from FFPE samples. The assay measures the expression of a panel of 21 genes (only " exact="HER2" post=" is included among the HER family genes) and the results are provided as a recurrence score. Althou" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="HC or central FISH studies in patients with metastatic breast cancer. Interestingly, patients with " exact="HER2" post=" gene amplification by FISH but low HER2 protein expression or homodimer levels as measured by HERm" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4394616/results/gene/human/results.xml">
   <result pre="ancers using combinations of targeted agents. Activating mutations in the PI3K and MAPK pathways ( " exact="PIK3CA" post=" and KRAS), and expression of the HER3 ligand heregulin determined sensitivity to combinatio" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="nations of targeted agents. Activating mutations in the PI3K and MAPK pathways ( PIK3CA and " exact="KRAS" post="), and expression of the HER3 ligand heregulin determined sensitivity to combinations of inhibitors" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre=" dysregulated in human cancers, one of the most common mechanisms of which is amplification of the " exact="ERBB2" post=" gene, 24 resulting in overexpression of the surface receptor HER2 and constitutive " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="ticularly in the metastatic setting. 25 Exposure to the HER3 ligand heregulin (HRG; " exact="NRG1" post="), for example, induces HER2/HER3 heterodimer signaling and resistance to Herceptin in preclinical " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre=", we defined molecular subtypes within HER2+ cancers based on a combination of genetic mutations ( " exact="PIK3CA" post=" and KRAS) and microenvironment context (the HER3-ligand heregulin). By matching optimal dru" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="ular subtypes within HER2+ cancers based on a combination of genetic mutations ( PIK3CA and " exact="KRAS" post=") and microenvironment context (the HER3-ligand heregulin). By matching optimal drug combinations t" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="ce of these genetic alterations in HER2+ cancer, copy number and mutational profiles for the genes " exact="ERBB2" post=", and commonly mutated components of the PI3K ( PIK3CA, PIK3R1, and PTEN) and MAPK ca" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="r the genes ERBB2, and commonly mutated components of the PI3K ( PIK3CA, PIK3R1, and " exact="PTEN" post=") and MAPK cascades ( BRAF, KRAS, HRAS, NRAS) were extracted from primary tumor genome seque" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="Co-occurrence of " exact="ERBB2" post=" gene amplification with PI3K and MAPK pathway activating mutations, and predicted treatment strate" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="ay activating mutations, and predicted treatment strategies for the respective subpopulations. (a) " exact="ERBB2" post="-amplified cancers represented in TCGA were segregated by PI3K ( PIK3CA, PIK3R1, PTEN) and M" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="ines, in the presence and absence of 5nM exogenous HRG ligand. This panel included cells harboring " exact="PIK3CA" post=" mutations (E545K and H1047R), KRAS mutations (G12D/C), as well as PI3K and MAPK &quot;wildtype&quot; " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="genous HRG ligand. This panel included cells harboring PIK3CA mutations (E545K and H1047R), " exact="KRAS" post=" mutations (G12D/C), as well as PI3K and MAPK &quot;wildtype&quot; (WT) cells. One WT cell (NCI-N87) was gene" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="3K and MAPK &quot;wildtype&quot; (WT) cells. One WT cell (NCI-N87) was genetically engineered to express the " exact="PIK3CA" post=" mutants, providing a syngeneic platform to assess the effect of these single point mutations. The " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="tro growth inhibitory responses to assess model predictions. Consistent with predictions, both " exact="PIK3CA" post=" and KRAS mutations significantly reduced the activity of the MHL combination and correspond" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="ibitory responses to assess model predictions. Consistent with predictions, both PIK3CA and " exact="KRAS" post=" mutations significantly reduced the activity of the MHL combination and correspondingly enhanced s" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="Ki)-containing) and cell genotype (WT, KRAS, PIK3CA-mutant). (b) Average regression coefficients ( " exact="BETA" post=") for each drug across the three genetic ally defined cell populations, +/− heregulin (HRG). (c) Tr" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="vidual drugs. Average values of these five parameters were computed for each genetic subgroup (WT, " exact="KRAS" post="-, and PIK3CA-mutant) in the presence and absence of exogenous HRG stimulation, resulting in" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="age values of these five parameters were computed for each genetic subgroup (WT, KRAS-, and " exact="PIK3CA" post="-mutant) in the presence and absence of exogenous HRG stimulation, resulting in 5 × 2 × 3 = 30 summ" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre=" HRG antagonist. 7 Consistent with model predictions ( Figure 4 b), " exact="KRAS" post="-mutant cells are the most sensitive to the MEK inhibitor, WT cells to lapatinib, and PIK3CA" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre=", KRAS-mutant cells are the most sensitive to the MEK inhibitor, WT cells to lapatinib, and " exact="PIK3CA" post="-mutant cells to the AKT inhibitor. The differential sensitivity of the PIK3CA mutant cells " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="apatinib, and PIK3CA-mutant cells to the AKT inhibitor. The differential sensitivity of the " exact="PIK3CA" post=" mutant cells to AKT inhibition, however, is less pronounced than predicted. We attribute this to a" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="macologically distinct subtypes within HER2+ cancers based on a combination of genetic mutations ( " exact="PIK3CA" post=" and KRAS) and microenvironmental context (the HER3-ligand Heregulin). Optimal drug combinat" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="inct subtypes within HER2+ cancers based on a combination of genetic mutations ( PIK3CA and " exact="KRAS" post=") and microenvironmental context (the HER3-ligand Heregulin). Optimal drug combinations were matche" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="an be overcome with an HRG antagonist such as MM-111. Second, constitutive activating mutations in " exact="PIK3CA" post=" and KRAS can drive resistance to dual HER2/HER3-targeted therapies, which can be overcome b" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="h an HRG antagonist such as MM-111. Second, constitutive activating mutations in PIK3CA and " exact="KRAS" post=" can drive resistance to dual HER2/HER3-targeted therapies, which can be overcome by switching the " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="gely unfeasible. Consider that the Cancer Cell Line Encyclopedia (CCLE) annotates 57 cell lines as " exact="ERBB2" post="-amplified (copy number ≥ 4N). 44 Molecular information available on these cells inc" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="on of the specific drug combinations, and the genetically defined cell lines to test the effect of " exact="PIK3CA" post=" and KRAS mutations on drug combination response patterns. " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre=" drug combinations, and the genetically defined cell lines to test the effect of PIK3CA and " exact="KRAS" post=" mutations on drug combination response patterns. " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="itional assays may be run on the tissue sample, including an assessment for mutations in the genes " exact="PIK3CA" post=" and KRAS (or other pathway activating mutations such as in PTEN or BRAF), and" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre=" be run on the tissue sample, including an assessment for mutations in the genes PIK3CA and " exact="KRAS" post=" (or other pathway activating mutations such as in PTEN or BRAF), and expression of H" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="tions in the genes PIK3CA and KRAS (or other pathway activating mutations such as in " exact="PTEN" post=" or BRAF), and expression of HRG (either protein via immunohistochemistry, or the surrogate " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="nes PIK3CA and KRAS (or other pathway activating mutations such as in PTEN or " exact="BRAF" post="), and expression of HRG (either protein via immunohistochemistry, or the surrogate mRNA transcript" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre=", and expression of HRG (either protein via immunohistochemistry, or the surrogate mRNA transcript " exact="NRG1" post=" via quantitative reverse-transcription polymerase chain reaction (qRT-PCR) or in situ-hybri" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="omic profiling is becoming an increasingly routine part of clinical practice 45 and " exact="NRG1" post=" transcript expression can be quantified from tumor biopsies, 46 measurement of the " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="sho-AKT and -ERK, the relative balance determined by empirical weighting parameters w " exact="AKT" post=" and w ERK . PI3K pathway dependence was thus simulated by setting" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e determined by empirical weighting parameters w AKT and w " exact="ERK" post=" . PI3K pathway dependence was thus simulated by setting w AKT  = 0" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" ERK . PI3K pathway dependence was thus simulated by setting w " exact="AKT" post="  = 0.95 and w ERK  = 0.05, and conversely for MAPK pathway depende" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ependence was thus simulated by setting w AKT  = 0.95 and w " exact="ERK" post="  = 0.05, and conversely for MAPK pathway dependence. Tumor heterogeneity was simulated via M" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="✓Activating mutations in the PI3K and MAPK signaling pathways ( " exact="PIK3CA" post=" and KRAS genes), combined with expression of the HER3-ligand Heregulin determine sensitivit" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[2]/div[1]/div[4]/ul[1]/li[1]/p[1]" name="human"/>
   <result pre="✓Activating mutations in the PI3K and MAPK signaling pathways ( PIK3CA and " exact="KRAS" post=" genes), combined with expression of the HER3-ligand Heregulin determine sensitivity of HER2+ cance" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4396883/results/gene/human/results.xml">
   <result pre="Genetic amplification of " exact="HER2" post=" drives tumorigenesis and cancer progression in a subset of patients with gastric cancer (GC), and " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="pecimens from Chinese GC patients. Whole genome sequencing was performed on the three samples with " exact="HER2" post=" fusion to discover the DNA integration structure. A multicolor FISH assay for HER2 split sc" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="les with HER2 fusion to discover the DNA integration structure. A multicolor FISH assay for " exact="HER2" post=" split screening was conducted to confirm HER2 fusion and IHC (HercepTest™) was used to dete" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ration structure. A multicolor FISH assay for HER2 split screening was conducted to confirm " exact="HER2" post=" fusion and IHC (HercepTest™) was used to detect the membranous expression of HER2. Fusion c" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="o confirm HER2 fusion and IHC (HercepTest™) was used to detect the membranous expression of " exact="HER2" post=". Fusion cDNA were transfected into NIH/3T3 cells and generate stable cell line by lentivirus. The " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="fected into NIH/3T3 cells and generate stable cell line by lentivirus. The expression of exogenous " exact="HER2" post=" fusion proteins and pHER2 were examined by western blot analysis. In vitro efficacy " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="es were also conducted by PD assay and softagar assay in cell line expression wild type and fusion " exact="HER2" post=". T-DM1 was used to assess its binding to NIH/ 3T3 cells ectopically expressing wild-type an" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=". Finally, the anti-tumor efficacy of trastuzumab was tested in NIH/3 T3 xenografts expressing the " exact="HER2" post=" fusion variants. " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="We identified three new " exact="HER2" post=" fusions with ZNF207, MDK, or NOS2 in 21 HER2-amplified GC samples (14%" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="We identified three new HER2 fusions with " exact="ZNF207" post=", MDK, or NOS2 in 21 HER2-amplified GC samples (14%; 3/21). Two of the fusions" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="We identified three new HER2 fusions with ZNF207, " exact="MDK" post=", or NOS2 in 21 HER2-amplified GC samples (14%; 3/21). Two of the fusions, ZNF207-" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="We identified three new HER2 fusions with ZNF207, MDK, or " exact="NOS2" post=" in 21 HER2-amplified GC samples (14%; 3/21). Two of the fusions, ZNF207-HER2, and &lt;i" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre=" " exact="HER2" post=" gene amplification was initially discovered as an oncogene in breast cancer (BC), which led to the" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="olecular diagnosis for patient selection [ 6- 8]. In addition to BC, " exact="HER2" post=" amplification and overexpression was also found in about 20% of GC patients [ 9]. T" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ucidate molecular insights in HER2-positive GC. In this study, for the first time, we report three " exact="HER2" post=" gene fusions in HER2-positive GC in Chinese patients, and we characterize their oncogenic properti" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="HER2" post=", BRAF, KRAS, and PIK3CA gene mutations from the RNAseq data were analyzed usi" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HER2, " exact="BRAF" post=", KRAS, and PIK3CA gene mutations from the RNAseq data were analyzed using ArrayStudi" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre=" HER2, BRAF, " exact="KRAS" post=", and PIK3CA gene mutations from the RNAseq data were analyzed using ArrayStudio software ( " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre=" HER2, BRAF, KRAS, and " exact="PIK3CA" post=" gene mutations from the RNAseq data were analyzed using ArrayStudio software ( &lt;a href=&quot;http://www" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="The primary antibodies used to detect the cytoplasmic domain of " exact="HER2" post=" were purchased from Merck and Abcam, and the antibody used to detect the external domain of HER2 w" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="A multicolor FISH assay for " exact="HER2" post=" split screening was conducted via a dual-probe FISH break-apart test. The N-terminal and C-termina" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ing was conducted via a dual-probe FISH break-apart test. The N-terminal and C-terminal probes for " exact="HER2" post=" were generated internally by directly labeling BAC (N-terminal: RP11-98 J2; C-terminal: RP11-1044P" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Cat #32-131017) for the centromeric region of chromosome 17 was used as an internal control of the " exact="HER2" post=" break-apart probes. Multicolor FISH was also used to confirm HER2 gene fusion with certain " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n internal control of the HER2 break-apart probes. Multicolor FISH was also used to confirm " exact="HER2" post=" gene fusion with certain partner genes. The ZNF207 and NOS2 FISH probes were generat" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=". Multicolor FISH was also used to confirm HER2 gene fusion with certain partner genes. The " exact="ZNF207" post=" and NOS2 FISH probes were generated internally by directly labeling BAC ( ZNF207: RP" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="was also used to confirm HER2 gene fusion with certain partner genes. The ZNF207 and " exact="NOS2" post=" FISH probes were generated internally by directly labeling BAC ( ZNF207: RP11-55 J8; NOS" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="The ZNF207 and NOS2 FISH probes were generated internally by directly labeling BAC ( " exact="ZNF207" post=": RP11-55 J8; NOS2: RP11-696H14) DNA with gold 525-dUTP (ENZO, Cat #ENZ42843). The FISH assa" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="S2 FISH probes were generated internally by directly labeling BAC ( ZNF207: RP11-55 J8; " exact="NOS2" post=": RP11-696H14) DNA with gold 525-dUTP (ENZO, Cat #ENZ42843). The FISH assays were performed as prev" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="In the break-apart assay, fused N-terminal (green) and C-terminal (red) signals represent a normal " exact="HER2" post=" gene. HER2 amplification status was defined as a ratio of fused HER2 signals to CEP1" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" assay, fused N-terminal (green) and C-terminal (red) signals represent a normal HER2 gene. " exact="HER2" post=" amplification status was defined as a ratio of fused HER2 signals to CEP17 (aqua) ≥2. The f" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="resent a normal HER2 gene. HER2 amplification status was defined as a ratio of fused " exact="HER2" post=" signals to CEP17 (aqua) ≥2. The following situations indicated the presence of HER2-involve" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="f fused HER2 signals to CEP17 (aqua) ≥2. The following situations indicated the presence of " exact="HER2" post="-involved fusion: 1) broken apart: more than one set of broken-apart N-terminal and C-terminal sign" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ed and/or broken-apart signals in ≥30% tumor cells. Then, a multicolor FISH assay was performed on " exact="HER2" post=" broken apart or N-terminal-deleted positive cases. The HER2 fusion was confirmed when HE" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lor FISH assay was performed on HER2 broken apart or N-terminal-deleted positive cases. The " exact="HER2" post=" fusion was confirmed when HER2 C-terminal red signals co-localized with a certain partner g" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="2 broken apart or N-terminal-deleted positive cases. The HER2 fusion was confirmed when " exact="HER2" post=" C-terminal red signals co-localized with a certain partner gene’s gold signals. " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="quently followed by RT-PCR/Sanger sequencing confirmation. This led to the identification of three " exact="HER2" post=" (chr17q12) in-frame fusion transcripts with 5’ partners of ZNF207 (chr17q11.2), MDK " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="the identification of three HER2 (chr17q12) in-frame fusion transcripts with 5’ partners of " exact="ZNF207" post=" (chr17q11.2), MDK (chr11p11.2), or NOS2 (chr17q11.2) in three HER2-positive GC sampl" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="HER2 (chr17q12) in-frame fusion transcripts with 5’ partners of ZNF207 (chr17q11.2), " exact="MDK" post=" (chr11p11.2), or NOS2 (chr17q11.2) in three HER2-positive GC samples of GC196, 431-9540474 " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ame fusion transcripts with 5’ partners of ZNF207 (chr17q11.2), MDK (chr11p11.2), or " exact="NOS2" post=" (chr17q11.2) in three HER2-positive GC samples of GC196, 431-9540474 T, and GC334, respectively (F" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre=" A summary of patients with gastric cancer harboring " exact="HER2" post=" fusions " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="*The amplification of MDK-HER2 was determined by aCGH, whereas the other two " exact="HER2" post=" fusion amplifications were defined by FISH and IHC assays. " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="were analyzed by whole genome sequencing. Consistent with the data from the RNAseq analysis, three " exact="HER2" post=" fusion genes— ZNF207 (exon 1–2)/ HER2 (exon 18–30), MDK (exon 1–4)/ HER2&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ome sequencing. Consistent with the data from the RNAseq analysis, three HER2 fusion genes— " exact="ZNF207" post=" (exon 1–2)/ HER2 (exon 18–30), MDK (exon 1–4)/ HER2 (exon 11–30), and NOS2" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre=" with the data from the RNAseq analysis, three HER2 fusion genes— ZNF207 (exon 1–2)/ " exact="HER2" post=" (exon 18–30), MDK (exon 1–4)/ HER2 (exon 11–30), and NOS2 (exon 1–2)/ HER2" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Aseq analysis, three HER2 fusion genes— ZNF207 (exon 1–2)/ HER2 (exon 18–30), " exact="MDK" post=" (exon 1–4)/ HER2 (exon 11–30), and NOS2 (exon 1–2)/ HER2 (exon 2–30)—were fur" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="&gt;HER2 fusion genes— ZNF207 (exon 1–2)/ HER2 (exon 18–30), MDK (exon 1–4)/ " exact="HER2" post=" (exon 11–30), and NOS2 (exon 1–2)/ HER2 (exon 2–30)—were further confirmed in these " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="207 (exon 1–2)/ HER2 (exon 18–30), MDK (exon 1–4)/ HER2 (exon 11–30), and " exact="NOS2" post=" (exon 1–2)/ HER2 (exon 2–30)—were further confirmed in these tumor DNA samples (Figure &lt;a h" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ER2 (exon 18–30), MDK (exon 1–4)/ HER2 (exon 11–30), and NOS2 (exon 1–2)/ " exact="HER2" post=" (exon 2–30)—were further confirmed in these tumor DNA samples (Figure 2). These re" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="mor DNA samples (Figure 2). These results demonstrate the existence of three novel " exact="HER2" post=" gene fusions in this cohort of HER2-positiv GC patients. " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="In the GC196 sample, over 100 reads were detected for " exact="ZNF207" post=" genomic sequences only composing the 5’ partner and HER2 sequences only composing the 3’ pa" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="over 100 reads were detected for ZNF207 genomic sequences only composing the 5’ partner and " exact="HER2" post=" sequences only composing the 3’ partner of the ZNF207-HER2 fusion; low reads (~20) were cap" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e detected, an average of 500 reads was also captured for the entire genomic sequence of wild-type " exact="HER2" post=" gene. " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="1359, and GC334 FPKM 2805). In the tumor harboring ZNF207-HER2, the increased expression of " exact="HER2" post=" mRNA was observed only after the fusion site, whereas the increased expression of ZNF207 mR" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n of HER2 mRNA was observed only after the fusion site, whereas the increased expression of " exact="ZNF207" post=" mRNA was detected only before the fusion site, further confirming that the amplification of the &lt;i" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ing MDK-HER2, overexpressed transcripts were detected for MDK-HER2 fusion, wild-type " exact="HER2" post=", and wild-type MDK, consistent with the heterogeneity populations of amplified wild-type &lt;i" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="pressed transcripts were detected for MDK-HER2 fusion, wild-type HER2, and wild-type " exact="MDK" post=", consistent with the heterogeneity populations of amplified wild-type HER2 with MDK-HER2" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="i&gt;, and wild-type MDK, consistent with the heterogeneity populations of amplified wild-type " exact="HER2" post=" with MDK-HER2 (Figure 3B). A similar observation was made in the GC334 samp" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ation was made in the GC334 sample, in which overexpression of both NOS2-HER2 and wild-type " exact="HER2" post=" were detected (Figure 3C). " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" mRNA expression levels of HER2 and fusion partners. A. DNA coverage and mRNA expression levels of " exact="HER2" post=" and ZNF207 in sample GC196. B. DNA coverage and mRNA expression levels of HER2 and &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" levels of HER2 and fusion partners. A. DNA coverage and mRNA expression levels of HER2 and " exact="ZNF207" post=" in sample GC196. B. DNA coverage and mRNA expression levels of HER2 and MDK in sampl" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ls of HER2 and ZNF207 in sample GC196. B. DNA coverage and mRNA expression levels of " exact="HER2" post=" and MDK in sample 431-9540474 T C. DNA coverage and mRNA expression levels of HER2 r" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; and ZNF207 in sample GC196. B. DNA coverage and mRNA expression levels of HER2 and " exact="MDK" post=" in sample 431-9540474 T C. DNA coverage and mRNA expression levels of HER2 region (includin" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="f HER2 and MDK in sample 431-9540474 T C. DNA coverage and mRNA expression levels of " exact="HER2" post=" region (including HER2 and nearby gene STARD3, TCAP, PNMT, PGAP3&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n sample 431-9540474 T C. DNA coverage and mRNA expression levels of HER2 region (including " exact="HER2" post=" and nearby gene STARD3, TCAP, PNMT, PGAP3 and MIEN1) and fusion" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="A coverage and mRNA expression levels of HER2 region (including HER2 and nearby gene " exact="STARD3" post=", TCAP, PNMT, PGAP3 and MIEN1) and fusion partner NOS2 in sample" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="mRNA expression levels of HER2 region (including HER2 and nearby gene STARD3, " exact="TCAP" post=", PNMT, PGAP3 and MIEN1) and fusion partner NOS2 in sample GC334. The D" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="on levels of HER2 region (including HER2 and nearby gene STARD3, TCAP, " exact="PNMT" post=", PGAP3 and MIEN1) and fusion partner NOS2 in sample GC334. The DNA integratio" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="HER2 region (including HER2 and nearby gene STARD3, TCAP, PNMT, " exact="PGAP3" post=" and MIEN1) and fusion partner NOS2 in sample GC334. The DNA integration sites were m" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="n (including HER2 and nearby gene STARD3, TCAP, PNMT, PGAP3 and " exact="MIEN1" post=") and fusion partner NOS2 in sample GC334. The DNA integration sites were marked in green ar" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="by gene STARD3, TCAP, PNMT, PGAP3 and MIEN1) and fusion partner " exact="NOS2" post=" in sample GC334. The DNA integration sites were marked in green arrows and the RNA fusion junction" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="2 and NOS2-HER2 fusion genes, as well as to dissect their relationship to the wild-type " exact="HER2" post=" gene in the GC196 and GC334 samples, respectively. Based on hematoxylin and eosin staining, both p" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="4 samples, respectively. Based on hematoxylin and eosin staining, both primary tumors with the two " exact="HER2" post=" fusions were defined as adenocarcinoma by pathologists (Figure 4A). The multicolor" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="igure 4A). The multicolor FISH assay detected the N-terminal and C-terminal of the " exact="HER2" post=" gene, along with the ZNF207 or NOS2 gene. As shown in Figure 4B, the" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lticolor FISH assay detected the N-terminal and C-terminal of the HER2 gene, along with the " exact="ZNF207" post=" or NOS2 gene. As shown in Figure 4B, the ZNF207-HER2 fusion gene was" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ay detected the N-terminal and C-terminal of the HER2 gene, along with the ZNF207 or " exact="NOS2" post=" gene. As shown in Figure 4B, the ZNF207-HER2 fusion gene was amplified homo" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre=" href=&quot;#Fig4&quot;&gt;4B, the ZNF207-HER2 fusion gene was amplified homogeneously without wild-type " exact="HER2" post=" amplification in the GC196 sample. However, co-amplification of both NOS2-HER2 and wild-typ" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="mplification in the GC196 sample. However, co-amplification of both NOS2-HER2 and wild-type " exact="HER2" post=" were observed in the GC334 specimen, but in separate tumor cell populations (Figure &lt;a href=&quot;#Fig4" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" populations (Figure 4C). The co-localization of 5’ partners and the C-terminus of " exact="HER2" post=" gene by the FISH analysis not only further confirmed the genomic fusions of the involved genes, bu" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="enomic fusions of the involved genes, but also indicated the intratumoral heterogeneity within the " exact="HER2" post="-amplified tumor. For the MDK-HER2 fusion, although a formalin-fixed and paraffin-embedded (" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="cing data suggested a mixture of tumor cell populations harboring gene amplifications of wild-type " exact="HER2" post=", MDK-HER2, and wild-type MDK (Figure 3). " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="populations harboring gene amplifications of wild-type HER2, MDK-HER2, and wild-type " exact="MDK" post=" (Figure 3). " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="on in primary tumor GC196. Representative images of break-apart FISH on GC196 shows normal copy of " exact="HER2" post=" N-terminal (green signals), coexistence of amplified HER2 C-terminal (red signals) and ampl" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ISH on GC196 shows normal copy of HER2 N-terminal (green signals), coexistence of amplified " exact="HER2" post=" C-terminal (red signals) and amplified ZNF207 (gold signals). Red and green signals represe" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="minal (green signals), coexistence of amplified HER2 C-terminal (red signals) and amplified " exact="ZNF207" post=" (gold signals). Red and green signals represent C-terminal (HER2-C-SR) and N-terminal (HER2-N-SG) " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="old signals). Red and green signals represent C-terminal (HER2-C-SR) and N-terminal (HER2-N-SG) of " exact="HER2" post=" gene, respectively; gold signals represent whole length of ZNF207 gene (ZNF207-WL-SGo); aqu" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="d N-terminal (HER2-N-SG) of HER2 gene, respectively; gold signals represent whole length of " exact="ZNF207" post=" gene (ZNF207-WL-SGo); aqua signal represent CEP17 as internal control. Cell nuclei were cou" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="; gold signals represent whole length of ZNF207 gene (ZNF207-WL-SGo); aqua signal represent " exact="CEP17" post=" as internal control. Cell nuclei were counterstained with DAPI. C. NOS2-HER2 gene fusion in" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="GC334 show NOS2-HER2 fusion with heterogeneity. The upper lane showed tumor cells with both " exact="HER2" post=" N-terminal (green signals) and C-terminal (red signals) amplified and normal copy number of NOS" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="R2 N-terminal (green signals) and C-terminal (red signals) amplified and normal copy number of " exact="NOS2" post=" (gold signals). The lower lane showed tumor cells with normal copy of HER2 N-terminal (gree" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="l copy number of NOS2 (gold signals). The lower lane showed tumor cells with normal copy of " exact="HER2" post=" N-terminal (green signals), coexistence of amplified HER2 C-terminal (red signals) and ampl" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="d tumor cells with normal copy of HER2 N-terminal (green signals), coexistence of amplified " exact="HER2" post=" C-terminal (red signals) and amplified NOS2 (gold signals). Red and green signals represent" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="minal (green signals), coexistence of amplified HER2 C-terminal (red signals) and amplified " exact="NOS2" post=" (gold signals). Red and green signals represent C-terminal and N-terminal of HER2 gene; gol" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="amplified NOS2 (gold signals). Red and green signals represent C-terminal and N-terminal of " exact="HER2" post=" gene; gold signals represent NOS2 gene; aqua signal represent CEP17 as internal cont" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" and green signals represent C-terminal and N-terminal of HER2 gene; gold signals represent " exact="NOS2" post=" gene; aqua signal represent CEP17 as internal control. Cell nuclei were counterstained with" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="and N-terminal of HER2 gene; gold signals represent NOS2 gene; aqua signal represent " exact="CEP17" post=" as internal control. Cell nuclei were counterstained with DAPI. D. IHC analysis of HER2. Represent" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" A summary of the " exact="HER2" post=" fusion status " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Together, these data demonstrate the gene amplification of the " exact="HER2" post=" fusions, which correlated with dis-regulation of both mRNA and protein expressions of the fusion v" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" variants. In addition, the HercepTest™ did not distinguish the fusion proteins from the wild-type " exact="HER2" post=". " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ve been reported recently in GC cases [ 8]. Thus, we aimed to determine whether the " exact="HER2" post=" fusions overlapped with the known oncogenic alterations. RNAseq and WGS data showed that the three" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="NAseq and WGS data showed that the three HER2-fusion-positive GC patients were negative for " exact="HER3" post=", BRAF, KRAS, PI3KCA, and HER2 mutations, and negative for amplificatio" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" data showed that the three HER2-fusion-positive GC patients were negative for HER3, " exact="BRAF" post=", KRAS, PI3KCA, and HER2 mutations, and negative for amplifications of FGFR" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="that the three HER2-fusion-positive GC patients were negative for HER3, BRAF, " exact="KRAS" post=", PI3KCA, and HER2 mutations, and negative for amplifications of FGFR2 and c &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="e HER2-fusion-positive GC patients were negative for HER3, BRAF, KRAS, " exact="PI3KCA" post=", and HER2 mutations, and negative for amplifications of FGFR2 and c MET (data no " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n-positive GC patients were negative for HER3, BRAF, KRAS, PI3KCA, and " exact="HER2" post=" mutations, and negative for amplifications of FGFR2 and c MET (data no shown), which" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="RAF, KRAS, PI3KCA, and HER2 mutations, and negative for amplifications of " exact="FGFR2" post=" and c MET (data no shown), which are common genetic alterations identified in GC [ &lt;a href=" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ommon genetic alterations identified in GC [ 18]. The mutually exclusive nature of " exact="HER2" post=" fusions from these known oncogenic alterations suggests that the HER2 fusions are oncogenic" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="y exclusive nature of HER2 fusions from these known oncogenic alterations suggests that the " exact="HER2" post=" fusions are oncogenic drivers. In addition, sequence analysis revealed that proteins encoded by &lt;i" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" would be a full-length HER2 protein as result of a stop codon that is introduced prior to the " exact="HER2" post=" start codon (Additional file 1: File S3). Based on the sequence predication that" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" href=&quot;#Fig5&quot;&gt;5A). This result indicates an aberrant activation of HER2 kinase by the fusions with " exact="MDK" post=" or ZNF207. Downstream-signaling AKT was also phosphorylated by the fusion variants (Figure " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="5A). This result indicates an aberrant activation of HER2 kinase by the fusions with MDK or " exact="ZNF207" post=". Downstream-signaling AKT was also phosphorylated by the fusion variants (Figure 5" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ssed by Lapatinib (Figure 5A), thus predicting the sensitivity of GC harboring the " exact="HER2" post=" fusions to the HER2 kinase inhibitor, such as Lapatinib. " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="2 and MDK-HER2 fusions. A. Modulation of HER2 signaling in NIH/3 T3 cells expressing " exact="HER2" post=" fusions. Cell lysates collected from cells stably expressing HER2 and HER2 fusions w" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="NIH/3 T3 cells expressing HER2 fusions. Cell lysates collected from cells stably expressing " exact="HER2" post=" and HER2 fusions were subjected to western blotting analysis with antibodies against phosph" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="xpressing HER2 fusions. Cell lysates collected from cells stably expressing HER2 and " exact="HER2" post=" fusions were subjected to western blotting analysis with antibodies against phospho and total HER2" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="pe (×150) under identical conditions. C. Anchorage-independent growth of NIH/3 T3 cells expressing " exact="HER2" post=" fusions. Cells were seeded in soft agar culture in 96-well plates for 14 days and colony formation" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="th of the cells in vitro, which was comparable to the oncogenic phenotypes caused by mutant " exact="KRAS" post=" (V12D) (Figure 5C). Together, these results demonstrate the oncogenic properties o" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ng capabilities of the HER2 fusions to T-DM1 predict different responsiveness of GC cells with the " exact="HER2" post=" fusions to trastuzumab-based anti-HER2 therapies. T-DM1 was effective in inhibiting the growth of " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" Response of NIH/3T3 cells expressing " exact="HER2" post=" fusions to T-DM1 and trastuzumab. A. Response of NIH/3 T3 cells expressing HER2 fusions to" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="xpressing HER2 fusions to T-DM1 and trastuzumab. A. Response of NIH/3 T3 cells expressing " exact="HER2" post=" fusions to T-DM1. Cells were treated with T-DM1 at indicated concentrations for 72 hrs and cell pr" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="unknown genetic alterations have been reported [ 22], including genetic fusions of " exact="HER2" post=" in human GC cell lines. For example, two HER2 fusions were identified at the same time in h" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ref=&quot;#CR22&quot;&gt;22], including genetic fusions of HER2 in human GC cell lines. For example, two " exact="HER2" post=" fusions were identified at the same time in human GC cell line MKN7 (HER2 positive): a fusion betw" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ions were identified at the same time in human GC cell line MKN7 (HER2 positive): a fusion between " exact="CDK12" post=" exon 12 and HER2 intron 4, and a second fusion between NEUROD2 exon 1 and HER2&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="he same time in human GC cell line MKN7 (HER2 positive): a fusion between CDK12 exon 12 and " exact="HER2" post=" intron 4, and a second fusion between NEUROD2 exon 1 and HER2 exon 8 [ &lt;a href=&quot;#CR2" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tive): a fusion between CDK12 exon 12 and HER2 intron 4, and a second fusion between " exact="NEUROD2" post=" exon 1 and HER2 exon 8 [ 22]. However, there was no direct evidence in that" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="&gt;CDK12 exon 12 and HER2 intron 4, and a second fusion between NEUROD2 exon 1 and " exact="HER2" post=" exon 8 [ 22]. However, there was no direct evidence in that report that demonstrat" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="wever, there was no direct evidence in that report that demonstrated the oncogenic driver of these " exact="HER2" post=" fusions. In the current study, we performed a whole-transcriptome sequencing of 21 HER2-positive G" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" sequencing of 21 HER2-positive GC tumor samples taken from Chinese patients, and discovered three " exact="HER2" post=" fusion transcripts due to HER2 gene fusions. Two of them, ZNF207-HER2 and MDK-HER2 were tru" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="or samples taken from Chinese patients, and discovered three HER2 fusion transcripts due to " exact="HER2" post=" gene fusions. Two of them, ZNF207-HER2 and MDK-HER2 were truncated in the N-terminal extracellular" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="in the kinase and transmembrane domains of HER2. The amplification and overexpression of the three " exact="HER2" post=" gene fusions were detected in the primary GC samples by multicolor FISH and RNAseq or IHC-based He" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="of ZNF207-HER2 and MDK-HER2 in the NIH/3T3 cells led to a constitutive activation of " exact="HER2" post=" and downstream signaling, and thus, cell transformation in vitro and tumorigenesis in vi" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt;MDK-HER2 but not ZNF207-HER2 were sensitive to trastuzumab . Interestingly, the " exact="HER2" post=" fusions were found to be mutually exclusive with mutations of PI3KCA, BRAF, KRAS&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=". Interestingly, the HER2 fusions were found to be mutually exclusive with mutations of " exact="PI3KCA" post=", BRAF, KRAS, and HER3 and amplifications of FGFR2 and c-MET. Co" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ngly, the HER2 fusions were found to be mutually exclusive with mutations of PI3KCA, " exact="BRAF" post=", KRAS, and HER3 and amplifications of FGFR2 and c-MET. Collectively, o" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="HER2 fusions were found to be mutually exclusive with mutations of PI3KCA, BRAF, " exact="KRAS" post=", and HER3 and amplifications of FGFR2 and c-MET. Collectively, our data confi" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="were found to be mutually exclusive with mutations of PI3KCA, BRAF, KRAS, and " exact="HER3" post=" and amplifications of FGFR2 and c-MET. Collectively, our data confirmed for the firs" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e with mutations of PI3KCA, BRAF, KRAS, and HER3 and amplifications of " exact="FGFR2" post=" and c-MET. Collectively, our data confirmed for the first time the presence of oncogenic &lt;i" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="i&gt; and c-MET. Collectively, our data confirmed for the first time the presence of oncogenic " exact="HER2" post=" arrangements in patients with GC. The ZNF207-HER2 fusion represents a novel intrinsic resis" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Despite the overall survival benefit achieved with trastuzumab in GC patients carrying " exact="HER2" post=" amplification, a significant portion of the patients do not respond clinically to the treatment, a" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nce. In contrast, the understanding of the mechanisms of both intrinsic and acquired resistance to " exact="HER2" post=" inhibitors in HER2-positive BC is far more advanced [ 15, 23]. For" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nding region [ 24, 25]; a splice variant that eliminates exon 16 ( " exact="HER2" post="-Δ16) in the extracellular domain of the HER2 receptor, preventing disruption of HER2 homodimers up" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="binding by trastuzumab [ 26]; In our study, we did not assess p95, but we did find " exact="HER2" post="-Δ16 in a GC tumor sample, which naturally harbored HER2-Δ16. Surprisingly, its correspondin" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="did not assess p95, but we did find HER2-Δ16 in a GC tumor sample, which naturally harbored " exact="HER2" post="-Δ16. Surprisingly, its corresponding patient-derived gastric cancer xenograft (PDGCX), which retai" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="6. Surprisingly, its corresponding patient-derived gastric cancer xenograft (PDGCX), which retains " exact="HER2" post="-Δ16 (data not shown), responded well to trastuzumab treatment, with a significant tumor regression" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ession being observed (data not shown). Given the lack of clinical evidence of association between " exact="HER2" post="-Δ16 and resistance to trastuzumab in BC, as well as the lack of preclinical data on the anti-tumor" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="l as the lack of preclinical data on the anti-tumor efficacy of trastuzumab in xenografts carrying " exact="HER2" post="-Δ16 [ 26], our data suggest that HER2-Δ16 was not a resistance mechanism to" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="of trastuzumab in xenografts carrying HER2-Δ16 [ 26], our data suggest that " exact="HER2" post="-Δ16 was not a resistance mechanism to trastuzumab in GC when tested in the PDGCX model. Additional" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Δ16 was not a resistance mechanism to trastuzumab in GC when tested in the PDGCX model. Additional " exact="HER2" post="-Δ16 positive PDGCX models are warranted to confirm this observation further. " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Surprisingly, in addition to the " exact="HER2" post=" fusions, we also found two recurrent in-frame BRAF fusion transcripts, BAIAP2L1-BRAF" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Surprisingly, in addition to the HER2 fusions, we also found two recurrent in-frame " exact="BRAF" post=" fusion transcripts, BAIAP2L1-BRAF (data not shown), in another cohort of HER2-amplif" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="-frame BRAF fusion transcripts, BAIAP2L1-BRAF (data not shown), in another cohort of " exact="HER2" post="-amplified GC patients. Although further work is needed to demonstrate its oncogenic activity and s" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ity or an IHC (HercepTest™) score of 3+ (HercepTest™ score of 2+ needs further FISH confirmation). " exact="HER2" post=" gene amplification is determined by the ratio between the numbers of signals from the hybridizatio" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lification is determined by the ratio between the numbers of signals from the hybridization of the " exact="HER2" post=" gene probe (covers the whole HER2 gene) and the number of signals from the hybridization of" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ween the numbers of signals from the hybridization of the HER2 gene probe (covers the whole " exact="HER2" post=" gene) and the number of signals from the hybridization of the reference chromosome 17 centromere p" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="gnizes the HER2 epitope located at the HER2 intracellular site, which is also covered by all three " exact="HER2" post=" fusions (Figure 1A). Therefore, the current HER2 tests cannot distinguish between " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="HER2 fusions and that of the wild-type. The use of multicolor FISH and RT-PCR assays to detect the " exact="HER2" post=" fusions developed in this study demonstrated the feasibility of detecting HER2 fusions as c" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="o detect the HER2 fusions developed in this study demonstrated the feasibility of detecting " exact="HER2" post=" fusions as clinical biomarkers in either FFPE or frozen surgical GC specimens. This finding warran" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="he small-molecule inhibitor against HER2 kinase is a potential option for cancer patients with the " exact="HER2" post=" fusions. This notion is further supported by our observations that NIH/3T3 cells expressing either" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="-dependent probe amplification (MLPA) and FISH analysis and revealed intratumoral heterogeneity of " exact="HER2" post=" amplification in 41% (21/51) of HER2-amplified tumors. The mutually exclusive co-amplificat" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="SH analysis and revealed intratumoral heterogeneity of HER2 amplification in 41% (21/51) of " exact="HER2" post="-amplified tumors. The mutually exclusive co-amplification of HER2 with EGFR, FGFR" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ication in 41% (21/51) of HER2-amplified tumors. The mutually exclusive co-amplification of " exact="HER2" post=" with EGFR, FGFR2, FGFR2 and MET was also observed respectively in some" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="1/51) of HER2-amplified tumors. The mutually exclusive co-amplification of HER2 with " exact="EGFR" post=", FGFR2, FGFR2 and MET was also observed respectively in some of the tumors, s" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ER2-amplified tumors. The mutually exclusive co-amplification of HER2 with EGFR, " exact="FGFR2" post=", FGFR2 and MET was also observed respectively in some of the tumors, suggesting the " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ied tumors. The mutually exclusive co-amplification of HER2 with EGFR, FGFR2, " exact="FGFR2" post=" and MET was also observed respectively in some of the tumors, suggesting the potential chal" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="utually exclusive co-amplification of HER2 with EGFR, FGFR2, FGFR2 and " exact="MET" post=" was also observed respectively in some of the tumors, suggesting the potential challenges for desi" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="ults. However, the advantage of co-amplification of MDK-HER2 and NOS2-HER2 with wild " exact="HER2" post=" (intra-tumor heterogeneity) is yet to be uncovered. Further studies to explore the responsiveness " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="In summary, we uncovered three previously unidentified " exact="HER2" post=" fusion genes in GC patients whose tumors were clinically classified as HER2-positive. Our results " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" patients whose tumors were clinically classified as HER2-positive. Our results suggest that these " exact="HER2" post=" fusions are genetically amplified driver oncogenes that respond differently to the HER2-neutralizi" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ibody trastuzumab. The resistance of ZNF207-HER2 to trastuzumab and the existence of the recurrent " exact="BRAF" post=" fusion variants warrant molecular subtype diagnoses of HER 2-positive GC patients for more " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4405013/results/gene/human/results.xml">
   <result pre="cell adhesion, cell migration, spindle formation, and chromosome segregation [ 28]. " exact=" APC" post=" mutations are the second most frequent mutations in gastric cancer and have been observed in 30–40" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="inal type cancer and in less than 2% of diffuse type cancer [ 29]. The mutations of " exact=" APC" post=" have also been identified in gastric adenoma and intestinal metaplasia, indicating that they occur" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="plastic stage of gastric cancer development. LOH and mutations of phosphatase and tensin homolog ( " exact="PTEN" post=") were observed in gastric cancers as well as in precancerous lesions [ 30]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" name="human"/>
   <result pre="&gt;infection induces aberrant promoter methylation in tumor-suppressor genes, including p16, " exact=" LOX" post=", and CDH1. Furthermore, a number of tumor suppressor genes, including hMLM1, p" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="s aberrant promoter methylation in tumor-suppressor genes, including p16, LOX, and " exact=" CDH1" post=". Furthermore, a number of tumor suppressor genes, including hMLM1, p14, p15&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="urthermore, a number of tumor suppressor genes, including hMLM1, p14, p15, " exact=" GSTP1" post=", RASSF1, COX-2, APC, CDH4, DAP-K, THBS1, TIMP-" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="umber of tumor suppressor genes, including hMLM1, p14, p15, GSTP1, " exact=" RASSF1" post=", COX-2, APC, CDH4, DAP-K, THBS1, TIMP-3, RARβ&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=", including hMLM1, p14, p15, GSTP1, RASSF1, COX-2, " exact=" APC" post=", CDH4, DAP-K, THBS1, TIMP-3, RARβ, MGMT, CHFR&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt; hMLM1, p14, p15, GSTP1, RASSF1, COX-2, APC, " exact=" CDH4" post=", DAP-K, THBS1, TIMP-3, RARβ, MGMT, CHFR, DCC&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; p15, GSTP1, RASSF1, COX-2, APC, CDH4, DAP-K, " exact=" THBS1" post=", TIMP-3, RARβ, MGMT, CHFR, DCC, RUNX3, and TSL" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" COX-2, APC, CDH4, DAP-K, THBS1, TIMP-3, RARβ, " exact=" MGMT" post=", CHFR, DCC, RUNX3, and TSLC1, are known to be silenced by hypermet" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; APC, CDH4, DAP-K, THBS1, TIMP-3, RARβ, MGMT, " exact=" CHFR" post=", DCC, RUNX3, and TSLC1, are known to be silenced by hypermethylation in ga" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CDH4, DAP-K, THBS1, TIMP-3, RARβ, MGMT, CHFR, " exact=" DCC" post=", RUNX3, and TSLC1, are known to be silenced by hypermethylation in gastric cancer " xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; DAP-K, THBS1, TIMP-3, RARβ, MGMT, CHFR, DCC, " exact=" RUNX3" post=", and TSLC1, are known to be silenced by hypermethylation in gastric cancer [ &lt;a href=&quot;#B31" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="BS1, TIMP-3, RARβ, MGMT, CHFR, DCC, RUNX3, and " exact=" TSLC1" post=", are known to be silenced by hypermethylation in gastric cancer [ 31] ( &lt;a href=&quot;#f" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4407294/results/gene/human/results.xml">
   <result pre="orm provides quantitative values for proliferation, luminal gene expression, estrogen receptor 1 ( " exact="ESR1" post="), progesterone receptor gene ( PGR), and HER2. Moreover, on the same tissue used for" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="eration, luminal gene expression, estrogen receptor 1 ( ESR1), progesterone receptor gene ( " exact="PGR" post="), and HER2. Moreover, on the same tissue used for MammaPrint, the BluePrint test can be per" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="gene expression, estrogen receptor 1 ( ESR1), progesterone receptor gene ( PGR), and " exact="HER2" post=". Moreover, on the same tissue used for MammaPrint, the BluePrint test can be performed. BluePrint " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="comes. The principal characteristic of this group is the luminal expression signature, composed of " exact="ESR1" post=", GATA3, FOXA1, XBP1, and cMYB. The most frequent mutations in the lumi" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="incipal characteristic of this group is the luminal expression signature, composed of ESR1, " exact="GATA3" post=", FOXA1, XBP1, and cMYB. The most frequent mutations in the luminal A subtype " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="teristic of this group is the luminal expression signature, composed of ESR1, GATA3, " exact="FOXA1" post=", XBP1, and cMYB. The most frequent mutations in the luminal A subtype are PIK3CA&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="is group is the luminal expression signature, composed of ESR1, GATA3, FOXA1, " exact="XBP1" post=", and cMYB. The most frequent mutations in the luminal A subtype are PIK3CA (45%), &lt;i" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="&gt;FOXA1, XBP1, and cMYB. The most frequent mutations in the luminal A subtype are " exact="PIK3CA" post=" (45%), MAP3K1 and GATA3 (13% each), TP53 (12%), and CDH1 (9%). The mos" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="i&gt;, and cMYB. The most frequent mutations in the luminal A subtype are PIK3CA (45%), " exact="MAP3K1" post=" and GATA3 (13% each), TP53 (12%), and CDH1 (9%). The most frequent mutations " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="&gt;. The most frequent mutations in the luminal A subtype are PIK3CA (45%), MAP3K1 and " exact="GATA3" post=" (13% each), TP53 (12%), and CDH1 (9%). The most frequent mutations in luminal B tumo" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="tions in the luminal A subtype are PIK3CA (45%), MAP3K1 and GATA3 (13% each), " exact="TP53" post=" (12%), and CDH1 (9%). The most frequent mutations in luminal B tumors are TP53 and &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="subtype are PIK3CA (45%), MAP3K1 and GATA3 (13% each), TP53 (12%), and " exact="CDH1" post=" (9%). The most frequent mutations in luminal B tumors are TP53 and PIK3CA (29% each)" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="ach), TP53 (12%), and CDH1 (9%). The most frequent mutations in luminal B tumors are " exact="TP53" post=" and PIK3CA (29% each), GATA3 (13%), and TTN (12%) gene mutations (Table &lt;a hr" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="&gt; (12%), and CDH1 (9%). The most frequent mutations in luminal B tumors are TP53 and " exact="PIK3CA" post=" (29% each), GATA3 (13%), and TTN (12%) gene mutations (Table 3) [ &lt;a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="9%). The most frequent mutations in luminal B tumors are TP53 and PIK3CA (29% each), " exact="GATA3" post=" (13%), and TTN (12%) gene mutations (Table 3) [ 17, &lt;a href" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="utations in luminal B tumors are TP53 and PIK3CA (29% each), GATA3 (13%), and " exact="TTN" post=" (12%) gene mutations (Table 3) [ 17, 18]. In addit" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="gene mutations (Table 3) [ 17, 18]. In addition to " exact="TP53" post=" mutations, frequently within luminal B subtypes, several other events may intervene in other steps" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="minal B subtypes, several other events may intervene in other steps of the same pathway, including " exact="ATM" post=" loss and MDM2 amplification. Table 3 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="veral other events may intervene in other steps of the same pathway, including ATM loss and " exact="MDM2" post=" amplification. Table 3 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="for endocrine resistance have been described, including the amplification or overexpression of the " exact="HER2" post=" proto-oncogene and the hyperactivation of the PI3K/AKT/mTOR pathway [ 19]. The mos" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="mplifications in the PI3K/AKT/mTOR pathway affect the genes encoding the PI3K catalytic subunits ( " exact="PIK3CA" post=", PIK3CB), PI3K regulatory subunit ( PIK3R1), receptor tyrosine kinases ( HER2, FG" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="n the PI3K/AKT/mTOR pathway affect the genes encoding the PI3K catalytic subunits ( PIK3CA, " exact="PIK3CB" post="), PI3K regulatory subunit ( PIK3R1), receptor tyrosine kinases ( HER2, FGFR1), K-Ras" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="es encoding the PI3K catalytic subunits ( PIK3CA, PIK3CB), PI3K regulatory subunit ( " exact="PIK3R1" post="), receptor tyrosine kinases ( HER2, FGFR1), K-Ras, PI3K effectors ( AKT1, AKT2, PDK1" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="osine kinases ( HER2, FGFR1), K-Ras, PI3K effectors ( AKT1, AKT2, PDK1), and loss of " exact="PTEN" post=" and INPP4B [ 20]. The activation of this parallel pathway may provide alter" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="HER2, FGFR1), K-Ras, PI3K effectors ( AKT1, AKT2, PDK1), and loss of PTEN and " exact="INPP4B" post=" [ 20]. The activation of this parallel pathway may provide alternative proliferati" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="tor status. In particular, ER positivity is linked to the methylation of specific genes, including " exact="RASSF1A" post=", CCND2, GSTP1, and TWIST. Vesuna and colleagues [ 25] reporte" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="articular, ER positivity is linked to the methylation of specific genes, including RASSF1A, " exact="CCND2" post=", GSTP1, and TWIST. Vesuna and colleagues [ 25] reported that TWIS" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="positivity is linked to the methylation of specific genes, including RASSF1A, CCND2, " exact="GSTP1" post=", and TWIST. Vesuna and colleagues [ 25] reported that TWIST, a gene " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="ed to the methylation of specific genes, including RASSF1A, CCND2, GSTP1, and " exact="TWIST" post=". Vesuna and colleagues [ 25] reported that TWIST, a gene overexpressed in h" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ND2, GSTP1, and TWIST. Vesuna and colleagues [ 25] reported that " exact="TWIST" post=", a gene overexpressed in high-grade BC, promotes downregulation of ER through the recruitment of H" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="DNA amplification of " exact="HER2" post=" gene is considered the main mechanism of HER2 protein overexpression in HER2-positive tumors. This" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="mal growth factor receptor (EGFR), HER2 itself (80%), and genes within the HER2 amplicon (that is, " exact="GRB7" post="). On the other hand, the luminal mRNA subtypes show higher expression of the luminal signature, in" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="e other hand, the luminal mRNA subtypes show higher expression of the luminal signature, including " exact="GATA3" post=", BCL2, and ESR1. In HER2-enriched tumors, the main somatic mutations were TP53&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="the luminal mRNA subtypes show higher expression of the luminal signature, including GATA3, " exact="BCL2" post=", and ESR1. In HER2-enriched tumors, the main somatic mutations were TP53 mutations (" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="subtypes show higher expression of the luminal signature, including GATA3, BCL2, and " exact="ESR1" post=". In HER2-enriched tumors, the main somatic mutations were TP53 mutations (72%) and PIK3C" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="&gt;GATA3, BCL2, and ESR1. In HER2-enriched tumors, the main somatic mutations were " exact="TP53" post=" mutations (72%) and PIK3CA mutations (39%), whereas GATA3 mutations were observed on" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="ESR1. In HER2-enriched tumors, the main somatic mutations were TP53 mutations (72%) and " exact="PIK3CA" post=" mutations (39%), whereas GATA3 mutations were observed only in luminal subtypes [ &lt;a href=&quot;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="main somatic mutations were TP53 mutations (72%) and PIK3CA mutations (39%), whereas " exact="GATA3" post=" mutations were observed only in luminal subtypes [ 17, 20]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre=" " exact="TP53" post=" mutations are the most frequent clonal aberrations in basal-like tumors (80%), but the loss of TP5" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="gh gene mutations or dysfunctions in the TP53 pathway, occurs within almost all basal-like tumors. " exact="TP53" post=" is a tumor-suppressor gene that, after the activation by oncogenic stress signals, promotes either" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="tress signals, promotes either cell cycle arrest and DNA repair or cell apoptosis. The activity of " exact="TP53" post=" is achieved by downstream targets (p21), indirect targets (PTEN), cell cycle regulation proteins (" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="translational modifications and histone acetylation, which applies epigenetic modifications to the " exact="TP53" post=" gene. Mutated TP53 represents a potential target for TNBC treatment but this approach remai" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="s and histone acetylation, which applies epigenetic modifications to the TP53 gene. Mutated " exact="TP53" post=" represents a potential target for TNBC treatment but this approach remains a challenge on several " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="&gt;38]. In addition to loss of TP53, loss of RB1 and BRCA1 functions are common basal-like features. " exact="PIK3CA" post=" is the next most commonly mutated gene (9%). However, interferences in PI3K pathway activity are e" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="rferences in PI3K pathway activity are even more frequent in basal-like tumors and include loss of " exact="PTEN" post=" and INPP4B. Furthermore, in basal-like cancers, many of the elements of the PI3K/AKT/mTOR a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[3]" name="human"/>
   <result pre="K pathway activity are even more frequent in basal-like tumors and include loss of PTEN and " exact="INPP4B" post=". Furthermore, in basal-like cancers, many of the elements of the PI3K/AKT/mTOR and RAS/RAF/MEK/MAP" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4427936/results/gene/human/results.xml">
   <result pre="Legend: cTnT Cardiac Troponin T, " exact="ANP" post=" Atrial Natriuretic Peptide, NT-BNP N-terminal Brain Natriuretic Peptide, ACR, anthac" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="onin T, ANP Atrial Natriuretic Peptide, NT-BNP N-terminal Brain Natriuretic Peptide, " exact="ACR" post=", anthacyclines, LVEF Left ventricular ejection fraction, HF Heart failure, 95 % C" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/div[2]/p[1]" name="human"/>
   <result pre="atriuretic Peptide, NT-BNP N-terminal Brain Natriuretic Peptide, ACR, anthacyclines, " exact="LVEF" post=" Left ventricular ejection fraction, HF Heart failure, 95 % CI 95 % Confidence Interv" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" 95 % Confidence Interval, RR Relative risk, OR, Odds ratio, HR Hazard ratio, " exact="RCT" post=" Randomised controlled trial. " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4440424/results/gene/human/results.xml">
   <result pre="most frequently enhanced oncogenic pathway in breast cancer. Among mechanisms of PI3K enhancement, " exact="PIK3CA" post=" mutations are most frequently (∼30%) observed, along with protein loss of PTEN. Since the first di" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="are most frequently (∼30%) observed, along with protein loss of PTEN. Since the first discovery of " exact="PIK3CA" post=" mutations in solid malignancies in 2004, numerous studies have revealed the prognostic and therape" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="rmed, some have been carved in stone by the level of consistency they have shown among studies: 1) " exact="PIK3CA" post=" mutations are most likely to be observed in ER-positive/HER2-negative tumors, and are associated w" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" in ER-positive/HER2-negative tumors, and are associated with other good prognostic characters; 2) " exact="PIK3CA" post=" mutations can coexist with other PI3K-enhancing mechanisms, such as HER2 amplification and " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="c characters; 2) PIK3CA mutations can coexist with other PI3K-enhancing mechanisms, such as " exact="HER2" post=" amplification and PTEN protein loss; 3) PIK3CA mutations are potentially a good prognostic " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" with other PI3K-enhancing mechanisms, such as HER2 amplification and PTEN protein loss; 3) " exact="PIK3CA" post=" mutations are potentially a good prognostic marker; 4) PIK3CA may predict a poorer tumor re" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ion and PTEN protein loss; 3) PIK3CA mutations are potentially a good prognostic marker; 4) " exact="PIK3CA" post=" may predict a poorer tumor response to trastuzumab-based therapies, but its impact on disease-free" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="free survival and overall survival is uncertain; and 5) based on reports of early clinical trials, " exact="PIK3CA" post=" mutations do not guarantee a dramatic response to PI3K inhibitors. Collectively, there is currentl" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="bitors. Collectively, there is currently no sufficient evidence to recommend routine genotyping of " exact="PIK3CA" post=" in clinical practice. Given that PIK3CA-mutant breast cancer appears to have a distinct tum" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ficient evidence to recommend routine genotyping of PIK3CA in clinical practice. Given that " exact="PIK3CA" post="-mutant breast cancer appears to have a distinct tumor biology, development of more individualized " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" have a distinct tumor biology, development of more individualized targeted therapies based on the " exact="PIK3CA" post=" genotype is awaited. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="sm that potentially enhances the pathway. These PI3K-enhancing mechanisms include mutations of the " exact="PI3K" post=" gene, more specifically PIK3CA gene mutations. First discovered in 2004 in various solid tu" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="hway. These PI3K-enhancing mechanisms include mutations of the PI3K gene, more specifically " exact="PIK3CA" post=" gene mutations. First discovered in 2004 in various solid tumors, including breast cancer, &lt;a href" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" we focus on the many studies that have explored the prognostic value and therapeutic relevance of " exact="PIK3CA" post=" mutations since their discovery. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="lytic domain and p85 regulatory domain. There are three isoforms of p110, namely p110α (encoded by " exact="PIK3CA" post="), p110β, and p110δ. While p110δ is expressed almost exclusively in leukocytes, p110α and p110β are" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="quitously in all types of cells. 4 In humans, PI3K regulatory subunit 1 ( " exact="PIK3R1" post="), PIK3R2, and PIK3R3 code p85α (or its splicing variant p55α or p50α), p85β, and p55" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" types of cells. 4 In humans, PI3K regulatory subunit 1 ( PIK3R1), " exact="PIK3R2" post=", and PIK3R3 code p85α (or its splicing variant p55α or p50α), p85β, and p55γ, respectively." xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" href=&quot;#b4-bctt-7-111&quot;&gt;4 In humans, PI3K regulatory subunit 1 ( PIK3R1), PIK3R2, and " exact="PIK3R3" post=" code p85α (or its splicing variant p55α or p50α), p85β, and p55γ, respectively. &lt;a href=&quot;#b4-bctt-" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Somatic mutations of " exact="PIK3CA" post=" coding p110α in various solid malignancies were first reported in 2004. 3" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="g the most frequently affected cancers (~30%) ( Table 1). The majority of " exact="PIK3CA" post=" somatic mutations are located in two &quot;hot spots&quot;: E542K or E545K in exon 9, and H1047R or H1047L i" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Preceding the discovery of " exact="PIK3CA" post=" mutations, gene amplification of PIK3CA was reported in various malignancies, including app" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Preceding the discovery of PIK3CA mutations, gene amplification of " exact="PIK3CA" post=" was reported in various malignancies, including approximately 10% of cases of breast cancer. &lt;a hr" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ately 10% of cases of breast cancer. 4, 10 Like " exact="PIK3CA" post=" mutations, PIK3CA amplification has been shown to lead to increased PI3K activity. &lt;a href=" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ast cancer. 4, 10 Like PIK3CA mutations, " exact="PIK3CA" post=" amplification has been shown to lead to increased PI3K activity. 11 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="The " exact="PIK3R1" post=" gene product p85α appears to play a tumor-suppressor role by stabilizing p110α. &lt;a href=&quot;#b12-bctt" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ct p85α appears to play a tumor-suppressor role by stabilizing p110α. 12 " exact="PIK3R1" post=" mutations have been found in breast cancer, although with much lower occurrence than PIK3CA" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="PIK3R1 mutations have been found in breast cancer, although with much lower occurrence than " exact="PIK3CA" post=" mutations (~3%). 12, 13 PIK3R1 mutation" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="nce than PIK3CA mutations (~3%). 12, 13 " exact="PIK3R1" post=" mutations are located at the inter-SH2 domain, which is required for connection of p85α to p110α. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ntually leading to PI3K hyperactivation. 5 In contrast with the rarity of " exact="PIK3R1" post=" mutations in breast cancer, reduced PIK3R1 messenger ribonucleic acid (RNA) expression, def" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="#b5-bctt-7-111&quot;&gt;5 In contrast with the rarity of PIK3R1 mutations in breast cancer, reduced " exact="PIK3R1" post=" messenger ribonucleic acid (RNA) expression, defined as &amp;amp;lt;0.5-fold of normal breast tissue, " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" activated by being connected with RTK directly or indirectly via adaptor proteins. Gene-amplified " exact="HER2" post=" is the best-characterized RTK with regard to breast cancer tumorigenesis. While HER2 can theoretic" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="PI3K complex and subsequent PI3K–AKT signaling pathway play central roles in cell proliferation in " exact="HER2" post="-amplified cells. 20, 21 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="AKT1" post=" mutations (E17K) have been found in 1.4%–8% of breast cancers. 12, &lt;a hr" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=", a large-scale genotyping effort (547 breast tumor and 41 breast cancer cell lines) revealed that " exact="AKT1" post=" mutations were exclusively observed in tumors expressing both ER and PgR. &lt;a href=&quot;#b23-bctt-7-111" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="they provide the same selective pressure for clonal expansion. As an example, somatic mutations of " exact="EGFR" post=" and K-RAS and ALK rearrangements have been consistently shown to be mutually exclusi" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ressure for clonal expansion. As an example, somatic mutations of EGFR and K-RAS and " exact="ALK" post=" rearrangements have been consistently shown to be mutually exclusive in lung adenocarcinoma. &lt;a hr" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="usive in lung adenocarcinoma. 25 As shown later in this review, however, " exact="PIK3CA" post=" mutations and HER2 amplification often coexist. An early study demonstrated that PIK3CA&lt;" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=". 25 As shown later in this review, however, PIK3CA mutations and " exact="HER2" post=" amplification often coexist. An early study demonstrated that PIK3CA mutations and PTEN los" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="PIK3CA mutations and HER2 amplification often coexist. An early study demonstrated that " exact="PIK3CA" post=" mutations and PTEN loss, another PI3K-enhancing change frequently observed in breast cancer, were " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="clusivity of the two molecular changes. 27, 28 " exact="PIK3CA" post=" mutations and gain of copy number of PIK3CA and PTEN loss and PTEN mutations have al" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="27-bctt-7-111&quot;&gt;27, 28 PIK3CA mutations and gain of copy number of " exact="PIK3CA" post=" and PTEN loss and PTEN mutations have also been reported to coexist. &lt;a href=&quot;#b11-bctt-7-1" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="-bctt-7-111&quot;&gt;28 PIK3CA mutations and gain of copy number of PIK3CA and PTEN loss and " exact="PTEN" post=" mutations have also been reported to coexist. 11, &lt;a href=&quot;#b23-bctt-7-1" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="#b23-bctt-7-111&quot;&gt;23, 28, 29 On the other hand, " exact="PIK3CA" post=", PTEN, AKT1, and PIK3R1 mutations are reported to be mutually exclusive, alth" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="&quot;&gt;23, 28, 29 On the other hand, PIK3CA, " exact="PTEN" post=", AKT1, and PIK3R1 mutations are reported to be mutually exclusive, although the low " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="=&quot;#b28-bctt-7-111&quot;&gt;28, 29 On the other hand, PIK3CA, PTEN, " exact="AKT1" post=", and PIK3R1 mutations are reported to be mutually exclusive, although the low frequency of " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="&quot;&gt;28, 29 On the other hand, PIK3CA, PTEN, AKT1, and " exact="PIK3R1" post=" mutations are reported to be mutually exclusive, although the low frequency of the latter three li" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="y of the finding. 12, 23 One study showed that " exact="PIK3CA" post=" mutations and reduced PIK3R1 messenger RNA expression are mutually exclusive. &lt;a href=&quot;#b12" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="-7-111&quot;&gt;12, 23 One study showed that PIK3CA mutations and reduced " exact="PIK3R1" post=" messenger RNA expression are mutually exclusive. 12 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="utual exclusivity is maintained between some PI3K-enhancing molecular changes, three major types – " exact="HER2" post=" amplification, PIK3CA mutations, and PTEN loss – appear to coexist, indicating that none of" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ined between some PI3K-enhancing molecular changes, three major types – HER2 amplification, " exact="PIK3CA" post=" mutations, and PTEN loss – appear to coexist, indicating that none of these three mechanisms may b" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Among studies, the correlation of " exact="PIK3CA" post=" mutations with hormone-receptor status has received the most extensive investigation. A meta-analy" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="xtensive investigation. A meta-analysis involving 26 studies found significant association between " exact="PIK3CA" post=" mutations and ER and PgR expressions (for ER, odds ratio [OR] 1.92, 95% confidence interval [CI] 1" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="In terms of HER2 status, an early study showed a positive correlation between " exact="PIK3CA" post=" mutation and HER2 overexpression. 26 However, subsequent studies demonst" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="xpression. 26 However, subsequent studies demonstrated no association of " exact="PIK3CA" post=" with HER2 status, 31, 32 or rather an associat" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Further, some studies found associations of " exact="PIK3CA" post=" mutations with good prognostic features, such as lower histological grade, &lt;a href=&quot;#b33-bctt-7-11" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Overall, it appears safe to say that " exact="PIK3CA" post=" mutations are most likely found in luminal-type (HR-positive/HER2-negative) tumors, in particular " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Hot-spot " exact="PIK3CA" post=" mutations were found to be gain-of-function mutations, and resulted in higher phosphorylation of d" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="higher phosphorylation using tumors obtained from patients. However, results of the correlation of " exact="PIK3CA" post=" mutations and level of phosphorylated AKT (Ser473 or Thr308), the most frequently used biomarker o" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="111&quot;&gt;27, 42, 43 Results of studies correlating " exact="PIK3CA" post=" mutations with phosphorylated mTOR (p-mTOR) expression have also been inconsistent, with positive " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="tein array, which enables more comprehensive protein analysis, failed to show a difference between " exact="PIK3CA" post="-mutant tumors and PIK3CA wild-type tumors in the phosphorylation of AKT, GSK3, mTOR, or p70" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="omprehensive protein analysis, failed to show a difference between PIK3CA-mutant tumors and " exact="PIK3CA" post=" wild-type tumors in the phosphorylation of AKT, GSK3, mTOR, or p70S6K. 2" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Based on these inconsistent results, correlation between " exact="PIK3CA" post=" mutations and downstream protein activation must be considered inconclusive, at least in clinical " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Although few studies solely showed prognostic value of " exact="PIK3CA" post=" mutations for recurrence-free survival (RFS) with statistical significance, many of these indicate" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="(RFS) with statistical significance, many of these indicated the tendency for patients with mutant " exact="PIK3CA" post=" to have better RFS ( Table 1). In fact, one meta-analysis involving five " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" href=&quot;#b39-bctt-7-111&quot;&gt;39, 40 demonstrated a significant correlation of " exact="PIK3CA" post=" mutation with better RFS (hazard ratio [HR] 0.76, 95% CI 0.59–0.98; P=0.03). &lt;a href=&quot;#b30-" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="It remains unclear, however, whether " exact="PIK3CA" post=" mutation itself biologically affects tumor character or is just a product of confounding effects b" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="on itself biologically affects tumor character or is just a product of confounding effects between " exact="PIK3CA" post=" mutations and other good prognostic factors, such as ER positivity, HER2 negativity, lower Ki67, a" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="l consequence of the disease, their involvement precludes evaluation of &quot;pure&quot; prognostic value of " exact="PIK3CA" post=" mutations. In fact, a recent study that collected tumor samples from ER-positive postmenopausal pa" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ls comparing adjuvant use of tamoxifen for 1–3 years with observation failed to show any impact of " exact="PIK3CA" post=" mutations on RFS among patients assigned to the observation arm (HR 0.62, 95% CI 0.25–1.59; P&lt;/" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ref=&quot;#t1-bctt-7-111&quot;&gt;Table 1). 38 Similarly, another study that analyzed " exact="PIK3CA" post=" genotype in 342 tumors obtained from nonmetastatic lymph node-negative patients who had not had ad" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="s who had not had adjuvant therapy did not find any difference in metastasis-free survival between " exact="PIK3CA" post="-mutant tumors and wild-type tumors ( Table 1). " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ment, which varies astronomically. As a reference, a meta-analysis of seven studies indicated that " exact="PIK3CA" post=" mutations had no prognostic impact on OS (HR 1.14, 95% CI 0.72–1.82; P=0.57). &lt;a href=&quot;#b30" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Unlike the case for early breast cancer, the prognostic value of " exact="PIK3CA" post=" mutations for advanced cases has not been studied extensively. One study evaluated the prognostic " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="cases has not been studied extensively. One study evaluated the prognostic and predictive value of " exact="PIK3CA" post=" mutations in patients who received paclitaxel alone or in combination with lapatinib in a prospect" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" in a prospective randomized trial setting. 47 This study concluded that " exact="PIK3CA" post=" mutations were an adverse prognostic factor for survival, but were not predictive for lapatinib be" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Although both exon 9 and exon 20 hot-spot " exact="PIK3CA" post=" mutations were initially found to be gain-of-function and transforming mutations, &lt;a href=&quot;#b6-bct" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" whereas patients with exon 20-mutant tumors were associated with better prognosis than those with " exact="PIK3CA" post=" wild-type tumors. 32 Consistently, a recent study found that more exon 9" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="uggested that the HER2/HER3/PI3K complex and subsequent PI3K–AKT signaling pathway was critical in " exact="HER2" post="-amplified cells, and shown that disruption of this complex was a molecular mechanism of action of " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="series of preclinical studies tested this hypothesis by transfecting wild-type and mutant forms of " exact="PIK3CA" post=" in HER2-amplified breast cancer cells. 50, &lt;a href=&quot;#b51-bctt-7-1" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ical studies tested this hypothesis by transfecting wild-type and mutant forms of PIK3CA in " exact="HER2" post="-amplified breast cancer cells. 50, 51 Results " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ancer cells. 50, 51 Results showed that mutant " exact="PIK3CA" post=" transfection resulted in resistance to trastuzumab or lapatinib, a small-molecule HER2 inhibitor. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="tt-7-111&quot;&gt;50, 51 Consistent with these previous studies, our study using " exact="HER2" post="-amplified breast cancer cell lines showed that cell lines with PIK3CA hot-spot mutations we" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tudies, our study using HER2-amplified breast cancer cell lines showed that cell lines with " exact="PIK3CA" post=" hot-spot mutations were significantly more resistant to trastuzumab and CL-387,785, a small-molecu" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="han those without mutations. 52 However, another preclinical study using " exact="HER2" post="-amplified breast cancer cell lines provided different conclusions. It showed that while PIK3CA&lt;" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt;HER2-amplified breast cancer cell lines provided different conclusions. It showed that while " exact="PIK3CA" post=" mutations themselves did not correlate with in vitro resistance to either trastuzumab or lapatinib" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="utations themselves did not correlate with in vitro resistance to either trastuzumab or lapatinib, " exact="PIK3CA" post=" mutations and/or PTEN-low cell lines as a group correlated with trastuzumab resistance, while stil" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="have supported the hypothesis generated by preclinical studies. A retrospective study analyzed the " exact="PIK3CA" post=" genotype in tumor samples from 240 HER2-positive early breast cancer patients who had been treated" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="n an adjuvant trial setting. 45 Results showed that patients with mutant " exact="PIK3CA" post=" had a shorter OS than those with wild-type PIK3CA (multivariate HR for OS 2.14, 95% CI 1.01" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" Results showed that patients with mutant PIK3CA had a shorter OS than those with wild-type " exact="PIK3CA" post=" (multivariate HR for OS 2.14, 95% CI 1.01–4.51; P=0.046), with no difference in DFS. &lt;a hre" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="&gt;=0.046), with no difference in DFS. 45 Similarly, in another study, the " exact="PIK3CA" post=" genotype was analyzed in samples obtained from 80 HER2-positive patients who participated in a Pha" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ed combinations and docetaxel and 1 year’s trastuzumab. Results showed better DFS in patients with " exact="PIK3CA" post=" wild-type tumors than in those with PIK3CA-mutant tumors (HR for DFS 0.23, 95% CI 0.08–0.71" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="umab. Results showed better DFS in patients with PIK3CA wild-type tumors than in those with " exact="PIK3CA" post="-mutant tumors (HR for DFS 0.23, 95% CI 0.08–0.71; P=0.0063). 54 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ized trials that compared trastuzumab with no trastuzumab, which enables better distinction of the " exact="PIK3CA" post=" genotype as a prognostic factor from a predictive factor with regard to trastuzumab benefit, compa" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="b. In a biomarker study associated with the FinHER trial, a Phase III trial in which patients with " exact="HER2" post="-amplified tumors were randomized to either 9 weeks’ trastuzumab or control combined with chemother" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="’ trastuzumab or control combined with chemotherapy, tumors were genotyped for 20 genes, including " exact="PIK3CA" post=". 39 The study found no clear difference in benefit from trastuzumab ther" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="b39-bctt-7-111&quot;&gt;39 The study found no clear difference in benefit from trastuzumab therapy between " exact="PIK3CA" post="-mutant and wild-type patients, 39 though the sample size was relatively " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ype patients, 39 though the sample size was relatively small (total 157; " exact="PIK3CA" post=" wild-type 123, PIK3CA-mutant 34) and the duration of trastuzumab treatment was shorter than" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ctt-7-111&quot;&gt;39 though the sample size was relatively small (total 157; PIK3CA wild-type 123, " exact="PIK3CA" post="-mutant 34) and the duration of trastuzumab treatment was shorter than the current standard of 1 ye" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" href=&quot;#b39-bctt-7-111&quot;&gt;39 More recently, a biomarker study evaluating the predictive value of the " exact="PIK3CA" post=" genotype in an adjuvant setting using 672 archived tumor samples from the National Surgical Adjuva" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="itaxel phase. 55 Results showed that the DFS benefit from trastuzumab in " exact="PIK3CA" post="-mutant tumors (HR 0.44, 95% CI 0.24–0.82; P=0.009) was similar to the benefit in PIK3CA&lt;" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="PIK3CA-mutant tumors (HR 0.44, 95% CI 0.24–0.82; P=0.009) was similar to the benefit in " exact="PIK3CA" post=" wild-type tumors (HR 0.51, 95% CI 0.37–0.71; P=001), 55 suggestin" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="I 0.37–0.71; P=001), 55 suggesting a lack of predictive value for " exact="PIK3CA" post=" in trastuzumab efficacy, consistent with the FinHER trial. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Overall, it should be still considered inconclusive whether " exact="PIK3CA" post=" genotype has predictive value for a gain in DFS from adjuvant trastuzumab therapy ( &lt;a href=&quot;#t2-b" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Two recent large-scale studies evaluated the influence of " exact="PIK3CA" post=" genotypes on p-CR rate when trastuzumab was involved in neoadjuvant systemic therapy in HER2-posit" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" involved in neoadjuvant systemic therapy in HER2-positive patients. The first study evaluated the " exact="PIK3CA" post=" genotype in 504 tumor samples from participants in three independent neoadjuvant studies, in which" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="mbination plus anthracycline–taxane chemotherapy. 56 Results showed that " exact="PIK3CA" post=" mutation was significantly associated with a lower p-CR rate ( PIK3CA-mutant vs wild-type, " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="6 Results showed that PIK3CA mutation was significantly associated with a lower p-CR rate ( " exact="PIK3CA" post="-mutant vs wild-type, 19.4% vs 32.8%, OR 0.49, 95% CI 0.29–0.83; P=0.008) in the overall pop" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="lation. 56 On classification by type of anti-HER2 therapy, p-CR rates in " exact="PIK3CA" post="-mutant group were 16%, 24.3%, and 17.4% with lapatinib, trastuzumab, and their combination, respec" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="zumab, and their combination, respectively, and were 18.2%, 33.0%, and 37.1%, respectively, in the " exact="PIK3CA" post=" wild-type group. These results suggest that the influence of the PIK3CA genotype is greater" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="espectively, in the PIK3CA wild-type group. These results suggest that the influence of the " exact="PIK3CA" post=" genotype is greater in patients treated with trastuzumab-containing regimens than in those treated" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" note, this study did not find differences in DFS or OS between patients with mutant and wild-type " exact="PIK3CA" post=" ( Table 2). 56 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="e study produced similar results to those in the first study: a tendency for greater p-CR rates in " exact="PIK3CA" post="-wild-type tumors than in wild-type tumors, particularly in the trastuzumab-containing group (p-CR " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ith lapatinib, trastuzumab, and their combination of 14.8%, 20.0%, and 28.6%, respectively, in the " exact="PIK3CA" post="-mutant group, and 20.4%, 28.4%, and 55.8%, respectively, in the PIK3CA wild-type group). &lt;a" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="respectively, in the PIK3CA-mutant group, and 20.4%, 28.4%, and 55.8%, respectively, in the " exact="PIK3CA" post=" wild-type group). 57 In terms of event-free survival and OS, the PIK3" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="3CA wild-type group). 57 In terms of event-free survival and OS, the " exact="PIK3CA" post=" genotype again had no influence ( Table 2). 57 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="An initial study analyzing the " exact="PIK3CA" post=" genotype in tumor samples obtained from HER2-positive metastatic breast cancer patients who had un" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="patients who had undergone trastuzumab-based therapy showed an association between the presence of " exact="PIK3CA" post=" mutations and reduced time to progression (TTP). 50 Results of subsequen" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="east tumor samples from patients who had been treated with trastuzumab-based therapies showed that " exact="PIK3CA" post=" mutation itself was not associated with the clinical benefit rate (CR + partial response [PR] + st" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="lf was not associated with the clinical benefit rate (CR + partial response [PR] + stable disease; " exact="PIK3CA" post=" wild-type vs mutant, 60% vs 58%; P=1.000), or OS ( P=0.172). &lt;a href=&quot;#b28-bctt-7-11" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="&quot;#b28-bctt-7-111&quot;&gt;28 However, the clinical benefit rate was significantly reduced in patients with " exact="PIK3CA" post=" mutations and/or PTEN loss ( P=0.047). 28 In another retrospectiv" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ER2-positive metastatic cancer treated with trastuzumab alone or in combination with chemotherapy, " exact="PIK3CA" post=" mutation was associated with increased risk of progression (HR 2.50, 95% CI 1.35–4.61; P=0." xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="5% CI 1.35–4.61; P=0.003), but not with OS. Multivariate analysis revealed PTEN loss and/or " exact="PIK3CA" post=" mutation as an independent single parameter associated with shorter TTP (HR 2.16, 95% CI 1.27–3.66" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="The predictive value of the " exact="PIK3CA" post=" genotype for lapatinib is controversial from preclinical and clinical perspectives. In neoadjuvant" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" as discussed earlier, the difference in clinical CR (c-CR) rate after lapatinib treatment between " exact="PIK3CA" post="-mutant and wild-type groups was trivial. 56, 5" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="&quot;&gt;57 In a Phase II trial of lapatinib monotherapy in HER2-positive metastatic breast cancer, three " exact="PIK3CA" post="-mutant patients were detected, and one durable PR and two stable disease responses were observed. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="th the inconsistent preclinical findings, 53 the predictive value of the " exact="PIK3CA" post=" genotype for lapatinib may not be as high as that for trastuzumab ( Table" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="volving pertuzumab and trastuzumab in combination with chemotherapy, showed that patients carrying " exact="PIK3CA" post=" mutations tended to have a lower p-CR rate compared to patients with wild-type PIK3CA, alth" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="rying PIK3CA mutations tended to have a lower p-CR rate compared to patients with wild-type " exact="PIK3CA" post=", although the difference did not reach statistical significance. 59 This" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="that the addition of pertuzumab may not be sufficient to overcome trastuzumab resistance caused by " exact="PIK3CA" post=" mutations. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="n of pertuzumab to trastuzumab resulted in an improvement in progression-free survival in both the " exact="PIK3CA" post="-mutant and PIK3CA wild-type groups, 57 suggesting that the PIK" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="zumab resulted in an improvement in progression-free survival in both the PIK3CA-mutant and " exact="PIK3CA" post=" wild-type groups, 57 suggesting that the PIK3CA genotype does not" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="CA-mutant and PIK3CA wild-type groups, 57 suggesting that the " exact="PIK3CA" post=" genotype does not predict a benefit from the addition of pertuzumab when trastuzumab is given as b" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Because " exact="PIK3CA" post=" mutations are most frequently found in ER-positive tumors, the question of whether these mutations" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="auses tamoxifen resistance. 62 One study analyzed the correlation of the " exact="PIK3CA" post=" genotype and response to neoadjuvant endocrine therapy consisting of either tamoxifen, letrozole, " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="trozole, or exemestane in three different clinical trials (n=235). Results showed that tumors with " exact="PIK3CA" post=" mutation tended not to respond to these therapies compared to those with wild-type PIK3CA (" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="h PIK3CA mutation tended not to respond to these therapies compared to those with wild-type " exact="PIK3CA" post=" (RR, PIK3CA-mutant [exon 9] vs PIK3CA-mutant [exon 20] vs PIK3CA wild-type, 1" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ation tended not to respond to these therapies compared to those with wild-type PIK3CA (RR, " exact="PIK3CA" post="-mutant [exon 9] vs PIK3CA-mutant [exon 20] vs PIK3CA wild-type, 14 of 25 [56%] vs 29" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ese therapies compared to those with wild-type PIK3CA (RR, PIK3CA-mutant [exon 9] vs " exact="PIK3CA" post="-mutant [exon 20] vs PIK3CA wild-type, 14 of 25 [56%] vs 29 of 51 [57%] vs 111 of 159 [70%];" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="th wild-type PIK3CA (RR, PIK3CA-mutant [exon 9] vs PIK3CA-mutant [exon 20] vs " exact="PIK3CA" post=" wild-type, 14 of 25 [56%] vs 29 of 51 [57%] vs 111 of 159 [70%]; P=0.0459). &lt;a href=&quot;#b41-b" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ed study involving tamoxifen and observation groups, however, failed to show a predictive value of " exact="PIK3CA" post=" mutation measured with RFS from adjuvant tamoxifen treatment. 38 Another" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="d with RFS from adjuvant tamoxifen treatment. 38 Another study analyzing " exact="PIK3CA" post=" genotypes in tumors from 447 ER-positive metastatic patients who had undergone first-line tamoxife" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="h treatment outcome measured by TTP. 36 On the other hand, patients with " exact="PIK3CA" post="-mutant tumors treated with first-line aromatase inhibitors showed a longer TTP than patients with " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="-mutant tumors treated with first-line aromatase inhibitors showed a longer TTP than patients with " exact="PIK3CA" post=" wild-type tumors, though the sample size was small (n=84). 36 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="he PI3K pathway, which is indicated for breast cancer. While a preclinical study demonstrated that " exact="PIK3CA" post=" mutations can sensitize cells to everolimus, 63 clinical validation rema" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" under preclinical and clinical development. 64 One study correlated the " exact="PIK3CA" post=" genotype and tumor response in patients who participated in Phase I studies of various PI3K/AKT/mT" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="various PI3K/AKT/mTOR inhibitors. 65 Results showed that patients with a " exact="PIK3CA" post=" H1047R mutation had a higher PR rate than those with other PIK3CA mutations or wild-type &lt;i" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="owed that patients with a PIK3CA H1047R mutation had a higher PR rate than those with other " exact="PIK3CA" post=" mutations or wild-type PIK3CA treated under the same protocols (six of 16 [38%] vs five of " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="i&gt; H1047R mutation had a higher PR rate than those with other PIK3CA mutations or wild-type " exact="PIK3CA" post=" treated under the same protocols (six of 16 [38%] vs five of 50 [10%] vs 23 of 174, [13%], respect" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Vigorous investigations of " exact="PIK3CA" post=" mutations in breast cancer have led to the carving of several matters in stone with a certain leve" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="r have led to the carving of several matters in stone with a certain level of consistency. Namely, " exact="PIK3CA" post=" mutations 1) are most likely to be observed in ER-positive/HER2-negative tumors, 2) can coexist wi" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" in ER-positive/HER2-negative tumors, 2) can coexist with other PI3K-enhancing mechanisms, such as " exact="HER2" post=" amplification and PTEN loss, 3) may potentially be a good prognostic marker, 4) may predict resist" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="or relapse and thus need more potent treatment. As reviewed in this paper, many studies have found " exact="PIK3CA" post=" mutations to be good prognostic markers in patients with early breast cancer. However, it has to b" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" markers in patients with early breast cancer. However, it has to be emphasized that at this point " exact="PIK3CA" post=" should not be used to determine the intensity of systemic therapies for individual patients. This " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="pies for individual patients. This is because most studies that reported good prognostic impact of " exact="PIK3CA" post=" mutations were retrospectively conducted in a single hospital base, which limits their reliability" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="he cancer disease in an untreated individual&quot;. In fact, two studies that retrospectively genotyped " exact="PIK3CA" post=" in patients untreated after surgery failed to show any prognostic impact of PIK3CA mutation" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="enotyped PIK3CA in patients untreated after surgery failed to show any prognostic impact of " exact="PIK3CA" post=" mutations. 32, 36 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="re likely or unlikely to benefit from a certain treatment. Among studies conducted to evaluate the " exact="PIK3CA" post=" genotype as a predictive biomarker for various therapies, those involving trastuzumab-based therap" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="lving trastuzumab-based therapies in the neoadjuvant setting provided the most consistent results: " exact="PIK3CA" post=" was associated with a lower p-CR rate. 56, 57 " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" It is unclear, however, whether or not trastuzumab can be omitted in patients with HER2-positive/ " exact="PIK3CA" post="-mutant tumors, and a definitive answer will not be available in the future, because clinical trial" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" impossible to conduct. Rather, the development of therapies to overcome trastuzumab resistance by " exact="PIK3CA" post=" mutations is awaited. One potential solution would be the combination of anti-HER2 drugs and PI3K-" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=". Numerous PI3K-targeting drugs are under preclinical and clinical development, and HER2-positive/ " exact="PIK3CA" post="-mutant tumors are among their main targets. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Despite consistently lower p-CR rates in " exact="PIK3CA" post="-mutant HER2-positive patients treated with trastuzumab-containing neoadjuvant therapies than in &lt;i" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="i&gt;-mutant HER2-positive patients treated with trastuzumab-containing neoadjuvant therapies than in " exact="PIK3CA" post=" wild-type counterparts, no difference in DFS, a true end point for perisurgi-cal systemic therapy," xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="t for perisurgi-cal systemic therapy, was observed in large adjuvant or neoadjuvant trials between " exact="PIK3CA" post="-mutant and wild-type patients. This is seemingly contradictory, based on two widely accepted postu" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="At the time of discovery of frequent " exact="PIK3CA" post=" somatic mutations in 2004, 3 which happened almost simultaneously with th" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="e run&quot; target, providing dramatic tumor regression when targeted, as had already been witnessed in " exact="EGFR" post="-mutant lung adenocarcinoma and KIT-mutant gastrointestinal stromal tumors. However, the res" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ression when targeted, as had already been witnessed in EGFR-mutant lung adenocarcinoma and " exact="KIT" post="-mutant gastrointestinal stromal tumors. However, the results of early clinical trials of various P" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="uggested that this would not be the case ( Table 2): RR was a mere 17% in " exact="PIK3CA" post="-mutant tumors, albeit somewhat higher than in PIK3CA wild-type tumors. &lt;a href=&quot;#b65-bctt-7" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="-7-111&quot;&gt;Table 2): RR was a mere 17% in PIK3CA-mutant tumors, albeit somewhat higher than in " exact="PIK3CA" post=" wild-type tumors. 65 As discussed in this review, PIK3CA mutation" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre=" than in PIK3CA wild-type tumors. 65 As discussed in this review, " exact="PIK3CA" post=" mutations can be coobserved with other PI3K-enhancing molecular changes, such as HER2 ampli" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="ew, PIK3CA mutations can be coobserved with other PI3K-enhancing molecular changes, such as " exact="HER2" post=" amplification and PTEN loss, which suggests that PIK3CA mutations themselves solely indicat" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="-enhancing molecular changes, such as HER2 amplification and PTEN loss, which suggests that " exact="PIK3CA" post=" mutations themselves solely indicate a high level of cellular addiction to the pathway. In additio" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="In conclusion, there is presently no sufficient evidence to support the clinical usefulness of " exact="PIK3CA" post=" genotyping in daily practice. Given that PIK3CA-mutant breast cancer appears to have distin" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="dence to support the clinical usefulness of PIK3CA genotyping in daily practice. Given that " exact="PIK3CA" post="-mutant breast cancer appears to have distinct tumor biology, the development of more individualize" xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="e individualized targeted therapies, such as a combination of two or more targeted drugs, based on " exact="PIK3CA" post=" genotype is awaited. " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Studies evaluating prognostic impact of " exact="PIK3CA" post=" mutations with recurrence-free survival (RFS) as end point " xpath="/html[1]/body[1]/article[1]/div[5]/div[5]/p[1]" name="human"/>
   <result pre="Summary of predictive value of " exact="PIK3CA" post=" mutations in clinical settings " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4447178/results/gene/human/results.xml">
   <result pre="C) detection of overexpression, the rate of detection of activating mutations or amplifications of " exact="MET" post=" gene is higher, 6 defining a small group of tumors with aggressive clinic" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="erated dose. 7 In the small subset of 13 heavily pretreated patients with " exact="MET" post="-amplified gastroesophageal tumors exposed to AMG 337, the investigators observed a notable 62% rat" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="oma (EHCCA) and gall bladder carcinoma (GBCA) share genomic alterations in cell cycle regulation ( " exact="CDKN2B" post=") and chromatin remodeling ( ARID1A). IHCCA features FGFR fusions, isocitrate dehydrogenase " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="CA) share genomic alterations in cell cycle regulation ( CDKN2B) and chromatin remodeling ( " exact="ARID1A" post="). IHCCA features FGFR fusions, isocitrate dehydrogenase ( IDH)-1/2 substitutions, BRAF&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="and chromatin remodeling ( ARID1A). IHCCA features FGFR fusions, isocitrate dehydrogenase ( " exact="IDH" post=")-1/2 substitutions, BRAF substitutions, and MET amplification, with a low KRAS&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="RID1A). IHCCA features FGFR fusions, isocitrate dehydrogenase ( IDH)-1/2 substitutions, " exact="BRAF" post=" substitutions, and MET amplification, with a low KRAS-mutation frequency. EHCCA and " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre=" fusions, isocitrate dehydrogenase ( IDH)-1/2 substitutions, BRAF substitutions, and " exact="MET" post=" amplification, with a low KRAS-mutation frequency. EHCCA and GBCA feature ERBB2 ampl" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="IDH)-1/2 substitutions, BRAF substitutions, and MET amplification, with a low " exact="KRAS" post="-mutation frequency. EHCCA and GBCA feature ERBB2 amplifications (GBCA &amp;amp;gt; EHCCA) and &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="s, and MET amplification, with a low KRAS-mutation frequency. EHCCA and GBCA feature " exact="ERBB2" post=" amplifications (GBCA &amp;amp;gt; EHCCA) and PIK3CA/ MTOR pathway alterations. EHCCA has" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="&gt;-mutation frequency. EHCCA and GBCA feature ERBB2 amplifications (GBCA &amp;amp;gt; EHCCA) and " exact="PIK3CA" post="/ MTOR pathway alterations. EHCCA has a high KRAS-mutation frequency, whereas the " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="uency. EHCCA and GBCA feature ERBB2 amplifications (GBCA &amp;amp;gt; EHCCA) and PIK3CA/ " exact="MTOR" post=" pathway alterations. EHCCA has a high KRAS-mutation frequency, whereas the KRAS geno" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="cations (GBCA &amp;amp;gt; EHCCA) and PIK3CA/ MTOR pathway alterations. EHCCA has a high " exact="KRAS" post="-mutation frequency, whereas the KRAS genomic alteration in GBCA is low. Knowledge of releva" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="/i&gt;/ MTOR pathway alterations. EHCCA has a high KRAS-mutation frequency, whereas the " exact="KRAS" post=" genomic alteration in GBCA is low. Knowledge of relevant genomic alterations will be a fundamental" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="tion to increase the effectiveness of targeted therapies and particularly in developing a &quot;beyond- " exact="RAS" post="&quot; strategy; 37 many works from all over the world have explored new scree" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ata from two multinational screening platforms show that collaborative genomic analysis beyond the " exact="RAS" post=" is feasible and might be used to run next-generation trials with targeted agents. The European Org" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" has evaluated a total of 361 tumor samples in the first 6 months to detect rare mutations such as " exact="PI3KCA" post=" and BRAF mutations. 39 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="otal of 361 tumor samples in the first 6 months to detect rare mutations such as PI3KCA and " exact="BRAF" post=" mutations. 39 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="pursued. The combination of the EGFR inhibitor panitumumab with the BRAF inhibitor vemurafenib for " exact="BRAF" post="-mutant metastatic CRC has shown interesting hints of activity. 40 Two of" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[4]" name="human"/>
   <result pre="f the same assumption that activation of the EGFR pathway is the leading cause of failure of anti- " exact="BRAF" post=" monotherapy, a randomized Phase II trial of irinotecan plus cetuximab with or without vemurafenib " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4453607/results/gene/human/results.xml">
   <result pre="We analysed the clinical significance of EGFR overexpression and " exact="EGFR" post=" gene copy number alterations in 242 HER2-positive primary breast cancers. In addition, we examined" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="Of the 242 primary cases, the level of EGFR overexpression was 2+ in 12.7% and 3+ in 11.8%. High " exact="EGFR" post=" gene copy number was detected in 10.3%. Epidermal growth factor receptor overexpression was associ" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="tivity and high Ki-67 proliferation index. In survival analyses, EGFR overexpression, but not high " exact="EGFR" post=" copy number, was associated with poor disease-free survival in all patients, and in the subgroup n" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="Epidermal growth factor receptor overexpression, but not high " exact="EGFR" post=" copy number, is a poor prognostic factor in HER2-positive primary breast cancer. Epidermal growth " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="i&gt;et al, 2011a ; Martin et al, 2012 ). Recently, we reported that high " exact="EGFR" post=" copy number because of EGFR amplification or high polysomy is an independent prognostic fac" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="3&quot;&gt;Martin et al, 2012 ). Recently, we reported that high EGFR copy number because of " exact="EGFR" post=" amplification or high polysomy is an independent prognostic factor for poor disease-free survival " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="reast cancer ( Park et al, 2014 ). However, the prognostic significance of " exact="EGFR" post=" copy number in HER2-positive breast cancer is not clear. " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="In this study, we assessed the clinicopathologic significance of EGFR overexpression and " exact="EGFR" post=" copy number alteration in a large series of HER2-positive primary breast cancers from two institut" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="A total of 50 tumour cells were evaluated for each core, and the genetic variables evaluated were: " exact="EGFR" post=" gene copy number, chromosome 7 copy number and average EGFR gene : chromosome 7 ratio. The " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="netic variables evaluated were: EGFR gene copy number, chromosome 7 copy number and average " exact="EGFR" post=" gene : chromosome 7 ratio. The University of Colorado Cancer Center criteria for the EGFR g" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="e EGFR gene : chromosome 7 ratio. The University of Colorado Cancer Center criteria for the " exact="EGFR" post=" gene were used as follows: disomy (⩽2 copies in ⩾90% of cells), low trisomy (⩽2 copies in ⩾40% of " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="d high polysomy (⩾4 copies in ⩾40% of cells). For gene amplification, the criterion was a ratio of " exact="EGFR" post=" to chromosome 7 of ⩾2 or ⩾15 copies of EGFR per cell in ⩾10% of the analysed cells ( &lt;a hre" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="ene amplification, the criterion was a ratio of EGFR to chromosome 7 of ⩾2 or ⩾15 copies of " exact="EGFR" post=" per cell in ⩾10% of the analysed cells ( Cappuzzo et al, 2005 ). For furthe" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="et al, 2005 ). For further analysis, the patients were divided into two groups according to " exact="EGFR" post=" copy number as follows: low EGFR copy number (disomy, low trisomy, high trisomy and low pol" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="is, the patients were divided into two groups according to EGFR copy number as follows: low " exact="EGFR" post=" copy number (disomy, low trisomy, high trisomy and low polysomy) and high EGFR copy number " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="follows: low EGFR copy number (disomy, low trisomy, high trisomy and low polysomy) and high " exact="EGFR" post=" copy number (high polysomy and gene amplification). " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="version 18.0 for Windows (SPSS, Chicago, IL, USA). The correlation between EGFR overexpression and " exact="EGFR" post=" gene : chromosome 7 ratio was determined by Spearman's correlation analysis. The associations of E" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="was determined by Spearman's correlation analysis. The associations of EGFR overexpression or high " exact="EGFR" post=" copy number with clinicopathological characteristics of the tumours were analysed using Student's " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="e detected in 11 (4.7%) and 13 cases (5.6%), respectively. The distribution of EGFR IHC scores and " exact="EGFR" post=" copy number did not differ between the two institutions ( χ 2 square test, P&lt;" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="We compared the results of EGFR IHC and " exact="EGFR" post=" FISH in each TMA core. Epidermal growth factor receptor protein overexpression of 3+ and 2+ or mor" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="dermal growth factor receptor protein overexpression of 3+ and 2+ or more was associated with high " exact="EGFR" post=" copy number (all P&amp;amp;lt;0.001; Table 1). In a correlation analysis, a wea" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="elation analysis, a weak but significant positive correlation was found between EGFR IHC score and " exact="EGFR" post=": chromosome 7 ratio ( ρ=0.282, P&amp;amp;lt;0.001). Of the 11 cases in which EGFR" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="EGFR: chromosome 7 ratio ( ρ=0.282, P&amp;amp;lt;0.001). Of the 11 cases in which " exact="EGFR" post=" was amplified, five scored as 3+, three as 2+ and three as 0 ( Supplementary Table" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="in breast cancer. Clinicopathologic characteristics of tumours showing EGFR overexpression or high " exact="EGFR" post=" copy number are summarised in Table 2. Epidermal growth factor receptor overexpres" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="ely; EGFR overexpression of 2+ or more, P&amp;amp;lt;0.001, P=0.003, respectively). High " exact="EGFR" post=" copy number tended to be associated with hormone receptor negativity, but this did not reach stati" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="=&quot;#fig2&quot;&gt;Figure 2B) was associated with worse disease-free survival of the patients. However, high " exact="EGFR" post=" copy number was not associated with disease-free survival ( P=0.521; Figure" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="ef=&quot;#fig2&quot;&gt;Figure 2C). The overall survival of the patients was not affected by EGFR expression or " exact="EGFR" post=" copy number alteration ( Figures 2D–F). Pattern of EGFR overexpression (heterogene" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="not receiving adjuvant trastuzumab ( n=209), but EGFR overexpression of 2+ or more and high " exact="EGFR" post=" copy number were not associated with disease-free survival. However, as only a small number of pat" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="a href=&quot;#bib3&quot;&gt;Cancer Genome Atlas N, 2012). One corresponded to the subtype which is enriched for " exact="HER2" post=" mRNA and in which there is high expression of receptor tyrosine kinases including EGFR, " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" for HER2 mRNA and in which there is high expression of receptor tyrosine kinases including " exact="EGFR" post=", HER2 and FGFR4. The other is the luminal mRNA subtype with high expression of GA" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="/i&gt; mRNA and in which there is high expression of receptor tyrosine kinases including EGFR, " exact="HER2" post=" and FGFR4. The other is the luminal mRNA subtype with high expression of GATA3, B" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="which there is high expression of receptor tyrosine kinases including EGFR, HER2 and " exact="FGFR4" post=". The other is the luminal mRNA subtype with high expression of GATA3, BCL2 and ES" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="R, HER2 and FGFR4. The other is the luminal mRNA subtype with high expression of " exact="GATA3" post=", BCL2 and ESR1, the so-called luminal cluster of genes. In our study, the correlatio" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre=" and FGFR4. The other is the luminal mRNA subtype with high expression of GATA3, " exact="BCL2" post=" and ESR1, the so-called luminal cluster of genes. In our study, the correlation between EGF" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="4. The other is the luminal mRNA subtype with high expression of GATA3, BCL2 and " exact="ESR1" post=", the so-called luminal cluster of genes. In our study, the correlation between EGFR overexpression" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="The relationship between EGFR overexpression and high " exact="EGFR" post=" copy number has not been clearly defined. In this study, analysis of TMA cores revealed a positive" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="been clearly defined. In this study, analysis of TMA cores revealed a positive correlation between " exact="EGFR" post=" gene status and EGFR protein overexpression. In particular, cases with high levels of EGFR " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre=" EGFR gene status and EGFR protein overexpression. In particular, cases with high levels of " exact="EGFR" post=" amplification (case nos. 196 and 224; Supplementary Table S3) yielded 3+ EGFR IHC " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="o revealed that EGFR overexpression had low specificity and low positive predictive value for high " exact="EGFR" post=" copy number as not all tumours with high EGFR copy number overexpressed EGFR and not all EG" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="ty and low positive predictive value for high EGFR copy number as not all tumours with high " exact="EGFR" post=" copy number overexpressed EGFR and not all EGFR-overexpressing tumours had high EGFR copy n" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="h high EGFR copy number overexpressed EGFR and not all EGFR-overexpressing tumours had high " exact="EGFR" post=" copy numbers. Furthermore, while EGFR overexpression was associated with poor prognosis in HER2-po" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="xpression was associated with poor prognosis in HER2-positive primary breast cancer patients, high " exact="EGFR" post=" copy number did not have prognostic significance. These results suggest that besides increased " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="/i&gt; copy number did not have prognostic significance. These results suggest that besides increased " exact="EGFR" post=" gene copy number, EGFR overexpression may be induced by other mechanisms, such as mutation, aberra" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="( Geyer et al, 2006 ). Fabi et al (2013) evaluated " exact="EGFR" post=" gene copy number and responses to lapatinib, and identified increased EGFR copy number as a" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="2013) evaluated EGFR gene copy number and responses to lapatinib, and identified increased " exact="EGFR" post=" copy number as a positive predictive factor for lapatinib response. In addition to lapatinib, othe" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre=" " exact="EGFR" post=" fluorescence in situ hybridisation and EGFR immunohistochemistry . An example of EGFR&lt;/i" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="i&gt;EGFR fluorescence in situ hybridisation and EGFR immunohistochemistry . An example of " exact="EGFR" post=" amplification ( A) showing strong (3+) EGFR overexpression ( B). An example of EGFR high polysomy " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre=" Disease-free and overall survival according to EGFR overexpression and " exact="EGFR" post=" copy number alteration in HER2-positive primary breast cancer . EGFR overexpression defined as 3+ " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="xpression defined as 2+ or more ( B) were associated with poor disease-free survival, whereas high " exact="EGFR" post=" copy number ( C) was not associated with disease-free survival. EGFR overexpression defined as 3+ " xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre=" with disease-free survival. EGFR overexpression defined as 3+ ( D) or as 2+ or more ( E), or high " exact="EGFR" post=" copy number ( F) was not associated with overall survival. " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4464713/results/gene/human/results.xml">
   <result pre=" " exact="BCS" post=" breast conserving surgery, RT postoperative radiotherapy " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/div[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" RT radiotherapy, " exact="BCS" post=" breast conserving surgery, IBE ipsilateral breast events, IBCR invasive breast cance" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/div[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" RT radiotherapy, BCS breast conserving surgery, " exact="IBE" post=" ipsilateral breast events, IBCR invasive breast cancer recurrence " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/div[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt;RT radiotherapy, BCS breast conserving surgery, IBE ipsilateral breast events, " exact="IBCR" post=" invasive breast cancer recurrence " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/div[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="BCS" post=" breast conserving surgery " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4469402/results/gene/human/results.xml">
   <result pre="ARCB1, VHL, MLH1, CTNNB1, KDR, FBXW7, APC, CSF1R, NPM1, SMO, ERBB4, CDKN2A, NOTCH1, JAK3, and " exact="PTPN11" post=". Primers for PCR amplification included the 190-primer pair pool provided by the vendor with an ad" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="HER2-positive tumors IHC 3+, FISH " exact="HER2" post="/centromere 17 ratio ≥2.0 or both " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="HER2-positive tumors (IHC 3+, FISH " exact="HER2" post="/centromere 17 ratio ≥2.0 or both " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="at trastuzumab disrupts ligand-independent ErbB2/ErbB3/PI3K complexes blocking AKT signaling; when " exact="PI3K" post=" is mutated or dysfunctional, complex disruption does not inhibit AKT [ 35]." xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="g AKT signaling; when PI3K is mutated or dysfunctional, complex disruption does not inhibit " exact="AKT" post=" [ 35]. Another possible explanation could involve the higher rate of KRAS m" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="it AKT [ 35]. Another possible explanation could involve the higher rate of " exact="KRAS" post=" mutations seen in intrahepatic cholangiocarcinomas as compared with gallbladder cancers, possibly " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4472207/results/gene/human/results.xml">
   <result pre="mutation status in patients with metastatic urothelial carcinoma (UC), and its impact on survival. " exact="ERBB2" post=" mutation was determined by hotspot sequencing. mRNA expression was assessed using NanoString count" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="Human epidermal growth factor receptor 2 (HER2) overexpression (encoded by the " exact="ERBB2" post=" gene) has long been a prognostic marker and predictive tool in the treatment of breast cancer, and" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="y in esophagogastric cancer 2, 3. In breast cancer, overexpression and " exact="ERBB2" post=" DNA amplification are generally closely linked. For specimens with intermediate HER2 protein expre" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="In addition to amplification and overexpression, mutations in " exact="ERBB2" post=" have been reported in multiple cancer types, including UC, and are oncogenic in vitro &lt;a href=&quot;#b5" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="enic in vitro 5– 8. Recently, mutations in the extracellular domain of " exact="ERBB2" post=" were found to be present in 40% of micropapillary UC 9. Since extracellular domain m" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=" micropapillary UC 9. Since extracellular domain mutations may confer sensitivity to " exact="ERBB2" post=" kinase inhibitors, these findings may result in new therapeutic opportunities in selected UC patie" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=" developed metastatic disease, by evaluating immunohistochemical (IHC) staining for HER2, FISH for " exact="ERBB2" post=" on two cohorts of patients, targeted ERBB2 mutation hotspot sequencing, mRNA expression by " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="ohistochemical (IHC) staining for HER2, FISH for ERBB2 on two cohorts of patients, targeted " exact="ERBB2" post=" mutation hotspot sequencing, mRNA expression by NanoString, and ERBB2 copy number by array-" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="of patients, targeted ERBB2 mutation hotspot sequencing, mRNA expression by NanoString, and " exact="ERBB2" post=" copy number by array-based comparative genomic hybridization (aCHG) in primary tumors from one of " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=". (d) HER2-negative urothelial cancer, showing no membranous HER2 expression, and scored as 0. (B) " exact="ERBB2" post=" status in urothelial carcinoma. (a) Normal, nonamplified (ratio = 1), (b) polysomic, nonamplified " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="To assess the genetic status of " exact="ERBB2" post=", FISH was performed on FFPE tissue from TMAs. Detailed laboratory methods can be found in &lt;a href=" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="of ratios below 1.8 were considered negative and ratios more than 2.2 were considered positive for " exact="ERBB2" post=" gene amplification. Ratios varied between 1.8 and 2.2 were considered as equivocal. In these cases" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="oftware version 3.4 (Agilent Technologies, Santa Clara, CA, US) was used to analyze the aCGH data. " exact="ERBB2" post=" copy number gain was determined as specimens with a log base 2 ratio greater than 0.9. " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="mpared to internal NanoString Technologies, Seattle, Wa, US controls, several housekeeping genes ( " exact="ACTB" post=", GAPDH, HPRT1, LDHA, PFKP, PGAM1, STAT1, TUBA4A, " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="ernal NanoString Technologies, Seattle, Wa, US controls, several housekeeping genes ( ACTB, " exact="GAPDH" post=", HPRT1, LDHA, PFKP, PGAM1, STAT1, TUBA4A, VIM), a" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="ng Technologies, Seattle, Wa, US controls, several housekeeping genes ( ACTB, GAPDH, " exact="HPRT1" post=", LDHA, PFKP, PGAM1, STAT1, TUBA4A, VIM), and invariant g" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="s, Seattle, Wa, US controls, several housekeeping genes ( ACTB, GAPDH, HPRT1, " exact="LDHA" post=", PFKP, PGAM1, STAT1, TUBA4A, VIM), and invariant genes ( ANG" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="a, US controls, several housekeeping genes ( ACTB, GAPDH, HPRT1, LDHA, " exact="PFKP" post=", PGAM1, STAT1, TUBA4A, VIM), and invariant genes ( ANGEL1, D" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="s, several housekeeping genes ( ACTB, GAPDH, HPRT1, LDHA, PFKP, " exact="PGAM1" post=", STAT1, TUBA4A, VIM), and invariant genes ( ANGEL1, DDX19A, " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="sekeeping genes ( ACTB, GAPDH, HPRT1, LDHA, PFKP, PGAM1, " exact="STAT1" post=", TUBA4A, VIM), and invariant genes ( ANGEL1, DDX19A, NAGA, R" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="s ( ACTB, GAPDH, HPRT1, LDHA, PFKP, PGAM1, STAT1, " exact="TUBA4A" post=", VIM), and invariant genes ( ANGEL1, DDX19A, NAGA, RPS10, RP" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=", GAPDH, HPRT1, LDHA, PFKP, PGAM1, STAT1, TUBA4A, " exact="VIM" post="), and invariant genes ( ANGEL1, DDX19A, NAGA, RPS10, RPS16, " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="HA, PFKP, PGAM1, STAT1, TUBA4A, VIM), and invariant genes ( " exact="ANGEL1" post=", DDX19A, NAGA, RPS10, RPS16, RPS24, RPS29) in UC. These " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=", PGAM1, STAT1, TUBA4A, VIM), and invariant genes ( ANGEL1, " exact="DDX19A" post=", NAGA, RPS10, RPS16, RPS24, RPS29) in UC. These invariant genes" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="/i&gt;, STAT1, TUBA4A, VIM), and invariant genes ( ANGEL1, DDX19A, " exact="NAGA" post=", RPS10, RPS16, RPS24, RPS29) in UC. These invariant genes were identif" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=", TUBA4A, VIM), and invariant genes ( ANGEL1, DDX19A, NAGA, " exact="RPS10" post=", RPS16, RPS24, RPS29) in UC. These invariant genes were identified by analyzi" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="A, VIM), and invariant genes ( ANGEL1, DDX19A, NAGA, RPS10, " exact="RPS16" post=", RPS24, RPS29) in UC. These invariant genes were identified by analyzing gene expres" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="/i&gt;), and invariant genes ( ANGEL1, DDX19A, NAGA, RPS10, RPS16, " exact="RPS24" post=", RPS29) in UC. These invariant genes were identified by analyzing gene expression variances" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="riant genes ( ANGEL1, DDX19A, NAGA, RPS10, RPS16, RPS24, " exact="RPS29" post=") in UC. These invariant genes were identified by analyzing gene expression variances in several pu" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="chemistry. Only mutations found in iPLEX and confirmed by hME were considered validated mutations. " exact="ERBB2" post=" hotspot mutations sequenced are listed in Table S1. " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="T3 cells (ATCC Cell Lines, Middlesex, UK) transfected with pBabe-puro constructs containing mutant " exact="ERBB2" post=" cDNAs were maintained in Dulbecco's Modification of Eagle's Medium (DMEM) (Cellgro/Mediatech, Mana" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="t tests were used to measure associations between patient clinical characteristics and HER2 IHC or " exact="ERBB2" post=" FISH amplification. Since there is no standard scoring for HER2 in bladder cancer, we followed the" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=" " exact="ERBB2" post=" amplification by FISH was more frequent in the Spanish cohort compared to the Greek cohort (14/71 " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=" " exact="ERBB2" post=" mutations were identified at amino acid 755 and 777 in two (2%) patients in the Spanish cohort. Th" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=" S5). HER2-negative IHC staining demonstrated a high predictive value and specificity for negative " exact="ERBB2" post=" gene amplification, suggesting that it is a reasonable screening test for HER2 status in bladder c" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="at subtle differences in fixation and storage could contribute to changes in HER2 antigenicity and " exact="ERBB2" post=" DNA, it is unlikely that these would affect DNA and proteins in the same manner. " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="ts with high-grade UC. This study identified mutations in 32 genes. Mutations or amplifications in " exact="ERRB2" post=" were also identified in 9% of patients 35. Interestingly, some of these molecular a" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="We identified a low frequency of " exact="ERBB2" post=" activating mutations in patients who developed metastatic UC. Not using next-generation sequencing" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="mutations in bladder cancer. Limitations include the targeted rather than whole gene sequencing of " exact="ERBB2" post=", which may underestimate the frequency of mutations and the relatively small sample size. In addit" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="impact of HER2 status on UC prognosis remains controversial. Our data suggest that neither IHC nor " exact="ERBB2" post=" gene amplification in the primary tumor play a role in prognosis after diagnosis of metastatic dis" xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=" Figure S2. NIH-3T3 " exact="ERBB2" post=" western blot. HER2 V777L is associated with increased C-terminal phosphorylation. " xpath="/html[1]/body[1]/article[1]/div[4]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=" Table S1. " exact="ERBB2" post=" mutation hotspots. " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4479882/results/gene/human/results.xml">
   <result pre="DNA blood Mini kit, Qiagen). Subsequently, polymerase chain reaction (PCR) was used to amplify the " exact="PI3K" post=" gene (NM_006218) (NCBI-National Center for Biotechnology Information). PCR products were purified " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="f=&quot;#pone.0131241.ref016&quot;&gt;16]. In patients treated with trastuzumab, activating mutations of PI3K ( " exact="PI3KCA" post=") were associated with poor response and survival [ 44]. Eichhom PJ " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" response and survival [ 44]. Eichhom PJ et al also reported " exact="PI3KCA" post=" mutations as responsible of lapatinib resistance [ 15]. In this stu" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="atinib resistance [ 15]. In this study, we have shown that although " exact="PI3KCA" post=" mutations (PIK3CA_E545K mutation in SK TR cells and PIK3CA_E542K mutation in SK LR and SKLTR cells" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4484424/results/gene/human/results.xml">
   <result pre=" A. mRNA expression of " exact="MRP3" post=", MRP4, MRP5, hENT1, hCNT1, hCNT3, RRM1, RRM2 and " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" A. mRNA expression of MRP3, " exact="MRP4" post=", MRP5, hENT1, hCNT1, hCNT3, RRM1, RRM2 and dCK wa" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" A. mRNA expression of MRP3, MRP4, " exact="MRP5" post=", hENT1, hCNT1, hCNT3, RRM1, RRM2 and dCK was analyzed in" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="RNA expression of MRP3, MRP4, MRP5, hENT1, hCNT1, hCNT3, " exact="RRM1" post=", RRM2 and dCK was analyzed in NT and ErbB2-KD cells by qRT–PCR. The histogram repres" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre="n of MRP3, MRP4, MRP5, hENT1, hCNT1, hCNT3, RRM1, " exact="RRM2" post=" and dCK was analyzed in NT and ErbB2-KD cells by qRT–PCR. The histogram represents the rati" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre="In order to evaluate the impact of the loss of ErbB2 on SN-38 metabolism, expression levels of " exact="MRP1" post=", MRP2, MDR1 or ABCG2 mRNA were measured by qRT-PCR in CAPAN-2 ErbB2-KD cells " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="to evaluate the impact of the loss of ErbB2 on SN-38 metabolism, expression levels of MRP1, " exact="MRP2" post=", MDR1 or ABCG2 mRNA were measured by qRT-PCR in CAPAN-2 ErbB2-KD cells compared to N" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="he impact of the loss of ErbB2 on SN-38 metabolism, expression levels of MRP1, MRP2, " exact="MDR1" post=" or ABCG2 mRNA were measured by qRT-PCR in CAPAN-2 ErbB2-KD cells compared to NT control cel" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e loss of ErbB2 on SN-38 metabolism, expression levels of MRP1, MRP2, MDR1 or " exact="ABCG2" post=" mRNA were measured by qRT-PCR in CAPAN-2 ErbB2-KD cells compared to NT control cells (Figure &lt;a hr" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre=" NT control cells (Figure 3A). CAPAN-2 ErbB2-KD cells strongly overexpressed mRNA of " exact="ABCG2" post=" (7-fold, * p = 0.0207), MRP1 (25-fold, * p = 0.0126)) and MRP2 (68-fol" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre=" CAPAN-2 ErbB2-KD cells strongly overexpressed mRNA of ABCG2 (7-fold, * p = 0.0207), " exact="MRP1" post=" (25-fold, * p = 0.0126)) and MRP2 (68-fold, * p = 0.0192). MDR1 mRNA c" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="RNA of ABCG2 (7-fold, * p = 0.0207), MRP1 (25-fold, * p = 0.0126)) and " exact="MRP2" post=" (68-fold, * p = 0.0192). MDR1 mRNA could not be detected. Strong overexpression of M" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="0207), MRP1 (25-fold, * p = 0.0126)) and MRP2 (68-fold, * p = 0.0192). " exact="MDR1" post=" mRNA could not be detected. Strong overexpression of MRP2 protein was confirmed at the protein lev" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rexpression of MRP2 protein was confirmed at the protein level (Figure 3B). Level of " exact="MRP2" post=" mRNA was increased in both CAPAN-1 and CAPAN-2 cells following transient inhibition of ErbB2 by si" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" MRP2 expression (Figure 5C). We also observed that transient ErbB2 silencing led to " exact="MRP1" post=" mRNA increase in CAPAN-1 cells whereas ABCG2 mRNA was increased in both CAPAN-1 and CAPAN-2" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" observed that transient ErbB2 silencing led to MRP1 mRNA increase in CAPAN-1 cells whereas " exact="ABCG2" post=" mRNA was increased in both CAPAN-1 and CAPAN-2 cells ( supplemental Figure S3). Fin" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre=" A. mRNA expression of " exact="MRP1" post=", MRP2, ABCG2 and GAPDH was analyzed in NT and ErbB2-KD cells by qRT–PCR. B. W" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" A. mRNA expression of MRP1, " exact="MRP2" post=", ABCG2 and GAPDH was analyzed in NT and ErbB2-KD cells by qRT–PCR. B. Western blots " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" A. mRNA expression of MRP1, MRP2, " exact="ABCG2" post=" and GAPDH was analyzed in NT and ErbB2-KD cells by qRT–PCR. B. Western blots were performed" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre=" A. mRNA expression of MRP1, MRP2, ABCG2 and " exact="GAPDH" post=" was analyzed in NT and ErbB2-KD cells by qRT–PCR. B. Western blots were performed to analyze the e" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre="Our results indicate that transient inhibition of ErbB2, Erk1/2 and " exact="JNK" post=" using siRNA led to a significant increase of MRP2 mRNA expression in CAPAN-2 cells (4-, 2.1" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ibition of ErbB2, Erk1/2 and JNK using siRNA led to a significant increase of " exact="MRP2" post=" mRNA expression in CAPAN-2 cells (4-, 2.1- and 2.3-fold, p &amp;amp;lt; 0.01, p &amp;amp;lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e NCBI Gene Expression Omnibus (GEO, GSE28735) database, ErbB2, hCNT1, hCNT3, " exact="ABCG2" post=", MRP1 and MRP2 mRNA expression was measured in 45 tumors (T) and adjacent non tumor " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre="pression Omnibus (GEO, GSE28735) database, ErbB2, hCNT1, hCNT3, ABCG2, " exact="MRP1" post=" and MRP2 mRNA expression was measured in 45 tumors (T) and adjacent non tumor tissues (ANT)" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" (GEO, GSE28735) database, ErbB2, hCNT1, hCNT3, ABCG2, MRP1 and " exact="MRP2" post=" mRNA expression was measured in 45 tumors (T) and adjacent non tumor tissues (ANT). We observed th" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="was measured in 45 tumors (T) and adjacent non tumor tissues (ANT). We observed that ErbB2, " exact="MRP1" post=" and MRP2 expression significantly differed (*** p &amp;amp;lt; 0.001) with ErbB2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="45 tumors (T) and adjacent non tumor tissues (ANT). We observed that ErbB2, MRP1 and " exact="MRP2" post=" expression significantly differed (*** p &amp;amp;lt; 0.001) with ErbB2 and MRP1 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" MRP2 expression significantly differed (*** p &amp;amp;lt; 0.001) with ErbB2 and " exact="MRP1" post=" increased in tumor tissues whereas MRP2 mRNA level was reduced (Figure 6A). W" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="(*** p &amp;amp;lt; 0.001) with ErbB2 and MRP1 increased in tumor tissues whereas " exact="MRP2" post=" mRNA level was reduced (Figure 6A). We confirmed these alterations in GSE16515 datas" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt;n = 10) mRNA level for ErbB2 were sorted (*** p &amp;amp;lt; 0.001). We found that " exact="MRP2" post=" mRNA level was significantly reduced in ErbB2 high tumors (* p = 0.0239) compare" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="gure 6B). Moreover, we observed a mild converse correlation between ErbB2 and " exact="MRP2" post=" mRNA overall expression in the 45 tumors collection ( R 2 = 0.27, p = 0.0" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" A. ErbB2, hCNT1, hCNT3, " exact="ABCG2" post=", MRP1 and MRP2 mRNA expression was evaluated in PDAC datasets of the NCBI Gene Expre" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre=" A. ErbB2, hCNT1, hCNT3, ABCG2, " exact="MRP1" post=" and MRP2 mRNA expression was evaluated in PDAC datasets of the NCBI Gene Expression Omnibus" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" A. ErbB2, hCNT1, hCNT3, ABCG2, MRP1 and " exact="MRP2" post=" mRNA expression was evaluated in PDAC datasets of the NCBI Gene Expression Omnibus (GEO, GSE28735)" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tumor tissues. Statistical analyses were performed using paired t-test. B. ErbB2 and " exact="MRP2" post=" mRNA level in 10 ErbB2 high and 10 ErbB2 low patients C. correlation of M" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" mRNA level in 10 ErbB2 high and 10 ErbB2 low patients C. correlation of " exact="MRP2" post=" and ErbB2 mRNA levels in 45 tumor samples. Statistical analyses were performed using Pearso" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ee of resistance to various anticancer drugs [ 29]. We observed that mRNA levels of " exact="MRP1" post=" and MRP2 are altered in tumors compared to adjacent non tumoral tissue. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" to various anticancer drugs [ 29]. We observed that mRNA levels of MRP1 and " exact="MRP2" post=" are altered in tumors compared to adjacent non tumoral tissue. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="CAPAN-2 ErbB2-KD cells strongly overexpressed mRNA of " exact="ABCG2" post=", MRP1 and MRP2 transporters. ABCG2 has been described as directly involved in acquir" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre="CAPAN-2 ErbB2-KD cells strongly overexpressed mRNA of ABCG2, " exact="MRP1" post=" and MRP2 transporters. ABCG2 has been described as directly involved in acquired resistance" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="CAPAN-2 ErbB2-KD cells strongly overexpressed mRNA of ABCG2, MRP1 and " exact="MRP2" post=" transporters. ABCG2 has been described as directly involved in acquired resistance to SN-38 in col" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ef=&quot;#R30&quot;&gt;30, 31]. Mohelnikova-Duchonova et al described the upregulation of " exact="ABCG2" post=" mRNA in PDAC and proposed that ABCG2 in tumors may contribute to the generally poor treatment resp" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre="independent experiments. Expression level of genes of interest was normalized to the mRNA level of " exact="GAPDH" post=" housekeeping gene. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre="Transient inhibitions of " exact="ABCG2" post=" (sc-41151), MRP1 (sc-35962) MRP2 (sc-35963), Akt (sc-43609) and p38 (s" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" name="human"/>
   <result pre="Transient inhibitions of ABCG2 (sc-41151), " exact="MRP1" post=" (sc-35962) MRP2 (sc-35963), Akt (sc-43609) and p38 (sc-29433) were performed " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Transient inhibitions of ABCG2 (sc-41151), MRP1 (sc-35962) " exact="MRP2" post=" (sc-35963), Akt (sc-43609) and p38 (sc-29433) were performed using a pool of siRNA d" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="up&gt; (Qiagen) as described by the manufacturer. Transient KD for ErbB2, Erk1 (MAPK3), " exact="JNK1" post=" (MAPK8), NF- κB (p105 NF-κB) was performed using siRNA from Dharmacon (Thermo Scient" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4488128/results/gene/human/results.xml">
   <result pre=" aFor neoadjuvant cohort, AJCC clinical stage is shown. " exact="HER2" post=" pos Human epidermal growth factor receptor overexpressing, IBC invasive" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" shown. HER2 pos Human epidermal growth factor receptor overexpressing, " exact="IBC" post=" invasive breast cancer, T + C trastuzumab and chemotherapy, AJCC American Joint Comm" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ptor overexpressing, IBC invasive breast cancer, T + C trastuzumab and chemotherapy, " exact="AJCC" post=" American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="dy population. In this study, 87 patients with human epidermal growth factor receptor 2-positive ( " exact="HER2" post=" pos ) breast cancer were enrolled; all tumors were histologically confirmed as " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" breast cancer were enrolled; all tumors were histologically confirmed as invasive breast cancer ( " exact="IBC" post=") with HER2 overexpression (3+ or 2+/fluorescence in situ hybridization (FISH)-positive). Cohorts a" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="emotherapy ( T + C) was 26 (IQR 16.5–31.0) months. pCR pathologic complete response, " exact="DCI" post=" type 1-polarized dendritic cell, Adj adjuvant, mo months " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Interferon (IFN)-γ + anti-human epidermal growth factor receptor 2 ( " exact="HER2" post=") CD4 + T cell response variations in HER2 pos patients with invasive breast " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ated with Neoadjuvant T + C (n = 40) and those treated with Adjuvant T + C (n = 25). " exact="SFC" post=" spot-forming cells " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="non-pCR (n = 4; white bars) were stimulated ex vivo with two HER2-derived class I peptides, " exact="HER2" post=" 369– 377 and HER2 689–697, and IFN-γ product" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="x vivo with two HER2-derived class I peptides, HER2 369– 377 and " exact="HER2" post=" 689–697, and IFN-γ production via ELISPOT was compared. Phorbol-12-myristate 1" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="9–697, and IFN-γ production via ELISPOT was compared. Phorbol-12-myristate 13-acetate ( " exact="PMA" post=") and ionomycin served as positive control. Results are expressed as mean spot-forming cells ( S" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=") and ionomycin served as positive control. Results are expressed as mean spot-forming cells ( " exact="SFC" post=")/2 × 10 5 cells ± standard error of the mean " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="sion analysis to determine independent correlates to pCR. pCR pathologic complete response, " exact="BMI" post=" body mass index, AJCC American Joint Committee on Cancer, ER estrogen receptor, P" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ndependent correlates to pCR. pCR pathologic complete response, BMI body mass index, " exact="AJCC" post=" American Joint Committee on Cancer, ER estrogen receptor, PR progesterone receptor, " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="trogen receptor, PR progesterone receptor, AC/TH Adriamycin/Cytoxan/Taxol/Herceptin, " exact="BCS" post=" breast-conserving surgery, XRT radiotherapy " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e receptor, AC/TH Adriamycin/Cytoxan/Taxol/Herceptin, BCS breast-conserving surgery, " exact="XRT" post=" radiotherapy " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="dominant phenotype contributing to interferon-γ + ( IFN-γ + ) " exact="CD4" post=" + T cell deficit in patients without pathologic complete response ( " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="enotypes to HER2 peptide-specific IFN-γ + cells in peripheral blood mononuclear cells ( " exact="PBMC" post=") from pCR and non-pCR patients. Representative stains within groups are shown after gating on CD4 " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" SEM ( top panel). Donor-matched cumulative IFN-γ and IL-4 production (spot-forming cells ( " exact="SFC" post=")/10 6 cells) across six HER2 class II peptides compared in pCR and non-pCR patients. Re" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="l T cell anergy, or increase in immunosuppressive phenotypes. Peripheral blood mononuclear cells ( " exact="PBMC" post=") from pCR and non-pCR patients did not differ significantly in ( a) immune competence – measured b" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="HER2" post=" human epidermal growth factor receptor 2, DC1 type 1-polarized dendritic cell, IBC i" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HER2 human epidermal growth factor receptor 2, " exact="DC1" post=" type 1-polarized dendritic cell, IBC invasive breast cancer, HLA human leukocyte ant" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HER2 human epidermal growth factor receptor 2, DC1 type 1-polarized dendritic cell, " exact="IBC" post=" invasive breast cancer, HLA human leukocyte antigen (A2 yes/no), ER estrogen recepto" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" factor receptor 2, DC1 type 1-polarized dendritic cell, IBC invasive breast cancer, " exact="HLA" post=" human leukocyte antigen (A2 yes/no), ER estrogen receptor, PR progesterone receptor," xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="p post-neoadjuvant pathologic stage, AC/TH Adriamycin/Cyclophosphamide/Taxol/Herceptin, " exact="MRM" post=" modified radical mastectomy, FISH fluorescence in situ hybridization, TC Taxotere, C" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" AC/TH Adriamycin/Cyclophosphamide/Taxol/Herceptin, MRM modified radical mastectomy, " exact="FISH" post=" fluorescence in situ hybridization, TC Taxotere, Cyclophosphamide " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="cells) increase progressively in patients with non-pCR at the 3-month and 6-month time points. " exact="SFC" post=" spot-forming cells " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="10, 24]. Indeed, the association between improved HER2 369–377-specific " exact="CD8" post=" + T-cell immune responses and tumor eradication in pCR patients may reflect th" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lper type-1 (Th1) metrics utilized herein. PBMC are plated in triplicate, and spot-forming cells ( " exact="SFC" post=") following ex vivo human epidermal growth factor receptor (HER)2-derived class II peptide stimulat" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4494975/results/gene/human/results.xml">
   <result pre="and OS [ 36]. The authors also highlighted the independence of this effect from the " exact="KRAS" post=" mutation status and suggested that patients' constitutional factors were possibly involved in the " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[5]/p[1]" name="human"/>
   <result pre="An optional ancillary study assessed the predictive value of individual biomarkers, such as " exact="KRAS" post=" mutations, HER1 and HER2 expression, and Fcγ receptor polymorphisms (FcγRIIA-H131R and FcγRIIIA-V1" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[5]/p[1]" name="human"/>
   <result pre="cal specimens was evaluated by immunohistochemistry, as previously described [ 23]. " exact="KRAS" post=" mutations in tumor tissues were determined by high resolution melt analysis and direct sequencing " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4504492/results/gene/human/results.xml">
   <result pre="and AKT targeted drugs. Several studies have shown that HER2 + tumors with mutations in " exact="PIK3CA" post=" or PTEN respond differently to HER2 targeted therapies than HER2 + tumor without" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="drugs. Several studies have shown that HER2 + tumors with mutations in PIK3CA or " exact="PTEN" post=" respond differently to HER2 targeted therapies than HER2 + tumor without these mutation" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="e.0133219.ref016&quot;&gt;16, 18, 22]. Since " exact="PIK3CA" post=" mutations occur in about a third of HER2 amplified breast tumors [ " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre=" lapatinib in combination with AKT inhibitors was synergistic in HER2 + cell lines with " exact="PIK3CA" post=" mutations (HER2 +/PKK3CA mut) but not in HER + cells with wildtyp" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="ed on RPPA consisting of 174 validated proteins to analyze the specific effects of introduction of " exact="PIK3CA" post=" mutants into the wild type line SKBR3 (both full RPPA data sets that were used to generate the res" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="cDNAs encoding helical or kinase mutants of the " exact="PIK3CA" post=" gene were obtained from Frank McCormick (UCSF) in pENTR vectors and recombined with pBABE puro des" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="We measured responses to drugs targeting HER2 and AKT administered singly and in combination in 22 " exact="HER2" post=" + amplified breast cancer cell lines (see Table 1 for list" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="This is consistent with the notion that effective inhibition of PI3K-AKT signaling by lapatinib in " exact="HER2" post=" + cells is one of the major requirements for therapeutic response. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="). Interestingly, 5/5 of the lines that had significant synergy also harbored hotspot mutations in " exact="PIK3CA" post=" ( P&amp;amp;lt;0.001 for the association between synergy and mutation status by Fisher’s exact " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="sher’s exact test; see Fig 2A). Two of the synergistic lines harbored " exact="PIK3CA" post=" E545K (helical domain) mutations (MDAMB361 and HCC202) and three of the lines " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="ee Fig 2A). Two of the synergistic lines harbored PIK3CA " exact="E545K" post=" (helical domain) mutations (MDAMB361 and HCC202) and three of the lines had PIK3CA &lt;" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="p&gt; E545K (helical domain) mutations (MDAMB361 and HCC202) and three of the lines had " exact="PIK3CA" post=" H1047R (kinase domain) mutations (HCC1954, SUM190PT, and UACC893). In contrast" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="p&gt; (helical domain) mutations (MDAMB361 and HCC202) and three of the lines had PIK3CA " exact="H1047R" post=" (kinase domain) mutations (HCC1954, SUM190PT, and UACC893). In contrast, only 1/17 non-syne" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="54, SUM190PT, and UACC893). In contrast, only 1/17 non-synergistic lines had a hotspot mutation in " exact="PIK3CA" post=". The exception was MDAMB453 that had both an H1047R PIK3CA mutation and an inactivating PTEN&lt;/i" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="PIK3CA. The exception was MDAMB453 that had both an H1047R PIK3CA mutation and an inactivating " exact="PTEN" post=" mutation. This line showed responses to both lapatinib and GSK690693, but has one of the lowest le" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="n. This line showed responses to both lapatinib and GSK690693, but has one of the lowest levels of " exact="HER2" post=" amplification by copy number analysis [ 24], and some have question" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="T inhibitors is unclear. One possibility is that EFM192A has a rare, non-hotspot C420R mutation in " exact="PIK3CA" post=" that may be activating and that may cause subtle differences in inhibitor binding or efficacy. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="We explored the hypothesis that " exact="PIK3CA" post=" mutations are causally linked to the synergistic response to lapatinib plus GSK690693 by introduci" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="nse to lapatinib plus GSK690693 by introducing PIK3CA hotspot mutations (E545K or H1047R) into the " exact="PIK3CA" post=" wild type cell line SKBR3 by retroviral transduction. Immunoblotting showed that the introduction " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="gnificantly blunted in the mutant cells. Western blot analysis of cell lysates from non-engineered " exact="PIK3CA" post=" mut cells confirmed that there was a reduced recovery of p-HER3 compared to &lt;i" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="i&gt; mut cells confirmed that there was a reduced recovery of p-HER3 compared to " exact="PIK3CA" post=" WT cells following treatment with lapatinib ( Fig" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre=" A. Western blots of SKBR3 cells transduced with retroviruses encoding either PIK3CA " exact="H1047R" post=" or E545K mutant alleles or control vector (mCherry). Mutant transduced " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="KBR3 cells transduced with retroviruses encoding either PIK3CA H1047R or " exact="E545K" post=" mutant alleles or control vector (mCherry). Mutant transduced lines show increased levels o" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ib treatment. D. Western blotting confirms the lack of recovery in non-engineered cells lines with " exact="PIK3CA" post=" mutations compared to PIK3CA wild type lines. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="nfirms the lack of recovery in non-engineered cells lines with PIK3CA mutations compared to " exact="PIK3CA" post=" wild type lines. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="We found that the model described the observed changes in pAKT and p-S6RP levels in both " exact="PIK3CA" post=" mutant and wild-type cell lines. Furthermore, the model allowed us to compute downstream AKT pathw" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre=" inhibited. These findings show that a subtle change to signaling network topology associated with " exact="PIK3CA" post=" mutation status is capable of explaining the synergistic effect of GSK690693 and lapatinib within " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="the cell line panel and the engineered SKBR3 cells. We found that introduction of a mutant form of " exact="PIK3CA" post=" resulted in decreased responsiveness to lapatinib but led to synergistic interactions between lapa" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="93. Down-regulation of elements of the PI3K-AKT pathway was notably less in cell lines with mutant " exact="PIK3CA" post=" compared to their wild-type counterparts when treated with lapatinib or alone. However, with the c" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="ber of specific mechanisms for synergy. The key causal hypothesis encoded in the model is that the " exact="PIK3CA" post=" mutation confers specific regulation that in turn leads to synergy. To experimentally test the put" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre=" regulation that in turn leads to synergy. To experimentally test the putative causal link between " exact="PIK3CA" post=" mutation and synergy we asked whether introduction of PIK3CA mutations into wild-type lines" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="e putative causal link between PIK3CA mutation and synergy we asked whether introduction of " exact="PIK3CA" post=" mutations into wild-type lines could change response patterns from non-synergistic to synergistic." xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="It is important to note that several of the non-synergistic lines harbored other mutations in " exact="PIK3CA" post=" that have been previously observed at a much lower frequency. The first of these was BT474, which " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="bserved at a much lower frequency. The first of these was BT474, which harbors a K111N mutation in " exact="PIK3CA" post=". This mutation has been reported to confer weak oncogenicity, unlike the other PIK3CA mutat" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="on in PIK3CA. This mutation has been reported to confer weak oncogenicity, unlike the other " exact="PIK3CA" post=" mutations, which are strongly transforming in chick embryo fibroblasts [ &lt;a href=&quot;#pone.0133219.re" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="sts [ 36]. Similarly, JIMT1 and the EFM192 lines all harbor another " exact="PIK3CA" post=" mutation (C420R). Interestingly, EFM192A showed significant synergy with GSK2141795. The C420R mut" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre=" may be a threshold of PI3K pathway activity that must be overcome in HER2 + cells with " exact="PIK3CA" post=" mutations that can be suppressed with AKT inhibitors, resulting in synergistic interactions with l" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre=" The lack of response (and even evidence of antagonistic interaction) in cell lines with wild-type " exact="PIK3CA" post=" with such combinations speaks against a role for feedback related pathway activation and resistanc" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[8]" name="human"/>
   <result pre="e while the other is more consistent with ER negative tumors [ 23]. " exact="PIK3CA" post=" mutations are reported to be prevalent in both groups, suggesting that combination therapies may b" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4506361/results/gene/human/results.xml">
   <result pre="Somatic " exact="ERBB2" post=" amplification or activating mutations occur in approximately 2–5% of metastatic colorectal adenoca" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="pulmonary metastases, who had progressed on both standard of care cytotoxic chemotherapy and anti- " exact="EGFR" post=" targeted therapy. Comprehensive genomic profiling (FoundationOne ®) identified amplific" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre=" therapy. Comprehensive genomic profiling (FoundationOne ®) identified amplification of " exact="ERBB2" post=" and a TP 53 mutation in the metastatic lesion. Treatment with trastuzumab with " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre=" abdomino-perineal resection was performed and subsequent molecular testing confirmed the tumor as " exact="KRAS" post=" wild-type. Anti- EGFR combination treatment with FOLFIRI and cetuximab was initiated and co" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="was performed and subsequent molecular testing confirmed the tumor as KRAS wild-type. Anti- " exact="EGFR" post=" combination treatment with FOLFIRI and cetuximab was initiated and continued for 9 months until te" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="Comprehensive genomic profiling identified amplification of " exact="ERBB2" post=" (quantitatively estimated as 21 copies) in the metastatic tumor, as well as a loss of function poi" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="timated as 21 copies) in the metastatic tumor, as well as a loss of function point mutation within " exact="TP53" post=". Combination therapy of trastuzumab with a backbone of capecitabine and oxaliplatin was started. T" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="was eliminated after 6 months of treatment. Imaging with PET/CT scans at 3 and 5 months post anti- " exact="ERBB2" post=" treatment showed reduction of tumor burden with SUV in the lesion at the apex of the right lung fa" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre=" " exact="ERBB2" post=" encodes the receptor tyrosine kinase HER2, a member of the epidermal growth factor receptor family" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="growth factor receptor family that has been linked to normal cell proliferation and tissue growth. " exact="ERBB2" post=" amplification (2.5–3%) or mutation (~2%) is present in a small subset of CRC patients [ &lt;a href=&quot;#" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="CRC, although a recent meta-analysis found no significant effect on survival [ 10]. " exact="ERBB2" post=" amplification and HER2 overexpression have best been characterized in carcinomas of the breast whe" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="acy in combination with cytotoxic chemotherapy [ 12, 13]. Studies of " exact="ERBB2" post=" amplification in gastric and breast cancer patients have shown a correlation between copy number a" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="The efficacy of trastuzumab in breast and gastric cancers suggests by analogy that patients with " exact="ERBB2" post=" amplified CRC may also benefit from targeted anti-HER2 therapies such as trastuzumab, as in the ca" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre=" as in the case reported here. At least two case studies have demonstrated consistent responses of " exact="ERBB2" post=" amplified left sided colorectal carcinoma and rectal carcinoma to trastuzumab monotherapy [ &lt;a hre" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="ectal carcinoma may predict response to anti-HER2 targeted therapy, akin to the same phenomenon in " exact="ERBB2" post=" amplified breast cancer, but quantitative estimates of copy number were not available for the prev" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="ef=&quot;#R18&quot;&gt;18]. Although preliminary, treatment with trastuzumab and lapatinib in this sub group of " exact="ERBB2" post=" amplified cancer as identified by FISH or IHC was without significant toxicity and demonstrated mo" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="nts a year in the US alone. Comprehensive genomic profiling offers both quantitative estimation of " exact="ERBB2" post=" amplification as well as assessment of the remainder of the genomic profile, and when applied in t" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre=" of clinical care could provide greater insight into the efficacy of anti-HER2 targeted therapy in " exact="ERBB2" post=" amplified CRC patients. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre=" [ 21, 22]. In this patient, the additional activating alteration of " exact="TP53" post=" also identified through comprehensive genomic profiling has been associated with poor survival [ &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre="enomic profiling has been associated with poor survival [ 23]. This patient with an " exact="ERBB2" post=" amplified rectal carcinoma, after exhausting prior guideline driven therapies, responded for 12 mo" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[5]" name="human"/>
   <result pre=" that the efficacy was driven by the addition of trastuzumab, likely linked to the relatively high " exact="ERBB2" post=" amplification in this case quantitatively estimated to be 21 copies. " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4524128/results/gene/human/results.xml">
   <result pre=" " exact="ECOG" post=" Eastern Cooperative Oncology Group " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4529453/results/gene/human/results.xml">
   <result pre="ceptor 2 (HER2) is a protein on the surface of cancer cells that stimulates tumor growth. When the " exact="HER2" post=" gene is amplified, it triggers overproduction, commonly called overexpression, of HER2 [ &lt;a href=&quot;" xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt;1] protein. Tumors that strongly overexpress HER2 and/or those with a proven amplification of the " exact="HER2" post=" gene are classified as being HER2 positive. HER2-positive cancers are associated with poor overall" xpath="/html[1]/body[1]/article[1]/div[3]/div[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ges [ 2– 4]. In the early days of HER2 testing, amplification of the " exact="HER2" post=" gene and the corresponding overexpression of HER2 protein was found in approximately 25 to 30 % of" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4534500/results/gene/human/results.xml">
   <result pre="). α-KG, a substrate for multiple enzymes, is important for cellular response to oxidative stress. " exact="IDH" post=" mutation results in accumulation of D-2-hydroxyglutarate, predisposing cells to malignant transfor" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4535951/results/gene/human/results.xml">
   <result pre="), but not in PDX BL0269 (12 days versus 13 days in the control, p = 0.16) although both expressed " exact="HER2" post=". To screen for the most effective MTT, we evaluated three drugs (lapatinib, ponatinib, and BEZ235)" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ound to be altered in two or more tumors, only 5 mutations occurred in more than one tumor model ( " exact="ADCY2" post=" p.V147L, ERBB2 p.I655V, NCF2 p.H308Q, SYNE1 p.L885V, and ZNF814 p.158V" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="two or more tumors, only 5 mutations occurred in more than one tumor model ( ADCY2 p.V147L, " exact="ERBB2" post=" p.I655V, NCF2 p.H308Q, SYNE1 p.L885V, and ZNF814 p.158V). Most PDXs contained" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ly 5 mutations occurred in more than one tumor model ( ADCY2 p.V147L, ERBB2 p.I655V, " exact="NCF2" post=" p.H308Q, SYNE1 p.L885V, and ZNF814 p.158V). Most PDXs contained 3–10 somatic mutatio" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ed in more than one tumor model ( ADCY2 p.V147L, ERBB2 p.I655V, NCF2 p.H308Q, " exact="SYNE1" post=" p.L885V, and ZNF814 p.158V). Most PDXs contained 3–10 somatic mutations (in 3–10 genes), ex" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="model ( ADCY2 p.V147L, ERBB2 p.I655V, NCF2 p.H308Q, SYNE1 p.L885V, and " exact="ZNF814" post=" p.158V). Most PDXs contained 3–10 somatic mutations (in 3–10 genes), except for PDXs BL0269 and BL" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="pectively. Notably, mutations in functionally active genes were identified in every PDX, including " exact="ARID1A" post=", ATM, CASP8, CDH1, KALRN, KMT2C, NCF2, MTOR, P" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="bly, mutations in functionally active genes were identified in every PDX, including ARID1A, " exact="ATM" post=", CASP8, CDH1, KALRN, KMT2C, NCF2, MTOR, PIK3CA, &lt;" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ns in functionally active genes were identified in every PDX, including ARID1A, ATM, " exact="CASP8" post=", CDH1, KALRN, KMT2C, NCF2, MTOR, PIK3CA, TSC1, an" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ally active genes were identified in every PDX, including ARID1A, ATM, CASP8, " exact="CDH1" post=", KALRN, KMT2C, NCF2, MTOR, PIK3CA, TSC1, and TP53" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="enes were identified in every PDX, including ARID1A, ATM, CASP8, CDH1, " exact="KALRN" post=", KMT2C, NCF2, MTOR, PIK3CA, TSC1, and TP53; 6–10 mutatio" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="tified in every PDX, including ARID1A, ATM, CASP8, CDH1, KALRN, " exact="KMT2C" post=", NCF2, MTOR, PIK3CA, TSC1, and TP53; 6–10 mutations in bladder " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="y PDX, including ARID1A, ATM, CASP8, CDH1, KALRN, KMT2C, " exact="NCF2" post=", MTOR, PIK3CA, TSC1, and TP53; 6–10 mutations in bladder cancer driver" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ing ARID1A, ATM, CASP8, CDH1, KALRN, KMT2C, NCF2, " exact="MTOR" post=", PIK3CA, TSC1, and TP53; 6–10 mutations in bladder cancer driver genes were f" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=", ATM, CASP8, CDH1, KALRN, KMT2C, NCF2, MTOR, " exact="PIK3CA" post=", TSC1, and TP53; 6–10 mutations in bladder cancer driver genes were found in 5 of 8 " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="&gt;, CASP8, CDH1, KALRN, KMT2C, NCF2, MTOR, PIK3CA, " exact="TSC1" post=", and TP53; 6–10 mutations in bladder cancer driver genes were found in 5 of 8 models ( &lt;a h" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="CDH1, KALRN, KMT2C, NCF2, MTOR, PIK3CA, TSC1, and " exact="TP53" post="; 6–10 mutations in bladder cancer driver genes were found in 5 of 8 models ( &lt;a href=&quot;#pone.013434" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=" 71 mutations found, there were approximately 29 &quot;expressed&quot; mutations in 20 genes ( e. g., " exact="ARID1A" post=", CASP8, KLF5, MLH1, NOTCH1, PIK3CA, and SYNE2) that exce" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ound, there were approximately 29 &quot;expressed&quot; mutations in 20 genes ( e. g., ARID1A, " exact="CASP8" post=", KLF5, MLH1, NOTCH1, PIK3CA, and SYNE2) that exceeded the cut-o" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="re approximately 29 &quot;expressed&quot; mutations in 20 genes ( e. g., ARID1A, CASP8, " exact="KLF5" post=", MLH1, NOTCH1, PIK3CA, and SYNE2) that exceeded the cut-off of low/mod" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ely 29 &quot;expressed&quot; mutations in 20 genes ( e. g., ARID1A, CASP8, KLF5, " exact="MLH1" post=", NOTCH1, PIK3CA, and SYNE2) that exceeded the cut-off of low/moderate transcr" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ssed&quot; mutations in 20 genes ( e. g., ARID1A, CASP8, KLF5, MLH1, " exact="NOTCH1" post=", PIK3CA, and SYNE2) that exceeded the cut-off of low/moderate transcript abundance (" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=" in 20 genes ( e. g., ARID1A, CASP8, KLF5, MLH1, NOTCH1, " exact="PIK3CA" post=", and SYNE2) that exceeded the cut-off of low/moderate transcript abundance ( i. e., " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=". g., ARID1A, CASP8, KLF5, MLH1, NOTCH1, PIK3CA, and " exact="SYNE2" post=") that exceeded the cut-off of low/moderate transcript abundance ( i. e., ≥10 FPKM or fragme" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ters of the bladder cancer PDXs contained aberrations in one or more of the tumor suppressor genes " exact="TP53" post=", RB1, and CDKN2A ( Fig 4) . Specifically, these include" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ladder cancer PDXs contained aberrations in one or more of the tumor suppressor genes TP53, " exact="RB1" post=", and CDKN2A ( Fig 4) . Specifically, these included somatic mu" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="Xs contained aberrations in one or more of the tumor suppressor genes TP53, RB1, and " exact="CDKN2A" post=" ( Fig 4) . Specifically, these included somatic mutations of TP53&lt;" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="KN2A ( Fig 4) . Specifically, these included somatic mutations of " exact="TP53" post=" (R248Q, R280T, E177*, and E285K) and RB1 (R358X), and copy number variants of RB1 (i" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="Specifically, these included somatic mutations of TP53 (R248Q, R280T, E177*, and E285K) and " exact="RB1" post=" (R358X), and copy number variants of RB1 (in BL0293, BL0429, and BL0479) and CDKN2A " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="f TP53 (R248Q, R280T, E177*, and E285K) and RB1 (R358X), and copy number variants of " exact="RB1" post=" (in BL0293, BL0429, and BL0479) and CDKN2A (in BL0269, BL0382, BL0429, and BL0479). Most of" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="and RB1 (R358X), and copy number variants of RB1 (in BL0293, BL0429, and BL0479) and " exact="CDKN2A" post=" (in BL0269, BL0382, BL0429, and BL0479). Most of the TP53 somatic mutations were heterozygous (all" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=" E177X truncating mutation in BL0382, the latter of which was also accompanied by markedly reduced " exact="TP53" post=" transcript levels ( Fig 4A and 4B) . A corresponding decrease in M" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=" transcript levels ( Fig 4A and 4B) . A corresponding decrease in " exact="MDM2" post=" expression was observed in the BL0293 and BL0479 tumors that contain R248Q and R280T mutations in " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=" expression was observed in the BL0293 and BL0479 tumors that contain R248Q and R280T mutations in " exact="TP53" post=", respectively. Copy number losses or deletions, occurring at the RB1 and CDKN2A loci" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="nd R280T mutations in TP53, respectively. Copy number losses or deletions, occurring at the " exact="RB1" post=" and CDKN2A loci, were validated by comparison with the RNA-Seq data demonstrating a nearly " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ons in TP53, respectively. Copy number losses or deletions, occurring at the RB1 and " exact="CDKN2A" post=" loci, were validated by comparison with the RNA-Seq data demonstrating a nearly complete absence o" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="of mRNA Expression, Mutations, and Copy Number was performed for genes in the " exact="TP53" post=" and RB1 tumor suppressor pathways. Gene-level expression (FPKM) values for pathway member g" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ssion, Mutations, and Copy Number was performed for genes in the TP53 and " exact="RB1" post=" tumor suppressor pathways. Gene-level expression (FPKM) values for pathway member genes are presen" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=" (green = lower than the median, red = greater than the median). Mutations (amino acid changes) in " exact="TP53" post=" and RB1 are indicated. Gene copy numbers are presented, and variants indicated as losses ( " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="than the median, red = greater than the median). Mutations (amino acid changes) in TP53 and " exact="RB1" post=" are indicated. Gene copy numbers are presented, and variants indicated as losses ( i. e., &amp;" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="6 Table) . In addition, several exhibited universally high expression in the PDX models, including " exact="AHNAK" post=", BCL2L1, CDKN1A, CTNNB1, HRAS, RHOA, and YWHAZ. Similarl" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="addition, several exhibited universally high expression in the PDX models, including AHNAK, " exact="BCL2L1" post=", CDKN1A, CTNNB1, HRAS, RHOA, and YWHAZ. Similarly, evaluation o" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="al exhibited universally high expression in the PDX models, including AHNAK, BCL2L1, " exact="CDKN1A" post=", CTNNB1, HRAS, RHOA, and YWHAZ. Similarly, evaluation of the 291 high-" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="iversally high expression in the PDX models, including AHNAK, BCL2L1, CDKN1A, " exact="CTNNB1" post=", HRAS, RHOA, and YWHAZ. Similarly, evaluation of the 291 high-confidence driv" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="expression in the PDX models, including AHNAK, BCL2L1, CDKN1A, CTNNB1, " exact="HRAS" post=", RHOA, and YWHAZ. Similarly, evaluation of the 291 high-confidence driver (HCD) gene" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=" the PDX models, including AHNAK, BCL2L1, CDKN1A, CTNNB1, HRAS, " exact="RHOA" post=", and YWHAZ. Similarly, evaluation of the 291 high-confidence driver (HCD) genes identified " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="including AHNAK, BCL2L1, CDKN1A, CTNNB1, HRAS, RHOA, and " exact="YWHAZ" post=". Similarly, evaluation of the 291 high-confidence driver (HCD) genes identified via pan-cancer ana" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="poptosis were also significantly enriched (25 genes, p = 3.95 X 10 −06), such as " exact="DAD1" post=", MCL1, SOD1, TPT1, and YWHAZ, implicating the presence of a generalized survi" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre=" also significantly enriched (25 genes, p = 3.95 X 10 −06), such as DAD1, " exact="MCL1" post=", SOD1, TPT1, and YWHAZ, implicating the presence of a generalized survival advantage" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="cantly enriched (25 genes, p = 3.95 X 10 −06), such as DAD1, MCL1, " exact="SOD1" post=", TPT1, and YWHAZ, implicating the presence of a generalized survival advantage. " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="ed (25 genes, p = 3.95 X 10 −06), such as DAD1, MCL1, SOD1, " exact="TPT1" post=", and YWHAZ, implicating the presence of a generalized survival advantage. " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="hed therapy testing ( S1 Fig) : fibroblast growth factor receptor 3 ( " exact="FGFR3" post="), ephrin type B receptor 4 ( EphB4), proto-oncogene tyrosine-protein kinase Src, hum" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="d 3 ( HER2/3) and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha ( " exact="PIK3CA" post="). Among these five targets, FGFR3 was a particularly attractive target as it was highly exp" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="tol-4,5-bisphosphate 3-kinase, catalytic subunit alpha ( PIK3CA). Among these five targets, " exact="FGFR3" post=" was a particularly attractive target as it was highly expressed in four of eight PDX models (57.4–" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="0134346.g005&quot;&gt;Fig 5B , five of the eight PDXs (BL0269, BL0382, BL0429, BL0479 and BL0440) had high " exact="HER2" post=" mRNA levels as determined by RNA-seq, and high (3+) HER2 protein levels as determined by IH" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="L0429, BL0479 and BL0440) had high HER2 mRNA levels as determined by RNA-seq, and high (3+) " exact="HER2" post=" protein levels as determined by IHC staining, and manifested by the chicken wire pattern of HER2 s" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" on the cell membrane ( Fig 5C upper panels); two were positive for " exact="HER3" post=" (BL0429 and BL0440); five were positive for FGFR3 with a representative staining shown in " xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="g 5C upper panels); two were positive for HER3 (BL0429 and BL0440); five were positive for " exact="FGFR3" post=" with a representative staining shown in Fig 5C left lower panel (BL" xpath="/html[1]/body[1]/article[1]/div[4]/div[3]/div[8]/div[2]/p[1]" name="human"/>
   <result pre="rget protein expression with IHC. Only selected imagings were shown. PDX BL0440 was stained 3+ for " exact="HER2" post=" with chicken wire pattern of positive staining at cell membrane while BL0515 was stained negative." dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4538762/results/gene/human/results.xml">
   <result pre=" HR+ = ER and/or PR positive tumor, HR- = ER and/or PR negative tumor, " exact="HER2" post=" human epidermal growth factor receptor type 2 oncogene, HER2+ = HER2 over expressed or ampl" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4541732/results/gene/human/results.xml">
   <result pre="d by immunoblotting (IB) with ( I): anti-HER2 ECD, ( II) HER2 ICD (CB11 clone) and ( " exact="III" post=") anti-actin. b Representative Ariol system images from control slides with SKBR3 cells. ( a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="( A-D) cells while low ( E-H) or no ECD ( I-L) was identified in SCOV3 cells. " exact="ECD" post=" extracellular domain, HER2 human epidermal growth factor receptor 2, ICD intracellul" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="i&gt;E-H) or no ECD ( I-L) was identified in SCOV3 cells. ECD extracellular domain, " exact="HER2" post=" human epidermal growth factor receptor 2, ICD intracellular domain " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="COV3 cells. ECD extracellular domain, HER2 human epidermal growth factor receptor 2, " exact="ICD" post=" intracellular domain " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HER2 CTCs. c Number of CTCs with p95HER2 and HER2 phenotype. CTCs circulating tumor cells, " exact="HER2" post=" human epidermal growth factor receptor 2, p95HER2 the truncated form of HER2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" Abbreviations: ER estrogen receptor, PR progesterone receptor, " exact="HER2" post=" human epidermal growth factor receptor 2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" Abbreviations: ER estrogen receptor, PR progesterone receptor, " exact="HER2" post=" human epidermal growth factor receptor 2, CTCs circulating tumor cells; CK cytokerat" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="A45-B/B3) antibodies and ( b) CTCs with full length receptor. CTCs circulating tumor cells, " exact="ECD" post=" extracellular domain, HER2 human epidermal growth factor receptor 2, ICD intracellul" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="s with full length receptor. CTCs circulating tumor cells, ECD extracellular domain, " exact="HER2" post=" human epidermal growth factor receptor 2, ICD intracellular domain " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="umor cells, ECD extracellular domain, HER2 human epidermal growth factor receptor 2, " exact="ICD" post=" intracellular domain " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" after trastuzumab-based chemotherapy. CK cytokeratin, CTCs circulating tumor cells, " exact="HER2" post=" human epidermal growth factor receptor 2, p95HER2 the truncated form of HER2 " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4542411/results/gene/human/results.xml">
   <result pre="of chemotherapeutic drugs. 50 A few multidrug resistance genes including " exact="MRP2" post=" and MDR1 are upregulated by hypoxia. An induction of MDR1 by HIF-1α has been reported in br" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tic drugs. 50 A few multidrug resistance genes including MRP2 and " exact="MDR1" post=" are upregulated by hypoxia. An induction of MDR1 by HIF-1α has been reported in breast, colon, and" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4546491/results/gene/human/results.xml">
   <result pre=" stem cell pluripotency pathway enrichment and highlighted recurring, significant amplification of " exact="SOX2" post=", PIK3CA, NTRK1, GNAS, CTNNB1, and FGFR1. For a subset of the me" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="uripotency pathway enrichment and highlighted recurring, significant amplification of SOX2, " exact="PIK3CA" post=", NTRK1, GNAS, CTNNB1, and FGFR1. For a subset of the metastatic brain " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="way enrichment and highlighted recurring, significant amplification of SOX2, PIK3CA, " exact="NTRK1" post=", GNAS, CTNNB1, and FGFR1. For a subset of the metastatic brain tumor samples " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre=" and highlighted recurring, significant amplification of SOX2, PIK3CA, NTRK1, " exact="GNAS" post=", CTNNB1, and FGFR1. For a subset of the metastatic brain tumor samples (n=4) we comp" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ted recurring, significant amplification of SOX2, PIK3CA, NTRK1, GNAS, " exact="CTNNB1" post=", and FGFR1. For a subset of the metastatic brain tumor samples (n=4) we compared patient-ma" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ificant amplification of SOX2, PIK3CA, NTRK1, GNAS, CTNNB1, and " exact="FGFR1" post=". For a subset of the metastatic brain tumor samples (n=4) we compared patient-matched primary brea" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="iteria there were no recurring gene losses. Among the recurrent gene amplifications were oncogenes " exact="PIK3CA" post=" and MYC, also known to be frequently amplified in breast cancers. Ingenuity Pathways Analys" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="no recurring gene losses. Among the recurrent gene amplifications were oncogenes PIK3CA and " exact="MYC" post=", also known to be frequently amplified in breast cancers. Ingenuity Pathways Analysis (IPA) of the" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="href=&quot;#F1&quot;&gt;1); genes in this pathway showing copy number aberrations in the metastatic tumors were " exact="PIK3CA" post=", SOX2 and the neurotrophin receptor NTRK1. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="genes in this pathway showing copy number aberrations in the metastatic tumors were PIK3CA, " exact="SOX2" post=" and the neurotrophin receptor NTRK1. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="aberrations in the metastatic tumors were PIK3CA, SOX2 and the neurotrophin receptor " exact="NTRK1" post=". " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="e that were recurrent, the numbers of analyzed genes mapping to this pathway increased, to include " exact="SOX2" post=", PIK3CA, NTRK1 as well as GNAS, CTNNB1, and FGFR1 (Figure &lt;a hr" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ecurrent, the numbers of analyzed genes mapping to this pathway increased, to include SOX2, " exact="PIK3CA" post=", NTRK1 as well as GNAS, CTNNB1, and FGFR1 (Figure 2). In" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="umbers of analyzed genes mapping to this pathway increased, to include SOX2, PIK3CA, " exact="NTRK1" post=" as well as GNAS, CTNNB1, and FGFR1 (Figure 2). In addition, amo" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre=" mapping to this pathway increased, to include SOX2, PIK3CA, NTRK1 as well as " exact="GNAS" post=", CTNNB1, and FGFR1 (Figure 2). In addition, among all the genes in thi" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="his pathway increased, to include SOX2, PIK3CA, NTRK1 as well as GNAS, " exact="CTNNB1" post=", and FGFR1 (Figure 2). In addition, among all the genes in this analyzed data" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ed, to include SOX2, PIK3CA, NTRK1 as well as GNAS, CTNNB1, and " exact="FGFR1" post=" (Figure 2). In addition, among all the genes in this analyzed data set 13 amplified " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="red in the primary tumor, but 6 cancer gene aberrations were observed in the metastatic tumor with " exact="ERBB2" post=" having the highest copy number gain. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="e metastatic tumor labeled 13-19 shows a high-level, focused amplification encompassing the entire " exact="ERBB2" post=" gene on chromosome 17q12 (Figure 4a). Analysis of the matched primary tumor by aCGH " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ref=&quot;#F4&quot;&gt;4a). Analysis of the matched primary tumor by aCGH showed that specimen was negative for " exact="ERBB2" post=" amplification. This negative result concurs with the clinical pathology report for the original br" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="t concurs with the clinical pathology report for the original breast cancer biopsy specimen, where " exact="ERBB2" post=" gene was not amplified according to FISH (Figure 4b). However, the original patholog" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="In this specific patient example, a. according to aCGH analysis high copy number gain for " exact="ERBB2" post=" was observed in the metastatic brain tumor specimen. ERBB2 is the only translated gene that" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="alysis high copy number gain for ERBB2 was observed in the metastatic brain tumor specimen. " exact="ERBB2" post=" is the only translated gene that mapped to the focal amplification coordinates HG19: Chr17: 378633" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="e original biopsied breast cancer specimen concluded that there was normal diploid copy number for " exact="ERBB2" post=" in DNA, and this agrees with results of our aCGH analysis of the primary specimen that were also n" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre=" this agrees with results of our aCGH analysis of the primary specimen that were also negative for " exact="ERBB2" post=" amplification. c. IHC analysis of the primary breast cancer specimen indicates that although not D" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="tastatic tumor specimens included genes known to be frequently amplified in breast cancers such as " exact="PIK3CA" post=" and MYC. Pathway analysis of gene sets comprising amplifications showed significant enrichm" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="cimens included genes known to be frequently amplified in breast cancers such as PIK3CA and " exact="MYC" post=". Pathway analysis of gene sets comprising amplifications showed significant enrichment for the Ste" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="em Cell Pluripotency pathway, highlighting our discovery of recurring significant amplification of " exact="SOX2" post=", PIK3CA, NTRK1, GNAS, CTNNB1, and FGFR1 in the samples analyzed" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="potency pathway, highlighting our discovery of recurring significant amplification of SOX2, " exact="PIK3CA" post=", NTRK1, GNAS, CTNNB1, and FGFR1 in the samples analyzed. This contribu" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre=", highlighting our discovery of recurring significant amplification of SOX2, PIK3CA, " exact="NTRK1" post=", GNAS, CTNNB1, and FGFR1 in the samples analyzed. This contributes genomic ev" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre=" our discovery of recurring significant amplification of SOX2, PIK3CA, NTRK1, " exact="GNAS" post=", CTNNB1, and FGFR1 in the samples analyzed. This contributes genomic evidence to rei" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="y of recurring significant amplification of SOX2, PIK3CA, NTRK1, GNAS, " exact="CTNNB1" post=", and FGFR1 in the samples analyzed. This contributes genomic evidence to reinforce the impo" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ificant amplification of SOX2, PIK3CA, NTRK1, GNAS, CTNNB1, and " exact="FGFR1" post=" in the samples analyzed. This contributes genomic evidence to reinforce the importance of cancer s" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="Copy number gains are activating for oncogenes such as " exact="ERBB2" post=" (identified in 2 of 10 metastatic tumor specimens analyzed) because they cause corresponding aberr" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ed in our analysis (amplified in 4 of 10 metastatic tumors analyzed) was the neurotrophin receptor " exact="NTRK1" post=", a tyrosine kinase growth factor receptor. According to database queries NTRK1 is normally " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="hin receptor NTRK1, a tyrosine kinase growth factor receptor. According to database queries " exact="NTRK1" post=" is normally highly expressed in central and peripheral nervous system tissues and only the lowest " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="according to data from The Cancer Genome Atlas (TCGA) — accessed and analyzed via the cBioPortal — " exact="NTRK1" post=" copy number gains occur in 12% of invasive breast carcinomas (of 962 samples) [ 33," xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ltogether, the data provide early evidence to indicate that amplification and/or overexpression of " exact="NTRK1" post=" has a potential role in the incidence of metastatic breast tumors and warrants further study. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="t showed nearly identical cancer gene aberration profiles (Figure 3a). For this pair " exact="CCND1" post=" specifically demonstrated a high amplification in the primary cancer (1.32 log2 ratio amplificatio" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="static tumor (a 752,615 base pair, 2.2 log2 ratio amplification comprising only 6 genes, including " exact="CCND1" post=", MRGPRD, MRGPRF, TPCN2, MYEOV and ORAOV1). AKT2 amplific" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="a 752,615 base pair, 2.2 log2 ratio amplification comprising only 6 genes, including CCND1, " exact="MRGPRD" post=", MRGPRF, TPCN2, MYEOV and ORAOV1). AKT2 amplification was detec" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="pair, 2.2 log2 ratio amplification comprising only 6 genes, including CCND1, MRGPRD, " exact="MRGPRF" post=", TPCN2, MYEOV and ORAOV1). AKT2 amplification was detected only in the" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ratio amplification comprising only 6 genes, including CCND1, MRGPRD, MRGPRF, " exact="TPCN2" post=", MYEOV and ORAOV1). AKT2 amplification was detected only in the metastatic tu" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ation comprising only 6 genes, including CCND1, MRGPRD, MRGPRF, TPCN2, " exact="MYEOV" post=" and ORAOV1). AKT2 amplification was detected only in the metastatic tumor samples, a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="only 6 genes, including CCND1, MRGPRD, MRGPRF, TPCN2, MYEOV and " exact="ORAOV1" post="). AKT2 amplification was detected only in the metastatic tumor samples, as part of a broad " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="cluding CCND1, MRGPRD, MRGPRF, TPCN2, MYEOV and ORAOV1). " exact="AKT2" post=" amplification was detected only in the metastatic tumor samples, as part of a broad low level ampl" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="(0.4 log2 ratio, 2.5Mb comprising more than 75 genes/transcripts). Together, the data suggest that " exact="AKT2" post=" is not causal for the metastatic lesion, but that CCND1 likely has a role in the primary br" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="ts). Together, the data suggest that AKT2 is not causal for the metastatic lesion, but that " exact="CCND1" post=" likely has a role in the primary breast cancer that is reinforced in the metastatic cancer. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="in the metastasis. In one instance, for only the primary tumor (set 13-02 Figure 3b) " exact="MET" post=" was part of a focal amplification event (1.1 log2 ratio spanning 287,678 base pairs and 2 genes: &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="&gt; was part of a focal amplification event (1.1 log2 ratio spanning 287,678 base pairs and 2 genes: " exact="MET" post=" and CAV1); also, broad amplification events comprising MYC and DDR2 were iden" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre=" focal amplification event (1.1 log2 ratio spanning 287,678 base pairs and 2 genes: MET and " exact="CAV1" post="); also, broad amplification events comprising MYC and DDR2 were identified in both p" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="8 base pairs and 2 genes: MET and CAV1); also, broad amplification events comprising " exact="MYC" post=" and DDR2 were identified in both primary and metastatic samples (≤0.8 log2 ratio, spanning " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="d 2 genes: MET and CAV1); also, broad amplification events comprising MYC and " exact="DDR2" post=" were identified in both primary and metastatic samples (≤0.8 log2 ratio, spanning from 5Mb to 40Mb" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="for a number of genes in the metastatic tumor sample; including focused, high copy number gain for " exact="ERBB2" post=". FISH analysis verified aCGH ERBB2-negative results in the cancer-of-origin specimen, but t" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[7]" name="human"/>
   <result pre="mor sample; including focused, high copy number gain for ERBB2. FISH analysis verified aCGH " exact="ERBB2" post="-negative results in the cancer-of-origin specimen, but the alternative measure that detected high " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4552740/results/gene/human/results.xml">
   <result pre="ell proliferation and tamoxifen-resistance. Here, we show high level of expression and function of " exact="BCAR4" post=" in human breast cancer. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" " exact="BCAR4" post=" mRNA expression was evaluated by (q)RT-PCR in a panel of human normal tissues, primary breast canc" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Except for placenta, all human normal tissues tested were " exact="BCAR4" post="-negative. In primary breast cancers, BCAR4 expression was comparatively rare (10%), but ass" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="r placenta, all human normal tissues tested were BCAR4-negative. In primary breast cancers, " exact="BCAR4" post=" expression was comparatively rare (10%), but associated with enhanced proliferation. Relative high" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="expression was comparatively rare (10%), but associated with enhanced proliferation. Relative high " exact="BCAR4" post=" mRNA expression was identified in IPH-926, a cell line derived from an endocrine-resistant lobular" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="tified in IPH-926, a cell line derived from an endocrine-resistant lobular breast cancer. Moderate " exact="BCAR4" post=" expression was evident in MDA-MB-134 and MDA-MB-453 breast cancer cells. BCAR4 protein was detecte" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="-453 breast cancer cells. BCAR4 protein was detected in breast cancer cells with ectopic (ZR-75-1- " exact="BCAR4" post=") and endogenous (IPH-926, MDA-MB-453) BCAR4 mRNA expression. Knockdown of BCAR4 inhi" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="d in breast cancer cells with ectopic (ZR-75-1- BCAR4) and endogenous (IPH-926, MDA-MB-453) " exact="BCAR4" post=" mRNA expression. Knockdown of BCAR4 inhibited cell proliferation. A similar effect was obse" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="5-1- BCAR4) and endogenous (IPH-926, MDA-MB-453) BCAR4 mRNA expression. Knockdown of " exact="BCAR4" post=" inhibited cell proliferation. A similar effect was observed upon knockdown of ERBB2/3 and exposure" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=". A similar effect was observed upon knockdown of ERBB2/3 and exposure to lapatinib, implying that " exact="BCAR4" post=" acts in an ERBB2/3-dependent manner. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" " exact="BCAR4" post=" encodes a functional protein, which drives proliferation of endocrine-resistant breast cancer cell" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="-resistant breast cancer cells. Lapatinib, a clinically approved EGFR/ERBB2 inhibitor, counteracts " exact="BCAR4" post="-driven tumor cell growth, a clinical relevant observation. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="=&quot;#pone.0136845.ref007&quot;&gt;7]. We have previously isolated Breast Cancer Anti-estrogen Resistance 4 ( " exact="BCAR4" post="), a gene that can override tamoxifen-induced growth suppression in vitro [ &lt;a href=&quot;#pone.0" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" in vitro [ 8– 11]. In brief, " exact="BCAR4" post=" was identified by a functional genetic screening in the ER-positive and estrogen-dependent BC cell" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="oliferating cell colony, the inserted gene was identified by PCR and nucleotide sequence analysis. " exact="BCAR4" post=", which was solely recovered from the placenta-derived cDNA library, was the most frequently identi" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="-75–1 colonies [ 8]. Retroviral transduction of ZR-75-1 with only a " exact="BCAR4" post=" expression construct yielded the same phenotype [ 10]. ZR-75-1- " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="/i&gt; expression construct yielded the same phenotype [ 10]. ZR-75-1- " exact="BCAR4" post=" cells proliferated despite hormone deprivation or exposure to various anti-estrogens [ &lt;a href=&quot;#p" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="5.ref010&quot;&gt;10]. Functional characterization of this genetically engineered cell model revealed that " exact="BCAR4" post=" acts independently from ER-associated signal transduction and enhances cell proliferation via&lt;/" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Apart for these findings from in vitro models, the physiological function of " exact="BCAR4" post=" is ill defined. The BCAR4 gene is well conserved in primates [ &lt;a href=&quot;#pone.0136845.ref01" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ndings from in vitro models, the physiological function of BCAR4 is ill defined. The " exact="BCAR4" post=" gene is well conserved in primates [ 10]. Distant BCAR4 orth" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" The BCAR4 gene is well conserved in primates [ 10]. Distant " exact="BCAR4" post=" orthologues also exist in other placental species, but not in the rodents mouse and rat [ &lt;a href=" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="analyses of Gene Expression Omnibus (GEO) data sets have indicated a tissue-specific expression of " exact="BCAR4" post=" in the placenta in all stages of development [ 10]. Moreover, BC" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="4 in the placenta in all stages of development [ 10]. Moreover, " exact="BCAR4" post=" is expressed in matured and fertilized bovine oocytes [ 12]. BCA" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="R4 is expressed in matured and fertilized bovine oocytes [ 12]. " exact="BCAR4" post=" is annotated as a long non-coding RNA (LncRNA) [ 13, &lt;a href=&quot;#pone" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="mutation, disrupting the predicted open reading frame, abrogates the pro-proliferative activity of " exact="BCAR4" post=" [ 8]. This implies the existence of a putative BCAR4 protein. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="In clinical BC specimens, " exact="BCAR4" post=" mRNA is detectable in approximately 10–27% of cases, depending on the tumor collection and the ass" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="9]. In patients treated with tamoxifen for advanced disease, higher " exact="BCAR4" post=" mRNA levels are associated with an aggressive tumor phenotype and reduced progression-free surviva" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ession-free survival [ 9]. Human BC cell lines with high endogenous " exact="BCAR4" post=" expression have not been described, so far [ 10]. This has limited " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ave not been described, so far [ 10]. This has limited studies into " exact="BCAR4" post=" function to genetically engineered cells, whose physiological relevance is uncertain. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Here, we report on the high endogenous " exact="BCAR4" post=" mRNA and protein expression in IPH-926, a cell line derived from an endocrine-resistant lobular BC" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" BC [ 15– 18]. Our results show that " exact="BCAR4" post=" encodes for a functional protein, which is critical for cell proliferation. Lapatinib, a clinicall" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="inib, a clinically approved ERBB2/EGFR inhibitor [ 19], counteracts " exact="BCAR4" post="-driven tumor cell growth. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="g, ICRF, London. Transfected or retroviral transduced ZR-75-1 cells with ectopic overexpression of " exact="BCAR1" post=", BCAR3, BCAR4 and EGFR have been described previously [ &lt;a href=&quot;#pone.013684" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="n. Transfected or retroviral transduced ZR-75-1 cells with ectopic overexpression of BCAR1, " exact="BCAR3" post=", BCAR4 and EGFR have been described previously [ 11, " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" or retroviral transduced ZR-75-1 cells with ectopic overexpression of BCAR1, BCAR3, " exact="BCAR4" post=" and EGFR have been described previously [ 11, &lt;a href=&quot;#pone" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ansduced ZR-75-1 cells with ectopic overexpression of BCAR1, BCAR3, BCAR4 and " exact="EGFR" post=" have been described previously [ 11, &lt;a href=&quot;#pone.0136845.ref010&quot;" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="with expression vector pEGFP-N1 (Clontech, Westburg B.V., Leusden, the Netherlands) or an EGFP-N1- " exact="BCAR4" post=" fusion construct. All cell lines were authenticated by short tandem repeat (STR) profiling with th" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="rlands). The IPH-926 cell line was additionally authenticated by PCR-based detection of its unique " exact="CDH1" post=" 241ins4 frameshift mutation, as described previously [ 15]. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="136845.ref015&quot;&gt;15]. Quantitative assessment of gene expression normalized to the housekeeping gene " exact="GUSB" post=" was performed with Platinum Taq DNA polymerase (Invitrogen, Karlsruhe, Germany), Sybr Green I (Inv" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="merase (Invitrogen, Karlsruhe, Germany), Sybr Green I (Invitrogen) and the QuantiTect ® " exact="BCAR4" post=" primer assay (Qiagen, Hilden, Germany) on an ABI Prism 7700 system (Applied Biosystems, Foster Cit" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="700 system (Applied Biosystems, Foster City, U.S.A.). For monitoring of siRNA-mediated inhibition, " exact="HPRT" post=", B2M and PBGD were employed as reference genes for normalization. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="pplied Biosystems, Foster City, U.S.A.). For monitoring of siRNA-mediated inhibition, HPRT, " exact="B2M" post=" and PBGD were employed as reference genes for normalization. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ms, Foster City, U.S.A.). For monitoring of siRNA-mediated inhibition, HPRT, B2M and " exact="PBGD" post=" were employed as reference genes for normalization. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ere 25 nM for the siRNA and 0.1% for the transfection reagent. In experiments using siRNAs against " exact="EGFR" post=" media were supplemented with 10 ng/ml EGF (Roche Diagnostics, Almere, the Netherlands). For each c" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ere On TARGETplus-SMARTpools, each consisting of three different oligonucleotides directed against " exact="EGFR" post=" (L-003114-00-0005), ERBB2 (L-003126-00-005), ERBB3 (L-003127-00-0005) or ERBB4&lt;/i" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ch consisting of three different oligonucleotides directed against EGFR (L-003114-00-0005), " exact="ERBB2" post=" (L-003126-00-005), ERBB3 (L-003127-00-0005) or ERBB4 (L003128-00-0005) (Dharmacon). " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" oligonucleotides directed against EGFR (L-003114-00-0005), ERBB2 (L-003126-00-005), " exact="ERBB3" post=" (L-003127-00-0005) or ERBB4 (L003128-00-0005) (Dharmacon). The siRNAs directed against B" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="EGFR (L-003114-00-0005), ERBB2 (L-003126-00-005), ERBB3 (L-003127-00-0005) or " exact="ERBB4" post=" (L003128-00-0005) (Dharmacon). The siRNAs directed against BCAR4 (siBCAR4, AM 16708A, IDs 2" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" (L-003127-00-0005) or ERBB4 (L003128-00-0005) (Dharmacon). The siRNAs directed against " exact="BCAR4" post=" (siBCAR4, AM 16708A, IDs 276004, 268474 and 268475) were purchased from Life Technologies (Darmsta" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" used to monitor gene silencing as described above. Mean inhibition of mRNA expression was 65% for " exact="BCAR4" post=", 89% for ERBB2, 91% for ERBB3, and 62% for ERBB4 in IPH-926 cells. After five" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="silencing as described above. Mean inhibition of mRNA expression was 65% for BCAR4, 89% for " exact="ERBB2" post=", 91% for ERBB3, and 62% for ERBB4 in IPH-926 cells. After five days in culture, a WS" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" above. Mean inhibition of mRNA expression was 65% for BCAR4, 89% for ERBB2, 91% for " exact="ERBB3" post=", and 62% for ERBB4 in IPH-926 cells. After five days in culture, a WST-1 proliferation assa" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" mRNA expression was 65% for BCAR4, 89% for ERBB2, 91% for ERBB3, and 62% for " exact="ERBB4" post=" in IPH-926 cells. After five days in culture, a WST-1 proliferation assay (Roche Diagnostics) was " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Meta-analysis of published microarray datasets has indicated a tissue-specific expression of " exact="BCAR4" post=" in the placenta [ 10]. We subjected various human normal tissues to" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="in the placenta [ 10]. We subjected various human normal tissues to " exact="BCAR4" post=" mRNA assessment by quantitative real-time RT-PCR (q)RT-PCR. BCAR4 mRNA levels were low or u" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="s human normal tissues to BCAR4 mRNA assessment by quantitative real-time RT-PCR (q)RT-PCR. " exact="BCAR4" post=" mRNA levels were low or undetectable in normal tissues, except for placenta ( &lt;a href=&quot;#pone.01368" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="A). In addition, we analyzed a panel of human BC cell lines and thereby identified relatively high " exact="BCAR4" post=" expression in IPH-926 BC cells ( Fig 1B). Moderate BCAR4 expre" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" high BCAR4 expression in IPH-926 BC cells ( Fig 1B). Moderate " exact="BCAR4" post=" expression was detected in MDA-MB-134 and MDA-MB-453. Consistent with previous findings [ &lt;a href=" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" findings [ 10], other BC cell lines showed barely detectable or no " exact="BCAR4" post=". Features of BC cell lines with high/moderate BCAR4 mRNA included (i) a luminal subtype, (i" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ll lines showed barely detectable or no BCAR4. Features of BC cell lines with high/moderate " exact="BCAR4" post=" mRNA included (i) a luminal subtype, (ii) mutation of CDH1/E-cadherin and (iii) an origin f" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="C cell lines with high/moderate BCAR4 mRNA included (i) a luminal subtype, (ii) mutation of " exact="CDH1" post="/E-cadherin and (iii) an origin from endocrine-resistant tumors ( Fig " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ef017&quot;&gt;17, 16, 15]. To rule out that " exact="BCAR4" post=" expression in BC cell lines is an artifact due to in vitro cultivation, we analyzed the ori" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ected to (q)RT-PCR. Compared with IPH-926, the original tumor specimens showed only slightly lower " exact="BCAR4" post=" mRNA levels ( Fig 1C). Hence, BCAR4 mRNA in the tumor has been" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="showed only slightly lower BCAR4 mRNA levels ( Fig 1C). Hence, " exact="BCAR4" post=" mRNA in the tumor has been maintained in the derived BC cell line. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ure. Grey indicates: Positive for ER, PR and ERBB2; or mutated/aberrantly methylated for the genes " exact="TP53" post=", PIK3CA and CDH1/E-cadherin; or lobular for original tumor histology; or luminal for" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="icates: Positive for ER, PR and ERBB2; or mutated/aberrantly methylated for the genes TP53, " exact="PIK3CA" post=" and CDH1/E-cadherin; or lobular for original tumor histology; or luminal for molecular subt" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="or ER, PR and ERBB2; or mutated/aberrantly methylated for the genes TP53, PIK3CA and " exact="CDH1" post="/E-cadherin; or lobular for original tumor histology; or luminal for molecular subtype; or derived " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Next, " exact="BCAR4" post=" mRNA expression was analyzed in a series of primary, pre-treatment BCs. Since BC cell lines with h" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ion was analyzed in a series of primary, pre-treatment BCs. Since BC cell lines with high/moderate " exact="BCAR4" post=" mRNA expression featured CDH1/E-cadherin mutations, this tumor series was enriched for lobu" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="y, pre-treatment BCs. Since BC cell lines with high/moderate BCAR4 mRNA expression featured " exact="CDH1" post="/E-cadherin mutations, this tumor series was enriched for lobular carcinomas, which lack E-cadherin" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="6) BCAR4-positive cases ( Fig 2A). Only 2.1% (2/96) BCs showed " exact="BCAR4" post=" mRNA levels comparable with IPH-926 or MDA-MB-134. BCAR4-positive cases were associated wit" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="e status and expression of cytokeratin 5/14 ( Table 2). Consistently, " exact="BCAR4" post="-positive cases were also associated with high proliferation, as determined via the Ki67 lab" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="arker panel [ 23, 24], revealed high " exact="BCAR4" post=" mRNA expression in a small subset of luminal-B BCs, which are associated with endocrine resistance" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Cases are ordered by " exact="BCAR4" post=" mRNA expression level (A), or by molecular subtype (B). Error bars represent SEM. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Several lines of evidence suggest that " exact="BCAR4" post=" encodes a protein [ 8, 12], but clas" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ficity of this new antibody was verified by western blot analysis of ZR-75–1 cells transduced with " exact="BCAR4" post=", BCAR4-EGFP, EGFP, or with the anti-estrogen resistance related genes BCAR1, " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="erified by western blot analysis of ZR-75–1 cells transduced with BCAR4, BCAR4-EGFP, " exact="EGFP" post=", or with the anti-estrogen resistance related genes BCAR1, BCAR3 and EGFR [ &lt;" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="h BCAR4, BCAR4-EGFP, EGFP, or with the anti-estrogen resistance related genes " exact="BCAR1" post=", BCAR3 and EGFR [ 11]. Only ZR-75-1- BCAR4 cel" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=", BCAR4-EGFP, EGFP, or with the anti-estrogen resistance related genes BCAR1, " exact="BCAR3" post=" and EGFR [ 11]. Only ZR-75-1- BCAR4 cells showed a ba" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="i&gt;, EGFP, or with the anti-estrogen resistance related genes BCAR1, BCAR3 and " exact="EGFR" post=" [ 11]. Only ZR-75-1- BCAR4 cells showed a band migrating at " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="nes BCAR1, BCAR3 and EGFR [ 11]. Only ZR-75-1- " exact="BCAR4" post=" cells showed a band migrating at approximately 13 kd, the predicted size of the putative BCAR4 pro" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" the predicted size of the putative BCAR4 protein ( Fig 3A). ZR-75-1- " exact="BCAR4" post="- EGFP displayed a band migrating at approximately 37 kd. The increased size is due to the E" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" size of the putative BCAR4 protein ( Fig 3A). ZR-75-1- BCAR4- " exact="EGFP" post=" displayed a band migrating at approximately 37 kd. The increased size is due to the EGFP-tag in th" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=", but not in MDA-MB-134 and UACC-893 ( Fig 3C and 3D). Using ZR-75-1- " exact="BCAR4" post=" cells as a functional model, we have previously shown that BCAR4 enhances cell proliferatio" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="3C and 3D). Using ZR-75-1- BCAR4 cells as a functional model, we have previously shown that " exact="BCAR4" post=" enhances cell proliferation and renders genetically engineered BC cells hormone-independent [ &lt;a h" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="[ 18]. Accordingly, we used siRNA-mediated gene silencing to assess " exact="BCAR4" post=" functions as a pro-proliferative factor in IPH-926 ( Fig 3E). Suffici" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ro-proliferative factor in IPH-926 ( Fig 3E). Sufficient knockdown of " exact="BCAR4" post=" was verified by (q)RT-PCR (details in materials and methods). As expected, BCAR4 siRNAs, bu" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ockdown of BCAR4 was verified by (q)RT-PCR (details in materials and methods). As expected, " exact="BCAR4" post=" siRNAs, but not EGFR siRNAs, significantly suppressed proliferation of IPH-926 ( &lt;a href=&quot;#" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="erified by (q)RT-PCR (details in materials and methods). As expected, BCAR4 siRNAs, but not " exact="EGFR" post=" siRNAs, significantly suppressed proliferation of IPH-926 ( Fig 3E). " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Fig 3E). A similar effect was observed in MDA-MB-453 cells. In UACC-893 and MDA-MB-134, which lack " exact="BCAR4" post=" mRNA or protein, proliferation was not affected by BCAR4 inhibition ( &lt;a href=&quot;#pone.013684" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ACC-893 and MDA-MB-134, which lack BCAR4 mRNA or protein, proliferation was not affected by " exact="BCAR4" post=" inhibition ( Fig 3E). Hence, BCAR4 is expressed as a protein and driv" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="cipitation in human BC cell lines. (E) Human BC cell lines were exposed to siRNAs directed against " exact="BCAR4" post=" (siBCAR4, average of three individual siRNAs), EGFR (siEGFR) or to the transfection mix (TF" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ere exposed to siRNAs directed against BCAR4 (siBCAR4, average of three individual siRNAs), " exact="EGFR" post=" (siEGFR) or to the transfection mix (TF-mix) reagents only. Subsequently, cell proliferation was m" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Using ZR-75-1- " exact="BCAR4" post=" cells as a model, we have previously shown that BCAR4 activates ERBB2/3 and its downstream " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Using ZR-75-1- BCAR4 cells as a model, we have previously shown that " exact="BCAR4" post=" activates ERBB2/3 and its downstream mediators AKT and ERK1/2 by phosphorylation [ &lt;a href=&quot;#pone." xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" ERK1/2 by phosphorylation [ 9, 11]. " exact="BCAR4" post="-induced cell proliferation was abrogated by knockdown of ERBB2 and ERBB3, suggesting that BCAR4" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="CAR4-induced cell proliferation was abrogated by knockdown of ERBB2 and ERBB3, suggesting that " exact="BCAR4" post=" acts in an ERBB2/3-dependent manner [ 9]. High BCAR4 express" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ng that BCAR4 acts in an ERBB2/3-dependent manner [ 9]. High " exact="BCAR4" post=" expression in IPH-926 was an unexpected finding, since these cells are ERBB2-negative as determine" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="were exposed to our previously validated siRNAs against various growth factor receptors, including " exact="ERBB2" post=" and ERBB3 ( Fig 4C). While siRNAs directed against EGFR" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ur previously validated siRNAs against various growth factor receptors, including ERBB2 and " exact="ERBB3" post=" ( Fig 4C). While siRNAs directed against EGFR and ERBB4" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="i&gt;ERBB2 and ERBB3 ( Fig 4C). While siRNAs directed against " exact="EGFR" post=" and ERBB4 had little or no effect, proliferation was suppressed by siRNAs against ERBB2&lt;" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ERBB3 ( Fig 4C). While siRNAs directed against EGFR and " exact="ERBB4" post=" had little or no effect, proliferation was suppressed by siRNAs against ERBB2 and ERBB3&lt;" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="&gt;EGFR and ERBB4 had little or no effect, proliferation was suppressed by siRNAs against " exact="ERBB2" post=" and ERBB3 ( Fig 4C). To rule out non-specific effects of siRNA" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ERBB4 had little or no effect, proliferation was suppressed by siRNAs against ERBB2 and " exact="ERBB3" post=" ( Fig 4C). To rule out non-specific effects of siRNAs against ERBB" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ls for EGFR [ 29]. (C) IPH-926 cells were exposed to siRNAs against " exact="EGFR" post=" (siEGFR), ERBB2 (siERBB2), ERBB3 (ERBB3), ERBB4 (ERBB4) or to the transfectio" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="&quot;#pone.0136845.ref029&quot;&gt;29]. (C) IPH-926 cells were exposed to siRNAs against EGFR (siEGFR), " exact="ERBB2" post=" (siERBB2), ERBB3 (ERBB3), ERBB4 (ERBB4) or to the transfection mix (TF-mix) reagents" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="9]. (C) IPH-926 cells were exposed to siRNAs against EGFR (siEGFR), ERBB2 (siERBB2), " exact="ERBB3" post=" (ERBB3), ERBB4 (ERBB4) or to the transfection mix (TF-mix) reagents only and cell prolifera" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="were exposed to siRNAs against EGFR (siEGFR), ERBB2 (siERBB2), ERBB3 (ERBB3), " exact="ERBB4" post=" (ERBB4) or to the transfection mix (TF-mix) reagents only and cell proliferation was measured with" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="We have previously identified the " exact="BCAR4" post=" gene as factor, whose ectopic overexpression can override tamoxifen-induced growth suppression " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="h suppression in vitro [ 8]. Follow-up studies revealed that " exact="BCAR4" post=" mRNA levels correlate with tumor aggressiveness in advanced stage BCs and that BCAR4 acts i" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="d that BCAR4 mRNA levels correlate with tumor aggressiveness in advanced stage BCs and that " exact="BCAR4" post=" acts in an ERBB2/3-dependent manner in ZR-75-1 and MCF7 cells [ 11," xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="5.ref010&quot;&gt;10, 9]. However, human BC cell lines with high endogenous " exact="BCAR4" post=" expression had not been identified [ 10]. Models for studying BC" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="4 expression had not been identified [ 10]. Models for studying " exact="BCAR4" post=" function remained limited to genetically engineered cells, such as ZR-75-1- BCAR4, whose ph" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" studying BCAR4 function remained limited to genetically engineered cells, such as ZR-75-1- " exact="BCAR4" post=", whose physiological relevance was uncertain [ 10]. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="The data reported herein are important in several ways. Detailed (q)RT-PCR analyses confirmed that " exact="BCAR4" post=" mRNA expression is restricted to the placenta in human normal tissues. We now successfully identif" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" successfully identified a human BC cell line with an endogenous, placenta-like high expression of " exact="BCAR4" post=". This cell line, IPH-926, had been established from an endocrine-resistant lobular BC and can be c" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="lar BC and can be considered as the physiologic counterpart of the genetically engineered ZR-75-1- " exact="BCAR4" post=" cell model. An anti-BCAR4 antibody was raised and showed for the first time that human BCAR4&lt;/i" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="i&gt;BCAR4 cell model. An anti-BCAR4 antibody was raised and showed for the first time that human " exact="BCAR4" post=" is expressed as a protein. Using IPH-926 cells as a new model and siRNA-mediated silencing of B" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" is expressed as a protein. Using IPH-926 cells as a new model and siRNA-mediated silencing of " exact="BCAR4" post=", we verified that this gene is critical for cell proliferation. Consistent with observations in ZR" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="d that this gene is critical for cell proliferation. Consistent with observations in ZR-75-1, high " exact="BCAR4" post=" expression was associated with sensitivity to ERBB2-inhibition, despite ERBB2 was expressed at ver" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="at very low levels in IPH-926 and ZR-75-1 cells. This substantiates our previous observation, that " exact="BCAR4" post=" acts in an ERBB2-dependent manner [ 11, &lt;a href=&quot;#pone.0136845.ref0" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ed ERBB2/EGFR inhibitor lapatinib emerges as a potential therapeutic alternative for patients with " exact="BCAR4" post="-positive tumors, showing endocrine resistance. Together, these data firmly establish the role of &lt;" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="&gt;-positive tumors, showing endocrine resistance. Together, these data firmly establish the role of " exact="BCAR4" post=" in breast cancer biology. " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="us studies in advanced stage BCs, the current work documents a lower rate of primary BC cases with " exact="BCAR4" post=" expression (10% versus 29%) and high expression (2% versus 14%). This may be related to the" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="assays used or the introduction of IPH-926 and human placenta tissue as a benchmark to define high " exact="BCAR4" post=" expression. Future translational studies will have to objectify the real prevalence of high BCA" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="R4 expression. Future translational studies will have to objectify the real prevalence of high " exact="BCAR4" post=" expression in unselected primary BCs. Even if high BCAR4 expression should be less common t" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ectify the real prevalence of high BCAR4 expression in unselected primary BCs. Even if high " exact="BCAR4" post=" expression should be less common than previously anticipated, BCAR4 would still represent o" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="imary BCs. Even if high BCAR4 expression should be less common than previously anticipated, " exact="BCAR4" post=" would still represent one of the best-characterized mechanisms of endocrine resistance known so fa" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" mechanisms of endocrine resistance known so far. Regarding cell signaling, it is interesting that " exact="ERBB2" post=" is expressed at barely detectable or low levels in IPH-926 and ZR-75-1, but still seems critically" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" at barely detectable or low levels in IPH-926 and ZR-75-1, but still seems critically involved in " exact="BCAR4" post="-induced cell proliferation. Other studies have also implied, that functionally relevant ERBB2 expr" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="xpression are not identified for targeted therapy [ 32]. Given that " exact="BCAR4" post=" is associated with ERBB2 activation and sensitivity to ERBB2-inhibition, but is not expressed in t" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="ut is not expressed in the normal mammary gland and most other human normal tissues, it seems that " exact="BCAR4" post=" might be an excellent biomarker to select patients with endocrine resistance for lapatinib therapy" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="Recently, the function of " exact="BCAR4" post=" was described as a LncRNA [ 33]. It was shown that the BCAR4" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="BCAR4 was described as a LncRNA [ 33]. It was shown that the " exact="BCAR4" post=" RNA is bound to two transcription factors SNIP1 and PNUTS (PPP1R10) activating a non-canonical Hed" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre=" Hedgehog/GLI2 transcription program. The binding site for SNIP1 is in the 5’ non-coding region of " exact="BCAR4" post=", the region that is dispensable for induction of tamoxifen resistance [ &lt;a href=&quot;#pone.0136845.ref" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="f010&quot;&gt;10]. Analysis of GEO expression data of IPH-926, oocyte and placenta with high expression of " exact="BCAR4" post=" showed absence or low expression of SNIP1, PNUTS and GLI target genes, which " xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="-926, oocyte and placenta with high expression of BCAR4 showed absence or low expression of " exact="SNIP1" post=", PNUTS and GLI target genes, which argues against a major role for the Hedgehog path" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" name="human"/>
   <result pre="nd placenta with high expression of BCAR4 showed absence or low expression of SNIP1, " exact="PNUTS" post=" and GLI target genes, which argues against a major role for the Hedgehog pathway in these t" xpath="/html[1]/body[1]/article[1]/div[4]/div[4]/p[6]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="high expression of BCAR4 showed absence or low expression of SNIP1, PNUTS and " exact="GLI" post=" target genes, which argues against a major role for the Hedgehog pathway in these tissues. Further" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558503/results/gene/human/results.xml">
   <result pre="Protein tyrosine kinase 6 (PTK6) expression, activation, and amplification of the " exact="PTK6" post=" gene have been reported in ERBB2/HER2-positive mammary gland cancers. To explore contributions of " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4558517/results/gene/human/results.xml">
   <result pre="nes representing a subgroup of HER2-positive breast tumors characterized by coamplification of the " exact="ERBB2" post=" and RARα genes. 20 This antitumor activity is remarkably stim" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" support our findings with SKBR3 ATG7-knockdown cells above, we silenced two additional ATG genes, " exact="ATG5" post=" and the class III phosphatidylinositol 3-kinase VPS34 in these cells. Following ATRA treatm" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" we silenced two additional ATG genes, ATG5 and the class III phosphatidylinositol 3-kinase " exact="VPS34" post=" in these cells. Following ATRA treatment, ATG5 and VPS34 depletion led to a consiste" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="the class III phosphatidylinositol 3-kinase VPS34 in these cells. Following ATRA treatment, " exact="ATG5" post=" and VPS34 depletion led to a consistent and significant increase in SKBR3 caspase-3/7 activ" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="osphatidylinositol 3-kinase VPS34 in these cells. Following ATRA treatment, ATG5 and " exact="VPS34" post=" depletion led to a consistent and significant increase in SKBR3 caspase-3/7 activity as compared w" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ramble control transfected cells ( Figure 5g). Knockdown efficiencies for ATG5 and " exact="VPS34" post=" are shown in Supplementary Figure 2d. This increased cell death response was paral" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" increased cell death response was paralleled by attenuated activation of autophagy as assessed by " exact="WIPI1" post=" transcript levels ( Supplementary Figure 2e). 23 Fin" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="a analysis were performed as described. 11 Gene Expression Assay for " exact="WIPI1" post=" and MAP1LC3B (microtubule-associated protein 1 light chain 3) used in a 96-well format on t" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="erformed as described. 11 Gene Expression Assay for WIPI1 and " exact="MAP1LC3B" post=" (microtubule-associated protein 1 light chain 3) used in a 96-well format on the StepOne plus sequ" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="em were Hs00215872_m1 and Hs00797944_s1, respectively (Applied Biosystems, Rotkreuz, Switzerland). " exact="HMBS" post=" ABL1 primers where 5′-TGGAGATAACACTCTAAGCATAACTAAAGGT-3′ and 5′-GATGTAGTTGCTTGGGACCCA-3′ an" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="215872_m1 and Hs00797944_s1, respectively (Applied Biosystems, Rotkreuz, Switzerland). HMBS " exact="ABL1" post=" primers where 5′-TGGAGATAACACTCTAAGCATAACTAAAGGT-3′ and 5′-GATGTAGTTGCTTGGGACCCA-3′ and probe was " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4567019/results/gene/human/results.xml">
   <result pre="Glycoprotein nonmetastatic B ( " exact="GPNMB" post=") is a potential oncogene that is particularly expressed in melanoma and breast cancer (BC). To cla" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" name="human"/>
   <result pre="First, the expression levels of " exact="GPNMB" post=" were evaluated using RT-PCR and western blot analysis. All cell lines (five BC cell lines, one imm" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" name="human"/>
   <result pre="ized normal breast cell line, six CC cell lines, and four GC cell lines) were subjected to RT-PCR. " exact="GPNMB" post=" was expressed in four of six (67%) BC cell lines (SK-BR-3, BT-474, MDA-MB-231, and MDA-MD-157). In" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" name="human"/>
   <result pre="olo320DM) of the six CC cell lines tested, two (MKN1 and MKN7) of the four GC cell lines expressed " exact="GPNMB" post=". We also examined the gene expression of various receptors, including ERα, HER2, and EGF" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" name="human"/>
   <result pre="MB. We also examined the gene expression of various receptors, including ERα, HER2, and " exact="EGFR" post="; however, GPNMB expression was independent from that of other receptors related to BC (Fig." xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" name="human"/>
   <result pre="ed the gene expression of various receptors, including ERα, HER2, and EGFR; however, " exact="GPNMB" post=" expression was independent from that of other receptors related to BC (Fig. 1A). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" name="human"/>
   <result pre="presentative BC cell lines (SK-BR-3, BT-474, and MDA-MB-157) also showed high expression levels of " exact="GPNMB" post=" (Fig. S1). " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4570757/results/gene/human/results.xml">
   <result pre=" IT intrathecal, " exact="CSF" post=" cerebrospinal fluid, RBC red blood cell, WBC white blood cell " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" IT intrathecal, CSF cerebrospinal fluid, " exact="RBC" post=" red blood cell, WBC white blood cell " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" IT intrathecal, CSF cerebrospinal fluid, RBC red blood cell, " exact="WBC" post=" white blood cell " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4578850/results/gene/human/results.xml">
   <result pre="ast, irrespective of ductal carcinoma in-situ or nodal involvement. CI confidence interval, " exact="HER2" post=" human epidermal growth factor receptor 2, HR hazard ratio. (Reproduced with permission from" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/ol[1]/li[2]/div[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" used. No multiplicity adjustment was made. HR hazard ratio, CI confidence interval, " exact="HER2" post=" human epidermal growth factor receptor 2. (Reproduced with permission from The Lancet, Cort" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/ol[1]/li[2]/div[1]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="DCIS" post=" ducal carcinoma in situ, pCR complete pathological response " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4586793/results/gene/human/results.xml">
   <result pre="&quot;#B12-cancers-07-00860&quot;&gt;12]. The benefit of cetuximab and Panitumumab was limited to patients with " exact="RAS" post=" wild-type tumors [ 10]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rs-07-00860&quot;&gt;129] ( Figure 1). JNK1, JNK2 and JNK3 are encoded by " exact="MAPK8" post=", MAPK9 and MAPK10. Although JNK1 and JNK2 are ubiquitously expressed, JNK3 is mainly" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="29] ( Figure 1). JNK1, JNK2 and JNK3 are encoded by MAPK8, " exact="MAPK9" post=" and MAPK10. Although JNK1 and JNK2 are ubiquitously expressed, JNK3 is mainly expressed in " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="ancers-07-00860-f001&quot;&gt;Figure 1). JNK1, JNK2 and JNK3 are encoded by MAPK8, MAPK9 and " exact="MAPK10" post=". Although JNK1 and JNK2 are ubiquitously expressed, JNK3 is mainly expressed in the brain and test" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="esses including proliferation, differentiation and apoptosis. In human cancer, mutations affecting " exact="MAPK9" post=" resulted in JNK1 high expression in liver and prostate cancers, while mutations of MAPK10 that led" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="es of cell cycle progression. This tumor suppressive role has been studied using mice disrupted in " exact="MEK3" post=" and MEK6 genes, where these mice exhibit increased tumorigenic potential and Ras-induced tr" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" progression. This tumor suppressive role has been studied using mice disrupted in MEK3 and " exact="MEK6" post=" genes, where these mice exhibit increased tumorigenic potential and Ras-induced transformation [ &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ost of cancer associated mutations affecting the MAP kinase signaling pathway involve mutations in " exact="RAS" post=" and RAF genes [ 143, 144]" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ssociated mutations affecting the MAP kinase signaling pathway involve mutations in RAS and " exact="RAF" post=" genes [ 143, 144]. Mutations in " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="molecules associated with this pathway have been found in several cancers. The somatic mutation of " exact="AKT1" post=" isoform associated with the substitution of glutamic acid by a lysine at amino acid 17 (E17K) of A" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="downstream signaling resulting in cell transformation. Furthermore, this mutation is also found in " exact="AKT3" post=" gene and results in an oncogenic protein product (Akt3 E17K) expressed in melanoma tumo" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="utations are diverse and include insertion, substitutions and deletions. Genetic amplifications in " exact="PIK3CA" post=", AKT1 and the AKT2 genes have also been reported. Other amplifications in the PIK" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="verse and include insertion, substitutions and deletions. Genetic amplifications in PIK3CA, " exact="AKT1" post=" and the AKT2 genes have also been reported. Other amplifications in the PIK3CA gene " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="sertion, substitutions and deletions. Genetic amplifications in PIK3CA, AKT1 and the " exact="AKT2" post=" genes have also been reported. Other amplifications in the PIK3CA gene were found in squamo" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="CA, AKT1 and the AKT2 genes have also been reported. Other amplifications in the " exact="PIK3CA" post=" gene were found in squamous cell lung carcinoma, head and neck, cervical, gastric, and oesophageal" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="174, 175]. Amplifications in the " exact="AKT1" post=" gene were associated with gastric cancer and in AKT2 gene with head and neck, pancreatic, o" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="-07-00860&quot;&gt;175]. Amplifications in the AKT1 gene were associated with gastric cancer and in " exact="AKT2" post=" gene with head and neck, pancreatic, ovary and breast cancers [ 1" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4589954/results/gene/human/results.xml">
   <result pre="finized 5-μm tissue sections using the PathVysion ERBB2 DNA probe kit and the ERBB2/centromere 17( " exact="HER2" post="/CEP17) probe mixture (Abbott Molecular, Des Plaines, IL, USA) [ 12, &lt;a href=&quot;#CR31" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="HER2" post=" human epidermal growth factor receptor 2, RT-PCR reverse transcriptase polymerase chain rea" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="epidermal growth factor receptor 2, RT-PCR reverse transcriptase polymerase chain reaction, " exact="IHC" post=" immunohistochemistry, FISH fluorescence in situ hybridization " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="2, RT-PCR reverse transcriptase polymerase chain reaction, IHC immunohistochemistry, " exact="FISH" post=" fluorescence in situ hybridization " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Distribution of HER2 by RT-PCR according to central HER2 by IHC. " exact="HER2" post=" human epidermal growth factor receptor 2, IHC immunohistochemistry, RT-PCR reverse t" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" by RT-PCR according to central HER2 by IHC. HER2 human epidermal growth factor receptor 2, " exact="IHC" post=" immunohistochemistry, RT-PCR reverse transcriptase polymerase chain reaction " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Distribution of HER2 by RT-PCR according to central FISH ratio. " exact="FISH" post=" fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, RT-PC" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="of HER2 by RT-PCR according to central FISH ratio. FISH fluorescence in situ hybridization, " exact="HER2" post=" human epidermal growth factor receptor 2, RT-PCR reverse transcriptase polymerase chain rea" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="line = estimate of hazard ratio; dashed lines = lower and upper 95 % confidence limits. " exact="DRFI" post=" distant recurrence-free interval, HER2 human epidermal growth factor receptor 2, RT-PCR&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" lines = lower and upper 95 % confidence limits. DRFI distant recurrence-free interval, " exact="HER2" post=" human epidermal growth factor receptor 2, RT-PCR reverse transcriptase polymerase chain rea" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Trastuzumab benefit by HER2 status by RT-PCR, FISH and IHC. " exact="FISH" post=" fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, IHC&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ab benefit by HER2 status by RT-PCR, FISH and IHC. FISH fluorescence in situ hybridization, " exact="HER2" post=" human epidermal growth factor receptor 2, IHC immunohistochemistry, RT-PCR reverse t" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="FISH fluorescence in situ hybridization, HER2 human epidermal growth factor receptor 2, " exact="IHC" post=" immunohistochemistry, RT-PCR reverse transcriptase polymerase chain reaction " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4593385/results/gene/human/results.xml">
   <result pre=" " exact="BCR" post="- ABL breakpoint cluster region-Abelson, CML chronic myeloid leukemia, KIT kit" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre=" BCR- " exact="ABL" post=" breakpoint cluster region-Abelson, CML chronic myeloid leukemia, KIT kit receptor ty" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" BCR- ABL breakpoint cluster region-Abelson, " exact="CML" post=" chronic myeloid leukemia, KIT kit receptor tyrosine kinase, GIST gastrointestinal st" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" BCR- ABL breakpoint cluster region-Abelson, CML chronic myeloid leukemia, " exact="KIT" post=" kit receptor tyrosine kinase, GIST gastrointestinal stromal tumor, PDGFRA platelet-d" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="ster region-Abelson, CML chronic myeloid leukemia, KIT kit receptor tyrosine kinase, " exact="GIST" post=" gastrointestinal stromal tumor, PDGFRA platelet-derived growth factor receptor A, EGFR&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="oid leukemia, KIT kit receptor tyrosine kinase, GIST gastrointestinal stromal tumor, " exact="PDGFRA" post=" platelet-derived growth factor receptor A, EGFR epidermal growth factor receptor, NSCLC&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="&gt;GIST gastrointestinal stromal tumor, PDGFRA platelet-derived growth factor receptor A, " exact="EGFR" post=" epidermal growth factor receptor, NSCLC non–small cell lung cancer, ALK anaplastic l" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="DGFRA platelet-derived growth factor receptor A, EGFR epidermal growth factor receptor, " exact="NSCLC" post=" non–small cell lung cancer, ALK anaplastic lymphoma kinase, HER2 human EGFR2, VEG" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="receptor A, EGFR epidermal growth factor receptor, NSCLC non–small cell lung cancer, " exact="ALK" post=" anaplastic lymphoma kinase, HER2 human EGFR2, VEGF(R) vascular endothelial cell grow" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="h factor receptor, NSCLC non–small cell lung cancer, ALK anaplastic lymphoma kinase, " exact="HER2" post=" human EGFR2, VEGF(R) vascular endothelial cell growth factor (receptor), HIF1 hypoxi" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="inase, HER2 human EGFR2, VEGF(R) vascular endothelial cell growth factor (receptor), " exact="HIF1" post=" hypoxia-inducible factor 1, MDSC myeloid-derived suppressor cell, CSC cancer stem ce" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="R) vascular endothelial cell growth factor (receptor), HIF1 hypoxia-inducible factor 1, " exact="MDSC" post=" myeloid-derived suppressor cell, CSC cancer stem cell, BRAF raf murine sarcoma viral" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="r (receptor), HIF1 hypoxia-inducible factor 1, MDSC myeloid-derived suppressor cell, " exact="CSC" post=" cancer stem cell, BRAF raf murine sarcoma viral oncogene homolog B, MAPK mitogen-act" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="oxia-inducible factor 1, MDSC myeloid-derived suppressor cell, CSC cancer stem cell, " exact="BRAF" post=" raf murine sarcoma viral oncogene homolog B, MAPK mitogen-activated protein kinase, PD&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="ressor cell, CSC cancer stem cell, BRAF raf murine sarcoma viral oncogene homolog B, " exact="MAPK" post=" mitogen-activated protein kinase, PD- 1 programmed cell death protein 1, PD- " xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="luding up-regulated multidrug resistance (MDR) proteins. However, mutations (such as T315I) in the " exact="BCR" post="- ABL gene were revealed to be the most common mechanism behind imatinib resistance, and the" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="gulated multidrug resistance (MDR) proteins. However, mutations (such as T315I) in the BCR- " exact="ABL" post=" gene were revealed to be the most common mechanism behind imatinib resistance, and they associate " xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="(ATP) mimetic compound, and it only binds to the inactive conformation of the enzyme. Mutations of " exact="BCR" post="- ABL that fix the kinase domain in its active configuration result in diminished binding to" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="c compound, and it only binds to the inactive conformation of the enzyme. Mutations of BCR- " exact="ABL" post=" that fix the kinase domain in its active configuration result in diminished binding to the compoun" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="R7&quot;&gt;7]. Likewise, in the case of GIST, imatinib resistance mainly results from mutations of the c- " exact="KIT" post=" and PDGFRA genes. Primary resistance in GIST occurs in 6 months of drug treatment, and it i" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="e, in the case of GIST, imatinib resistance mainly results from mutations of the c- KIT and " exact="PDGFRA" post=" genes. Primary resistance in GIST occurs in 6 months of drug treatment, and it is due to mutations" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="in GIST occurs in 6 months of drug treatment, and it is due to mutations in catalytic domain of c- " exact="KIT" post=" (exon 9) or PDGFRA (D842V). Moreover, secondary resistance to imatinib appears approximatel" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="ths of drug treatment, and it is due to mutations in catalytic domain of c- KIT (exon 9) or " exact="PDGFRA" post=" (D842V). Moreover, secondary resistance to imatinib appears approximately 2 years after the treatm" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="atinib appears approximately 2 years after the treatment, and it is associated with alternative c- " exact="KIT" post=" mutations such as V654A and N822K plus exon 11 mutations. In response to these challenges, sunitin" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="nventional cytotoxic chemotherapy in terms of RR and PFS time in lung adenocarcinoma patients with " exact="EGFR" post=" mutations such as L858R ( EGFR addiction). In addition, cetuximab in combination with radia" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="erms of RR and PFS time in lung adenocarcinoma patients with EGFR mutations such as L858R ( " exact="EGFR" post=" addiction). In addition, cetuximab in combination with radiation in head and neck cancer has deliv" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="tation, for which a currently available solution is combining cetuximab with afatinid. However, an " exact="EGFR" post=" mutation S492R in colorectal cancer leads to resistance to cetuximab, which can be overcome by the" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="ar contexts, many other compensatory pathways, such as Ras/phosphatidylinositol-3-kinases ( " exact="PI3K" post=") mutations and MET/human epidermal growth factor receptor 2 (HER2) high activity, have also been f" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ef=&quot;#CR14&quot;&gt;14, 15]. Similar to the scenarios in the above therapeutic targets, the " exact="ALK" post=" gene mutations such as C1156Y and L1196M have been reported as the molecular mode of crizotinib re" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="targeted by trastuzumab [ 16]. Moreover, enhanced HER2 dimerization resulting from " exact="PI3" post=" K mutations and/or loss of phosphatase and tensin homolog ( PTEN) was identified to " xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="ation resulting from PI3 K mutations and/or loss of phosphatase and tensin homolog ( " exact="PTEN" post=") was identified to play an important role in secondary resistance to trastuzumab [ " xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="=&quot;#CR2&quot;&gt;2]. Interestingly, the VEGFR inhibitors sunitinib and vandetanib coincidentally inhibit c- " exact="KIT" post=" and rearranged during transfection ( RET) genes, thereby having additional benefits for tre" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="sunitinib and vandetanib coincidentally inhibit c- KIT and rearranged during transfection ( " exact="RET" post=") genes, thereby having additional benefits for treating GIST and medullary thyroid carcinoma, resp" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="h represents a defined pathway driving cell growth and becomes an oncogene upon mutation. To date, " exact="BRAF" post=" mutations have been identified in many types of tumors, and are highly frequent in melanoma, color" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre=" frequent in melanoma, colorectal cancer, and papillary thyroid cancer. Over 50% of melanomas bear " exact="BRAF" post=" mutations at the advanced stage, of which approximately 80% appear as the substitution of glutamic" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="600K mutation. To circumvent these molecular targets, vemurafenib, a highly selective inhibitor of " exact="BRAF" post=" V600E mutation, was developed and have shown clear clinical benefits including significantly bette" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="pared with commonly utilized standard chemotherapy agents [ 22]. Recently, another " exact="BRAF" post=" mutation inhibitor, dabrafenib, has been approved by the United States Food and Drug Administratio" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="in other tumors, secondary mutations of the target gene in melanomas have not been found. Instead, " exact="BRAF" post=" amplification and new BRAF V600E splice isoforms appear to account for the drug resistance " xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="ns of the target gene in melanomas have not been found. Instead, BRAF amplification and new " exact="BRAF" post=" V600E splice isoforms appear to account for the drug resistance [ 24]. Another pos" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" name="human"/>
   <result pre="#CR24&quot;&gt;24]. Another possibility is BRAF-independent MAPK activation due to Ras bypass signaling or " exact="MEK" post=" mutations [ 2]. In this light, combining the MEK inhibitor trametinib with BRAF inh" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lated pharmacokinetic processes such as increased drug efflux out of responding cells mediated via " exact="MDR" post=" gene-encoded protein transporters [ 35], resistance to targeted therapy in oncolog" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4612451/results/gene/human/results.xml">
   <result pre="&quot;&gt; Fig. 5A ), although this was not statistically significant. In breast and ovarian cancer, HER2/ " exact="ERBB2" post=" gene amplification is generally associated with poor survival. While HER2 protein expression by im" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[1]" name="human"/>
   <result pre="HER2 protein expression by immunohistochemistry has less prognostic power than direct detection of " exact="ERBB2" post=" gene amplification, 35 previous studies have demonstrated that typ" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[1]" name="human"/>
   <result pre="ically only the highest scoring tumors for HER2 expression by immunohistology are found to harbour " exact="ERBB2" post=" gene amplification. 36 Therefore, we rationalized that perhaps the" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/p[1]" name="human"/>
   <result pre=" of 2 or 3 out of 3) were likely to progress early irrespective of PRP4K status because of greater " exact="ERBB2" post=" gene amplification. Indeed, when we compared HER2 high (2-3) versus HER2 low (0-1) patients within" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4619560/results/gene/human/results.xml">
   <result pre="Abbreviations: " exact="CBC" post=" complete blood count, CT computed tomography, DXA dual-energy x-ray absorptiometry, " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Abbreviations: CBC complete blood count, CT computed tomography, " exact="DXA" post=" dual-energy x-ray absorptiometry, MRI magnetic resonance imaging, ND no data, PET" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" complete blood count, CT computed tomography, DXA dual-energy x-ray absorptiometry, " exact="MRI" post=" magnetic resonance imaging, ND no data, PET-CT positron emission tomography–computed" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Abbreviation: " exact="ABC" post=" advanced breast cancer, CT chemotherapy, HT hormone therapy, Trx treatment " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Abbreviations: " exact="AJCC" post=" American Joint Committee on Cancer, ECOG Eastern Cooperative Oncology Group, PgR pro" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Abbreviations: AJCC American Joint Committee on Cancer, " exact="ECOG" post=" Eastern Cooperative Oncology Group, PgR progesterone receptor " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Abbreviations: " exact="ABC" post=" advanced breast cancer, CTx chemotherapy, HT hormone therapy, mo month, NA" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Abbreviations: " exact="HCP" post=" healthcare professional, NA not applicable " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Abbreviation: " exact="ABC" post=" advanced breast cancer " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4621756/results/gene/human/results.xml">
   <result pre="strogen receptor signaling, and, the over-expression of human epidermal growth factor receptor 2 ( " exact="HER2" post=") predicts sensitivity to pertuzumab, trastuzumab and lapatinib. Additional biomarkers would be of " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="in all models ( Supplementary Information Table 4). The three predictors are HER2 ( " exact="ERBB2" post=", UniProt Accession number P04626), Disintegrin and metalloproteinase domain-containing protein 10 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="teinase domain-containing protein 10 ( ADAM10, O14672) and Junctional adhesion molecule A ( " exact="F11R" post=", Q9Y624). These three proteins are also among the 92 predictors identified in the elastic net mode" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="l lines that do not over-express HER2 on the linear relation (blue symbols). In addition to HER2 ( " exact="ERBB2" post=" or P04626), the lasso model included SLC7A5 (large neutral amino acids transporter small su" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="r relation (blue symbols). In addition to HER2 ( ERBB2 or P04626), the lasso model included " exact="SLC7A5" post=" (large neutral amino acids transporter small subunit 1, Q01650), BST2 (bone marrow stromal " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="asso model included SLC7A5 (large neutral amino acids transporter small subunit 1, Q01650), " exact="BST2" post=" (bone marrow stromal antigen 2, Q10589) and A2ML1 (alpha 2 macroglobulin-like protein 1, A8" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="cids transporter small subunit 1, Q01650), BST2 (bone marrow stromal antigen 2, Q10589) and " exact="A2ML1" post=" (alpha 2 macroglobulin-like protein 1, A8K2U0); these are the four predictors identified most ofte" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4624825/results/gene/human/results.xml">
   <result pre=" AC anthracycline, " exact="CAD" post=" coronary artery disease, CCB calcium channel blocker, CHF congestive heart failure, " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[2]/p[1]" name="human"/>
   <result pre=" AC anthracycline, CAD coronary artery disease, " exact="CCB" post=" calcium channel blocker, CHF congestive heart failure, DVT deep venous thrombosis, &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" AC anthracycline, CAD coronary artery disease, CCB calcium channel blocker, " exact="CHF" post=" congestive heart failure, DVT deep venous thrombosis, ER endoplasmic reticulum, H" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" coronary artery disease, CCB calcium channel blocker, CHF congestive heart failure, " exact="DVT" post=" deep venous thrombosis, ER endoplasmic reticulum, HTN hypertension, LV left v" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" congestive heart failure, DVT deep venous thrombosis, ER endoplasmic reticulum, " exact="HTN" post=" hypertension, LV left ventricular dysfunction, NO nitric oxide, PH pulmonary " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" dysfunction, NO nitric oxide, PH pulmonary hypertension, TK tyrosine kinase, " exact="TKI" post=" tyrosine kinase inhibitors, VEGF vascular endothelial growth factor " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt;PH pulmonary hypertension, TK tyrosine kinase, TKI tyrosine kinase inhibitors, " exact="VEGF" post=" vascular endothelial growth factor " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627342/results/gene/human/results.xml">
   <result pre="ion was done with reverse transcriptase (Promega Corp., Madison, WI). Oligonucleotides primers for " exact="ABCB1" post=" and GAPDH were synthesized commercially (Invitrogen Co., China). They included ABCB1" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[12]/p[1]" name="human"/>
   <result pre=" reverse transcriptase (Promega Corp., Madison, WI). Oligonucleotides primers for ABCB1 and " exact="GAPDH" post=" were synthesized commercially (Invitrogen Co., China). They included ABCB1 (homo sapiens), " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[12]/p[1]" name="human"/>
   <result pre="ABCB1 and GAPDH were synthesized commercially (Invitrogen Co., China). They included " exact="ABCB1" post=" (homo sapiens), sense primer, 5′-CCCATCATTGCAATAGCAGG-3′, antisense primer, 5′-GTTCAAACTTCTGCTCCTG" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[12]/p[1]" name="human"/>
   <result pre="/i&gt; (mus), sense primer, 5′-CCCATGGCTGCATCAGTGTT-3′, antisense primer, 5′-GCTGAGTGCCTTTGTCTCCT-3′; " exact="GAPDH" post=", sense primer, 5′-GAAGGTGAAGGTCGGAGTC-3′, antisense primer, 5′-GAAGATGGTGATGGGATTTC-3′. Regular PC" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[12]/p[1]" name="human"/>
   <result pre="or 2 min, 95°C for 5 min and 40 cycles at 95°C for 15 s, 60°C for 30 s. Relative quantification of " exact="ABCB1" post=" was performed using the 2 −ΔΔCt method [ 46]. All experiments were repea" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4627999/results/gene/human/results.xml">
   <result pre=" " exact="CNS" post=" central nervous system, EBC early breast cancer, MBC metastatic breast cancer " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CNS central nervous system, " exact="EBC" post=" early breast cancer, MBC metastatic breast cancer " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CNS central nervous system, EBC early breast cancer, " exact="MBC" post=" metastatic breast cancer " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CI confidence interval, " exact="CNS" post=" central nervous system, EBC early breast cancer, HR hazard ratio, MBC metasta" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CI confidence interval, CNS central nervous system, " exact="EBC" post=" early breast cancer, HR hazard ratio, MBC metastatic breast cancer " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="terval, CNS central nervous system, EBC early breast cancer, HR hazard ratio, " exact="MBC" post=" metastatic breast cancer " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648606/results/gene/human/results.xml">
   <result pre="otein (&amp;amp;gt;30% of invasive tumor cells with intense membrane staining) or amplification of the " exact="HER2" post=" gene on fluorescence in situ hybridization (ratio of HER2 to chromosome 17 centromere ≥2.0)" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="staining) or amplification of the HER2 gene on fluorescence in situ hybridization (ratio of " exact="HER2" post=" to chromosome 17 centromere ≥2.0); 29 4) pathologically and/or radiologi" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4648969/results/gene/human/results.xml">
   <result pre="Patient characteristics. " exact="LVEF" post=" left ventricular ejection fraction, CA cancer antigen " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650834/results/gene/human/results.xml">
   <result pre=" " exact="AUC" post=" area under the curve, CI confidence interval, ECOG-PS Eastern Cooperative Oncology G" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" estrogen receptor , HER2 human epidermal growth factor receptor 2, HR hazard ratio, " exact="LACB" post=" locally advanced breast cancer, LVEF left ventricular ejection fraction, mBC metasta" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rmal growth factor receptor 2, HR hazard ratio, LACB locally advanced breast cancer, " exact="LVEF" post=" left ventricular ejection fraction, mBC metastatic breast cancer, NA not available, " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" left ventricular ejection fraction, mBC metastatic breast cancer, NA not available, " exact="NPLD" post=" nonpegylated liposomal doxorubicin, ORR overall response rate, OS overall survival, " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="metastatic breast cancer, NA not available, NPLD nonpegylated liposomal doxorubicin, " exact="ORR" post=" overall response rate, OS overall survival, PD progression of disease, PFS pr" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n, ORR overall response rate, OS overall survival, PD progression of disease, " exact="PFS" post=" progression-free survival, PgR progesterone receptor, RECIST Response Evaluation Cr" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt; progression of disease, PFS progression-free survival, PgR progesterone receptor, " exact=" RECIST" post=" Response Evaluation Criteria In Solid Tumors, T1 treatment 1, T2 treatment 2, TTP" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ST Response Evaluation Criteria In Solid Tumors, T1 treatment 1, T2 treatment 2, " exact="TTP" post=" time to progression " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ef=&quot;#CR32&quot;&gt;32] are not displayed because OS results were not provided. OS overall survival, " exact="PFS" post=" progression-free survival " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CI confidence interval, " exact="CNS" post=" central nervous system, ECOG-PS Eastern Cooperative Oncology Group performance status, H" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" central nervous system, ECOG-PS Eastern Cooperative Oncology Group performance status, " exact="HER2" post=" human epidermal growth factor receptor 2, HR hazard ratio, LVEF left ventricular eje" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" performance status, HER2 human epidermal growth factor receptor 2, HR hazard ratio, " exact="LVEF" post=" left ventricular ejection fraction mBC metastatic breast cancer, NA not available, &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; left ventricular ejection fraction mBC metastatic breast cancer, NA not available, " exact="NYR" post=" not yet reached, OS overall survival, PD progression of disease, PFS progress" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ailable, NYR not yet reached, OS overall survival, PD progression of disease, " exact="PFS" post=" progression-free survival, T1 treatment 1, T2 treatment 2, T-DM1 trastuzumab " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n-free survival, T1 treatment 1, T2 treatment 2, T-DM1 trastuzumab emtansine, " exact="TTP" post=" time to progression " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" 03–05, German Breast Group 26/Breast International Group 03–05 study. OS overall survival, " exact="PFS" post=" progression-free survival " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4650980/results/gene/human/results.xml">
   <result pre="nct molecular pathways in SCC compared with adenocarcinoma. For example, inactivating mutations of " exact="NOTCH1" post=" were identified in 21% of SCCs but were not observed in adenocarcinoma [ 6]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" name="human"/>
   <result pre="rials, rash appeared predictive of response to treatment. Other biomarkers were examined including " exact="RAS" post=" mutational status. However, the numbers were too small to draw any definite conclusions [ &lt;a href=" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="PFS ∼5 months, OS ∼9 months) [ 37]. Notably, this trial was amended to allow " exact="RAS" post=" mutational testing on a subset of tumor samples. However, just as in REAL-3, no conclusions could " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" on a subset of tumor samples. However, just as in REAL-3, no conclusions could be drawn regarding " exact="RAS" post=" as a biomarker in this clinical setting. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="hibition has shown significant benefit, there are biomarkers available that predict response (e.g. " exact="RAS" post=" wild-type status in colorectal cancers and activating mutations in EGFR in lung cancer), but these" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4657380/results/gene/human/results.xml">
   <result pre=" " exact="CDK" post=" cyclin-dependent kinase, HER2 human epidermal growth factor receptor 2, mTOR mammali" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CDK cyclin-dependent kinase, " exact="HER2" post=" human epidermal growth factor receptor 2, mTOR mammalian target of rapamycin, PARP p" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=", HER2 human epidermal growth factor receptor 2, mTOR mammalian target of rapamycin, " exact="PARP" post=" poly ADP ribose polymerase, PCI prophylactic cranial irradiation, PI3K phosphatidyli" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tor receptor 2, mTOR mammalian target of rapamycin, PARP poly ADP ribose polymerase, " exact="PCI" post=" prophylactic cranial irradiation, PI3K phosphatidylinositol 3-kinase, SRS stereotact" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="of rapamycin, PARP poly ADP ribose polymerase, PCI prophylactic cranial irradiation, " exact="PI3K" post=" phosphatidylinositol 3-kinase, SRS stereotactic radiosurgery, VEGF vascular endothel" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="olymerase, PCI prophylactic cranial irradiation, PI3K phosphatidylinositol 3-kinase, " exact="SRS" post=" stereotactic radiosurgery, VEGF vascular endothelial growth factor, WBRT whole-brain" xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nial irradiation, PI3K phosphatidylinositol 3-kinase, SRS stereotactic radiosurgery, " exact="VEGF" post=" vascular endothelial growth factor, WBRT whole-brain radiation therapy " xpath="/html[1]/body[1]/article[1]/div[3]/div[6]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ol 3-kinase, SRS stereotactic radiosurgery, VEGF vascular endothelial growth factor, " exact="WBRT" post=" whole-brain radiation therapy " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4659935/results/gene/human/results.xml">
   <result pre="inib resistance, the most abundant private mutation in plasma was in the tyrosine kinase domain of " exact="ERBB4" post=" (p.H809G; plasma cluster 5; Fig. 2b,d and Supplementary Fig. 11). This" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre=";2% AF in any of the analysed tumour biopsies. Amongst these was an actionable hotspot mutation in " exact="PIK3CA" post=" (p.E542K), identified in plasma with an AF of 3.5% at the time of progression on trastuzumab and t" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre=" in two tumour biopsies (axillary lymph node and vertebral metastasis). These results suggest this " exact="PIK3CA" post=" mutation originated from a minor tumour sub-clone that increased in size during treatment with tam" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="e mutations in each tumour (3–70), we calculated plasma abundance relative to T1. ( d) Dynamics of " exact="ERBB4" post=" mutation (p.H809G) in deep sequencing data. ( e) Allele fractions measured by deep amplicon sequen" xpath="/html[1]/body[1]/article[1]/div[5]/div[2]/p[1]" name="human"/>
   <result pre="H809G) in deep sequencing data. ( e) Allele fractions measured by deep amplicon sequencing for the " exact="PIK3CA" post=" mutation (p.E542K) identified in exome sequencing of plasma sample T2. Mutation was significantly " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4666271/results/gene/human/results.xml">
   <result pre=" " exact="ALT" post=" alanine aminotransferase, AST aspartate aminotransferase " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" ALT alanine aminotransferase, " exact="AST" post=" aspartate aminotransferase " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="CBR" post=" clinical benefit rate (CR; PR; SD ≥24 weeks), CR complete response, NE not evaluable" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="linical benefit rate (CR; PR; SD ≥24 weeks), CR complete response, NE not evaluable, " exact="ORR" post=" overall tumor response rate, PD progressive disease, PR partial response, SD " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="AUC" post=" (0– 24) area under the curve from 0 to 24 h, CI confidence inter" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="AUC" post=" (0– 24) area under the curve, AUC (0– inf) &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" AUC (0– 24) area under the curve, " exact="AUC" post=" (0– inf) area under the curve extrapolated to infinity, C " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4669075/results/gene/human/results.xml">
   <result pre="icing alterations have been reported in human cancers, we focus on aberrant splicing of ER, " exact="HER2" post=", and CD44 genes from the viewpoint of BC development. ERα36, a splice variant from t" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" have been reported in human cancers, we focus on aberrant splicing of ER, HER2, and " exact="CD44" post=" genes from the viewpoint of BC development. ERα36, a splice variant from the ER1 loc" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="nd CD44 genes from the viewpoint of BC development. ERα36, a splice variant from the " exact="ER1" post=" locus, governs nongenomic membrane signaling pathways triggered by estrogen and confers 4-hydroxyt" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="trogen and confers 4-hydroxytamoxifen resistance in BC therapy. The alternative spliced isoform of " exact="HER2" post=" lacking exon 20 (Δ16HER2) has been reported in human BC; this isoform is associated with transform" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e wild-type HER2 and recapitulates the phenotypes of endocrine therapy-resistant BC. Although both " exact="CD44" post=" splice isoforms ( CD44s, CD44v) play essential roles in BC development, CD44v is mor" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="Aberrant splicing of genomic loci for estrogen receptors (ERs), HER2/neu, Cyclin D1, " exact="BRCA1" post=", BARD1, Tenscin-C, and CD44 has been shown to contribute to breast carcinogen" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="ing of genomic loci for estrogen receptors (ERs), HER2/neu, Cyclin D1, BRCA1, " exact="BARD1" post=", Tenscin-C, and CD44 has been shown to contribute to breast carcinogenesis. This rev" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="eptors (ERs), HER2/neu, Cyclin D1, BRCA1, BARD1, Tenscin-C, and " exact="CD44" post=" has been shown to contribute to breast carcinogenesis. This review focuses on the splicing mechani" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="contribute to breast carcinogenesis. This review focuses on the splicing mechanisms for ER, " exact="HER2" post=", and CD44 genomic loci, which play essential roles in breast carcinogenesis and development" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ast carcinogenesis. This review focuses on the splicing mechanisms for ER, HER2, and " exact="CD44" post=" genomic loci, which play essential roles in breast carcinogenesis and development. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="tant role in the development and progression of BC. ERα and ERβ are encoded by two distinct genes, " exact="ESR1" post=" ( Fig. 1A) and ESR2, that are on human chromosomes 6q24–27 and" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="and ERβ are encoded by two distinct genes, ESR1 ( Fig. 1A) and " exact="ESR2" post=", that are on human chromosomes 6q24–27 and 14q21–22, respectively. Hormone-activated ERs form homo" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="i&gt; ( Fig. 1A). 46 The Wilms’ tumor gene " exact="WT1" post=" encodes a zinc-finger protein WT1 that functions as a dual transcription regulator to activate or " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="igh levels of wild-type (the phenotype of the nonmutated form of a species as it occurs in nature) " exact="WT1" post=" are found in acute leukemias and solid tumors with poor prognosis, 5" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="er levels and ERα36 at a very low level. 55 MCF-7 cells depleted for " exact="WT1" post=" expressed a reduced level of ERα66 with an increased level of ERα36, suggesting that WT1 increases" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre=" no correlation between loss of heterozygosity (LOH) at 14q22–24 (genomic locus at the ERβ/ " exact="ESR2" post=" locus) and ERβ1 expression in primary BCs, a negative correlation between ERβ1 mRNA express" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="ymph node metastasis, and poor clinical outcomes of patients. It is widely accepted that wild-type " exact="HER2" post=" gene amplification is necessary but not sufficient to induce transformation. &lt;a href=&quot;#b107-geg-7-" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ane region have not been reported in human BCs, several studies have reported the expression of an " exact="HER2" post=" alternatively spliced isoform in normal mammary cells and in human breast carcinomas. &lt;a href=&quot;#b1" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="gh-grade, and metastatic mammary tumors in ΔHER2 transgenic mice with short latency, driven by the " exact="MMTV" post=" promoter. 125, 126 " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Splicing in " exact="HER2" post=" is supposed to trigger the kinase activity by promoting intermolecular disulfide bonding, which, i" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="modimers capable of transforming cells. 132 Since the levels of the " exact="HER2" post=" splice variant represent only 9% of those observed with the wild-type receptor, HER2 protein overe" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e do not discuss this issue further since this mutant is not considered to be a splice variant for " exact="HER2" post=". " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" been associated with the basal-like subtype of BC, especially those with hereditary mutations for " exact="BRCA1" post=". 149 The role of CD44 as a marker for CSCs will be discussed later " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="The human " exact="CD44" post=" gene is located on chromosome 11p13 and consists of 20 coding exons of which 10, located between c" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="ry mode, right), dependent on the biological conditions of cells. The neurofibromatosis-2 ( " exact="NF2" post=") gene encodes merlin, an ERM-related protein that functions as a tumor suppressor that inhibits th" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="ession of the CD44 cell-surface molecule via binding to a noncanonical p53-binding sequence in the " exact="CD44" post=" promoter. In the absence of p53 function, increased CD44 expression accelerated the growth and tum" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="igher in advanced tumors and correlated with N-cadherin expression. Thus, the regulation of AS for " exact="CD44" post=" constitutes a critical mechanism in controlling EMT and cancer progression. &lt;a href=&quot;#b188-geg-7-2" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="arkably, EMT-induced repression of epithelial splicing regulatory protein 1 (ESRP1) controls AS of " exact="CD44" post=", causing a shift in the expression from the variant CD44v to CD44s isoform. &lt;a href=&quot;#b190-geg-7-2" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="f=&quot;#f4-geg-7-2015-019&quot;&gt;Fig. 4, right). Consistent with the tumor-suppressive role of CD44, loss of " exact="CD44" post=" has been reported in Burkitt’s lymphoma, neuroblastoma, prostate cancer, and BC. &lt;a href=&quot;#b192-ge" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="Tumor-suppressive activities for CD44 have been demonstrated in vivo using " exact="CD44" post="-deficient mice. SV40-transformed CD44-null fibroblasts injected subcutaneously into nude BA" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="ivities for CD44 have been demonstrated in vivo using CD44-deficient mice. SV40-transformed " exact="CD44" post="-null fibroblasts injected subcutaneously into nude BALB/C mice were highly tumorigenic, whereas th" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="( MMTV-polyoma middle T), Lopez et al 197 found that loss of " exact="CD44" post=" promoted tumor metastasis to the lung, but not the onset, suggesting its suppressive role for tumo" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="sion. CD44 was expressed in the myoepithelium of the developing mammary gland in mice. The loss of " exact="CD44" post=" resulted in defective luminal–myoepithelial cell–cell adhesion and promoted the mixing of luminal " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="8-geg-7-2015-019&quot;&gt;198 The ductal outgrowth and terminal end bud formation were delayed/impaired in " exact="CD44" post="-null mice. In BCs, CD44 was expressed in the basal cells of early-stage tumor cells but exhibited " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="ltered localization with the development of the disease. Collectively, global depletion of all the " exact="CD44" post=" isoforms leads to acceleration of tumorigenesis and metastasis, suggesting its tumor-suppressive r" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre=" range in each cell type/tissue to maintain the normal homeostasis, and any events that affect the " exact="CD44" post=" transcription, pre-mRNA splicing, translation, or posttrans-lational modifications result in incre" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="Although the " exact="HER2" post=" mutation that corresponds to neu has not been reported in human cancers, the Δ16HER2 varian" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="sion. Although Schmits et al 196 demonstrated the tumorigenicity of " exact="CD44" post="-deficient fibroblasts in vivo, the interpretation of their results is difficult since both Rb and " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="lly occurring human cancers. Interestingly, the same laboratory later reported that the absence of " exact="CD44" post=" prevented sarcoma metastasis using the more physiological min mutation model for colon canc" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="e has been no report on increased spontaneous or carcinogen/irradiation-induced tumor incidence in " exact="CD44" post="-deficient mice. Since CD44 has multiple splice variants with possible conflicting functions, it wi" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="ructures and their variants. ( A) The genomic structure for the human Estrogen Receptor 1 ( " exact="ESR1" post=") locus. The human ESRα locus consists of 10 exons with two different promoters. The ATG for" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="Activation of the " exact="HER2" post=" gene by alternative splicing at exon 20. ( A) HER2 splicing and generation of D16HER2&lt;/i" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Activation of the HER2 gene by alternative splicing at exon 20. ( A) " exact="HER2" post=" splicing and generation of D16HER2. 202 Constitutive express" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e HER2 gene by alternative splicing at exon 20. ( A) HER2 splicing and generation of " exact="D16HER2" post=". 202 Constitutive expression of a human HER2 alternative spl" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="eneration of D16HER2. 202 Constitutive expression of a human " exact="HER2" post=" alternative splice isoform carries an in-frame deletion in the same mutated region of the rat n" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Alternative splicing for the human " exact="CD44" post=" locus and its protein products. ( A) The genomic structure for the human CD44 locus. It has" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="for the human CD44 locus and its protein products. ( A) The genomic structure for the human " exact="CD44" post=" locus. It has 10 constant exons (exons 1–5 and 15–19) shown in tan that encode the extracellular, " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4678619/results/gene/human/results.xml">
   <result pre="well as the mutant genes and overexpressed proteins such as VEGF, PI3K/AKT/mTOR signaling pathway, " exact="ARID1A" post=", hepatocyte nuclear factor-1β, ZNF217. We also review targeted molecular therapeutics for e" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="oteins such as VEGF, PI3K/AKT/mTOR signaling pathway, ARID1A, hepatocyte nuclear factor-1β, " exact="ZNF217" post=". We also review targeted molecular therapeutics for epithelial ovarian cancer and discuss their ro" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="erized in CCC, including pre-, on-, post-, and off-target mechanisms, and slow cell proliferation. " exact="ABCC3" post=" ATP-binding cassette, subfamily C, member 3, ERCC1 excision repair cross-complementing rode" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="mechanisms, and slow cell proliferation. ABCC3 ATP-binding cassette, subfamily C, member 3, " exact="ERCC1" post=" excision repair cross-complementing rodent repair deficiency complementation group 1, EGFR " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ERCC1 excision repair cross-complementing rodent repair deficiency complementation group 1, " exact="EGFR" post=" epidermal growth factor receptor, HER2 human epidermal growth factor receptor 2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ng rodent repair deficiency complementation group 1, EGFR epidermal growth factor receptor, " exact="HER2" post=" human epidermal growth factor receptor 2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="ABCC3" post=" ATP-binding cassette, subfamily C, member 3, ABC ATP-binding cassette, CCC clear cel" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre=" ABCC3 ATP-binding cassette, subfamily C, member 3, " exact="ABC" post=" ATP-binding cassette, CCC clear cell carcinoma, SAC serous adenocarcinoma, GPx&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" ABCC3 ATP-binding cassette, subfamily C, member 3, ABC ATP-binding cassette, " exact="CCC" post=" clear cell carcinoma, SAC serous adenocarcinoma, GPx glutathione peroxidase, ERCC" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="cassette, subfamily C, member 3, ABC ATP-binding cassette, CCC clear cell carcinoma, " exact="SAC" post=" serous adenocarcinoma, GPx glutathione peroxidase, ERCC1 excision repair cross-compl" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="CCC clear cell carcinoma, SAC serous adenocarcinoma, GPx glutathione peroxidase, " exact="ERCC1" post=" excision repair cross-complementing rodent repair deficiency complementation group 1, NER n" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ERCC1 excision repair cross-complementing rodent repair deficiency complementation group 1, " exact="NER" post=" nucleotide excision repair, EGFR epidermal growth factor receptor, HER2 human epider" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lementing rodent repair deficiency complementation group 1, NER nucleotide excision repair, " exact="EGFR" post=" epidermal growth factor receptor, HER2 human epidermal growth factor receptor 2. We summari" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="tion group 1, NER nucleotide excision repair, EGFR epidermal growth factor receptor, " exact="HER2" post=" human epidermal growth factor receptor 2. We summarized the factors of platinum resistance in CCC." xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Previous studies have shown that the expression of the " exact="ABCC3" post=" gene is significantly greater in CCC than in SAC. Increased expression of ABCC3 may, at lea" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="sion of the ABCC3 gene is significantly greater in CCC than in SAC. Increased expression of " exact="ABCC3" post=" may, at least in part, be associated with the chemoresistant phenotype of CCC [ 19" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ER) system [ 14, 58]. One study revealed higher mRNA expression of " exact="ERCC1" post=" and XPB genes in CCC. These genes are involved in the NER pathway of EOC and are more preva" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ref=&quot;#CR14&quot;&gt;14, 58]. One study revealed higher mRNA expression of ERCC1 and " exact="XPB" post=" genes in CCC. These genes are involved in the NER pathway of EOC and are more prevalent in CCC tha" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="ARID1A" post=" AT-rich interactive domain 1A (SWI-like) gene, BRCA 1/2 breast cancer susceptibility gene 1" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="rich interactive domain 1A (SWI-like) gene, BRCA 1/2 breast cancer susceptibility gene 1/2, " exact="EGFR" post=" epidermal growth factor receptor, HER2 human epidermal growth factor receptor 2, HNF-1β&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="&gt;BRCA 1/2 breast cancer susceptibility gene 1/2, EGFR epidermal growth factor receptor, " exact="HER2" post=" human epidermal growth factor receptor 2, HNF-1β hepatocyte nuclear factor 1β, mTOR " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="receptor 2, HNF-1β hepatocyte nuclear factor 1β, mTOR mammalian target of rapamycin, " exact="PIK3CA" post=" phosphoinositide 3-kinase catalytic-α, PPMID protein phosphatase magnesium-dependent, PP" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="β, mTOR mammalian target of rapamycin, PIK3CA phosphoinositide 3-kinase catalytic-α, " exact="PPMID" post=" protein phosphatase magnesium-dependent, PP2R1A protein phosphatase 2, regulatory subunit A" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="A phosphoinositide 3-kinase catalytic-α, PPMID protein phosphatase magnesium-dependent, " exact="PP2R1A" post=" protein phosphatase 2, regulatory subunit A, VEGF vascular endothelial growth factor, ZN" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rotein phosphatase magnesium-dependent, PP2R1A protein phosphatase 2, regulatory subunit A, " exact="VEGF" post=" vascular endothelial growth factor, ZNF217 zinc finger protein 217 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="A protein phosphatase 2, regulatory subunit A, VEGF vascular endothelial growth factor, " exact="ZNF217" post=" zinc finger protein 217 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="Unlike high-grade serous EOCs, CCCs usually display a wild-type p53 and have a lower frequency of " exact="BRCA1" post=" and BRCA2 mutations [ 2, 76, 77]. Significan" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="e serous EOCs, CCCs usually display a wild-type p53 and have a lower frequency of BRCA1 and " exact="BRCA2" post=" mutations [ 2, 76, 77]. Significant differences wer" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ficant differences were reported in the distribution of mutations among histological subtypes, and " exact="TP53" post=" mutations were reportedly present in 67 and 21 % of cases with serous and nonserous cancers, respe" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="han in other EOC types [ 2]. Similarly, Alsop et al. reported that the frequency of " exact="BRCA1" post=" and BRCA2 mutations of CCC was 6.3 and 0 %, respectively [ 77]. However, ot" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="types [ 2]. Similarly, Alsop et al. reported that the frequency of BRCA1 and " exact="BRCA2" post=" mutations of CCC was 6.3 and 0 %, respectively [ 77]. However, other recent studie" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre=" " exact="ABL" post=" Abelson murine leukemia, BCR breakpoint cluster region, CA125 cancer antigen 125, &lt;i" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" ABL Abelson murine leukemia, " exact="BCR" post=" breakpoint cluster region, CA125 cancer antigen 125, EGFR epidermal growth factor re" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre=" ABL Abelson murine leukemia, BCR breakpoint cluster region, " exact="CA125" post=" cancer antigen 125, EGFR epidermal growth factor receptor, EPHA2 ephrin type-A recep" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt; Abelson murine leukemia, BCR breakpoint cluster region, CA125 cancer antigen 125, " exact="EGFR" post=" epidermal growth factor receptor, EPHA2 ephrin type-A receptor 2, GFR growth factor " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="int cluster region, CA125 cancer antigen 125, EGFR epidermal growth factor receptor, " exact="EPHA2" post=" ephrin type-A receptor 2, GFR growth factor receptor, HER2 human epidermal growth fa" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre=" antigen 125, EGFR epidermal growth factor receptor, EPHA2 ephrin type-A receptor 2, " exact="GFR" post=" growth factor receptor, HER2 human epidermal growth factor receptor 2, IGF-1R insuli" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" growth factor receptor, EPHA2 ephrin type-A receptor 2, GFR growth factor receptor, " exact="HER2" post=" human epidermal growth factor receptor 2, IGF-1R insulin like growth factor-1 receptor, " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="2, IGF-1R insulin like growth factor-1 receptor, mTOR mammalian target of rapamycin, " exact="PARP" post=" poly (ADP-ribose) polymerase, PDGFR platelet-derived growth factor receptor, VEGF va" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="r-1 receptor, mTOR mammalian target of rapamycin, PARP poly (ADP-ribose) polymerase, " exact="PDGFR" post=" platelet-derived growth factor receptor, VEGF vascular endothelial growth factor, VEGFR&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n, PARP poly (ADP-ribose) polymerase, PDGFR platelet-derived growth factor receptor, " exact="VEGF" post=" vascular endothelial growth factor, VEGFR vascular endothelial growth factor receptor " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="PDGFR platelet-derived growth factor receptor, VEGF vascular endothelial growth factor, " exact="VEGFR" post=" vascular endothelial growth factor receptor " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="al for neoplasia, including cell proliferation, adhesion, survival, and motility. The frequency of " exact="PIK3CA" post=" mutations in CCC has been estimated to be 40 %, and some studies suggest that the PI3K/AKT/mTOR pa" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre=" be an effective treatment for CCC [ 63]. Furthermore, Rahman et al. reported that " exact="PIK3CA" post=" mutations were associated with more favorable prognoses but did not predict the sensitivity of ova" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="The AT-rich interactive domain 1A (SWI-like) gene ( " exact="ARID1A" post=") encodes BAF250A, which is a member of the SWI/SNF ATP-dependent chromatin remodeling complex. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="/i&gt;) encodes BAF250A, which is a member of the SWI/SNF ATP-dependent chromatin remodeling complex. " exact="ARID1A" post=" plays an indispensable role in controlling gene expression and in tissue development and cellular " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="lar differentiation [ 70]. Moreover, CCCs reportedly have the highest frequency of " exact="ARID1A" post=" mutations (43–57 %) [ 62]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="sis. Moreover, loss of ARID1A protein expression is often coincident (not mutually exclusive) with " exact="PIK3CA" post=" mutation [ 90]. However, a previous study demonstrated that inactivation of ARID1A" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ired to drive tumorigenesis [ 91]. Chandler et al. also showed that the coexistent " exact="ARID1A" post="- PIK3CA mutations promote ovarian clear cell tumorigenesis [ 92]. Taken tog" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="umorigenesis [ 91]. Chandler et al. also showed that the coexistent ARID1A- " exact="PIK3CA" post=" mutations promote ovarian clear cell tumorigenesis [ 92]. Taken together, these st" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="udy regarding the targeting of ARID1A for ovarian CCC [ 93]. The study showed that " exact="ARID1A" post=" is mutated in over 50 % of ovarian CCCs and pharmacological inhibition of enhancer of zeste homolo" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre=" of enhancer of zeste homolog 2 (EZH2) represents a novel treatment strategy for cancers involving " exact="ARID1A" post=" mutations. The study showed that EZH2 inhibitor selectively suppressed the growth of ARID1A" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ARID1A mutations. The study showed that EZH2 inhibitor selectively suppressed the growth of " exact="ARID1A" post=" mutated cells in vitro and in vivo via upregulating the expression of PIK3IP1, which negati" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre=" the growth of ARID1A mutated cells in vitro and in vivo via upregulating the expression of " exact="PIK3IP1" post=", which negatively regulates PI3K/AKT signals. Further studies are expected to elucidate the detail" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="er studies are expected to elucidate the detailed mechanisms of the cellular dysfunction caused by " exact="ARID1A" post=" mutations in CCCs and to expose the potential of ARID1A as a therapeutic target. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="The " exact="ZNF217" post=" gene on human 20q13.2 encodes a transcription factor that is overexpressed in 30 % of breast tumor" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="umors and in several cell lines [ 96]. Several studies show that overexpression of " exact="ZNF217" post=" in several cancers is associated with poor prognosis [ 96, 97]. Am" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre=" prognosis [ 96, 97]. Among these, Littlepage et al. reported that " exact="ZNF217" post=" overexpression promotes metastasis and resistance to chemotherapy and inhibits signaling events in" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="s in vivo [ 96]. These authors also showed that triciribine inhibits the growth of " exact="ZNF217" post="-overexpressing cells in vitro and in vivo, indicating that it is a potential target for the treatm" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="pressing cells in vitro and in vivo, indicating that it is a potential target for the treatment of " exact="ZNF217" post="-overexpressing cancers. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="In a previous study, " exact="ZNF217" post=" overexpression was reported in 20.0 % of CCC cases [ 65]. Moreover, Rahman et al. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ion was reported in 20.0 % of CCC cases [ 65]. Moreover, Rahman et al. showed that " exact="ZNF217" post=" gene overexpression is significantly correlated with lymph node metastasis in ovarian CCC. In comp" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="mph node metastasis in ovarian CCC. In comparison with small interfering RNA-treated cells without " exact="ZNF217" post=" overexpression, profound inhibition of cell migration and invasion was observed in cells overexpre" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="xpression, profound inhibition of cell migration and invasion was observed in cells overexpressing " exact="ZNF217" post=" [ 98], suggesting that ZNF217 is a potential therapeutic target for CCC. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="invasion was observed in cells overexpressing ZNF217 [ 98], suggesting that " exact="ZNF217" post=" is a potential therapeutic target for CCC. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="As discussed above, the loss of " exact="ARID1A" post=" expression and/or PI3K activation is crucial for CCC tumorigenesis. Moreover, synergic effects of " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="and/or PI3K activation is crucial for CCC tumorigenesis. Moreover, synergic effects of the loss of " exact="ARID1A" post=" expression and PI3K/AKT pathway activation and ZNF217 overexpression may be related to ovar" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="over, synergic effects of the loss of ARID1A expression and PI3K/AKT pathway activation and " exact="ZNF217" post=" overexpression may be related to ovarian CCC development [ 99], warranting further" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4682234/results/gene/human/results.xml">
   <result pre=" †Median (Interquartile Range). " exact="FIGO" post=" International Federation of Gynecology and Obstetrics " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4689775/results/gene/human/results.xml">
   <result pre=" " exact="SERM" post=" selective estrogen receptor modulator, SERD selective estrogen receptor downregulator (fulv" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/ul[1]/li[1]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" SERM selective estrogen receptor modulator, " exact="SERD" post=" selective estrogen receptor downregulator (fulvestrant 500 mg/month with loading doses is the reco" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/ul[1]/li[1]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="th loading doses is the recommended schedule), GnRH gonadotropin hormone-releasing hormone, " exact="NSAI" post=" non-steroidal aromatase inhibitors (third generation), SAI steroidal aromatase inhibitors (" xpath="/html[1]/body[1]/article[1]/div[3]/div[7]/ul[1]/li[1]/div[1]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="opin hormone-releasing hormone, NSAI non-steroidal aromatase inhibitors (third generation), " exact="SAI" post=" steroidal aromatase inhibitors (third generation) " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694793/results/gene/human/results.xml">
   <result pre="s of stomach carcinogenesis have been characterized by genetic instability, telomerase activation, " exact="TP53" post=" loss/mutation, and inactivation of tumor suppressor genes and microRNAs by CpG island methylation " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="As by CpG island methylation [ 36]. Intestinal metaplasia has been characterized by " exact="TERT" post=" activation, loss of retinoic acid receptor β ( RARB) expression, TP53 overexpression" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="al metaplasia has been characterized by TERT activation, loss of retinoic acid receptor β ( " exact="RARB" post=") expression, TP53 overexpression, and an abnormal presence of CD44 transcripts. &quot;Gastric ad" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="aracterized by TERT activation, loss of retinoic acid receptor β ( RARB) expression, " exact="TP53" post=" overexpression, and an abnormal presence of CD44 transcripts. &quot;Gastric adenomas&quot; have been found t" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="rmal presence of CD44 transcripts. &quot;Gastric adenomas&quot; have been found to exhibit reduced levels of " exact="CDKN1B" post=" expression, overexpression of CCNE1, and mutations in the APC gene. Furthermore, in " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="adenomas&quot; have been found to exhibit reduced levels of CDKN1B expression, overexpression of " exact="CCNE1" post=", and mutations in the APC gene. Furthermore, in cases of advanced stage GC, reduced transfo" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="t reduced levels of CDKN1B expression, overexpression of CCNE1, and mutations in the " exact="APC" post=" gene. Furthermore, in cases of advanced stage GC, reduced transforming growth factor β (TGF-β) rec" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="nd KRAS/NRAS, as well as mutations in chromatin remodeling genes ( ARID1A, MLL3, and " exact="MLL" post=") have been observed [ 4, 6, 36– 38]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="include microsatellite instability (MSI), loss of E-cadherin function by deletions or mutations in " exact="CDH1" post=", amplification of MDM2 and MET and FGFR2F and RHOA mutations [ &lt;a href" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="lity (MSI), loss of E-cadherin function by deletions or mutations in CDH1, amplification of " exact="MDM2" post=" and MET and FGFR2F and RHOA mutations [ 36, 39," xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" of E-cadherin function by deletions or mutations in CDH1, amplification of MDM2 and " exact="MET" post=" and FGFR2F and RHOA mutations [ 36, 39, &lt;a href=&quot;#R40&quot;" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="function by deletions or mutations in CDH1, amplification of MDM2 and MET and " exact="FGFR2F" post=" and RHOA mutations [ 36, 39, 40]. The main gen" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ons or mutations in CDH1, amplification of MDM2 and MET and FGFR2F and " exact="RHOA" post=" mutations [ 36, 39, 40]. The main genomic and epigene" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="populations [ 46]. Approximately 80% of EBV-positive tumors harbor mutations in the " exact="PIK3CA" post=" gene [ 4], which encodes the PI3Kα protein [ 47]. PIK3CA is th" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="n the PIK3CA gene [ 4], which encodes the PI3Kα protein [ 47]. " exact="PIK3CA" post=" is the second most commonly mutated gene across many cancer types, and was detected in more than 1" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ected in more than 10% of the cancer cases examined by the TCGA [ 48]. Mutations in " exact="PIK3CA" post=" have been found in 3-42% of the other GC subtypes and in EBV-positive cases. Of particular interes" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="d with the panel of cancers studied by the TCGA network. Furthermore, promoter hypermethylation of " exact="CDKN2A" post=" has been detected in all EVB-positive samples, and this gene is considered to be one of the most i" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="sor genes involved in GC [ 49]. Amplifications of JAK2, CD274, PDCD1LG2, and " exact="ERBB2" post=" have also been detected in EBV-positive GC cases, as well as deletions in PTEN, SMAD4, CDKN2A&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="so been detected in EBV-positive GC cases, as well as deletions in PTEN, SMAD4, CDKN2A, and " exact="ARID1A" post=". The JAK/STAT signaling play an important role in proliferation, differentiation and apoptosis and" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="cases are generally characterized by accumulation of mutations in PIK3CA, ERBB3, ERBB2, and " exact="EGFR" post="; along with mutations present in ‘hotspot’ sites that have been identified in other cancers. Previ" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=". Previous studies have reported that the main cause of MSI in GC involves hypermethylation of the " exact="MLH1" post=" promoter, which is one of the genes involved in the DNA mismatch repair system [ 4, " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ol ( TGFBR2, EPHB2, E2F4), DNA damage repair ( MRE1, ATR), and apoptotic signaling ( " exact="BAX" post=") [ 56, 59, 60]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="nomas. The GS subtype is typically diagnosed in younger patients, it has a rather low frequency of " exact="TP53" post=" mutations, and a low degree of aneuploidy compared with chromosomally unstable GC (described below" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="idy compared with chromosomally unstable GC (described below) [ 4]. Mutations in the " exact="CDH1" post=" and RHOA genes have been detected in 13-37% and in 14-25% of diffuse-type GS adenocarcinoma" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="h chromosomally unstable GC (described below) [ 4]. Mutations in the CDH1 and " exact="RHOA" post=" genes have been detected in 13-37% and in 14-25% of diffuse-type GS adenocarcinoma cases, respecti" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="carcinogenesis of this histological type [ 4, 40, 61]. " exact="CDH1" post=" germline mutations are associated with hereditary diffuse GC, poorly differentiated phenotype and " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="orly differentiated phenotype and poor clinical outcome [ 62]. In contrast, mutated " exact="RHOA" post=" interacts with other cellular proteins to promote morphological changes and cell migration, functi" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ef=&quot;#R63&quot;&gt;63– 65]. Another genetic alteration related to RHOA activity involves the " exact="ARHGAP26" post=" gene, which encodes a GTPase-activating protein that modulates RHOA activation. Interchromosomal t" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="a GTPase-activating protein that modulates RHOA activation. Interchromosomal translocation between " exact="CLDN18" post=" and ARHGAP26 has been described, and it is likely that the chimeric product may affect regu" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="g protein that modulates RHOA activation. Interchromosomal translocation between CLDN18 and " exact="ARHGAP26" post=" has been described, and it is likely that the chimeric product may affect regulation of RHOA. Furt" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="product may affect regulation of RHOA. Furthermore, this genomic fusion may also disrupt wild-type " exact="CLDN18" post=", a tight junction protein that is widely expressed in stomach epithelium and affects cellular adhe" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="affects cellular adhesion. Interestingly, CLDN18-ARHGAP26 fusion is mutually exclusive with " exact="RHOA" post=" mutations [ 4]. Therefore, alterations in the cell adhesion pathways in this GC subt" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="enotype is mostly associated with the GEJ/cardia. Moreover, 71% of CIN GC tumors have mutations in " exact="TP53" post=", followed by mutations in ARID1A, KRAS, PIK3CA, RNF43, ERBB2, and APC genes. Elevate" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" mutations in TP53, followed by mutations in ARID1A, KRAS, PIK3CA, RNF43, ERBB2, and " exact="APC" post=" genes. Elevated expression of p53 is consistent with the frequency of TP53 mutations and an" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="3, ERBB2, and APC genes. Elevated expression of p53 is consistent with the frequency of " exact="TP53" post=" mutations and aneuploidy that are observed for CIN GC tumors. These findings are also partly consi" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="consistent with the observation that the highest frequency of loss of heterozygosity occurs at the " exact="APC" post=" (36%) and TP53 (33%) loci [ 4]. TP53 alterations have previously been " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="bservation that the highest frequency of loss of heterozygosity occurs at the APC (36%) and " exact="TP53" post=" (33%) loci [ 4]. TP53 alterations have previously been associated with gastri" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ss of heterozygosity occurs at the APC (36%) and TP53 (33%) loci [ 4]. " exact="TP53" post=" alterations have previously been associated with gastric precancerous lesions; thereby suggesting " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="EGFR) (pY1068) is also significantly elevated in the CIN subtype, consistent with the detection of " exact="EGFR" post=" amplification in this subtype. " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="), which leads to the promotion of aberrant cell growth. However, the gene that encodes the ligand " exact="VEGFA" post=", is also frequently amplified in this GC subtype, as demonstrated in studies of ramucirumab, a VEG" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="targeting antibody. In addition, amplifications of cell cycle mediators ( CCNE1, CCND1, and " exact="CDK6" post=") have been observed in the CIN subtype. Many of these genomic amplifications are amenable to block" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="f=&quot;#R29&quot;&gt;29, 30]. This correlates with 2-8% of GC cases, which are characterized by " exact="EGFR" post=" amplification [ 67– 69] or mutation (5%) [ 69]. Inter" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" this signaling pathway are mutually to one another in GC [ 67]. The latter include " exact="EGFR" post=", ERBB2, KRAS, FGFR2, and MET, and these genes are frequently amplified" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ng pathway are mutually to one another in GC [ 67]. The latter include EGFR, " exact="ERBB2" post=", KRAS, FGFR2, and MET, and these genes are frequently amplified in CIN molecu" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" mutually to one another in GC [ 67]. The latter include EGFR, ERBB2, " exact="KRAS" post=", FGFR2, and MET, and these genes are frequently amplified in CIN molecular subtype c" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="one another in GC [ 67]. The latter include EGFR, ERBB2, KRAS, " exact="FGFR2" post=", and MET, and these genes are frequently amplified in CIN molecular subtype cases of GC [ &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="r HER2), which share overlapping signaling pathways [ 86]. In colon cancer studies, " exact="RAS" post=" mutations ( KRAS and NRAS) have been investigated as predictive markers of anti-EGFR" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="erlapping signaling pathways [ 86]. In colon cancer studies, RAS mutations ( " exact="KRAS" post=" and NRAS) have been investigated as predictive markers of anti-EGFR treatments. In contrast" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ing pathways [ 86]. In colon cancer studies, RAS mutations ( KRAS and " exact="NRAS" post=") have been investigated as predictive markers of anti-EGFR treatments. In contrast, RAS mutation i" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" also commonly referred to as HER2) has been detected in 10-30% of GC cases, with amplification of " exact="ERBB2" post=" detected in 2-27% of GC cases [ 28– 30] and ERBB2 mutations d" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="fication of ERBB2 detected in 2-27% of GC cases [ 28– 30] and " exact="ERBB2" post=" mutations detected in 5% of GC cases [ 69]. Overexpression of ERBB2 has also been a" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="cted in 5% of GC cases [ 69]. Overexpression of ERBB2 has also been associated with " exact="ERBB2" post=" amplification in 24% of CIN GC cases and in 12% of EBV cases, while ERBB2 mutations have be" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="n associated with ERBB2 amplification in 24% of CIN GC cases and in 12% of EBV cases, while " exact="ERBB2" post=" mutations have been detected in 7% of MSI molecular subtypes [ 4]. Moreover, overexp" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="href=&quot;#F3&quot;&gt;3). Activation of the PI3K/AKT/mTOR pathway can be triggered by the activation of RTKs, " exact="PI3KCA" post="-activating mutations and amplifications, loss of PTEN function due to deletions or mutation" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="riggered by the activation of RTKs, PI3KCA-activating mutations and amplifications, loss of " exact="PTEN" post=" function due to deletions or mutations, and overexpression or activating mutations of AKT1." xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" PTEN function due to deletions or mutations, and overexpression or activating mutations of " exact="AKT1" post=". " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="The PI3K/AKT/mTOR pathway is frequently activated in GC, with overexpression of " exact="PI3KCA" post=" described in 35-80% of GC cases [ 108– 110], and phosphorylation o" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="asis [ 108, 109, 111]. Furthermore, alterations in " exact="PIK3CA" post=" have been detected in 80% and 42% of the EBV and MSI molecular subtypes of GC, respectively [ &lt;a h" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ase I trial with advanced stage GC patients that carry either a molecular alteration of PIK3CA, or " exact="ERBB2" post=" ampliﬁcation (NCT01613950) [ 92]. Due to the structural similarity of the catalytic" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="). The allosteric inhibitors of AKT, have been effective against breast cancer cell lines carrying " exact="PI3KCA" post=" mutations and ERBB2 ampliﬁcations [ 117]. Currently, MK2206 is being studie" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" of AKT, have been effective against breast cancer cell lines carrying PI3KCA mutations and " exact="ERBB2" post=" ampliﬁcations [ 117]. Currently, MK2206 is being studied in early phase trials in " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="onotherapy, has mediated partial responses in two patients that harbored tumor mutations in either " exact="AKT1" post=" or PI3KCA [ 120]. Similarly, GDC0068 has exhibited anti-tumor activity in h" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" mediated partial responses in two patients that harbored tumor mutations in either AKT1 or " exact="PI3KCA" post=" [ 120]. Similarly, GDC0068 has exhibited anti-tumor activity in human cancer cell " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=". Junk et al. [ 130] observed that 78% of patients with colorectal cancer with the " exact="PIK3CA" post=" mutation also had simultaneous KRAS mutation and did not respond to PI3K/AKT/mTOR axis ther" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" that 78% of patients with colorectal cancer with the PIK3CA mutation also had simultaneous " exact="KRAS" post=" mutation and did not respond to PI3K/AKT/mTOR axis therapy. By contrast, patients with ovarian can" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="PI3K/AKT/mTOR axis therapy. By contrast, patients with ovarian cancer and simultaneously occurring " exact="KRAS" post=" or BRAF mutations achieved a partial response with these inhibitors, thereby indicating tha" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="xis therapy. By contrast, patients with ovarian cancer and simultaneously occurring KRAS or " exact="BRAF" post=" mutations achieved a partial response with these inhibitors, thereby indicating that the RAS/RAF/M" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="/MEK pathway serves as a driver of resistance to PI3K inhibitors and suggesting that screening for " exact="PI3KCA" post=" (and RAS or RAF) could be used to predict PI3K/AKT/mTOR response clinically. In gast" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" as a driver of resistance to PI3K inhibitors and suggesting that screening for PI3KCA (and " exact="RAS" post=" or RAF) could be used to predict PI3K/AKT/mTOR response clinically. In gastric cancer, the " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="f resistance to PI3K inhibitors and suggesting that screening for PI3KCA (and RAS or " exact="RAF" post=") could be used to predict PI3K/AKT/mTOR response clinically. In gastric cancer, the PIK3CA mutatio" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="AKT inhibitors [ 118, 131]. In contrast, the predictive ability of " exact="KRAS" post=" and BRAF mutations has not been extensively studied, but a few reports have demonstrated th" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" 118, 131]. In contrast, the predictive ability of KRAS and " exact="BRAF" post=" mutations has not been extensively studied, but a few reports have demonstrated that the frequency" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="aspase 3. In tumor tissues from GC patients that were examined in vitro, AKT activation and " exact="PTEN" post=" loss were associated with increased resistance to multiple chemotherapeutic agents (5-FU, doxorubi" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ref=&quot;#R136&quot;&gt;136] and other cancer models [ 121], especially those characterized by " exact="PTEN" post=" loss [ 118]. A similar association was observed following activation of the PI3K/A" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="agents in other cancers [ 118, 119]. Based on the observation that " exact="PTEN" post=" loss was detected in a majority of ERBB2-positive GC cases [ 137], it is possible " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" was detected in a majority of ERBB2-positive GC cases [ 137], it is possible that " exact="PTEN" post=" loss explains the observed clinical resistance of ERBB2-positive GC patients to current anti-ERBB2" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" roles for the MET in cancer via crosstalk with other receptors and cell surface proteins, such as " exact="TGFB1" post=" and EGFR [ 141], and these interactions contribute to oncogenesis and drug " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="T in cancer via crosstalk with other receptors and cell surface proteins, such as TGFB1 and " exact="EGFR" post=" [ 141], and these interactions contribute to oncogenesis and drug resistance [ &lt;a " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="propriate MET signaling in cells can be triggered by several mechanisms. The first is related to a " exact="MET" post=" rearrangement generated by chromosomal translocation and fusion of a TPR (translocated promoter re" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="(translocated promoter region) locus on chromosome 1 to the 5′region of sequences derived from the " exact="MET" post=" locus on chromosome 7. This genomic rearrangement results in activation of MET via dimerization of" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ed to GC lesions include gene amplifications, gene mutations, and transcriptional up-regulation of " exact="MET" post=" and/or HGF genes. Correspondingly, MET gene amplification with consequent protein ov" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="nclude gene amplifications, gene mutations, and transcriptional up-regulation of MET and/or " exact="HGF" post=" genes. Correspondingly, MET gene amplification with consequent protein overexpression and c" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="tations, and transcriptional up-regulation of MET and/or HGF genes. Correspondingly, " exact="MET" post=" gene amplification with consequent protein overexpression and constitutive kinase activation has b" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ed in 2-4% [ 67, 153] of advanced stage GC cases, amplifications of " exact="MET" post=" have been detected in 8% of CIN GC lesions, and MET mutations are present in approximately " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="anced stage GC cases, amplifications of MET have been detected in 8% of CIN GC lesions, and " exact="MET" post=" mutations are present in approximately 3% of MSI subtype GCs [ 4]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ant monoclonal antibody is ABT-700, which has shown promising anti-tumor activity in patients with " exact="MET" post=" amplification solid tumors [ 159]. The ABT-700 was well tolerated at the recommend" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="Furthermore, a phase I study using ABT-700 monotherapy showed a 50% response rate in patients with " exact="MET" post="-amplified advanced gastric and esophageal cancer (NCT01472016) [ 160]. Interesting" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="ed advanced gastric and esophageal cancer (NCT01472016) [ 160]. Interestingly, the " exact="MET" post=" amplification appears to be more common in metastatic recurrent tumors than in primary tumors and " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="tastatic recurrent tumors than in primary tumors and this highlights the importance of identifying " exact="MET" post=" amplification as a predictive biomarker of clinical benefit in a treatment-refractory patient popu" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="href=&quot;#R163&quot;&gt;163]. In a phase I analysis of AMG 337 monotherapy, 14.4 % (13/90) of patients showed " exact="MET" post=" amplification. Among these 13 patients, 62% (8/13), achieved an objective response to AMG 337. The" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" degradation of the extracellular matrix [ 171]. In recent studies, well-described " exact="CDH1" post=" mutations, as well as RHOA mutations, have been found to be strongly related to histologic " xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="matrix [ 171]. In recent studies, well-described CDH1 mutations, as well as " exact="RHOA" post=" mutations, have been found to be strongly related to histologic diffuse-type gastric carcinogenesi" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="achment) and is characterized by an infiltrative phenotype. In three-dimensional cultures, mutated " exact="RHOA" post=" has been associated with an ability to promote escape from anoikis and to facilitate tumor growth," xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="Janus-associated kinase 2 ( " exact="JAK2" post=") is overexpressed in a subset of EBV-subtype GCs, and the JAK/STAT signaling pathway has been dete" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre=" its ligand WNT5, CTBP1, PTCH, and SFRP4 [ 220]. Moreover, increased expression of " exact="WNT5A" post=" (which leads to β-catenin -independent signaling) has been found to potentially correlate with poo" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="rs in GC [ 240, 241]. These results are consistent with a role for " exact="NOTCH1" post=" as an oncogene in many solid malignancies. To date, mutated NOTCH1 has only been detected i" xpath="/html[1]/body[1]/article[1]/div[3]/div[17]/p[2]" name="human"/>
   <result pre="nsistent with a role for NOTCH1 as an oncogene in many solid malignancies. To date, mutated " exact="NOTCH1" post=" has only been detected in T-cell acute lymphoblastic leukemia, and not in other common human cance" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694855/results/gene/human/results.xml">
   <result pre="The most common abnormalities involved the " exact="TP53" post=" gene (36/117 [30.8% of patients]), cyclin pathway ( CCND1, CDK4/6 or CDKN2A/B" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" common abnormalities involved the TP53 gene (36/117 [30.8% of patients]), cyclin pathway ( " exact="CCND1" post=", CDK4/6 or CDKN2A/B) (31/117 [26.5%]) and PI3K pathway ( PIK3CA, PIK3R1, P" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=", CDK4/6 or CDKN2A/B) (31/117 [26.5%]) and PI3K pathway ( PIK3CA, PIK3R1, " exact="PTEN" post=" or AKT1/3) (28/117 [23.9%]). In multivariate analysis, statistically significant co-existin" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="multivariate analysis, statistically significant co-existing aberrations were observed as follows: " exact="TP53" post=" and ERBB2 ( p = 0.01), cyclin pathway and MDM2 ( p = 0.03), and PI3K p" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="lysis, statistically significant co-existing aberrations were observed as follows: TP53 and " exact="ERBB2" post=" ( p = 0.01), cyclin pathway and MDM2 ( p = 0.03), and PI3K pathway and HRA" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="ions were observed as follows: TP53 and ERBB2 ( p = 0.01), cyclin pathway and " exact="MDM2" post=" ( p = 0.03), and PI3K pathway and HRAS ( p = 0.0001). We were able to identif" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="B2 ( p = 0.01), cyclin pathway and MDM2 ( p = 0.03), and PI3K pathway and " exact="HRAS" post=" ( p = 0.0001). We were able to identify possible cognate targeted therapies in most of the " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="ions that mostly differed from patient to patient. Significant associations between aberrations in " exact="TP53" post=" and ERBB2, the cyclin pathway and MDM2, and HRAS and the PI3K pathway were id" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" differed from patient to patient. Significant associations between aberrations in TP53 and " exact="ERBB2" post=", the cyclin pathway and MDM2, and HRAS and the PI3K pathway were identified. Most pa" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="gnificant associations between aberrations in TP53 and ERBB2, the cyclin pathway and " exact="MDM2" post=", and HRAS and the PI3K pathway were identified. Most patients had actionable alterations. T" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="tions between aberrations in TP53 and ERBB2, the cyclin pathway and MDM2, and " exact="HRAS" post=" and the PI3K pathway were identified. Most patients had actionable alterations. These results prov" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="gen and progesterone receptor protein expression by immunohistochemistry [ 15]; and " exact="PIK3CA" post=" [ 16] and BRAF mutations [ 16]. Interestingly, salivary duct " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="xpression by immunohistochemistry [ 15]; and PIK3CA [ 16] and " exact="BRAF" post=" mutations [ 16]. Interestingly, salivary duct carcinomas resemble breast cancer his" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" [ 18– 22]. However, when patients were selected for the presence of " exact="ERBB2" post="/HER2 or PIK3CA aberrations and were treated with appropriate targeting agents (trastuzumab and lap" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="Cyclin pathway aberrations included " exact="CCND1" post=", CDK4/6 or CDKN2A/B aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="PI3K pathway aberrations included " exact="PIK3CA" post=", PIK3R1, PTEN or AKT1/3 aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="PI3K pathway aberrations included PIK3CA, " exact="PIK3R1" post=", PTEN or AKT1/3 aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="PI3K pathway aberrations included PIK3CA, PIK3R1, " exact="PTEN" post=" or AKT1/3 aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="The most common aberration among all salivary gland tumors was in the " exact="TP53" post=" gene (36/117 patients [30.8%]), followed by anomalies in the cyclin pathway ( CCND1, CDK" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="s in the TP53 gene (36/117 patients [30.8%]), followed by anomalies in the cyclin pathway ( " exact="CCND1" post=", CDK4/6 or CDKN2A/B) (observed in 26.5% [31/117] of all salivary gland tumors). Aber" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="% [31/117] of all salivary gland tumors). Aberrations in the PI3K pathway ( PIK3CA, PIK3R1, " exact="PTEN" post=" or AKT) were the third most common set of aberrations among all salivary gland tumors (28/1" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="ll salivary gland tumors). Aberrations in the PI3K pathway ( PIK3CA, PIK3R1, PTEN or " exact="AKT" post=") were the third most common set of aberrations among all salivary gland tumors (28/117 [23.9%]). A" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="hird most common set of aberrations among all salivary gland tumors (28/117 [23.9%]). Anomalies in " exact="HRAS" post=" were seen in 11.1% (13/117) of salivary gland tumors, including 5 of 46 patients (10.9%) with aden" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="th adenocarcinoma, NOS (Table 1 and Figures 1A and 1C). Aberrations in " exact="ERBB2" post=" were found only in patients with adenocarcinoma, NOS (7/46 patients [15.2%] [two mutations and fiv" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="tients with adenoid cystic carcinoma ( N = 49) were NOTCH1/2 (26.5% [13/49]) (mainly " exact="NOTCH1" post=" (24.5% [12/49]) and KDM6A (26.5% [13/49]). Aberrations in the PI3K pathway represent the se" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="ma ( N = 49) were NOTCH1/2 (26.5% [13/49]) (mainly NOTCH1 (24.5% [12/49]) and " exact="KDM6A" post=" (26.5% [13/49]). Aberrations in the PI3K pathway represent the second most common genetic alterati" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="In univariate analysis, " exact="NF1" post=" aberrations were found to be significantly associated with TP53 aberrations (6 of 8 patient" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="In univariate analysis, NF1 aberrations were found to be significantly associated with " exact="TP53" post=" aberrations (6 of 8 patients [75.0%] with aberrant NF1 had a TP53 aberration; 30 of " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="to be significantly associated with TP53 aberrations (6 of 8 patients [75.0%] with aberrant " exact="NF1" post=" had a TP53 aberration; 30 of 109 patients [27.5%] with normal NF1 had a TP53 " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="ly associated with TP53 aberrations (6 of 8 patients [75.0%] with aberrant NF1 had a " exact="TP53" post=" aberration; 30 of 109 patients [27.5%] with normal NF1 had a TP53 aberration; p&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=".0%] with aberrant NF1 had a TP53 aberration; 30 of 109 patients [27.5%] with normal " exact="NF1" post=" had a TP53 aberration; p = 0.01). Anomalies in the PI3K pathway ( PIK3CA, " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="t NF1 had a TP53 aberration; 30 of 109 patients [27.5%] with normal NF1 had a " exact="TP53" post=" aberration; p = 0.01). Anomalies in the PI3K pathway ( PIK3CA, PIK3R1, PTE" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" normal NF1 had a TP53 aberration; p = 0.01). Anomalies in the PI3K pathway ( " exact="PIK3CA" post=", PIK3R1, PTEN or AKT1/3) were also found to be associated with TP53 ab" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="/i&gt; had a TP53 aberration; p = 0.01). Anomalies in the PI3K pathway ( PIK3CA, " exact="PIK3R1" post=", PTEN or AKT1/3) were also found to be associated with TP53 aberrations (13 o" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="53 aberration; p = 0.01). Anomalies in the PI3K pathway ( PIK3CA, PIK3R1, " exact="PTEN" post=" or AKT1/3) were also found to be associated with TP53 aberrations (13 of 28 patients" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" PIK3CA, PIK3R1, PTEN or AKT1/3) were also found to be associated with " exact="TP53" post=" aberrations (13 of 28 patients [46.4%] with anomalies in PI3K pathway had a TP53 aberration" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="iated with TP53 aberrations (13 of 28 patients [46.4%] with anomalies in PI3K pathway had a " exact="TP53" post=" aberration; 23 of 89 patients [25.8%] with normal PI3K pathway had a TP53 aberration; p&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="I3K pathway had a TP53 aberration; 23 of 89 patients [25.8%] with normal PI3K pathway had a " exact="TP53" post=" aberration; p = 0.06 [trend]). Interestingly, ERBB2 aberrations were also associated" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="%] with normal PI3K pathway had a TP53 aberration; p = 0.06 [trend]). Interestingly, " exact="ERBB2" post=" aberrations were also associated with TP53 aberrations (6 of 7 patients [85.7%] with aberra" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="ation; p = 0.06 [trend]). Interestingly, ERBB2 aberrations were also associated with " exact="TP53" post=" aberrations (6 of 7 patients [85.7%] with aberrant ERBB2 had a TP53 aberration; 30 o" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="errations were also associated with TP53 aberrations (6 of 7 patients [85.7%] with aberrant " exact="ERBB2" post=" had a TP53 aberration; 30 of 110 patients [27.3%] with normal ERBB2 had a TP53&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" associated with TP53 aberrations (6 of 7 patients [85.7%] with aberrant ERBB2 had a " exact="TP53" post=" aberration; 30 of 110 patients [27.3%] with normal ERBB2 had a TP53 aberration; p" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="%] with aberrant ERBB2 had a TP53 aberration; 30 of 110 patients [27.3%] with normal " exact="ERBB2" post=" had a TP53 aberration; p = 0.003). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="&gt;ERBB2 had a TP53 aberration; 30 of 110 patients [27.3%] with normal ERBB2 had a " exact="TP53" post=" aberration; p = 0.003). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="After multivariate analysis, anomalies in the PI3K pathway and " exact="ERBB2" post=" aberrations were found to have an increased association with TP53 aberrations ( p = " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" in the PI3K pathway and ERBB2 aberrations were found to have an increased association with " exact="TP53" post=" aberrations ( p = 0.04 and 0.01 respectively) (Table 2). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="Cyclin pathway aberrations included " exact="CCND1" post=", CDK4/6 or CDKN2A/B aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="PI3K pathway aberrations included " exact="PIK3CA" post=", PIK3R1, PTEN or AKT1/3 aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="PI3K pathway aberrations included PIK3CA, " exact="PIK3R1" post=", PTEN or AKT1/3 aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="PI3K pathway aberrations included PIK3CA, PIK3R1, " exact="PTEN" post=" or AKT1/3 aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="mal NOTCH1/2 had an abnormality in cyclin pathway; p = 0.09 [trend]). Presence of an " exact="MDM2" post=" aberration was associated with abnormalities in cyclin pathway by univariate analysis (6 of 10 pat" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="ith abnormalities in cyclin pathway by univariate analysis (6 of 10 patients [60.0%] with aberrant " exact="MDM2" post=" had an abnormality in cyclin pathway; 25 of 107 patients [23.4%] with normal MDM2 had an ab" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" aberrant MDM2 had an abnormality in cyclin pathway; 25 of 107 patients [23.4%] with normal " exact="MDM2" post=" had an abnormality in cyclin pathway; p = 0.02). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="After multivariate analysis, aberrations in " exact="MDM2" post=" remain positively associated with an aberrant cyclin pathway ( p = 0.03) (Table &lt;a href=&quot;#T" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="PI3K pathway aberrations included " exact="PIK3CA" post=", PIK3R1, PTEN or AKT1/3 aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="PI3K pathway aberrations included PIK3CA, " exact="PIK3R1" post=", PTEN or AKT1/3 aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="PI3K pathway aberrations included PIK3CA, PIK3R1, " exact="PTEN" post=" or AKT1/3 aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="In univariate analysis, aberrations in " exact="HRAS" post=" were associated with PI3K pathway abnormalities (10 of 13 patients [76.9%] with aberrant HRAS&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="&gt;HRAS were associated with PI3K pathway abnormalities (10 of 13 patients [76.9%] with aberrant " exact="HRAS" post=" had a PI3K pathway abnormality; 18 of 104 patients [17.3%] with normal HRAS had a PI3K path" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="] with aberrant HRAS had a PI3K pathway abnormality; 18 of 104 patients [17.3%] with normal " exact="HRAS" post=" had a PI3K pathway abnormality; p = &amp;amp;lt; 0.0001). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="A trend toward an association between aberrations in " exact="NF1" post=" and PI3K pathway abnormalities was noted (4 of 8 patients [50.0%] with aberrant NF1 had an " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="ions in NF1 and PI3K pathway abnormalities was noted (4 of 8 patients [50.0%] with aberrant " exact="NF1" post=" had an abnormality in the PI3K pathway; 24 of 109 patients [22.0%] with normal NF1 had an a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="aberrant NF1 had an abnormality in the PI3K pathway; 24 of 109 patients [22.0%] with normal " exact="NF1" post=" had an abnormality in PI3K pathway; p = 0.09 [trend]). As mentioned earlier (Table &lt;a href=" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="2), there was a positive correlation between PI3K pathway abnormalities and aberrant " exact="TP53" post=" (13 of 36 patients [36.1%] with aberrant TP53 had an abnormality in the PI3K pathway; 15 of" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="tween PI3K pathway abnormalities and aberrant TP53 (13 of 36 patients [36.1%] with aberrant " exact="TP53" post=" had an abnormality in the PI3K pathway; 15 of 81 patients [18.5%] with normal TP53 had an a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="aberrant TP53 had an abnormality in the PI3K pathway; 15 of 81 patients [18.5%] with normal " exact="TP53" post=" had an abnormality in the PI3K pathway; p = 0.06 [trend]). " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="The correlation between aberrant " exact="TP53" post=" and PI3K pathway was no longer seen after multivariate analysis (Tables 2 and &lt;a hre" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="e analysis (Tables 2 and 4). However, the association between aberrant " exact="HRAS" post=" and PI3K pathway abnormalities remained statistically significant ( p = 0.0001) (Table &lt;a h" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="Cyclin pathway aberrations included " exact="CCND1" post=", CDK4/6 or CDKN2A/B aberrations. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="uzumab and lapatinib for Her2-aberrant salivary tumors [ 23] or mTOR inhibitors for " exact="PIK3CA" post="-aberrant neoplasms [ 24]. We therefore investigated the genomic landscape of saliva" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="The most common genetic aberration among 117 patients with salivary gland tumors was " exact="TP53" post=" mutation (36/117 [30.8%]) (Table 1, Figure 1A and Suppl" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" is in agreement with previous reports demonstrating that 22–60% of salivary gland tumors harbor a " exact="TP53" post=" mutation [ 25– 27]. Although little is known about the role of TP" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="3 mutation [ 25– 27]. Although little is known about the role of " exact="TP53" post=" in the pathogenesis of salivary gland tumors, it has been suggested that alteration in this gene i" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="gression-free survival (PFS) when compared to non-bevacizumab-containing regimens in patients with " exact="TP53" post="-mutated advanced solid tumors (median 11.0 versus 4.0 months; PFS was not increased in patients wi" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="nced solid tumors (median 11.0 versus 4.0 months; PFS was not increased in patients with wild-type " exact="TP53" post=" on bevacizumab-based treatment [median = 5 months, p &amp;amp;lt; 0.0001]) [ 29]" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="These results require validation in a prospective study. Of interest, in our study, aberrations in " exact="ERBB2" post=" were associated with TP53 anomalies after multivariate analysis ( p = 0.01) (Table &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="n a prospective study. Of interest, in our study, aberrations in ERBB2 were associated with " exact="TP53" post=" anomalies after multivariate analysis ( p = 0.01) (Table 2). Anomalies in " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="/i&gt; anomalies after multivariate analysis ( p = 0.01) (Table 2). Anomalies in " exact="ERBB2" post=" may be targeted with lapatinib or trastuzumab [ 23, 30]. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="33]. This pathway can be altered through multiple mechanisms including increased signaling through " exact="CDK4" post=" and CDK6 amplification, overexpression of cyclin D1, and loss of inhibitors including CD" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="y can be altered through multiple mechanisms including increased signaling through CDK4 and " exact="CDK6" post=" amplification, overexpression of cyclin D1, and loss of inhibitors including CDKN2A (p16) a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="4 and CDK6 amplification, overexpression of cyclin D1, and loss of inhibitors including " exact="CDKN2A" post=" (p16) and/or CDKN2B (p15) [ 34– 37]. Mutation or loss of R" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="fication, overexpression of cyclin D1, and loss of inhibitors including CDKN2A (p16) and/or " exact="CDKN2B" post=" (p15) [ 34– 37]. Mutation or loss of RB1 (Rb; retinoblastoma)" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" (p16) and/or CDKN2B (p15) [ 34– 37]. Mutation or loss of " exact="RB1" post=" (Rb; retinoblastoma) also alters this pathway, but renders tumors resistant to CDK inhibitors. Onl" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="his pathway, but renders tumors resistant to CDK inhibitors. Only three patients in our series had " exact="RB1" post=" mutations. According to Etges et al [ 38], malignant salivary gland tumors e" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="such as with palbociclib [ 33] and further investigation is warranted. Of interest, " exact="MDM2" post=" amplifications were more likely to be associated with abnormalities in the cyclin pathway (6/10 [6" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="reported that five out of seven patients with diffuse large B cell lymphomas had co-aberrations in " exact="MDM2" post=" (amplification) and CDKN2A (deletion), when assessed by immunohistochemistry and polymerase" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="patients with diffuse large B cell lymphomas had co-aberrations in MDM2 (amplification) and " exact="CDKN2A" post=" (deletion), when assessed by immunohistochemistry and polymerase chain reaction respectively [ &lt;a " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="polymerase chain reaction respectively [ 39]. Since MDM2 is negatively regulated by " exact="CDKN2A" post=", MDM2 amplification and aberrations in the cyclin pathway will likely lead to suppression o" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="n reaction respectively [ 39]. Since MDM2 is negatively regulated by CDKN2A, " exact="MDM2" post=" amplification and aberrations in the cyclin pathway will likely lead to suppression of TP53" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="MDM2 amplification and aberrations in the cyclin pathway will likely lead to suppression of " exact="TP53" post=" ( TP53 is negatively regulated by MDM2) [ 40]. Thus, for patients wit" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="plification and aberrations in the cyclin pathway will likely lead to suppression of TP53 ( " exact="TP53" post=" is negatively regulated by MDM2) [ 40]. Thus, for patients with co-aberratio" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="in pathway will likely lead to suppression of TP53 ( TP53 is negatively regulated by " exact="MDM2" post=") [ 40]. Thus, for patients with co-aberrations in MDM2 and the CDK pathway, " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="gatively regulated by MDM2) [ 40]. Thus, for patients with co-aberrations in " exact="MDM2" post=" and the CDK pathway, inhibition of both MDM2 [ 41] and the cyclin pathway [ &lt;a href" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="Importantly, aberrations in the PI3K pathway ( PIK3CA, PIK3R1, " exact="PTEN" post=" or AKT) were commonly seen in salivary gland tumors (28/117 [23.9%]). Of interest, there wa" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="Importantly, aberrations in the PI3K pathway ( PIK3CA, PIK3R1, PTEN or " exact="AKT" post=") were commonly seen in salivary gland tumors (28/117 [23.9%]). Of interest, there was a statistica" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" (28/117 [23.9%]). Of interest, there was a statistically significant association between aberrant " exact="HRAS" post=" and PI3K pathway abnormalities (10/13 [76.9%] versus 18/104 [17.3%]; p = 0.0001 after multi" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" MAP (mitogen-activated protein) kinase-related genes are more frequently aberrant in the presence " exact="PIK3CA" post=" mutations than when PIK3CA is normal [ 43]. Since mutation in HRAS is" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="inase-related genes are more frequently aberrant in the presence PIK3CA mutations than when " exact="PIK3CA" post=" is normal [ 43]. Since mutation in HRAS is also capable of activating the MA" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" PIK3CA mutations than when PIK3CA is normal [ 43]. Since mutation in " exact="HRAS" post=" is also capable of activating the MAP kinase signaling pathway, merely blocking the PI3K pathway w" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="ling pathway, merely blocking the PI3K pathway will likely not be sufficient. Although the role of " exact="PIK3CA" post=" mutation as a predictive biomarker for everolimus or PI3K inhibitor response is controversial [ &lt;a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="previously reported literature where several aberrations including NOTCH1/2 (3/24 [12.5%]), " exact="KDM6A" post=" (2/24 [8.3%]), CDKN2A (1/24 [4.2%]) and PIK3CA (1/24 [4.2%]) were identified by whol" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="re where several aberrations including NOTCH1/2 (3/24 [12.5%]), KDM6A (2/24 [8.3%]), " exact="CDKN2A" post=" (1/24 [4.2%]) and PIK3CA (1/24 [4.2%]) were identified by whole exome sequencing of 24 pati" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="luding NOTCH1/2 (3/24 [12.5%]), KDM6A (2/24 [8.3%]), CDKN2A (1/24 [4.2%]) and " exact="PIK3CA" post=" (1/24 [4.2%]) were identified by whole exome sequencing of 24 patients with adenoid cystic carcino" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="inical history. Lastly, lumping the common pathway abnormalities together such as cyclin pathway ( " exact="CCND1" post=", CDK4/6 or CDKN2A/B) and PI3K pathway ( PIK3CA, PIK3R1, PTEN or" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="gether such as cyclin pathway ( CCND1, CDK4/6 or CDKN2A/B) and PI3K pathway ( " exact="PIK3CA" post=", PIK3R1, PTEN or AKT1/3) aberrations may be misleading since different mutati" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="cyclin pathway ( CCND1, CDK4/6 or CDKN2A/B) and PI3K pathway ( PIK3CA, " exact="PIK3R1" post=", PTEN or AKT1/3) aberrations may be misleading since different mutations can lead to" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="( CCND1, CDK4/6 or CDKN2A/B) and PI3K pathway ( PIK3CA, PIK3R1, " exact="PTEN" post=" or AKT1/3) aberrations may be misleading since different mutations can lead to diverse func" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="stinct aberrations. The most common aberrations in patients with salivary gland tumors were in the " exact="TP53" post=" gene, followed by alterations in the cyclin pathway and the PI3K pathway ( PIK3CA, PIK3R1, " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" gene, followed by alterations in the cyclin pathway and the PI3K pathway ( PIK3CA, PIK3R1, " exact="PTEN" post=" or AKT) (Table 1 and Figure 1A). Interestingly, in multivariate" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre=" by alterations in the cyclin pathway and the PI3K pathway ( PIK3CA, PIK3R1, PTEN or " exact="AKT" post=") (Table 1 and Figure 1A). Interestingly, in multivariate analysis, the" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" multivariate analysis, there was a significant independent association between alterations in the " exact="TP53" post=" and ERBB2 genes ( p = 0.01) (Table 2), cyclin pathway and the MDM2&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="alysis, there was a significant independent association between alterations in the TP53 and " exact="ERBB2" post=" genes ( p = 0.01) (Table 2), cyclin pathway and the MDM2 gene ( p&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="TP53 and ERBB2 genes ( p = 0.01) (Table 2), cyclin pathway and the " exact="MDM2" post=" gene ( p = 0.03) (Table 3), and between HRAS and the PI3K pathway ( &lt;i" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[10]" name="human"/>
   <result pre="), cyclin pathway and the MDM2 gene ( p = 0.03) (Table 3), and between " exact="HRAS" post=" and the PI3K pathway ( p = 0.0001) (Table 4), suggesting that dual targeting " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4694868/results/gene/human/results.xml">
   <result pre="utcome using publicly available breast cancer patient cohorts. We found the expression of the gene " exact="SERPINA1" post=" to have a significant predictive value for the overall survival (OS) of ER+ patients in the TCGA c" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="survival (OS) of ER+ patients in the TCGA cohort, and validated this finding in the Curtis cohort. " exact="SERPINA1" post=" also has a significant predictive value for the OS of ER+/HER2+ patients in the TCGA cohort, with " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="OS of ER+/HER2+ patients in the TCGA cohort, with validation in the Bild cohort. The expression of " exact="SERPINA1" post=" can be suppressed by fulvestrant and HER2 siRNA. Our results indicate that ER is constitutively ac" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="lts indicate that ER is constitutively activated, resulting in an E2-independent ER binding to the " exact="SERPINA1" post=" gene and upregulation of SERPINA1 expression. Importantly, results of survival correlation " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="tivated, resulting in an E2-independent ER binding to the SERPINA1 gene and upregulation of " exact="SERPINA1" post=" expression. Importantly, results of survival correlation suggests that high expression of SERPI" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="INA1 expression. Importantly, results of survival correlation suggests that high expression of " exact="SERPINA1" post=" could be predictive for a better clinical outcome of ER+ and ER+/HER2+ patients. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="reatment options for patients. Our extensive ER ChIP-seq analysis has resulted in a candidate gene " exact="SERPINA1" post=" that has a clear ER binding site in its promoter region and higher expression level in LTEDaro DMS" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="ter region and higher expression level in LTEDaro DMSO (i.e., in the absence of E2). The levels of " exact="SERPINA1" post=" mRNA have been found to be significantly higher in LTEDaro DMSO than in E2-treated MCF-7aro E2 [ &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="href=&quot;#R6&quot;&gt;6] with clincopathological information, we further hypothesize that the upregulation of " exact="SERPINA1" post=" in endocrine-resistant cells requires HER2 and has significant association with better survival ou" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" " exact="SERPINA1" post=", also known as α1-AntiTrypsin (AAT), is a protease inhibitor that can act on a variety of targets " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="bitor that can act on a variety of targets such as serine proteases. It has been demonstrated that " exact="SERPINA1" post=" expression can be stimulated by E2 in MCF-7 cells, and high expression of this protein inhibits co" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" in MCF-7 cells, and high expression of this protein inhibits colony formation [ 7]. " exact="SERPINA1" post=" has been proposed as a biomarker for various diseases such as Cutaneous Squamous Cell Carcinoma [ " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="14&quot;&gt;14– 16]. Unexpectedly, our results allow us to hypothesize that the single gene " exact="SERPINA1" post=" is a significant predictor of survival in ER+ and ER+/HER2+ breast cancer patients. Patients with " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="er for the treatment outcome of ER+/HER2+ breast cancers [ 19], thus the ability of " exact="SERPINA1" post=" to predict the survival of this intrinsic subtype of breast cancer patients is valuable. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="mina ChIP-seq and Affymetrix GeneChip gene expression microarray data, leading to the discovery of " exact="SERPINA1" post=" and its potential regulation by ER and HER2. B. SERPINA1 has an ER binding site proximal to" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" data, leading to the discovery of SERPINA1 and its potential regulation by ER and HER2. B. " exact="SERPINA1" post=" has an ER binding site proximal to the TSS with higher level of ER binding in the LTEDaro DMSO cel" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="in the MCF-7aro E2 cells instead. C. ChIP PCR validation of ER binding site proximal to the TSS of " exact="SERPINA1" post=" confirms the ER binding in LTEDaro, as detected by ChIP-seq. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="decided to focus on our analysis on the best candidate with strong ER binding in LTEDaro DMSO, the " exact="SERPINA1" post=" gene from the negative Cox score group. SERPINA1 was brought to our attention because it ha" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="ith strong ER binding in LTEDaro DMSO, the SERPINA1 gene from the negative Cox score group. " exact="SERPINA1" post=" was brought to our attention because it has been reported to be an ER-regulated gene in breast can" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" reported to be an ER-regulated gene in breast cancer cells [ 29]. In our analysis, " exact="SERPINA1" post=" has a well-defined ER binding site with the distinctive property that ER binding in LTEDaro DMSO w" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="r according to our qPCR analysis (Figure 4A). Further literature search reveals that " exact="SERPINA1" post=" is a known marker for good prognosis in cancer [ 12, 14]. As indicat" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="a href=&quot;#R12&quot;&gt;12, 14]. As indicated by a negative Cox score, a higher expression of " exact="SERPINA1" post=" was found to associate with better patient survival outcome in the TCGA large patient cohort, and " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="in the Kaplan Meier analyses. Before we performed the detailed survival analyses, we confirmed the " exact="SERPINA1" post=" ER binding and gene expression regulation by ER and HER2. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="Although E2 was reported to up regulate the expression of " exact="SERPINA1" post=" twenty years ago [ 7], the mechanism was unknown at that time. A direct ER-mediated " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="ported that E2 addition did not significantly enhance the ER binding to the ERE in the promoter of " exact="SERPINA1" post=". Our ER ChIP-seq analysis confirms that the SERPINA1 gene has an ER binding site within the" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" binding to the ERE in the promoter of SERPINA1. Our ER ChIP-seq analysis confirms that the " exact="SERPINA1" post=" gene has an ER binding site within the promoter region which overlaps with the TSS (Figure &lt;a href" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="To validate the activity and E2 response of the " exact="SERPINA1" post=" promoter, we cloned the full length and deletion mutants as described in the Materials and Methods" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" A. The " exact="SERPINA1" post=" full length promoter and two deletion mutants, with and without ERE, were cloned into luciferase r" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="In the MCF-7aro, LTEDaro and HER2-aro cell lines we examined, the " exact="SERPINA1" post=" expression is up regulated with E2 treatment and suppressed by the ER degrader, fulvestrant (ICI 1" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" suppressed by the ER degrader, fulvestrant (ICI 182, 780) (Figure 4A). A search for " exact="SERPINA1" post=" in the Gene Expression Omnibus (GEO) database provided support that SERPINA1 expression is " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=". A search for SERPINA1 in the Gene Expression Omnibus (GEO) database provided support that " exact="SERPINA1" post=" expression is stimulated by E2 in an ER-dependent manner [ 30, 31], " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" in ER+/HER2+ breast cancer cells, we performed experiments to determine whether the expression of " exact="SERPINA1" post=" could be regulated by HER2. The expression level of SERPINA1 in two tested HER2-overexpress" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="mine whether the expression of SERPINA1 could be regulated by HER2. The expression level of " exact="SERPINA1" post=" in two tested HER2-overexpressing cell lines, HER2-aro [ 5] and LTEDaro cells [ &lt;a h" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="f=&quot;#R33&quot;&gt;33], was found to be significantly higher than that in MCF-7aro cells, demonstrating that " exact="SERPINA1" post=" is a HER2 regulated gene (Figure 4A). The HER2-dependent regulation of SERPINA1&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="&gt;SERPINA1 is a HER2 regulated gene (Figure 4A). The HER2-dependent regulation of " exact="SERPINA1" post=" expression was confirmed further by the down regulation of its expression by the treatment of siRN" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="ref=&quot;#F4&quot;&gt;4B). In attempt to further support our findings in additional cell lines, we checked the " exact="SERPINA1" post=" expression level in BT474 and MDA-MB-361cells, which express both ER and HER2 endogenously. The re" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" ER and HER2 endogenously. The results show that E2 and ICI treatment did not significantly change " exact="SERPINA1" post=" levels, although there may be a weak induction by E2 in BT-474 cells ( Supplementar" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" A. Gene expression analysis of " exact="SERPINA1" post=" by qPCR shows that SERPINA1 expression in MCF-7aro E2, HER2-aro E2, and LTEDaro DMSO can be" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" A. Gene expression analysis of SERPINA1 by qPCR shows that " exact="SERPINA1" post=" expression in MCF-7aro E2, HER2-aro E2, and LTEDaro DMSO can be suppressed by ICI treatment. B. Co" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="CF-7aro E2, HER2-aro E2, and LTEDaro DMSO can be suppressed by ICI treatment. B. Comparison of the " exact="SERPINA1" post=" expression in the control-siRNA treated cells shows that HER2-aro and LTEDaro cells have a higher " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="nd LTEDaro cells have a higher expression compared to MCF-7aro. siRNA knockdown of HER2 shows that " exact="SERPINA1" post=" is downregulated by about 40% when HER2 levels are reduced. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="Based on our findings that the expression of " exact="SERPINA1" post=" is regulated by both ER and HER2, we then performed the Kaplan Meier survival analysis by dividing" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="y dividing the patients into high and low expression groups based on the median of the single gene " exact="SERPINA1" post=". We found that in the TCGA training cohort with 570 ER+ patients, this gene showed a statistically" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" A. The survival analysis in TCGA breast cancer cohort of ER+ and ER- patients shows that " exact="SERPINA1" post=" has a significant predictive value only in the ER+ patients but not the ER- patients. B. Validatio" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="patients. B. Validation with ER+ and ER- patients in the Curtis breast cancer cohort confirms that " exact="SERPINA1" post=" has a significant predictive value in the ER+ but not the ER- patients. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" 28] (Table 1). However, we failed to observe any correlation between " exact="SERPINA1" post=" levels and survival in other four cohorts of ER+ patients, namely Chin, Pawitan, Desmedt, Sotiriou" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="amely Chin, Pawitan, Desmedt, Sotiriou (data not shown). Since we confirmed that the expression of " exact="SERPINA1" post=" can also be regulated by HER2, we then checked the HER2 status of patients in the six cohorts and " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="1). Such observations led us to propose that the HER2 status is related to the predictive value of " exact="SERPINA1" post=" on patient survival outcome. To verify this hypothesis, we performed further survival analysis wit" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="tatus. In the TCGA cohort, we subdivided the ER+ patients based on HER2 status, and found that the " exact="SERPINA1" post=" has a significant predictive value in the ER+/HER2+ group with 82 patients ( p = 0.045) but" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="these results were not statistically significant. To further establish the value and uniqueness of " exact="SERPINA1" post=" as a predictive marker, we investigated the predictive ability of some well known ER target genes " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" as a predictive marker, we investigated the predictive ability of some well known ER target genes " exact="TFF1" post=" (pS2), PGR and GREB1. We performed the survival analyses by grouping the patients in" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="rker, we investigated the predictive ability of some well known ER target genes TFF1 (pS2), " exact="PGR" post=" and GREB1. We performed the survival analyses by grouping the patients in the TCGA cohort b" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="igated the predictive ability of some well known ER target genes TFF1 (pS2), PGR and " exact="GREB1" post=". We performed the survival analyses by grouping the patients in the TCGA cohort based on ER status" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="o separate the patients into high and low risk groups. This further supports the unique ability of " exact="SERPINA1" post=" to predict patient survival, because SERPINA1 is regulated by both ER and HER2. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=". This further supports the unique ability of SERPINA1 to predict patient survival, because " exact="SERPINA1" post=" is regulated by both ER and HER2. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" A. " exact="SERPINA1" post=" has a significant predictive value in the ER+/HER2+ but not the ER+/HER2- patients from TCGA cohor" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" analysis of ER+/HER2+ patients in Bild patient cohort shows that patients with high expression of " exact="SERPINA1" post=" has a better treatment outcome. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="ugh the bioinformatics analysis in combination with gene expression microarray data, we identified " exact="SERPINA1" post=" as one such ER target gene that clearly had E2-dependent ER binding in MCF-7aro cells and stronger" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" was significantly suppressed by the treatment of ER degrader, fulvestrant. Here we confirmed that " exact="SERPINA1" post=" is a direct ER target gene, as supported by our ER ChIP-seq, ChIP PCR validation, microarray, gene" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="CR validation, microarray, gene expression qPCR data, and siRNA results. Considering the fact that " exact="SERPINA1" post=" is highly expressed in LTEDaro, its expression must be up-regulated by ER through cross-talk with " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="rough cross-talk with growth factor-regulated pathways. From searching the GEO data, we found that " exact="SERPINA1" post=" is also a HER2-regulated gene. This was supported by the fact that HER2-aro cells had much higher " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="ated gene. This was supported by the fact that HER2-aro cells had much higher expression levels of " exact="SERPINA1" post=" than MCF-7aro cells. The expression of SERPINA1 in these resistant cells was reduced upon t" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" cells had much higher expression levels of SERPINA1 than MCF-7aro cells. The expression of " exact="SERPINA1" post=" in these resistant cells was reduced upon the treatment of HER2 siRNA (Figure 4B). B" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="s activated through phosphorylation by signaling pathways activated by HER2 [ 5] and " exact="SERPINA1" post=" is a unique gene whose expression can be induced by phosphorylated ER. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="ttempts pointed out some limitations in such effort. Our Kaplan Meier survival analysis found that " exact="SERPINA1" post=" expression had a significant association with patient survival in ER+ patients using TCGA and Curt" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="more meaningful prediction. Since the majority of breast cancer patients are ER+, our finding that " exact="SERPINA1" post=" can predict survival in ER+ patients suggests that it could be a potential prognostic marker, and " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="h the results were not expected originally, we are excited about the potential predictive value of " exact="SERPINA1" post=" transcript expression levels in the ER+/HER2+ breast cancer, since these patients have relatively " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="While the expression level of " exact="SERPINA1" post=" was found to be higher in endocrine resistant cells than responsive cells, unexpectedly, the Kapla" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="inal B subtype of breast cancer. To explain our findings, we hypothesize that a high expression of " exact="SERPINA1" post=" indicates the important roles of ER and HER2 in driving the growth of the tumors. Therefore, in ER" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" and HER2 in driving the growth of the tumors. Therefore, in ER+ breast cancers, the expression of " exact="SERPINA1" post=" could be an indication of estrogen-mediated ER activation and its expression levels correlate to t" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" to be a &quot;good&quot; response to both anti-ER and anti-HER2 therapies. Many ER-regulated genes, such as " exact="TFF1" post=", PGR and GREB1, are known to be induced in endocrine-resistant cancer, but did not s" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="d&quot; response to both anti-ER and anti-HER2 therapies. Many ER-regulated genes, such as TFF1, " exact="PGR" post=" and GREB1, are known to be induced in endocrine-resistant cancer, but did not show statisti" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="both anti-ER and anti-HER2 therapies. Many ER-regulated genes, such as TFF1, PGR and " exact="GREB1" post=", are known to be induced in endocrine-resistant cancer, but did not show statistical significant c" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="compare the limited treatment information that we have of the patients with high and low levels of " exact="SERPINA1" post=" expression, which corresponds to better and worse survival groups respectively ( Su" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre=" no major differences in the treatment strategies between good and bad responders, suggesting that " exact="SERPINA1" post=" could be an outcome predictor independent of treatment options. Chemotherapy and HER2-directed the" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="ective than trastuzumab + anastrozole. Therefore, for those ER+/HER2+ patients with high levels of " exact="SERPINA1" post=" expression, a less toxic or more cost-effective treatment may be also considered. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="d with clinical outcome in breast cancer. Based on our findings, we propose that the expression of " exact="SERPINA1" post=", an ER and HER2 regulated gene, is linked to the outcome of ER+ and ER+/HER2+ breast cancer. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="rs the TSS and upstream 2 kb region, with a total length of 2.1 kb, which contains the full length " exact="SERPINA1" post=" promoter. We also generated truncated versions of this promoter, with and without the predicted ER" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[8]/p[1]" name="human"/>
   <result pre="ve to the DMSO control. Primer sequences are provided in the Supplementary Table 1. " exact="SERPINA1" post=" gene expression primer sequences have been previously published [ 8]. " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4695049/results/gene/human/results.xml">
   <result pre="ype, there may be clinical benefit to treating BC with HER2-targeted agents even in the absence of " exact="HER2" post=" gene amplification. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="80% reduction in nuclear TAZ levels compared to vehicle-treated controls (Figure 3E, " exact="HCC1428" post="). In summary, RUNX2 interaction with TAZ is necessary to promote TAZ nuclear translocation and/or " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="r tumor suppressive or oncogenic activity, depending on expression of ER [ 63]. The " exact="RUNX2" post=" gene and protein are upregulated in early stage BC tissue [ 7, 8, &lt;a h" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/p[4]" name="human"/>
   <result pre="agents (trastuzumab) may have clinical benefit among a broad group of patients, even those without " exact="HER2" post=" gene amplification [ 6]. Furthermore, it was found that BC cells expressed HER2 in m" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4696215/results/gene/human/results.xml">
   <result pre=" AE adverse event, bev bevacizumab, " exact="HER2" post=" human epidermal growth factor receptor, nab-P nab-paclitaxel, OS overall surv" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" epidermal growth factor receptor, nab-P nab-paclitaxel, OS overall survival, " exact="PFS" post=" progression-free survival, TTP time to tumor progression, qw every week, q2w " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nab-P nab-paclitaxel, OS overall survival, PFS progression-free survival, " exact="TTP" post=" time to tumor progression, qw every week, q2w every 2 weeks, q3w every 3 week" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="IQR" post=" interquartile range " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="IQR" post=" interquartile range, q3w every 3 weeks " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" OS overall survival, " exact="TNTD" post=" time to next therapy or death " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" OS overall survival, q3w every 3 weeks, " exact="TNTD" post=" time to next therapy or death " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4700735/results/gene/human/results.xml">
   <result pre=" Abbreviations: mAb monoclonal antibody, " exact="EGF" post=" epidermal growth factor, EGFR epidermal growth factor receptor, FDA Food and Drug Ad" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" name="human"/>
   <result pre=" Abbreviations: mAb monoclonal antibody, EGF epidermal growth factor, " exact="EGFR" post=" epidermal growth factor receptor, FDA Food and Drug Administration, MMP matrix metal" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" name="human"/>
   <result pre="clonal antibody, EGF epidermal growth factor, EGFR epidermal growth factor receptor, " exact="FDA" post=" Food and Drug Administration, MMP matrix metalloproteinase, VEGF vascular endothelia" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="wth factor, EGFR epidermal growth factor receptor, FDA Food and Drug Administration, " exact="MMP" post=" matrix metalloproteinase, VEGF vascular endothelial growth factor, PDGF platelet-der" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="wth factor receptor, FDA Food and Drug Administration, MMP matrix metalloproteinase, " exact="VEGF" post=" vascular endothelial growth factor, PDGF platelet-derived growth factor, RET rearran" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ministration, MMP matrix metalloproteinase, VEGF vascular endothelial growth factor, " exact="PDGF" post=" platelet-derived growth factor, RET rearranged during transfection, FLT3 FMS-like ty" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="inase, VEGF vascular endothelial growth factor, PDGF platelet-derived growth factor, " exact="RET" post=" rearranged during transfection, FLT3 FMS-like tyrosine kinase-3 receptor, CDK cyclin" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" name="human"/>
   <result pre="wth factor, PDGF platelet-derived growth factor, RET rearranged during transfection, " exact="FLT3" post=" FMS-like tyrosine kinase-3 receptor, CDK cyclin-dependent kinase " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" name="human"/>
   <result pre="actor, RET rearranged during transfection, FLT3 FMS-like tyrosine kinase-3 receptor, " exact="CDK" post=" cyclin-dependent kinase " xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nhibition of tumor cell proliferation. TKIs provide more apparent benefits to patients with mutant " exact="EGFR" post=" compared with patients with translocated wild-type EGFR [ 24]. Gefitinib wa" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" name="human"/>
   <result pre="nt benefits to patients with mutant EGFR compared with patients with translocated wild-type " exact="EGFR" post=" [ 24]. Gefitinib was the first TKI used to treat cancer. Gefitinib exhibits biolog" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[5]/p[1]" name="human"/>
   <result pre="tion adenocarcinoma is not ideal [ 26]. This limited efficacy may result from rare " exact="EGFR" post=" mutations, particularly gefitinib-related mutations, such as delE746-A750 or L858R, in esophagogas" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706127/results/gene/human/results.xml">
   <result pre="st likely to derive benefit from targeted therapies in this disease are still needed. Indeed, only " exact="RAS" post=" mutations have been identified as predictive of lack of benefit from monoclonal antibodies against" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="anitumumab in combination with a chemotherapy backbone, in the first line setting in patients with " exact="RAS" post=" wild-type mCRC. Ongoing efforts are aimed at identifying smaller subsets of patients within the &lt;i" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt; wild-type mCRC. Ongoing efforts are aimed at identifying smaller subsets of patients within the " exact="RAS" post=" wild-type group that will derive the largest benefit from anti-EGFR therapy. In the meantime, trea" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="FR therapy. In the meantime, treatment with anti-EGFR therapy should be reserved for patients with " exact="RAS" post=" wild-type mCRC. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="r treatment is personalized according to the need for rapid response and the burden of disease and " exact="RAS" post=" status, drugs are often reintroduced if they showed activity in a previous line of therapy, and fi" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e of panitumumab, a monoclonal antibody against EGFR, as the first-line treatment in patients with " exact="KRAS" post=" exon 2 wild-type mCRC. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" at different levels resulting in increased EGFR ligands, increased EGFR expression and activating " exact="EGFR" post=" mutations. Activation of EGFR may result from binding to different ligands, including EGF, transfo" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=". 21, 22 Aberrations at the gene level involving " exact="EGFR" post=" have also been reported in CRC. A smaller subset of CRC patients (8%–12%) have EGFR amplifi" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="volving EGFR have also been reported in CRC. A smaller subset of CRC patients (8%–12%) have " exact="EGFR" post=" amplifications defined as &amp;amp;gt;5 gene copies/nucleus. 23 A search of T" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="a href=&quot;http://www.cbioportal.org&quot;&gt;www.cbioportal.org, data accessed on March 30, 2015) identified " exact="EGFR" post=" missense mutations in 8 (3.7%) patients with CRC (n=212). In addition, EGFR was amplified i" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="015) identified EGFR missense mutations in 8 (3.7%) patients with CRC (n=212). In addition, " exact="EGFR" post=" was amplified in one patient (0.4%). A similar search of COSMIC SANGER ( &lt;a href=&quot;http://www.cance" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="und EGFR mutations present in 96 (7%) of 1,294 tested samples. Early data suggested that increased " exact="EGFR" post=" copy number, evaluated by fluorescence in situ hybridization, could predict response to EGFR inhib" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" FOLFOX (folinic acid, 5-flurouracil, oxaliplatin) in the first-line treatment in exon 2 wild-type " exact="KRAS" post=" mCRC. This randomized Phase III study allocated 1,183 patients in a 1:1 fashion to FOLFOX4 plus pa" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="he study was initially designed to test treatment effect in all randomized patients. However, once " exact="KRAS" post=" was established as a predictive biomarker, the study was amended to compare outcomes according to " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" was established as a predictive biomarker, the study was amended to compare outcomes according to " exact="KRAS" post=" status. KRAS status was available for 93% of the patients enrolled in the study. &lt;a href=&quot;#" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="a predictive biomarker, the study was amended to compare outcomes according to KRAS status. " exact="KRAS" post=" status was available for 93% of the patients enrolled in the study. 36 Th" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" analysis, 30 months after the last patient was enrolled, showed improved PFS for exon 2 wild-type " exact="KRAS" post=" patients enrolled in the FOLFOX4 plus panitumumab arm (10 vs 8.6 months, hazard ratio [HR] =0.80; " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="rimental arm (23.8 vs 19.4 months, HR =0.83, 95% CI: 0.70–0.98, P=0.03) in exon 2 wild-type " exact="KRAS" post=" patients. Adding panitumumab also increased RR in exon 2 wild-type KRAS patients (57% vs 48" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="in exon 2 wild-type KRAS patients. Adding panitumumab also increased RR in exon 2 wild-type " exact="KRAS" post=" patients (57% vs 48%, odds ratio =1.47, 95% CI: 1.07–2.04, P=0.02). However, no differences" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=", P=0.02). However, no differences in complete resection rate were seen in exon 2 wild-type " exact="KRAS" post=" patients with the addition of panitumumab (10% vs 8%). A subset analysis, limited to patients with" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="Results from extended " exact="RAS" post=" analysis from this trial are discussed in the &quot;Predictive biomarkers: patient stratification&quot; sect" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="acy in combination with mFOLFOX6 Against bevacizumab plus mFOLFOX6 in mCRC subjects with wild-type " exact="KRAS" post=" tumors) was designed to address whether to include anti-EGFR vs anti-vascular endothelial growth f" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="l hypothesis testing was planned. A prespecified secondary objective was to evaluate PFS and OS in " exact="RAS" post=" wild-type patients (expanded RAS testing included exons 2, 3, and 4 of KRAS and N" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="pecified secondary objective was to evaluate PFS and OS in RAS wild-type patients (expanded " exact="RAS" post=" testing included exons 2, 3, and 4 of KRAS and NRAS). The study was negative for its" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="and OS in RAS wild-type patients (expanded RAS testing included exons 2, 3, and 4 of " exact="KRAS" post=" and NRAS). The study was negative for its primary objective since no statistically signific" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" wild-type patients (expanded RAS testing included exons 2, 3, and 4 of KRAS and " exact="NRAS" post="). The study was negative for its primary objective since no statistically significant difference w" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ince no statistically significant difference was detected in PFS in patients with exon 2 wild-type " exact="KRAS" post=" mCRC (PFS 10.9 vs 10.1 months, HR =0.87, P=0.35) ( Table 1). An ear" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="that second-line therapies may have impacted these results. Indeed, patients with exon 2 wild-type " exact="KRAS" post=" mCRC/other mutations in RAS in the panitumumab arm were more likely to receive bevacizumab " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="impacted these results. Indeed, patients with exon 2 wild-type KRAS mCRC/other mutations in " exact="RAS" post=" in the panitumumab arm were more likely to receive bevacizumab beyond progression (50% vs 7%) as w" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="udy 2005-0181 in the second-line setting. In this study, the addition of panitumumab to FOLFIRI in " exact="KRAS" post=" exon 2 wild-type resulted in an improved RR (36% vs 10%, P&amp;amp;lt;0.0001) and PFS (6.7 vs 4" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ombined panitumumab (6 mg/kg) with FOLFIRI every 2 weeks. 39 Mutations in " exact="KRAS" post=" exon 2 were assessed in 94% of the patients. Overall, with the caveat that this was not a randomiz" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="uration of response (13 vs 7.4 months), and R 0 resection (8% vs 5%) were higher in the " exact="KRAS" post=" exon 2 wild-type subset. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" 1,053 patients with mCRC. 41 The primary endpoint was PFS. Regardless of " exact="KRAS" post=" status, the addition of panitumumab was detrimental in this study in regards to both PFS (10 vs 11" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="Unfortunately, in CRC, advances in personalizing therapy have been scarce. Only " exact="RAS" post=" mutations have been identified as a negative predictive biomarker and incorporated in the clinical" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="The first evidence to support the role of " exact="KRAS" post=" exon 2 mutations as a negative predictor of response in mCRC came from a randomized Phase III clin" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="gents. 22 In this study, 427 out of 463 (92%) enrolled patients underwent " exact="KRAS" post=" exon 2 (codon 12 and 13) testing by real-time polymerase chain reaction (RT-PCR) in paraffin-embed" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="d 13) testing by real-time polymerase chain reaction (RT-PCR) in paraffin-embedded tumor sections. " exact="KRAS" post=" exon 2 mutations were found in 43% of patients. The primary study endpoint was PFS. In KRAS" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="KRAS exon 2 mutations were found in 43% of patients. The primary study endpoint was PFS. In " exact="KRAS" post=" exon 2 wild-type patients, panitumumab resulted in improved PFS (12.3 vs 7.3 weeks, HR =0.45, P" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ssion may have contributed to diluting benefit in OS. A detrimental effect from panitumumab in the " exact="KRAS" post=" mutant subset was not seen in this study. Within the population enrolled in this study, KRAS&lt;/i" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="i&gt;KRAS mutant subset was not seen in this study. Within the population enrolled in this study, " exact="KRAS" post=" exon 2 mutations were a prognostic biomarker, as survival for this molecular subtype was shorter i" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ines, oxaliplatin, and irinotecan were randomized to cetuximab vs BSC. 44 " exact="KRAS" post=" exon 2 mutations were evaluated by PCR in paraffin-embedded tumor samples from 394 (69%) of these " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="-embedded tumor samples from 394 (69%) of these patients. 45 Mutations in " exact="KRAS" post=" exon 2 were found in 42% of the patients evaluated. The primary endpoint of the study was OS. In &lt;" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="&gt; exon 2 were found in 42% of the patients evaluated. The primary endpoint of the study was OS. In " exact="KRAS" post=" exon 2 wild-type patients, cetuximab improved OS (9.5 vs 4.8 months, HR =0.55, P&amp;amp;lt;0.0" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="-ott-9-075&quot;&gt;44 Similar to the panitumumab trial, cetuximab had no negative impact on PFS/OS in the " exact="KRAS" post=" mutant subset. Different from that trial, in C0.17, KRAS mutations were not found to be pro" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="o negative impact on PFS/OS in the KRAS mutant subset. Different from that trial, in C0.17, " exact="KRAS" post=" mutations were not found to be prognostic of poor outcomes in the BSC group. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="Some early data suggested that not all " exact="KRAS" post=" mutations were resistant to anti-EGFR therapy. A retrospective, pooled exploratory analysis of 579" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="dy (ICECREAM) recently compared cetuximab vs cetuximab plus irinotecan in mCRC. The trial included " exact="RAS" post=" wild-type patients but allowed patients harboring G13D mutations. The study failed to show " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rinotecan in mCRC. The trial included RAS wild-type patients but allowed patients harboring " exact="G13D" post=" mutations. The study failed to show any benefit from single agent cetuximab in patients with KR" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="The clinical observation that a large subset of " exact="KRAS" post=" exon 2 wild-type patients will not respond to anti-EGFR therapy has prompted investigation of addi" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="Archival tissue samples from patients enrolled in the PRIME trial who had " exact="KRAS" post=" exon 2 wild-type mCRC were recently tested for additional RAS exons. Expanded RAS te" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="d in the PRIME trial who had KRAS exon 2 wild-type mCRC were recently tested for additional " exact="RAS" post=" exons. Expanded RAS testing included: KRAS exon 3 (codon 61) or exon 4 (codons 117 o" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="d KRAS exon 2 wild-type mCRC were recently tested for additional RAS exons. Expanded " exact="RAS" post=" testing included: KRAS exon 3 (codon 61) or exon 4 (codons 117 or 146); NRAS exon 2 " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="e mCRC were recently tested for additional RAS exons. Expanded RAS testing included: " exact="KRAS" post=" exon 3 (codon 61) or exon 4 (codons 117 or 146); NRAS exon 2 (codon 12 or 13), 3 (codon 61)" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="Expanded RAS testing included: KRAS exon 3 (codon 61) or exon 4 (codons 117 or 146); " exact="NRAS" post=" exon 2 (codon 12 or 13), 3 (codon 61), or 4; or BRAF exon 15 (codon 600). &lt;a href=&quot;#b49-ott" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="don 61) or exon 4 (codons 117 or 146); NRAS exon 2 (codon 12 or 13), 3 (codon 61), or 4; or " exact="BRAF" post=" exon 15 (codon 600). 49 Additional RAS mutations were found in 108" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="3), 3 (codon 61), or 4; or BRAF exon 15 (codon 600). 49 Additional " exact="RAS" post=" mutations were found in 108 of 639 (17%) patients with KRAS exon 2 wild-type mCRC. The surv" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="f=&quot;#b49-ott-9-075&quot;&gt;49 Additional RAS mutations were found in 108 of 639 (17%) patients with " exact="KRAS" post=" exon 2 wild-type mCRC. The survival analysis according to expanded RAS results showed that " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="(17%) patients with KRAS exon 2 wild-type mCRC. The survival analysis according to expanded " exact="RAS" post=" results showed that the benefit from adding panitumumab was even larger in the RAS wild-typ" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="expanded RAS results showed that the benefit from adding panitumumab was even larger in the " exact="RAS" post=" wild-type subset ( Table 1). In this molecular subtype, there was a 2-mont" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="-ott-9-075&quot;&gt;Figure 2). However, when panitumumab was added to FOLFOX4 in patients with a wild-type " exact="KRAS" post=" exon 2 but with a different RAS mutation, there was a nonsignificant decrease in PFS (7.3 v" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="itumumab was added to FOLFOX4 in patients with a wild-type KRAS exon 2 but with a different " exact="RAS" post=" mutation, there was a nonsignificant decrease in PFS (7.3 vs 8.0 months, HR =1.28, 95% CI: 0.79–2." xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" a new label for panitumumab on March 11, 2015, excluding from treatment patients whose tumors had " exact="KRAS" post=" exon 2 mutations and also those who had any RAS-positive mCRC. 31 " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="g from treatment patients whose tumors had KRAS exon 2 mutations and also those who had any " exact="RAS" post="-positive mCRC. 31 However, for patients with BRAF-positive mCRC th" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="those who had any RAS-positive mCRC. 31 However, for patients with " exact="BRAF" post="-positive mCRC there was still a trend toward increased PFS in patients treated with panitumumab in" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" PRIME trial (PFS – HR =0.58, 95% CI: 0.29–1.15, OS – HR =0.90). The small number of patients with " exact="BRAF" post="-positive mCRC (n=53) may not have been sufficiently robust to evaluate the benefit of adding panit" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="etuximab, a different EGFR mAb, was detrimental when added to fluoropyrimidines and oxaliplatin in " exact="BRAF" post="-positive patients with mCRC treated in the first line in the COIN trial. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="onally, two recent meta-analyses showed that there was no improvement in outcomes in patients with " exact="BRAF" post="-positive mCRC when either panitumumab or cetuximab is added to standard therapy. &lt;a href=&quot;#b51-ott" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ME study, the investigators in the PEAK study also retrospectively carried out additional extended " exact="RAS" post=" testing. Results from extended RAS testing were available in 233 out of 285 (82%) patients " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="udy also retrospectively carried out additional extended RAS testing. Results from extended " exact="RAS" post=" testing were available in 233 out of 285 (82%) patients from the PEAK study. Of patients with exon" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" available in 233 out of 285 (82%) patients from the PEAK study. Of patients with exon 2 wild-type " exact="KRAS" post=" mCRC, 23% had additional RAS mutations. In RAS wild-type patients the addition of pa" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="tients from the PEAK study. Of patients with exon 2 wild-type KRAS mCRC, 23% had additional " exact="RAS" post=" mutations. In RAS wild-type patients the addition of panitumumab to FOLFOX resulted in impr" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="y. Of patients with exon 2 wild-type KRAS mCRC, 23% had additional RAS mutations. In " exact="RAS" post=" wild-type patients the addition of panitumumab to FOLFOX resulted in improved PFS compared to FOLF" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=", respectively). An exploratory analysis of responses from the PEAK trial limited to patients with " exact="RAS" post=" wild-type mCRC was recently presented in abstract form. 58 Responses occu" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="The results of expanded " exact="RAS" post=" testing from the CRYSTAL (Cetuximab combined with Irinotecan in First-Line Therapy for Metastatic " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tudied FOLFIRI with/without cetuximab as first-line therapy, showed that the incidence of expanded " exact="RAS" post=" mutations was similar to the PRIME study. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="In the CRYSTAL study, expanded " exact="RAS" post=" testing was performed in samples available from 64% of enrolled patients. Of all exon 2 wild-type " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" testing was performed in samples available from 64% of enrolled patients. Of all exon 2 wild-type " exact="KRAS" post=" patients, 15% had RAS mutations. 59 In contrast to the PRIME study" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="les available from 64% of enrolled patients. Of all exon 2 wild-type KRAS patients, 15% had " exact="RAS" post=" mutations. 59 In contrast to the PRIME study, there was no negative effec" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="udy, there was no negative effect seen in the CRYSTAL trial when cetuximab was added to FOLFIRI in " exact="RAS" post="-positive patients. The reasons for these conflicting results are unclear. It is possible that the " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ackbone may have influenced these findings. However, given the potential for harm if patients with " exact="RAS" post="-positive disease are exposed to anti-EGFR therapy, expanded RAS testing is strongly recomme" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="l for harm if patients with RAS-positive disease are exposed to anti-EGFR therapy, expanded " exact="RAS" post=" testing is strongly recommended by ASCO prior to start any patient on these therapies. &lt;a href=&quot;#b" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="PI3KCA" post=" is constitutively activated in 15% of CRCs. 61 In CRC cell lines, constit" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ctivated in 15% of CRCs. 61 In CRC cell lines, constitutive activation of " exact="PIK3CA" post=" leads to increased AKT1 phosphorylation. 62 This results in decreased apo" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="This results in decreased apoptosis and increased cell migration and invasion in vitro. Similarly, " exact="PTEN" post=", a negative regulator of PI3K, is inactivated in 20% of CRC. 63 PTEN loss" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ysis of patients with mCRC treated with cetuximab across multiple centers in Europe suggested that " exact="PIK3CA" post=" mutations in exon 20 (catalytic domain), assessed by automated sequencing, and PTEN loss assessed " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="omparing cetuximab vs BSC) arrived at different conclusions after analyzing the predictive role of " exact="PIK3CA" post=" mutations and PTEN loss. 65 In this analysis, 407 of 572 (71%) samples we" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" PTEN loss. 65 In this analysis, 407 of 572 (71%) samples were tested for " exact="PIK3CA" post=" using a nested PCR procedure; 205 patients (35%) were assessed for PTEN loss by IHC using a rabbit" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" 205 patients (35%) were assessed for PTEN loss by IHC using a rabbit monoclonal antibody. Neither " exact="PIK3CA" post=" mutations nor PTEN loss were prognostic of survival in these patients. In addition, they were not " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="it from cetuximab. The lack of standardized methods used to evaluate some of these biomarkers (ie, " exact="PTEN" post=") may have contributed to these conflicting results. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" " exact="MET" post=" is an oncogene that encodes a tyrosine kinase receptor for hepatocyte growth factor. MET ma" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" MET is an oncogene that encodes a tyrosine kinase receptor for hepatocyte growth factor. " exact="MET" post=" may become constitutively activated as a result of copy number variation, overexpression, or activ" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ation, overexpression, or activating mutations. 66 Genetic aberrations in " exact="MET" post=" were found in 6 (3%) out of 212 tumor specimens from CRC patients for whom both sequencing and cop" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="r patients. One patient each had amplification (0.5%) and a homozygous deletion. In a recent work, " exact="MET" post=" amplifications were identified, at the time of progression to anti-EGFR therapy, in a small subset" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="xt-generation sequencing in posttreatment biopsies collected at the time of progression identified " exact="MET" post=" amplifications in three out of seven patients. MET amplifications were then confirmed by FI" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ed at the time of progression identified MET amplifications in three out of seven patients. " exact="MET" post=" amplifications were then confirmed by FISH (fluorescence in situ hybridization) analysis ( MET/" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="MET/CEP7 ratio &amp;amp;gt;3). Interestingly, in samples from patient-derived xenografts (PDXs) " exact="MET" post=" amplifications were mutually exclusive with mutations in KRAS, BRAF, NRAS, and PIK3CA&lt;/i" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=") MET amplifications were mutually exclusive with mutations in KRAS, BRAF, NRAS, and " exact="PIK3CA" post=" and with HER2 amplification. This work suggests that MET testing could help refine t" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ions were mutually exclusive with mutations in KRAS, BRAF, NRAS, and PIK3CA and with " exact="HER2" post=" amplification. This work suggests that MET testing could help refine the subset of patients" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="RAS, BRAF, NRAS, and PIK3CA and with HER2 amplification. This work suggests that " exact="MET" post=" testing could help refine the subset of patients most likely to benefit from anti-EGFR therapy. Ho" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="died in ASPECCT (A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With " exact="KRAS" post=" Wild-Type Metastatic Colorectal Cancer), a noninferiority trial with 1,010 patients with wt- KR" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="S Wild-Type Metastatic Colorectal Cancer), a noninferiority trial with 1,010 patients with wt- " exact="KRAS" post=" mCRC refractory to chemotherapy who were randomized to receive either panitumumab or cetuximab. OS" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" acquired mutations in the extracellular domain of EGFR (including S492R, S464L, G465R, and " exact="I491M" post=") which may predict resistance to cetuximab but not panitumumab, were recently identified. &lt;a href=" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Activation of HER2 signaling through " exact="HER2" post=" amplifications or activating mutations in the kinase domain of HER2 is present in 7% of patients w" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Whole exome sequencing of " exact="KRAS" post=" wild-type CRC PDX recently identified FGFR1 amplifications in 3% of PDX resistant to EGFR i" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="Whole exome sequencing of KRAS wild-type CRC PDX recently identified " exact="FGFR1" post=" amplifications in 3% of PDX resistant to EGFR inhibition. 77 In addition," xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="o EGFR inhibition. 77 In addition, mutations near the catalytic domain of " exact="PDGFRA" post=" were also found in 3% of tumorgrafts resistant to EGFR. Of note, single-agent pathway inhibition w" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ment due to AEs in the panitumumab arm. The distribution of grade 3–4 AE was similar regardless of " exact="KRAS" post=" status. The most common AE with panitumumab was acneiform rash (37% and 31% for KRAS wild-t" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ess of KRAS status. The most common AE with panitumumab was acneiform rash (37% and 31% for " exact="KRAS" post=" wild-type and KRAS mutant, respectively). The incidence of skin toxicity in the control arm" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" The most common AE with panitumumab was acneiform rash (37% and 31% for KRAS wild-type and " exact="KRAS" post=" mutant, respectively). The incidence of skin toxicity in the control arm was less than 2%. Rash wa" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="ed in face/upper trunk and appeared early during treatment, typically during the 1st month. In the " exact="KRAS" post=" wild-type group, patients who developed grade 2–4 skin rash had improved clinical outcomes measure" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="nitumumab to FOLFOX in first-line treatment resulted in improved RR, PFS, and OS for patients with " exact="KRAS" post=" exon 2 wild-type mCRC. Unfortunately, the identification of predictive biomarkers of response to t" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="omarkers of response to targeted therapy in mCRC is lagging behind compared to other malignancies. " exact="KRAS" post=" exon 2 mutations were identified as a negative predictor of response to anti-EGFR therapy in patie" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="mCRC nearly a decade ago. 22 However, a large percentage of patients with " exact="KRAS" post=" exon 2 wild-type mCRC still derive no benefit from the addition of anti-EGFR therapies. It is clea" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="t studies with anti-EGFR therapies to search for additional mutations in 1) different exons within " exact="KRAS" post=", 2) different members of the RAS family, 3) additional genes that may activate pathways dow" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="rch for additional mutations in 1) different exons within KRAS, 2) different members of the " exact="RAS" post=" family, 3) additional genes that may activate pathways downstream of KRAS and therefore dri" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ent members of the RAS family, 3) additional genes that may activate pathways downstream of " exact="KRAS" post=" and therefore drive resistance to therapy ( HER2, PIK3CA, PTEN), and 4) genes involved in a" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="). 77 In randomized trials with panitumumab in the first line, 17%–23% of " exact="KRAS" post=" exon 2 wild-type patients harbored additional mutations within KRAS (exon 3 and 4) or diffe" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" first line, 17%–23% of KRAS exon 2 wild-type patients harbored additional mutations within " exact="KRAS" post=" (exon 3 and 4) or different members of the RAS family ( NRAS). &lt;a href=&quot;#b37-ott-9-0" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="tients harbored additional mutations within KRAS (exon 3 and 4) or different members of the " exact="RAS" post=" family ( NRAS). 37, 49 In both trials, ex" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tional mutations within KRAS (exon 3 and 4) or different members of the RAS family ( " exact="NRAS" post="). 37, 49 In both trials, expanded RAS ana" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" ( NRAS). 37, 49 In both trials, expanded " exact="RAS" post=" analysis was performed using dideoxy DNA Sanger sequencing (detection threshold of 5% copies). It " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="xy DNA Sanger sequencing (detection threshold of 5% copies). It is important to note that expanded " exact="RAS" post=" analysis across trials testing cetuximab has been done using different methods. Pyrosequencing was" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="cted for the analysis). 59, 79 The prevalence of " exact="RAS" post=" mutations in KRAS exon 2 wild-type specimens from CRYSTAL, FIRE, and OPUS trials were 14.7%" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="59, 79 The prevalence of RAS mutations in " exact="KRAS" post=" exon 2 wild-type specimens from CRYSTAL, FIRE, and OPUS trials were 14.7%, 16%, and 31%, respectiv" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" key questions will need to be addressed in the future. First, is a dynamic definition of expanded " exact="RAS" post=" mutations needed or even acceptable? A recent meta-analysis showed a correlation higher than 92% b" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ons needed or even acceptable? A recent meta-analysis showed a correlation higher than 92% between " exact="KRAS" post=" mutations in primary and matched metastases in CRC. 80 However, most of t" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="thresholds as low as 0.01%. It is plausible that if the detection threshold is lowered, additional " exact="RAS" post=" mutations could be identified. Second, do all RAS isoforms signify a negative predictive ro" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="etection threshold is lowered, additional RAS mutations could be identified. Second, do all " exact="RAS" post=" isoforms signify a negative predictive role? Retrospective analysis suggests this is true, at leas" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ed. 49 However, it will be challenging to evaluate the predictive role of " exact="RAS" post=" mutations present only in rare clones or even the individual role of some of these mutations with " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="-9-075&quot;&gt;48 These patients should be spared from anti-EGFR therapies similar to other patients with " exact="RAS" post=" mutations. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Third, should " exact="BRAF" post=" be included in initial testing when data supporting the use of anti-EGFR therapy in this subset of" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="et of patients in the first line are conflicting? Fourth, the role of additional biomarkers beyond " exact="RAS" post=" will need to be better defined. For instance, the negative predictive value of PIK3CA mutat" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="s beyond RAS will need to be better defined. For instance, the negative predictive value of " exact="PIK3CA" post=" mutations or PTEN loss gleaned in a retrospective analysis across different European centers could" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="In summary, " exact="RAS" post=" mutations have been identified as a negative predictor of response to EGFR inhibitors, including p" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="biomarkers are currently investigated for which there is conflicting evidence. As only a subset of " exact="RAS" post="-wild type patients benefit from anti-EGFR therapies, additional work in this arena is urgently nee" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="PFS and OS according to exon 2 " exact="KRAS" post=" or RAS status in the PRIME 36 and PEAK 37" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre="PFS and OS according to exon 2 KRAS or " exact="RAS" post=" status in the PRIME 36 and PEAK 37 trials. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="acy in Combination with mFOLFOX6 Against Bevacizumab plus mFOLFOX6 in mCRC subjects with wild-type " exact="KRAS" post=" tumors. " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" name="human"/>
   <result pre=" from PRIME 36 and PEAK 37 studies stratified by " exact="RAS" post=" molecular subtypes " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/div[1]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="acy in Combination with mFOLFOX6 Against Bevacizumab plus mFOLFOX6 in mCRC subjects with wild-type " exact="KRAS" post=" tumors. " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4706528/results/gene/human/results.xml">
   <result pre="tudies suggest that the PI3K pathway is the most frequently altered pathway in human cancers, with " exact="PIK3CA" post=" 2 and PTEN 3 among the most frequentl" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="t frequently altered pathway in human cancers, with PIK3CA 2 and " exact="PTEN" post=" 3 among the most frequently altered oncogenes and tumor suppressor gene" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre=" substrate specificity, of which the class I PI3K is related to cancer. Within class IA, the genes " exact="PIK3CA" post=", PIK3CB, and PI3KCD, encode the homologous p110α, p110β, and p110δ isozymes respecti" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="ificity, of which the class I PI3K is related to cancer. Within class IA, the genes PIK3CA, " exact="PIK3CB" post=", and PI3KCD, encode the homologous p110α, p110β, and p110δ isozymes respectively. Class IB " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="he class I PI3K is related to cancer. Within class IA, the genes PIK3CA, PIK3CB, and " exact="PI3KCD" post=", encode the homologous p110α, p110β, and p110δ isozymes respectively. Class IB consists of PIK3" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="KCD, encode the homologous p110α, p110β, and p110δ isozymes respectively. Class IB consists of " exact="PIK3CG" post=", which encodes p110γ 9 . p110α and p110β are ubiquitously expressed whil" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="e up of a p110 catalytic subunit and a p85 regulatory subunit, and are involved in carcinogenesis. " exact="PIK3CA" post=" mutation occurs in approximately 35% of HR-positive breast cancers, in about 20%-25% of HER2-overe" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre=" tumor suppressor, is also known as serine/threonine kinase 11 (STK11), with germline mutations in " exact="LKB1" post="/ SKT11 causing the Peutz-Jeghers tumor predisposition syndrome. Inactivation of the LKB1-AM" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ssor, is also known as serine/threonine kinase 11 (STK11), with germline mutations in LKB1/ " exact="SKT11" post=" causing the Peutz-Jeghers tumor predisposition syndrome. Inactivation of the LKB1-AMPK pathway has" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" . As trastuzumab blocks the signaling pathway upstream from PI3K, a downstream aberration such as " exact="PTEN" post=" loss may override upstream inhibition. Preclinical studies indicate that inhibitors of the pathway" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="array comparative genomic hybridisation studies have shown that there is high frequency of loss of " exact="PTEN" post=" and INPP4B 35 - 37 , whic" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="e genomic hybridisation studies have shown that there is high frequency of loss of PTEN and " exact="INPP4B" post=" 35 - 37 , which correlates with " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="treatment effect in favour of everolimus was detected across the various genetic marker subgroups. " exact="PIK3CA" post=" mutation status was not predictive of increased benefit with addition of everolimus to exemestane." xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="h addition of everolimus to exemestane. However, women whose tumors had two or more alterations in " exact="PIK3CA" post=" or PTEN or FGFR1/2 or CCND1 genes did not derive benefit in terms of PFS with" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="rolimus to exemestane. However, women whose tumors had two or more alterations in PIK3CA or " exact="PTEN" post=" or FGFR1/2 or CCND1 genes did not derive benefit in terms of PFS with everolimus. Th" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="omen whose tumors had two or more alterations in PIK3CA or PTEN or FGFR1/2 or " exact="CCND1" post=" genes did not derive benefit in terms of PFS with everolimus. This suggests that concomitant alter" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre=" and PTEN levels were determined by IHC. Patients with hyperactive PI3K pathway (low PTEN or known " exact="PIK3CA" post=" or AKT1 E17K mutation) benefitted from everolimus, whereas those without PI3K pathway activ" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="were determined by IHC. Patients with hyperactive PI3K pathway (low PTEN or known PIK3CA or " exact="AKT1" post=" E17K mutation) benefitted from everolimus, whereas those without PI3K pathway activation did not (" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="th a non-statistically significant PFS increase from 5.1 to 6.6 months (HR =0.74; P=0.096). " exact="PIK3CA" post=" mutation status did not predict the benefit of addition of pictilisib to fulvestrant either, but t" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" name="human"/>
   <result pre="ed tumor specimens, which may not reflect the latest mutation status and underscores the fact that " exact="PI3K" post=" genotype may not be the most reliable biomarker of response. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[4]/p[3]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="lts may soon be available. This study also evaluates the role of PI3K pathway activation with both " exact="PIK3CA" post=" mutation status and PTEN loss on IHC on archival tumor samples, as well as mutation status based o" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4707213/results/gene/human/results.xml">
   <result pre="mmune evasion, in addition to other processes. Throughout this process, genes such as RHoC, " exact="VEGF" post=", MET, FGFR, and IL-11 play important roles in each step of metastasis. Virule" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=", in addition to other processes. Throughout this process, genes such as RHoC, VEGF, " exact="MET" post=", FGFR, and IL-11 play important roles in each step of metastasis. Virulence of tumor" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/p[2]" name="human"/>
   <result pre="n to other processes. Throughout this process, genes such as RHoC, VEGF, MET, " exact="FGFR" post=", and IL-11 play important roles in each step of metastasis. Virulence of tumor cells emerge" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4708008/results/gene/human/results.xml">
   <result pre="As shown in Figure 7(A), apigenin decreased mRNA levels of HIF-1α and " exact="VEGF" post=" that was slightly up-regulated by CoCl 2. Moreover, ELISA assay indicated that apigenin" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4708174/results/gene/human/results.xml">
   <result pre="ut are not limited to mutations and amplification of genes encoding receptor tyrosine kinases (eg, " exact="HER2" post=" or EGFR), PIK3CA mutations, PTEN mutation/loss, and KRAS mutations. &lt;a" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ted to mutations and amplification of genes encoding receptor tyrosine kinases (eg, HER2 or " exact="EGFR" post="), PIK3CA mutations, PTEN mutation/loss, and KRAS mutations. &lt;a href=&quot;#b1-ott-" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="ns and amplification of genes encoding receptor tyrosine kinases (eg, HER2 or EGFR), " exact="PIK3CA" post=" mutations, PTEN mutation/loss, and KRAS mutations. 1 As a ce" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="enes encoding receptor tyrosine kinases (eg, HER2 or EGFR), PIK3CA mutations, " exact="PTEN" post=" mutation/loss, and KRAS mutations. 1 As a central node of this path" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre=" kinases (eg, HER2 or EGFR), PIK3CA mutations, PTEN mutation/loss, and " exact="KRAS" post=" mutations. 1 As a central node of this pathway, PI3K is an attractive targ" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="l response, and 25 patients with stable disease. Clinical activity was not shown to correlate with " exact="PIK3CA" post=" mutation status, suggesting that alterations in other pathway components were responsible for PI3K" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="rlisib efficacy in the full population and in the PI3K pathway-activated subpopulation (defined as " exact="PIK3CA" post=" mutation and/or PTEN loss; NCT01610284). This study will assess the predictive value of single PI3" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre=" cell lines are sensitive to the PI3Kα inhibitor alpelisib in vitro, 2 and " exact="PIK3CA" post=" mutations and HER2 amplifications correlate with alpelisib sensitivity. &lt;a href=&quot;#b14-ott-9" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre=" the PI3Kα inhibitor alpelisib in vitro, 2 and PIK3CA mutations and " exact="HER2" post=" amplifications correlate with alpelisib sensitivity. 14 Targeting a singl" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="The first-in-human Phase I study of single-agent alpelisib in advanced solid tumors with " exact="PIK3CA" post=" alterations, and a subsequent study in combination with fulvestrant in ER-positive metastatic brea" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre=", and a subsequent study in combination with fulvestrant in ER-positive metastatic breast cancer ( " exact="PIK3CA" post="-altered and PIK3CA wild-type tumors), used patient selection and mandatory tissue collectio" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="n combination with fulvestrant in ER-positive metastatic breast cancer ( PIK3CA-altered and " exact="PIK3CA" post=" wild-type tumors), used patient selection and mandatory tissue collection (NCT01219699). Promising" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="lection and mandatory tissue collection (NCT01219699). Promising preliminary antitumor activity in " exact="PIK3CA" post="-altered tumors treated with alpelisib alone or with fulvestrant has been observed. &lt;a href=&quot;#b15-o" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="#b15-ott-9-203&quot;&gt;15, 16 Further analyses will reveal whether patients with " exact="PIK3CA" post="-altered tumors display greater sensitivity to alpelisib, or whether PIK3CA-altered and wild" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="er patients with PIK3CA-altered tumors display greater sensitivity to alpelisib, or whether " exact="PIK3CA" post="-altered and wild-type tumors are equally sensitive. The combination of alpelisib and fulvestrant i" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="tase inhibitor treatment (SOLAR-1; NCT02437318). Patients will be screened and stratified based on " exact="PIK3CA" post=" mutation status, and randomized to receive fulvestrant in combination with either alpelisib or pla" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="nhibitors or taxanes. In the study of alpelisib and letrozole, half of patients enrolled must have " exact="PIK3CA" post="-mutated tumors, and the provision of tumor tissue for correlative studies is mandatory. Explorator" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="ncer is employing targeted enrollment (NCT01923168). Two cohorts are being enrolled: patients with " exact="PIK3CA" post="-mutated tumors and those with PIK3CA wild-type disease. This study will enable the identifi" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="923168). Two cohorts are being enrolled: patients with PIK3CA-mutated tumors and those with " exact="PIK3CA" post=" wild-type disease. This study will enable the identification of the optimal strategy of PI3K pathw" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="n these molecular subtypes; the results will reveal whether alpelisib has superior efficacy in the " exact="PIK3CA" post="-mutant population and whether buparlisib is more beneficial in tumors where PI3K is activated by o" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="ib is more beneficial in tumors where PI3K is activated by other mechanisms, such as alteration of " exact="PTEN" post=" or INPP4B. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="ficial in tumors where PI3K is activated by other mechanisms, such as alteration of PTEN or " exact="INPP4B" post=". " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="zumab, trastuzumab, and docetaxel in first-line metastatic breast cancer (NCT00567190) established " exact="PIK3CA" post=" mutation as a negative prognostic factor in HER2-positive breast cancer; patients with tumors harb" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="ion as a negative prognostic factor in HER2-positive breast cancer; patients with tumors harboring " exact="PIK3CA" post=" mutations had a significantly worse PFS than those with PIK3CA wild-type disease. &lt;a href=&quot;" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="tients with tumors harboring PIK3CA mutations had a significantly worse PFS than those with " exact="PIK3CA" post=" wild-type disease. 19 Selective enrollment/target enrichment is therefore" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="isib in combination with trastuzumab and paclitaxel in HER2-positive breast cancer with or without " exact="PIK3CA" post=" mutations (NeoPHOEBE; NCT01816594) to establish whether PIK3CA mutation status can predict " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="reast cancer with or without PIK3CA mutations (NeoPHOEBE; NCT01816594) to establish whether " exact="PIK3CA" post=" mutation status can predict a benefit from combination therapy with anti-HER2 chemotherapy and a P" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="ity of buparlisib and trastuzumab combinations to overcome trastuzumab resistance in patients with " exact="PIK3CA" post="-activated and wild-type tumors. " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="PI3K–AKT–mTOR pathway alterations are implicated in almost a third of HNSCC, with " exact="PIK3CA" post=" commonly mutated and multiple PI3K–AKT–mTOR pathway aberrations associated with disease progressio" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="23 Furthermore, alpelisib sensitivity has been shown to be independent of " exact="PIK3CA" post=" mutation status. 23 Alpelisib and cetuximab have demonstrated synergistic" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="vity in HNSCC cell lines independently of molecular status, and also induced tumor regression in a " exact="PIK3CA" post="-mutant HNSCC xenograft model. 24 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre=" " exact="PIK3CA" post=" amplifications and mutations are associated with resistance to cetuximab therapy. &lt;a href=&quot;#b25-ot" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="assessing buparlisib in HNSCC that has progressed on platinum- and cetuximab-based chemotherapy in " exact="PIK3CA" post="-mutated and PIK3CA wild-type cohorts using the patient selection approach (NCT01737450). " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="SCC that has progressed on platinum- and cetuximab-based chemotherapy in PIK3CA-mutated and " exact="PIK3CA" post=" wild-type cohorts using the patient selection approach (NCT01737450). " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="tients screened for the Phase II BASALT-1 study (NCT01297491), PI3K pathway activation (defined as " exact="PIK3CA" post=" mutation, PTEN mutation, and/or PTEN loss), was observed in 16% and 11% of squamous and non" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="Phase II BASALT-1 study (NCT01297491), PI3K pathway activation (defined as PIK3CA mutation, " exact="PTEN" post=" mutation, and/or PTEN loss), was observed in 16% and 11% of squamous and nonsquamous tumors, respe" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre=", in GBM cell lines and xenograft models, buparlisib demonstrated antitumor activity regardless of " exact="PTEN" post=" or EGFR status. 37 Furthermore, synergistic activity was observed " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="ines and xenograft models, buparlisib demonstrated antitumor activity regardless of PTEN or " exact="EGFR" post=" status. 37 Furthermore, synergistic activity was observed with buparlisib" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="Furthermore, synergistic activity was observed with buparlisib in combination with temozolomide in " exact="PTEN" post="-null GBM mouse xenografts. 3 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="t enrichment; inclusion in one of the cohorts was dependent on PI3K pathway activation (defined as " exact="PIK3CA" post=" or PTEN mutation, or PTEN deletion; NCT01339052). Among the 40 patients who underwen" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="lusion in one of the cohorts was dependent on PI3K pathway activation (defined as PIK3CA or " exact="PTEN" post=" mutation, or PTEN deletion; NCT01339052). Among the 40 patients who underwent exome sequenc" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="rts was dependent on PI3K pathway activation (defined as PIK3CA or PTEN mutation, or " exact="PTEN" post=" deletion; NCT01339052). Among the 40 patients who underwent exome sequencing, there were four P" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre=" deletion; NCT01339052). Among the 40 patients who underwent exome sequencing, there were four " exact="PIK3CA" post=" (10%), two PIK3R1 (5%), and 13 PTEN (33%) mutations. The single-agent activity of bu" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="2). Among the 40 patients who underwent exome sequencing, there were four PIK3CA (10%), two " exact="PIK3R1" post=" (5%), and 13 PTEN (33%) mutations. The single-agent activity of buparlisib was marginal (me" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[6]/p[2]" name="human"/>
   <result pre="ho underwent exome sequencing, there were four PIK3CA (10%), two PIK3R1 (5%), and 13 " exact="PTEN" post=" (33%) mutations. The single-agent activity of buparlisib was marginal (median PFS of 1.8 months), " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4717619/results/gene/human/results.xml">
   <result pre="ion of the tumor cells, result in a multitude of pathway activations in both tumor and host cells. " exact="BBB" post=" blood–brain barrier, EGFR epidermal growth factor receptor, GABA gamma-aminobutyric " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n a multitude of pathway activations in both tumor and host cells. BBB blood–brain barrier, " exact="EGFR" post=" epidermal growth factor receptor, GABA gamma-aminobutyric acid, HER human epidermal " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" name="human"/>
   <result pre="umor and host cells. BBB blood–brain barrier, EGFR epidermal growth factor receptor, " exact="GABA" post=" gamma-aminobutyric acid, HER human epidermal growth factor receptor, IL interleukin," xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="–brain barrier, EGFR epidermal growth factor receptor, GABA gamma-aminobutyric acid, " exact="HER" post=" human epidermal growth factor receptor, IL interleukin, JAG jagged, MMP matri" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="gamma-aminobutyric acid, HER human epidermal growth factor receptor, IL interleukin, " exact="JAG" post=" jagged, MMP matrix metalloproteinase, TGF transforming growth factor, VEGF va" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="acid, HER human epidermal growth factor receptor, IL interleukin, JAG jagged, " exact="MMP" post=" matrix metalloproteinase, TGF transforming growth factor, VEGF vascular endothelial " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="th factor receptor, IL interleukin, JAG jagged, MMP matrix metalloproteinase, " exact="TGF" post=" transforming growth factor, VEGF vascular endothelial growth factor " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="in, JAG jagged, MMP matrix metalloproteinase, TGF transforming growth factor, " exact="VEGF" post=" vascular endothelial growth factor " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="HER" post=" human epidermal growth factor receptor, TNBC triple-negative breast cancer " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HER human epidermal growth factor receptor, " exact="TNBC" post=" triple-negative breast cancer " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="HER" post=" human epidermal growth factor receptor, ND not determined, TNBC triple-negative brea" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HER human epidermal growth factor receptor, ND not determined, " exact="TNBC" post=" triple-negative breast cancer " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="n specific regions were more commonly aborted in the BM. Protein kinase C, delta binding protein ( " exact="PRKCDBP" post=") was identified as the potential target gene in 11p15 loss, whereas EGFR was the driver for a narr" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" name="human"/>
   <result pre="berrations were rarely found among patients with bone metastases. Interestingly, mutations in both " exact="PTEN" post=" and EGFR are described as the main driver alterations for the very aggressive glioblastoma;" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" name="human"/>
   <result pre="rarely found among patients with bone metastases. Interestingly, mutations in both PTEN and " exact="EGFR" post=" are described as the main driver alterations for the very aggressive glioblastoma; therefore, the " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/p[4]" name="human"/>
   <result pre="his process [ 47]. Interestingly, heregulin treatment suppressed the expression of " exact="RECK" post=", a gene found to be downregulated in breast cancer BM [ 48]. " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4717845/results/gene/human/results.xml">
   <result pre="e show increased expression of the mitochondrial respiratory chain genes MT-CO2, MT- " exact="CYB" post=", and MT-ATP6/8 in the resistant cells ( Figure 1D–F) and confirmed that MT-" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tant cells ( Figure 3D). Consistent with this, we observed increased expression of " exact="GLS" post=", a glutaminase that converts glutamine to glutamate ( Supplemental Figure 3A), " xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="so be a therapeutic target in the resistant tumors. PGC1α is important for glutamine metabolism in " exact="ERBB2" post="-positive breast cancer ( McGuirk et al., 2013) and glutamine transporters are pro" xpath="/html[1]/body[1]/article[1]/div[5]/div[3]/p[1]" name="human"/>
   <result pre="b&gt;5 labeling (blue). Endogenous glutamate is unlabeled and shown in white. (E) Graph showing " exact="GLS" post=" mRNA levels in A375, A375/R, Colo829, Colo829/R, SKMEL5, SKMEL5/R, G361 and G361/R cells. Three in" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4718910/results/gene/human/results.xml">
   <result pre=" " exact="ECOG" post=" Eastern Cooperative Oncology Group, HER2 human epidermal growth factor receptor 2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" ECOG Eastern Cooperative Oncology Group, " exact="HER2" post=" human epidermal growth factor receptor 2 " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CI confidence interval, " exact="MRI" post=" magnetic resonance imaging, RECIST Response Evaluation Criteria In Solid Tumors " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CI confidence interval, MRI magnetic resonance imaging, " exact="RECIST" post=" Response Evaluation Criteria In Solid Tumors " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="AUC" post=" tau,ss area under the plasma concentration–time curve at steady state over the" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" AE adverse event, CR complete response, " exact="EGFR" post=" epidermal growth factor receptor, ER estrogen receptor, HER2 human epidermal growth " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre=" complete response, EGFR epidermal growth factor receptor, ER estrogen receptor, " exact="HER2" post=" human epidermal growth factor receptor 2, MBC metastatic breast cancer, mTOR mammali" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="actor receptor, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, " exact="MBC" post=" metastatic breast cancer, mTOR mammalian target of rapamycin, PFS progression-free s" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="factor receptor 2, MBC metastatic breast cancer, mTOR mammalian target of rapamycin, " exact="PFS" post=" progression-free survival, PgR progesterone receptor, PR partial response, SD" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4720061/results/gene/human/results.xml">
   <result pre="lts. FISH was performed using the PathVysion Kit (Abbott/Vysis Laboratories, Abbott Park, IL), and " exact="HER2" post=" gene amplification was defined as HER2:chromosome 17 ratio of ≥ 2.2. Whenever FISH tests re" xpath="/html[1]/body[1]/article[1]/div[3]/div[2]/div[3]/p[2]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="it (Abbott/Vysis Laboratories, Abbott Park, IL), and HER2 gene amplification was defined as " exact="HER2" post=":chromosome 17 ratio of ≥ 2.2. Whenever FISH tests results were available, they took precedence ove" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4729711/results/gene/human/results.xml">
   <result pre=" " exact="MRI" post=" magnetic resonance imaging, PET positron emission tomography, CT computed tomography" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" MRI magnetic resonance imaging, " exact="PET" post=" positron emission tomography, CT computed tomography, MDP methylene diphosphonate, &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="agnetic resonance imaging, PET positron emission tomography, CT computed tomography, " exact="MDP" post=" methylene diphosphonate, FNH focal nodular hyperplasia " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; positron emission tomography, CT computed tomography, MDP methylene diphosphonate, " exact="FNH" post=" focal nodular hyperplasia " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4730993/results/gene/human/results.xml">
   <result pre="ado-trastuzumab emtansine, and lapatinib, is a function of the overexpression/amplification of the " exact="HER2" post=" gene in luminal B/HER2-positive and HER2-enriched tumors. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="st for the presence of HER2 overexpression either at the protein level or overamplification of the " exact="HER2" post=" gene. Given the history of their use, estrogen receptor and progesterone receptor testing is not c" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="HER2 (gene designation: " exact="ERRB2" post=", HER2/neu), encoded by the protooncogene HER2/neu on chromosome 17, is a member of t" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rvival. In breast cancer, HER2 receptor overexpression results primarily from amplification of the " exact="HER2" post=" gene; 40 however, mutations in the HER2 gene &lt;a href=&quot;#b41-pgpm-9" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="from amplification of the HER2 gene; 40 however, mutations in the " exact="HER2" post=" gene 41 and transcriptional and posttranscriptional alterations may be m" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ond Oracle HER2 IHC system (Leica Biosystems, Wetzlar, Germany). The remaining four tests quantify " exact="HER2" post=" gene copy number; two via FISH assays (PathVysion HER2 DNA probe kit [Abbott Laboratories, Abbott " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="FISH, CISH, and silver-enhanced in situ hybridization assays quantify the " exact="HER2" post=" gene copy number per cell using a single- or dual-probe technique. FISH has become a widely accept" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ted systems such as INFORM HER2 Dual ISH, which combines silver-enhanced in situ hybridization for " exact="HER2" post=" copy number and CISH for enumeration of chromosome 17, are gaining favorability due to the reduced" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="escent-labeled (eg, FISH) or chromogenic-labeled (eg, CISH) DNA probes to compare the abundance of " exact="HER2" post=" gene copies to that of the number of chromosome 17 centromeres, as determined by the centromere en" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="3 ASCO/CAP guidelines consider a sample to be HER2 positive if the HER2/CEP17 ratio is ≥2.0 or the " exact="HER2" post=" copy number is ≥6.0 signals/cell. 44, 50 A sam" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="m-9-007&quot;&gt;50 A sample is considered negative if the HER2/CEP17 ratio is &amp;amp;lt;2.0 and the average " exact="HER2" post=" copy number is &amp;amp;lt;4.0 signals/cell. For equivocal cases, where the HER2/CEP17 ratio is &amp;amp;l" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="t;4.0 signals/cell. For equivocal cases, where the HER2/CEP17 ratio is &amp;amp;lt;2.0 but the average " exact="HER2" post=" copy number is ≥4.0 and &amp;amp;lt;6.0 signals/cell, reflex testing on the same specimen (by IHC or F" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" concept behind PAM50 is based on the inherent differences in the expression of key genes, such as " exact="ESR1" post=" (estrogen receptor gene), ERRB2, and genes involved in cell cycle activation and proliferat" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[4]/p[7]" name="human"/>
   <result pre="inherent differences in the expression of key genes, such as ESR1 (estrogen receptor gene), " exact="ERRB2" post=", and genes involved in cell cycle activation and proliferation, which are known to significantly a" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4734963/results/gene/human/results.xml">
   <result pre="m-2015-09-10&quot;&gt;20, 38]. Intriguingly, tumors of this subtype exhibit " exact="CD274" post=" and PDCD1LG2 amplification of which proteins PD-L1 and PD-L2, respectively, are related to " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" 38]. Intriguingly, tumors of this subtype exhibit CD274 and " exact="PDCD1LG2" post=" amplification of which proteins PD-L1 and PD-L2, respectively, are related to immune suppressive f" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" functions, particularly immune checkpoints. Further, amplification at the 9p24.1 locus containing " exact="JAK2" post=", which encodes an oncogenic receptor tyrosine kinase (RTK), is also a potential therapeutic target" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="AGC that expressed PD-L1 [ 21]. Predilection of EBV-positive GC for " exact="PIK3CA" post=" mutation, which is related to the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway, has also" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="PI3K)/Akt signaling pathway, has also been reported [ 20]. Frequent " exact="PIK3CA" post=" mutations warrant evaluation of PI3K inhibitors in EBV-positive GC. Although still in preclinical " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="lity and induce apoptosis in GC cell lines [ 22]. Additionally, the " exact="ARID1A" post=" mutation was detected in 10% of GC39 and was found most frequently in EBV-positive GC [ &lt;a href=&quot;#" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="5-09-10&quot;&gt;39]. Recently, it was reported that EZH2 inhibitor could be a novel therapeutic targeting " exact="ARID1A" post="-mutated cancers [ 40]. Therefore, the ARID1A mutation provid" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="eutic targeting ARID1A-mutated cancers [ 40]. Therefore, the " exact="ARID1A" post=" mutation provides another clinically actionable genetic alteration in EBV-positive GC that should " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="f=&quot;#b42-jptm-2015-09-10&quot;&gt;42]. Because the function of the MMR mechanism is defective mainly due to " exact="MLH1" post=" silencing by promoter hypermethylation [ 20], this subtype has more" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="ations in major histocompatibility complex (MHC) class I-related genes, including HLA-B and " exact="B2M" post=". Since these MHC class I genes function in proper antigen presentation to the host immune system, " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="ed to other subtypes and occurring at a relatively early age [ 20]. " exact="CDH1" post=" mutation is one of the representative mutations in the GS subtype. CDH1 germline mutations " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="tm-2015-09-10&quot;&gt;20]. CDH1 mutation is one of the representative mutations in the GS subtype. " exact="CDH1" post=" germline mutations are known to be related to hereditary diffuse GC. When patients harbor pathogen" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="known to be related to hereditary diffuse GC. When patients harbor pathogenic hotspot mutations in " exact="CDH1" post=", prophylactic gastrectomy is recommended [ 24]. However, only two &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="&gt;, prophylactic gastrectomy is recommended [ 24]. However, only two " exact="CDH1" post=" mutations, neither of which is a pathogenic hotspot mutation, were identified in a recent TCGA stu" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="CGA study [ 20]. Another study reported that somatic alterations of " exact="CDH1" post=" were present in approximately 30% of GC cases, and structural alterations in CDH1 were rela" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="ations of CDH1 were present in approximately 30% of GC cases, and structural alterations in " exact="CDH1" post=" were related to poor prognosis [ 53]. In addition to CDH1 mu" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="in CDH1 were related to poor prognosis [ 53]. In addition to " exact="CDH1" post=" mutations, GS subtype tumors have RHOA mutations and CLDN18-ARHGAP 6 or 26 fusions [" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="[ 53]. In addition to CDH1 mutations, GS subtype tumors have " exact="RHOA" post=" mutations and CLDN18-ARHGAP 6 or 26 fusions [ 20, &lt;a href=&quot;#" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="=&quot;#b20-jptm-2015-09-10&quot;&gt;20, 54, 55]. " exact="RHOA" post=" is known to modulate downstream Rho signaling, and its mutation imparts resistance to anoikis, a f" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="resistance to anoikis, a form of programmed cell death [ 54]. Also, " exact="RHOA" post=" acts to control actin-myosin-dependent cell contractility and motility [ &lt;a href=&quot;#b56-jptm-2015-0" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="e type GC [ 20], which is associated with poor prognosis. Thus, the " exact="RHOA" post=" mutation could be a good candidate for new approaches targeting GS subtype GC [ &lt;a href=&quot;#b37-jptm" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" 37]. CLDN18-ARHGAP6 or 26 fusions are mutually exclusive to " exact="RHOA" post=" and CDH1 mutation among GS tumors. The discovery of recurrent interchromosomal translocatio" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="ptm-2015-09-10&quot;&gt;37]. CLDN18-ARHGAP6 or 26 fusions are mutually exclusive to RHOA and " exact="CDH1" post=" mutation among GS tumors. The discovery of recurrent interchromosomal translocation between CLD" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="H1 mutation among GS tumors. The discovery of recurrent interchromosomal translocation between " exact="CLDN18" post=" and ARHGAP26 further implies biological significance of cell adhesion and deregulated Rho s" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="ong GS tumors. The discovery of recurrent interchromosomal translocation between CLDN18 and " exact="ARHGAP26" post=" further implies biological significance of cell adhesion and deregulated Rho signaling in GS tumor" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" implies biological significance of cell adhesion and deregulated Rho signaling in GS tumors since " exact="CLDN18" post=" is involved in intercellular tight junction structure, and ARHGAP26, a GTPase-activating protein, " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="nchymal transition (EMT) [ 58]. Therefore, the novel discoveries of " exact="RHOA" post=" mutation and CLDN18-ARHGAP26 fusion could be exploited to develop new therapeutic strategie" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="CIN subtype GC is related to intestinal type histology, frequent " exact="TP53" post=" mutations, and amplification of RTKs [ 20]. TP53 mutation is" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="y, frequent TP53 mutations, and amplification of RTKs [ 20]. " exact="TP53" post=" mutation is the most frequently detected mutation in GC, occurring in up to 50% of all cases [ &lt;a " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="#b59-jptm-2015-09-10&quot;&gt;59] and 71% of cases of CIN subtype GC [ 20]. " exact="TP53" post=" mutation is associated with high levels of somatic copy number variations in both chromosomal and " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="regions [ 60]. Also, other canonical tumor suppressor genes such as " exact="SMAD4" post=" and APC have been reported to be mutated in GC [ 61]. Since " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="=&quot;#b60-jptm-2015-09-10&quot;&gt;60]. Also, other canonical tumor suppressor genes such as SMAD4 and " exact="APC" post=" have been reported to be mutated in GC [ 61]. Since tumor suppresso" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="The frequency of " exact="HER2" post=" mutation was reported to be 5% (9/180) in GC, and the relationship between HER2 mutation an" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="requency of HER2 mutation was reported to be 5% (9/180) in GC, and the relationship between " exact="HER2" post=" mutation and responsiveness to trastuzumab has not yet been determined. Another clinically importa" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="nsiveness to trastuzumab has not yet been determined. Another clinically important issue regarding " exact="HER2" post=" mutation and amplification might be derived from a recent EGFR biomarker study in non-small cell l" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="om a recent EGFR biomarker study in non-small cell lung cancer patients receiving gefitinib, where " exact="EGFR" post=" mutation and amplification correlated with prolonged progression-free survival [ &lt;a href=&quot;#b65-jpt" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="5]. Based on this, it might be worthwhile to investigate the clinical benefit of HER2 inhibitor in " exact="HER2" post="-mutated and amplified GC as alternative candidates for HER2-targeted therapy [ &lt;a href=&quot;#b66-jptm-" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="KRAS" post=" is one of the members of the RAS family, and its mutation plays an important role in tumorigenesis" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="ant role in tumorigenesis by activating downstream pathways such as PI3K and RAF. The frequency of " exact="KRAS" post=" mutations in GC was reported as 1.5%–5.8%, and most of them were transversions [ &lt;a href=&quot;#b67-jpt" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" most of them were transversions [ 67]. Overexpression of wild-type " exact="KRAS" post=" seemed to be related to acquired resistance to inhibitors of other tyrosine kinase in GC cells [ &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="ial that evaluated the efficacy of selumetinib, an inhibitor of MEK1/MEK2, downstream of KRAS, for " exact="KRAS" post="-mutant non-small cell lung cancer demonstrated promising efficacy and thereby warrants further cli" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="9-jptm-2015-09-10&quot;&gt;69]. Thus, a MEK inhibitor could be a potential therapeutic agent for targeting " exact="KRAS" post="-mutated GC; however, evidence from a clinical trial is required. " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="Mesenchymal epithelial transition factor ( " exact="MET" post=") amplification was not common (2%, 10/489) in GC it was reported to be related with poor prognosis" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" " exact="BRAF" post=" mutations are related to tumorigenesis, and dysregulated BRAF activity instigates abnormal cell gr" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="iferation through MEK and ERK pathways [ 70]. The specific mutation " exact="BRAF" post=" V600E is the most common type of BRAF mutation in melanoma, and vemurafenib, a BRAF inh" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="tation in melanoma, and vemurafenib, a BRAF inhibitor, was found to be beneficial in patients with " exact="BRAF" post=" V600E-mutated melanoma [ 71]. BRAF mutations are " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" patients with BRAF V600E-mutated melanoma [ 71]. " exact="BRAF" post=" mutations are rarely observed in GC, with only 2.2% (7/319) of patients demonstrating BRAF " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" BRAF mutations are rarely observed in GC, with only 2.2% (7/319) of patients demonstrating " exact="BRAF" post=" mutation, most (five of seven BRAF mutations) of which were BRAF V599M [ " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" in GC, with only 2.2% (7/319) of patients demonstrating BRAF mutation, most (five of seven " exact="BRAF" post=" mutations) of which were BRAF V599M [ 72]; in add" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="ients demonstrating BRAF mutation, most (five of seven BRAF mutations) of which were " exact="BRAF" post=" V599M [ 72]; in addition, there were no BRAF mutations a" xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre="ial [ 26]. Furthermore, only 0.2% of patients (1/508) with GC had a " exact="BRAF" post=" V600E mutation in another study [ 67]. Therefore, it is " xpath="/html[1]/body[1]/article[1]/div[3]/div[9]/p[1]" name="human"/>
   <result pre=" mutation in another study [ 67]. Therefore, it is not yet clear if " exact="BRAF" post=" mutation is a driver mutation in GC. " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4735094/results/gene/human/results.xml">
   <result pre=" CT chemotherapy, ET endocrine therapy, " exact="FEC" post=" fluorouracil, epirubicin and cyclophosphamide, HER2 human epidermal growth factor receptor " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="emotherapy, ET endocrine therapy, FEC fluorouracil, epirubicin and cyclophosphamide, " exact="HER2" post=" human epidermal growth factor receptor 2, HR hormone receptor, NAT neoadjuvant thera" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="yclophosphamide, HER2 human epidermal growth factor receptor 2, HR hormone receptor, " exact="NAT" post=" neoadjuvant therapy, OS overall survival, pCR pathological complete response, T&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=", pCR pathological complete response, T- D target-directed therapy, T- " exact="DM1" post=" trastuzumab emtansine, TN triple negative " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ent subsets, and b classes of investigational target-directed agents in current or ongoing trials. " exact="HER2" post=" human epidermal growth factor receptor 2, HR hormone receptor, mTOR mammalian target" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="l growth factor receptor 2, HR hormone receptor, mTOR mammalian target of rapamycin, " exact="PARP" post=" poly ADP ribose polymerase, PK protein kinase " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="DFS" post=" disease-free survival, EFS event-free survival, ET endocrine therapy, HER2 hu" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" DFS disease-free survival, " exact="EFS" post=" event-free survival, ET endocrine therapy, HER2 human epidermal growth factor recept" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" name="human"/>
   <result pre=" DFS disease-free survival, EFS event-free survival, ET endocrine therapy, " exact="HER2" post=" human epidermal growth factor receptor 2, HR hormone receptor, mTOR mammalian target" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="l growth factor receptor 2, HR hormone receptor, mTOR mammalian target of rapamycin, " exact="PARP" post=" poly(ADP-ribose) polymerase, PI3K phosphoinositide 3-kinase, PFS progression-free su" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="mone receptor, mTOR mammalian target of rapamycin, PARP poly(ADP-ribose) polymerase, " exact="PI3K" post=" phosphoinositide 3-kinase, PFS progression-free survival, RFS relapse-free survival " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rget of rapamycin, PARP poly(ADP-ribose) polymerase, PI3K phosphoinositide 3-kinase, " exact="PFS" post=" progression-free survival, RFS relapse-free survival " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="P-ribose) polymerase, PI3K phosphoinositide 3-kinase, PFS progression-free survival, " exact="RFS" post=" relapse-free survival " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="investigational regimen short description. AA anti-angiogenic, AMPKi AMPK inhibitor, " exact="ASCI" post=" Antigen-Specific Cancer Immunotherapeutic, Bisph bisphosphonates, BRCA + BRCA-positi" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="PK inhibitor, ASCI Antigen-Specific Cancer Immunotherapeutic, Bisph bisphosphonates, " exact="BRCA" post=" + BRCA-positive, CDK4/6i cyclin-dependent kinase 4/6 inhibitor, c- KITi c-KIT" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" transferase inhibitor, GpNMB glycoprotein NMB, HDACi histone deacetylase inhibitor, " exact="HER2" post=" + human epidermal growth factor receptor-positive, HER2i human epidermal growth factor rece" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="CDK" post=" cyclin-dependent kinase, EGFR epidermal growth factor receptor, ER estrogen receptor" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CDK cyclin-dependent kinase, " exact="EGFR" post=" epidermal growth factor receptor, ER estrogen receptor, HER2 human epidermal growth " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" name="human"/>
   <result pre="yclin-dependent kinase, EGFR epidermal growth factor receptor, ER estrogen receptor, " exact="HER2" post=" human epidermal growth factor receptor 2, HER3 human epidermal growth factor receptor 3, &lt;i" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="actor receptor, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, " exact="HER3" post=" human epidermal growth factor receptor 3, HER4 human epidermal growth factor receptor, I" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt; human epidermal growth factor receptor 2, HER3 human epidermal growth factor receptor 3, " exact="HER4" post=" human epidermal growth factor receptor, IGFR insulin-like growth factor receptor, FGFR&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" human epidermal growth factor receptor 3, HER4 human epidermal growth factor receptor, " exact="IGFR" post=" insulin-like growth factor receptor, FGFR dibroblast growth factor receptor, mTOR ma" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt;HER4 human epidermal growth factor receptor, IGFR insulin-like growth factor receptor, " exact="FGFR" post=" dibroblast growth factor receptor, mTOR mammalian target of rapmycin, PARP poly(ADP-" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="receptor, FGFR dibroblast growth factor receptor, mTOR mammalian target of rapmycin, " exact="PARP" post=" poly(ADP-ribose) polymerase, PI3K phosphoinositide 3-kinase, PDGFR platelet-derived " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="actor receptor, mTOR mammalian target of rapmycin, PARP poly(ADP-ribose) polymerase, " exact="PI3K" post=" phosphoinositide 3-kinase, PDGFR platelet-derived growth factor receptor, RANKL rece" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="arget of rapmycin, PARP poly(ADP-ribose) polymerase, PI3K phosphoinositide 3-kinase, " exact="PDGFR" post=" platelet-derived growth factor receptor, RANKL receptor activator of nuclear factor kappa-B" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rase, PI3K phosphoinositide 3-kinase, PDGFR platelet-derived growth factor receptor, " exact="RANKL" post=" receptor activator of nuclear factor kappa-B ligand, T- DM1 trastuzumab emtansine, &lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="rowth factor receptor, RANKL receptor activator of nuclear factor kappa-B ligand, T- " exact="DM1" post=" trastuzumab emtansine, VEGF vascular endothelial growth factor " xpath="/html[1]/body[1]/article[1]/div[3]/div[5]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="&gt; receptor activator of nuclear factor kappa-B ligand, T- DM1 trastuzumab emtansine, " exact="VEGF" post=" vascular endothelial growth factor " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4751719/results/gene/human/results.xml">
   <result pre=" " exact="CTC" post=" circulating tumor cell, DTC disseminated tumor cell, ER estrogen receptor, HER2&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CTC circulating tumor cell, " exact="DTC" post=" disseminated tumor cell, ER estrogen receptor, HER2 human epidermal growth factor re" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt;CTC circulating tumor cell, DTC disseminated tumor cell, ER estrogen receptor, " exact="HER2" post=" human epidermal growth factor receptor 2, IHC immunhistochemstry, NACT neoadjuvant c" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ted tumor cell, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, " exact="IHC" post=" immunhistochemstry, NACT neoadjuvant chemotherapy, OS overall survival, PFS p" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="gen receptor, HER2 human epidermal growth factor receptor 2, IHC immunhistochemstry, " exact="NACT" post=" neoadjuvant chemotherapy, OS overall survival, PFS progression-free survival, PR&lt;" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=", IHC immunhistochemstry, NACT neoadjuvant chemotherapy, OS overall survival, " exact="PFS" post=" progression-free survival, PR progesterone receptor, slCTC stem cell–like circulatin" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="CTC" post=" circulating tumor cell, DTC disseminated tumor cell, NACT neoadjuvant chemotherapy " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CTC circulating tumor cell, " exact="DTC" post=" disseminated tumor cell, NACT neoadjuvant chemotherapy " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CTC circulating tumor cell, DTC disseminated tumor cell, " exact="NACT" post=" neoadjuvant chemotherapy " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ist-related protein 1) was detected in the sample. EpCAM epithelial cell adhesion molecule, " exact="ERCC1" post=" excision repair cross-complementing rodent repair deficiency, complementation group 1, HER2" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" name="human"/>
   <result pre="i&gt;ERCC1 excision repair cross-complementing rodent repair deficiency, complementation group 1, " exact="HER2" post=" human epidermal growth factor receptor 2, MUC1 mucin 1, cell surface associated " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" repair deficiency, complementation group 1, HER2 human epidermal growth factor receptor 2, " exact="MUC1" post=" mucin 1, cell surface associated " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" name="human"/>
   <result pre=" " exact="CTC" post=" circulating tumor cell, DTC disseminated tumor cell, ER estrogen receptor, PR" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CTC circulating tumor cell, " exact="DTC" post=" disseminated tumor cell, ER estrogen receptor, PR progesterone receptor, slCTC&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" " exact="CTC" post=" circulating tumor cell, DTC disseminated tumor cell, ER estrogen receptor, PR" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" CTC circulating tumor cell, " exact="DTC" post=" disseminated tumor cell, ER estrogen receptor, PR progesterone receptor, slCTC&lt;/i" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HR hazard ratio, " exact="NACT" post=" neoadjuvant chemotherapy, OS overall survival, PFS progression-free survival; n.a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" HR hazard ratio, NACT neoadjuvant chemotherapy, OS overall survival, " exact="PFS" post=" progression-free survival; n.a. not applicable, n.s. not significant. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" line = DTC/CTC/slCTC-positive patients. BM bone marrow, CI confidence interval, " exact="CTC" post=" circulating tumor cell, DTC disseminated tumor cell, HR hazard ratio, NACT ne" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="patients. BM bone marrow, CI confidence interval, CTC circulating tumor cell, " exact="DTC" post=" disseminated tumor cell, HR hazard ratio, NACT neoadjuvant chemotherapy, PFS " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="al, CTC circulating tumor cell, DTC disseminated tumor cell, HR hazard ratio, " exact="NACT" post=" neoadjuvant chemotherapy, PFS progression-free survival, slCTC stem cell–like circul" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" DTC disseminated tumor cell, HR hazard ratio, NACT neoadjuvant chemotherapy, " exact="PFS" post=" progression-free survival, slCTC stem cell–like circulating tumor cell " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="le (no events for slCTC-positive patients)]. BM bone marrow, CI confidence interval, " exact="CTC" post=" circulating tumor cell, DTC disseminated tumor cell, HR hazard ratio, NACT ne" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="tients)]. BM bone marrow, CI confidence interval, CTC circulating tumor cell, " exact="DTC" post=" disseminated tumor cell, HR hazard ratio, NACT neoadjuvant chemotherapy, OS o" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[5]/div[4]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="al, CTC circulating tumor cell, DTC disseminated tumor cell, HR hazard ratio, " exact="NACT" post=" neoadjuvant chemotherapy, OS overall survival, slCTC stem cell–like circulating tumo" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4758788/results/gene/human/results.xml">
   <result pre="ed, were identified. Among these LncRNAs, AFAP1-AS1 was the most dysregulated LncRNA, while " exact="ORM2" post=" was the most dysregulated mRNA. LOC100288637 had the highest positive correlation coefficie" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="LOC100288637 had the highest positive correlation coefficient of 0.93 with HER-2, while " exact="RPL13P5" post=" had the highest negative correlation coefficient of −0.87. The pathway act network showed that MAP" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="e highly related with HER-2-enriched subtype breast cancer. Coexpression network recognized " exact="LINC00636" post=", LINC01405, ADARB2-AS1, ST8SIA6-AS1, LINC00511, and DPP10-AS1 a" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="ith HER-2-enriched subtype breast cancer. Coexpression network recognized LINC00636, " exact="LINC01405" post=", ADARB2-AS1, ST8SIA6-AS1, LINC00511, and DPP10-AS1 as core genes. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="sion network recognized LINC00636, LINC01405, ADARB2-AS1, ST8SIA6-AS1, " exact="LINC00511" post=", and DPP10-AS1 as core genes. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="cR-NAs, AFAP1-AS1 (GeneID 84740) was the most dysregulated LncRNA with an FC of 9.79, while " exact="ORM2" post=" (GeneID 5005) was the most dysregulated mRNA with an FC of 9.85. " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[3]/p[1]" name="human"/>
   <result pre="eneID 100288637) had the highest positive correlation coefficient of 0.93 with HER-2, while " exact="RPL13P5" post=" (GeneID 283345) had the highest negative correlation coefficient of −0.87. " name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4759568/results/gene/human/results.xml">
   <result pre="e Luminal B case, it was found that estrogen-related receptors α and γ (ERRα and ERRγ) up-regulate " exact="MAOB" post=" gene activity, whereas estrogen receptors α and β (ERα and ERβ) decrease stimulation in both a lig" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/div[2]/p[1]" name="human"/>
   <result pre="one receptor negative status and with a better overall survival rates 24. Moreover, " exact="ACADL" post=" gene has been reported to be related with ER positive, as well as with Luminal A and TN tumors &lt;a " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/div[2]/p[1]" name="human"/>
   <result pre="be related with ER positive, as well as with Luminal A and TN tumors 25. Concerning " exact="CDKN2A" post=", it has been indicated to be overexpressed in the majority of TN breast and HER2-enriched cancer c" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/div[2]/p[1]" name="human"/>
   <result pre="r drug. Finally, the gene (FOS) from the breast cancer stage II pattern, physically interacts with " exact="JUN" post=", a target gene of Vinblastine Breast cancer drug and with NR3C1, a target gene of Megestrol Breast" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/div[2]/p[1]" name="human"/>
   <result pre="m breast cancer stage III network pattern (KRT8, KRT17, KRT18 and HOXC10) physically interact with " exact="EGFR" post=", a target gene of Lapatinib Breast cancer drug which is quite similar (greater than 50%) to Paroxe" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/div[2]/p[1]" name="human"/>
   <result pre="mal samples ( Table 7). Concerning staging, selection of stages I, II, " exact="III" post=" and IV was performed based on the clinical records accompanying each sample, while for the " xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="Negative for ER-, PR-, HER2-. The eight distinct TCGA dataset were statistically analyzed with the " exact="LIMMA" post=" R package in order to select the Differentially Expressed Genes (DEGs) in breast cancer samples co" dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4763414/results/gene/human/results.xml">
   <result pre="Heatmap for HER family and " exact="ESR1" post=" gene expression. a Training set ( N = 203); b Validation set ( N = 84) " xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[3]/p[1]" name="human"/>
   <result pre="Box plots for the expression level of HER family genes and " exact="ESR1" post=" gene. (A) Training set ( N = 203). (B) Validation set ( N = 84). (C) Group consistin" xpath="/html[1]/body[1]/article[1]/div[4]/div[1]/div[1]/div[1]/div[3]/p[1]" name="human"/>
   <result pre="ast cancer ( N = 52). Figure S2. Relationship among expression of the ERBB family genes and " exact="ESR1" post=" gene in TNBC. Figure S3. Survival analysis according to the expression level of ESR1 and ERBB4 exp" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4764922/results/gene/human/results.xml">
   <result pre="ancer leads to invasive carcinoma but the mechanism is not clearly understood. Here we report that " exact="TOM1L1" post=" is co-amplified with ERBB2 and defines a subgroup of HER2 + /" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="ut the mechanism is not clearly understood. Here we report that TOM1L1 is co-amplified with " exact="ERBB2" post=" and defines a subgroup of HER2 + /ER + tumou" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="ood. Here we report that TOM1L1 is co-amplified with ERBB2 and defines a subgroup of " exact="HER2" post=" + /ER + tumours with early metastatic relapse. T" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=" + /ER + tumours with early metastatic relapse. " exact="TOM1L1" post=" encodes a GAT domain-containing trafficking protein and is a SRC substrate that negatively regulat" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="how that TOM1L1 is an important element of an ERBB2-driven proteolytic invasive programme and that " exact="TOM1L1" post=" amplification potentially enhances the metastatic progression of ERBB2-positive breast cancers. " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="tic and epigenetic alterations in breast cancer cells eventually result in invasive carcinoma. The " exact="ERBB2" post=" oncogene (also known as HER2 or neu), which encodes a tyrosine kinase receptor of the EGFR family," xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="observed that TOM1L1, which is located on chromosome 17q22, is frequently co-amplified with " exact="ERBB2" post=" in breast cancer 18, suggesting that TOM1L1 could have a pro-oncogenic function. TO" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="TOLLIP. Thus, TOM1L1 is an important element of an ERBB2-driven proteolytic invasive programme and " exact="TOM1L1" post=" amplification potentially enhances the metastatic progression of ERBB2-positive breast cancers. " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="We first confirmed that in breast cancer, the " exact="ERBB2" post=" locus at 17q12 (37.85 Mb) is frequently co-amplified with loci located at 17q22 (53 Mb) and 17q23 " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="23 ( Fig. 1a) 18. Analysis of a set of 402 breast tumours showed that " exact="TOM1L1" post=" was the most frequently co-amplified gene with ERBB2 in the 17q22-q23 region ( &lt;a href=&quot;#S1" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="set of 402 breast tumours showed that TOM1L1 was the most frequently co-amplified gene with " exact="ERBB2" post=" in the 17q22-q23 region ( Supplementary Table 1). TOM1L1 gene amplification w" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre=". Finally, metastasis-free survival was reduced in patients with ERBB2+/ER+ breast cancer in which " exact="TOM1L1" post=" was also amplified compared with those without TOM1L1 amplification (patients selected from" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="ith ERBB2+/ER+ breast cancer in which TOM1L1 was also amplified compared with those without " exact="TOM1L1" post=" amplification (patients selected from our previous work 26) ( Fig. 1e" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="east cancer and shows that its pro-oncogenic activity is induced by gene co-amplification with the " exact="ERRB2" post=" oncogene. In addition, we have identified one mechanism involved in this process that involves the" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="indings that this TOM1L1 pro-invasive activity is present also in transformed fibroblasts and that " exact="TOM1L1" post=" is amplified in other cancer types ( www.bioportal.com) suggest" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre=" role in this malignant process has not been addressed yet, but available genomic data highlighted " exact="GGA3" post=" amplification in some human tumours ( www.cbioportal.org). We " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="Our results show that " exact="ERBB2" post=" and TOM1L1 are frequently co-amplified and define a subgroup of patients with ER-positive c" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="Our results show that ERBB2 and " exact="TOM1L1" post=" are frequently co-amplified and define a subgroup of patients with ER-positive cancer with worse p" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="or example, oestrogen signalling inhibits the invasive phenotype by repressing RELB and its target " exact="BCL2" post=" (ref. 45). Conversely, cell transformation by ERBB2 can affect ER signalling as it " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="can affect ER signalling as it induces tamoxifen resistance 46. Co-amplification of " exact="TOM1L1" post=" and ERBB2 significantly reduces survival of patients with ER-positive cancers. This suggest" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="alling as it induces tamoxifen resistance 46. Co-amplification of TOM1L1 and " exact="ERBB2" post=" significantly reduces survival of patients with ER-positive cancers. This suggests a potential fun" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="ple and the median value of all tumours. The same thresholds as before were applied after checking " exact="ALB" post=", DCK and GAPDH variations. " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="median value of all tumours. The same thresholds as before were applied after checking ALB, " exact="DCK" post=" and GAPDH variations. " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre=" all tumours. The same thresholds as before were applied after checking ALB, DCK and " exact="GAPDH" post=" variations. " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="Mock or short hairpin RNA (shRNA) specific to human " exact="TOM1L1" post=" were cloned in the pSiren retroviral vector (mock: 5′-GACACTCGGTAGTCTATAC-3′; sh- TOM1L1-1:" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="CAAGAGACTGCTCAAAT-3′ or sh- TOM1L1-2: 5′-CAGAAGGAAGCCAATA-3′). The siRNA specific for human " exact="TOLLIP" post=" (sequence: 5′-AAGTTGGCCAAGAATTACGGCdTdT-3′) was designed with the Qiagen design tool and obtained " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre=", 202 (3T3-neu TOM1L1), 101 (3T3-neuΔGAT), 108 (3T3-neu TOM1L1 ctrl-siRNA) and 112 (3T3-neu TOM1L1 " exact="TOLLIP" post=" siRNA) were tracked in a minimum of 10 different cells. For lysosome tracking, ≈160 different lyso" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="( a) The " exact="ERBB2" post=" and TOM1L1 loci are frequently co-amplified in breast cancer. Upper part: cumulative array-" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="( a) The ERBB2 and " exact="TOM1L1" post=" loci are frequently co-amplified in breast cancer. Upper part: cumulative array-CGH copy number fr" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="per part: cumulative array-CGH copy number frequency plots of chromosome 17 in breast tumours with " exact="ERBB2" post=" amplification. Copy number gains are in blue, losses in red. Tumours with a log2 ratio higher than" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="our). The colour code is the same as in the upper part. About 52.5% of ERBB2-positive tumours show " exact="TOM1L1" post=" co-amplification. ( b) Representative images showing TOM1L1 protein expression in breast cancer sa" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="+/ER+ breast cancer from the database of ref. 27. Patients were stratified based on " exact="TOM1L1" post=" amplification (red curve) and were compared with patients with no amplification (green curve). The" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="per panel: invasion of SKBR3 cells infected as indicated and transfected twice with control (−) or " exact="TOLLIP" post=" siRNAs (+) was assessed and quantified as in b ( n=5). Mean±s.e.m * P&amp;amp;lt;0.05 (S" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="al imaging ( x/z) of BT-474 shTOM1L1-infected cells were transfected with control (Ctrl) or " exact="TOLLIP" post=" siRNA, then transfected with mCherry–MT1-MMP and GFP–TOM1L1 and plated on gelatin-coated coverslip" xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="/i&gt;-test). ( f) Western blot showing the efficiency of TOLLIP depletion 48 h after transfection of " exact="TOLLIP" post=" or control siRNAs in BT-474 cells. " xpath="/html[1]/body[1]/article[1]/div[5]/div[6]/p[1]" name="human"/>
   <result pre="( a) Endosome tracking assay. About 48 h after mCherry–MT1-MMP transfection with Ctrl or mouse " exact="TOLLIP" post=" siRNA, 3T3 cells infected as indicated were plated on gelatin-coated glass bottom dishes. Time-lap" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4769490/results/gene/human/results.xml">
   <result pre="resents with high expression in mRNA and protein levels of the Luminal expression signature (e.g., " exact="ESR1" post=", GATA3, FOXA1, XBP1, and MYB) [ 5, 7]. L" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="high expression in mRNA and protein levels of the Luminal expression signature (e.g., ESR1, " exact="GATA3" post=", FOXA1, XBP1, and MYB) [ 5, 7]. Luminal-B BC in" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="n in mRNA and protein levels of the Luminal expression signature (e.g., ESR1, GATA3, " exact="FOXA1" post=", XBP1, and MYB) [ 5, 7]. Luminal-B BC includes ER-posi" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="protein levels of the Luminal expression signature (e.g., ESR1, GATA3, FOXA1, " exact="XBP1" post=", and MYB) [ 5, 7]. Luminal-B BC includes ER-positive but also" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre=" the Luminal expression signature (e.g., ESR1, GATA3, FOXA1, XBP1, and " exact="MYB" post=") [ 5, 7]. Luminal-B BC includes ER-positive but also ER-negative his" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="ast to Luminal A, Luminal-B BC has an increased expression not only of proliferation genes such as " exact="KI67" post=" and cyclin B1 but also frequently overexpresses epidermal growth factor receptor (EGFR) and HER" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="67 and cyclin B1 but also frequently overexpresses epidermal growth factor receptor (EGFR) and " exact="HER2" post=" [ 7]. Basal-like BC or triple-negative breast cancer (TNBC) is characterized by ER-" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="NBC) is characterized by ER-negative, PR-negative, and Her2-negative tumors with high frequency of " exact="TP53" post=" (80 %) and PIK3CA (9 %) mutation [ 5]. Her2-positive (Her2-enriched) BC is c" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="y ER-negative, PR-negative, and Her2-negative tumors with high frequency of TP53 (80 %) and " exact="PIK3CA" post=" (9 %) mutation [ 5]. Her2-positive (Her2-enriched) BC is characterized by the ampli" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="[ 5]. Her2-positive (Her2-enriched) BC is characterized by the amplification of the " exact="HER2" post=" gene and other genes of the HER2 amplicon including STARD3 and GRB7 [ &lt;a href" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="-enriched) BC is characterized by the amplification of the HER2 gene and other genes of the " exact="HER2" post=" amplicon including STARD3 and GRB7 [ 6, 8]. Her2 in pa" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="by the amplification of the HER2 gene and other genes of the HER2 amplicon including " exact="STARD3" post=" and GRB7 [ 6, 8]. Her2 in particular acts as a coreceptor and" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="on of the HER2 gene and other genes of the HER2 amplicon including STARD3 and " exact="GRB7" post=" [ 6, 8]. Her2 in particular acts as a coreceptor and enhances signal" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="iently transfected with indicated amounts of small interfering RNA (siRNA) siGENOME SMART pools of " exact="MCL1" post=" (4170) and HER2 (2064), or the nontargeting control (mock) siRNA (Upstate Cell Signaling So" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre=" indicated amounts of small interfering RNA (siRNA) siGENOME SMART pools of MCL1 (4170) and " exact="HER2" post=" (2064), or the nontargeting control (mock) siRNA (Upstate Cell Signaling Solutions/Dharmacon RNA T" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="The inhibitory effect of hypoxia, si " exact="MCL1" post=", or si HER2 on BC cell lines was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl t" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="The inhibitory effect of hypoxia, si MCL1, or si " exact="HER2" post=" on BC cell lines was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="R amplification was performed using Taq DNA polymerase (Qiagen). The primers used to amplify human " exact="MCL1" post=" were 5′-ATCTCTCGGTACCTTCGGGAGC-3′ (sense) and 5′-CCTGATGCCACCTTCTAGGTCC-3′ (antisense). The primer" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="ein levels were due to elevated transcription or post-transcriptional regulation, we next detected " exact="MCL1" post=" mRNA levels over a period of 24 hours using semiquantitative reverse transcription PCR. Our result" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="of 24 hours using semiquantitative reverse transcription PCR. Our results show that mRNA levels of " exact="MCL1" post=" did not change over time, indicating a transient hypoxia-mediated increase in Mcl-1 stability (Add" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="sfected the Her2-positive BC cell lines BT-474 and SKBR3 with a pool of siRNA directed against the " exact="MCL1" post=" gene ( siMCL1) and tested for both Her2 and Hif-1α protein levels. Our data demonstrate mar" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="nregulation of Her2 and Hif-1α in Her2-positive BC cells depleted of Mcl-1. Moreover, silencing of " exact="MCL1" post=" induced cell death as evidenced by PARP cleavage (Fig. 2a). Surprisingly, in contr" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre="ons [ 24, 25, 29], siRNA-mediated knockdown of the " exact="HER2" post=" gene ( siHER2) in Her2-positive BC cells did not affect Mcl-1 protein levels under hypoxic " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="duced downregulation of Her2 and Hif-1α is not triggered by caspase-mediated off-target effects of " exact="MCL1" post=" siRNA. Her2-positive BC cells were transfected with siMCL1 for 2 days and then exposed to h" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" name="human"/>
   <result pre=", Hif hypoxia-inducible factor, kD kilodalton, Mcl-1 myeloid cell leukemia-1, " exact="PARP" post=" Poly (ADP-ribose) polymerase " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=", Hif hypoxia-inducible factor, kD kilodalton, Mcl-1 myeloid cell leukemia-1, " exact="MEF" post=" murine embryonic fibroblast, PARP Poly (ADP-ribose) polymerase " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="i&gt;kD kilodalton, Mcl-1 myeloid cell leukemia-1, MEF murine embryonic fibroblast, " exact="PARP" post=" Poly (ADP-ribose) polymerase " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre=", Hif hypoxia-inducible factor, kD kilodalton, Mcl-1 myeloid cell leukemia-1, " exact="PARP" post=" Poly (ADP-ribose) polymerase " xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ion of Her2 with Her2 or heterodimerization of Her2 with Her3 enhances phospho-inositol 3-kinase ( " exact="PI3K" post=")/AKT and RAS/mitogen-activated protein kinase ( MAPK) pathways, which regulate BC cell prol" xpath="/html[1]/body[1]/article[1]/div[3]/div[4]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="3 enhances phospho-inositol 3-kinase ( PI3K)/AKT and RAS/mitogen-activated protein kinase ( " exact="MAPK" post=") pathways, which regulate BC cell proliferation, survival, and migration, as well as angiogenesis " dictionary="hgnc" dictionaryCheck="false" name="human"/>
  </snippets>
 </snippetsTree>
 <snippetsTree>
  <snippets file="target/tutorial/brcancer/PMC4772532/results/gene/human/results.xml">
   <result pre=" a ER/PR Estrogen/Progesterone receptor, b " exact="HER2" post=" Human epidermal growth factor receptor; c EGFR epidermal growth factor, d&lt;/" xpath="/html[1]/body[1]/article[1]/div[3]/div[3]/div[2]/p[1]" dictionary="hgnc" dictionaryCheck="false" name="human"/>
   <result pre="ogesterone receptor, b HER2 Human epidermal growth factor receptor; c " exact="EGFR" post=" epidermal growth factor, d CK5-6 Cytokeratin 5/6; e LA luminal" name="human"/>
  </snippets>
 </snippetsTree>
</projectSnippetsTree>
